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ABSTRACT OF THE DISSERTATION
Potentiation of TMEM16A Currents by CLCA1 in Cystic Fibrosis Airway
By
Kayla Nicole Berry
Doctor of Philosophy in Biology and Biomedical Sciences
Immunology
Washington University in St. Louis, 2021
Professor Tom J. Brett, Chair

In the airway, proper activity of the anion channel cystic fibrosis transmembrane
conductance regulator (CFTR) contributes to innate immune defense by maintaining a hydrated
and alkaline mucus layer through the conductance of chloride and bicarbonate ions. This allows
potentially pathogenic microorganisms to be trapped, quickly killed, and cleared via mucociliary
clearance, thus preventing microbial colonization of the lungs. In cystic fibrosis (CF), this
activity is impaired, resulting in repeated pulmonary infections that damage the lung and, if
severe and prolonged, may lead to premature death without lung transplantation. Available
therapies remain focused on targeted rescue of the CFTR mutation. However, given the
thousands of mutations found in this patient population, individualized rescue of each would be
difficult. This dissertation explores the potential of an alternative and mutation-agnostic strategy
to restore healthy airway properties by activating an alternate anion channel in the lung, the
calcium activated chloride channel (CaCC), TMEM16A. TMEM16A conducts both chloride and
bicarbonate, making it an ideal surrogate for CFTR activity. Our group has identified a secreted
xiii

potentiator of TMEM16A, calcium activated chloride channel regulator 1 (CLCA1), that directly
engages TMEM16A on the cell surface and prevents its internalization on the order of minutes,
thereby increasing TMEM16A surface density and anion currents through the cell. A detailed
molecular understanding of the interaction between CLCA1 and TMEM16A will be important
towards developing a CF therapy that can be modeled after the interaction.
Therefore, the goal of this dissertation was two-fold: 1) uncover the molecular determinants
governing the interaction between CLCA1 and TMEM16A, and 2) examine the effects of
CLCA1 on TMEM16A currents and mucociliary properties of CF airway. Towards developing a
model of this interaction, this study presents the X-ray crystal structure of the human CLCA1
vWA domain to 2.0 Å, the first structure of any CLCA family member. Human TMEM16A was
purified and a structural model of the CLCA1-TMEM16A interaction pursued by single-particle
cryo-electron microscopy. To understand the specificity of the interaction, the remaining human
CLCA family members, CLCA2 and CLCA4, were investigated functionally and structurally, as
both can potentiate CaCC. CLCA4 specifically potentiates anion currents through the CaCC
TMEM16B and not through TMEM16A, indicating that CLCA proteins potentiate specific
TMEM16 channels. To translate these discoveries to disease, CLCA1 was applied to CF airway
of multiple genotypes. Treatment with CLCA1 demonstrated the ability to potentiate TMEM16A
currents and restore mucociliary clearance. This effect on TMEM16A, however, was not
observed in normal CFTR-sufficient airway epithelial cells, and evidence indicates that this
discrepancy may be due to different TMEM16A isoforms expressed in normal versus CF airway
epithelial cells. Together, these studies indicate that CLCA1 vWA domain may restore healthy
mucus properties to CF airway and highlights the exciting potential for universal CF treatment
modeled after the CLCA1 vWA domain/TMEM16A interaction.
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Chapter 1: Potentiation of TMEM16A
currents in Cystic Fibrosis using CLCA1

1

1.1 Cystic Fibrosis
1.1.1 Cystic Fibrosis Disease
Cystic fibrosis (CF) is a genetic disorder that primarily affects the lungs, digestive organs
and reproductive system. The disease is characterized by thick, sticky mucus that lines the
mucosal surfaces of the lungs and pancreas. In the lungs, this mucus is not easily cleared and
obstructs the airways, encouraging the development of pulmonary infections, primarily by
Staphylococcus aureus and Pseudomonas aeruginosa, that is a hallmark of the disease. These
infections are frequent, and may cause severe damage to the lung with time, necessitating lung
transplant or resulting in death (1, 2). In the pancreas, the thick mucus can obstruct pancreatic
secretions into the digestive tract, resulting in nutritional deficiencies. As CF primarily affects
the lungs and pulmonary infection is the most common cause of death for patients with cystic
fibrosis, this thesis will focus on the pulmonary aspects of the disease.
In the US, the prevalence of CF is 30,000, and worldwide, 70,000 individuals are living
with the disease(3). CF is an autosomal recessive disorder that primarily affects those of
Caucasian descent (1 in 2500 or 3500), and is rare or undiagnosed in African and Asian
populations but estimated to be 1 in 17,000 or 1 in 31,000, respectively (4-6). Though rare in the
general population, CF is the most common fatal genetic disorder, with patients typically
surviving into their 30s and 40s. However, with the advancement of therapies for this patient
population, many individuals with CF are living into their 50s and 60s (3).
In 1989, Kerem et al. (7) identified the molecular basis for the pathogenesis of cystic
fibrosis by discovering mutations within the cystic fibrosis transmembrane conductance regulator
(CFTR) gene. This gene encodes the CFTR anion channel of the ATP-binding cassette (ABC)
transporter family. It is a 12 pass transmembrane channel with two nucleotide-binding domains
2

(NBD1 and NBD2) and a regulatory subunit (R domain) required for gating regulation (8). This
channel is expressed in epithelial cells, and highly expressed in pulmonary ionocytes(9, 10), at
mucosal surfaces and is responsible for secreting chloride and bicarbonate (HCO3–) into the
mucus layer (2, 11, 12). In the airways, these anions play an important role in the proper
organization and activity of the mucus layer, and the mucus layer, in turn, is integral to innate
immune defense for the lungs (12, 13), being exposed to the outside environment and susceptible
to colonization by pathogenic microorganisms. Secretory epithelial cells and glands in the
mucosal surface secrete mucin glycoproteins (primarily MUC5B and the MUC5AC) that must be
hydrated and alkalinized in order to form a gel-like network that can trap particles and
pathogens. Motile cilia on ciliated epithelial cells beat in synchrony to move the mucus out of the
lungs, either to be expectorated or swallowed. Together, this mechanism constitutes mucociliary
clearance (14-16). Chloride secretion by CFTR draws water into this mucus layer. Hydration of
the mucins allows them to expand and organize into a mesh-like network. Bicarbonate secretion
by CFTR is thought to assist in the expansion and organization of the mucus network (the
negative charge of the bicarbonate interacting with the negatively charged groups on mucins)
(12) and also to provide the proper alkaline pH necessary for optimal activity of anti-microbial
proteins, such as lysozyme, lactoferrin and defensins. Altogether, chloride and bicarbonate
secretion by CFTR contributes to the quick killing and clearance of pathogens that may enter the
lung(17).
Mutations in CFTR that result in its reduced activity (by a variety of mechanisms
discussed below) can have dramatic effects on the properties of the mucus layer. Without
chloride and bicarbonate, the mucus layer becomes excessively viscous and adhered to the
epithelial layer(13, 18-20) and it becomes acidified, impairing mucin unpacking and anti-
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microbial defenses (17, 20-23). In sum, these changes to mucus properties allow pathogenic
bacteria, and possibly fungi, to survive and proliferate, causing damage to the lung with repeated
infection.

1.1.2 Mutations and CFTR Therapies in Cystic Fibrosis
Over 2000 mutations within CFTR are thought to result in CF disease. They are grouped
into six classes based on their mechanism of dysfunction. These six classes may become
important when considering which therapies could be efficacious for an individual with CF (24).
It should be noted, however, that many mutants often display characteristics from multiple
classes. Thus, under the “refined classification”, some mutants could be described as belonging
to multiple classes (for example, under the refined classification, ΔF508 is classified as II-III-VI
though it was originally defined as Class II) (25). Thus, the refined classification recognizes that
a particular mutant may benefit from CFTR therapies that target multiple classes (i.e. benefit
from combinatorial therapy).
CFTR Mutation Classes
Class I
Class I mutations result in no functional CFTR channels, either due to the introduction of stop
codons or frameshift mutations that would eventually result in stop codons in the transcript.
Some common mutations include G542X, Y1282X, R553X and 621+1GàT. Theoretically,
therapies that could rescue CFTR activity would have no effect for this class of mutants since no
protein is produced. About 22% of patients have one allele from this class (3).
Class II
Class II mutants result in CFTR that cannot be properly trafficked to the cell surface. This class
is the largest, as ~80% of patients harbor one allele, the ΔF508 mutation, which belongs to this
4

class(3). Roughly 50% of the CF population is homozygous recessive for this allele
(ΔF508/ΔF508) (24). Thus, resolving disease for this group of patients would have a large
impact. Mutations in this class tend to destabilize the channel in a way that prevents it from
reaching the plasma membrane, often due to misfolding. Lumacaftor (discussed further below), a
drug developed for the ΔF508 allele, is thought to stabilize the misfolded channel so that it may
reach the cell surface(26, 27). Besides the ΔF508 mutation, N1303K, I507del and R560T also
belong to this class(24).
Class III
This class of mutants produces CFTR channels that are able to reach the plasma membrane but
are defectively regulated or have altered channel gating. Mutants belonging to this class could
potentially be rescued by therapies that correct channel gating. Importantly, the drug ivacaftor
(discussed more below) was developed to treat the G551D mutation belonging to this class. For
patients who have a G551D allele, ivacaftor has proven effective in improving disease outcomes.
Other common mutants in this class are G178R, G551S and S549N(24). Roughly 6% of the CF
population has one Class III allele(3)
Class IV
Class IV CFTR mutants also reach the cell surface but display reduced channel conductance.
Ivacaftor is also approved for use for this class of mutations. Mutatitions in this class include
R117H, R347P, R117C, and R334Y(24). Roughly 6% of the CF population has one Class III
allele(3).
Class V
Class V mutations are the result of splicing defects with the consequence of reduced or incorrect
CFTR transcripts and thus reduced functional CFTR. CFTR gene mutations 3849+10kbCàT,
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2789+5GàA and 3120+1GàA belong to this class(24). Roughly 5% of the CF population has
one Class III allele(3).
Class VI
Mutations belonging to Class VI decrease the stability of CFTR protein at the membrane. These
mutations are rare. Mutations in this class include 4326delTC, Q1412X and 4279insA(24).
CF Therapies
In addition to managing the infections and other symptoms, such as muco-obstruction, that
plague CF patients, a number of drugs are approved or are being developed to treat the CFTR the
mutation itself. For Class I mutants, gene therapy would be necessary to address these alleles,
and would also be universally capable of rescuing any CFTR mutant. The gene therapy field has
struggled to develop viral vectors that can efficiently transduce airway epithelia. To address the
stop codons, ataluren, a small molecule that encourages ribosomal read-through of stop codons,
was in Phase 3 clinical trials in 2012, but did not prove efficacious, possibly because many of the
patients were prescribed aminoglycosides to treat infection, which are thought to inhibit ataluren
activity(24, 28).
For patients with a Class II mutation, correctors, drugs that rescue CFTR misfolding, have or
are being developed. For CF patients with a ΔF508/ΔF508 genotype, lumacaftor was developed
to stabilize misfolded protein and increase surface localized CFTR(26, 27). However, alone this
drug was not successful, possibly because the mutated protein even at the surface does not
function optimally. Thus, ivacaftor (trade name Kalydeco), which increases channel
conductance, was added in combination to increase the activity of misfolded CFTR that does
reach the cell surface(26). The FDA approved the use of the lumacaftor/ivacaftor combination
(trade name Orkambi) in this patient population with modest success(29). Later generations of
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correctors, such as tezacaftor, combined with ivacaftor appear to be slightly more successful than
the lumacaftor/ivacaftor combination. This combination is also being approved for use in
patients who show positive in vitro testing with this drug (30). Triple therapy with VX-445
(another corrector), tezacaftor and ivacaftor recently showed very strong promise at 6 months of
treatment, prompting the drug developer, Vertex Pharmaceuticals, to seek FDA approval (31)
which was granted in November 2019. However, its long-term benefit has yet to be determined.
For Class III and class IV mutants, potentiators, drugs that enhance CFTR activity (either for
wild-type or mutant CFTR channels), were developed. Patients with Class III and IV mutations
G551D, R117H and other class III gating defect mutants have been approved to use ivacaftor.
The use of ivacaftor in this population has been a success of CFTR-specific therapy(32). No
specific treatments for Class V and VI have been developed, but ivacaftor may have the potential
to improve outcomes for these CF patients (24).
Even with the success of many of these specific CFTR therapies, use of these treatments for
any given individual may not be effective. With the advent of using patient samples to develop
organoids for personalized testing, it has been possible to determine whether a patient may
respond to specific CFTR therapies. Dekkers et al. (33) developed intestinal organoids from
rectal samples of cystic fibrosis patients and tested various CFTR specific therapies in swelling
assays. Interestingly, even patients with the same mutations did not respond similarly to the same
treatments. A possible explanation for these difference is that other genes are known to modify
disease severity of CF (34). So while these CFTR modulators may have an effect on the channel
itself in cellular assays, they may not have the ability to alter or overcome the deleterious effects
of other genes influencing defective CFTR.
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1.1.3 Activation of alternate anion currents
The current paradigm of CFTR treatment aims to correct the CFTR defect that exists.
However, developing treatments for the thousands of mutations and their defects would be
challenging. In addition, that even patients with the same mutation may respond differently to the
same medications (33) presents an additional challenge. One proposed solution to this problem is
to activate alternative sources of endogenous anion currents. Like gene therapy, treatments
activating other anion currents in the lung would have the potential to resolve disease regardless
of the CFTR mutations present. The focus of this idea eventually centered on activating calcium
activated chloride currents (CaCCs) in the airway(12, 35). Two drugs, duramycin and denufosol,
were in trials to be universal treatments for CF via CaCC activation. Duramycin increases
intracellular calcium, and denufosol is a UTP analog that increases intracellular calcium via P2Y2
receptor activation. Both of these drugs did not directly target a CaCC, as the primary CaCC in
the lung had not yet been identified. Rather, they nonspecifically activated CaCCs via influx of
intracellular calcium(12). These drugs eventually failed, likely because of short half-life and
nonspecific activation of the channel(36-39), notwithstanding potential side effects that would
arise due to a nonspecific influx of intracellular calcium, undoubtedly activating a number of
other pathways that are driven by intracellular calcium. In 2008, three separate groups identified
the major CaCC in the airway epithelium as TMEM16A (Anoctamin 1), making the specific
targeting of CaCC possible and more tractable(40-42).

1.2 TMEM16A
1.2.1 TMEM16 Family
The TMEM16 family consists of 10 members, TMEM16 A through K, excluding I. This
family was originally given the name of Anoctamin (or abbreviated, ANO1 through ANO10),
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because it was believed that these were anion channels (an-) with eight transmembrane segments
(-octa-). This was predicted by early computer programs and from experiments in which
insertion of epitope tags into TMEM16G appeared to support the 8-pass predicted topology(43,
44). This topology was later proved to be incorrect, with the crystal and cryo-EM structures of
TMEM16 family members demonstrating that these membrane proteins instead have 10
transmembrane segments(45-48). The notion that the TMEM16 family consisted of anion
channels was also a misnomer, since the family seems to be a mix of cation and anion channels,
and importantly, lipid scramblases, with individual members reported to display both ion channel
and lipid scrambling activity (43, 49). The perplexing juxtaposition of these activities in the same
family has prompted research into how these channels can both conduct anion currents (which
would require shielding of the ion from the lipophilic membrane) and mediate flipping of lipids
from one leaflet to the other. The reported structures of the TMEM16 family has begun to shed
light on this conundrum.
The mammalian TMEM16 families and their reported activities are summarized in Table
1. A few of the members that have been reported to conduct anion currents (and thus could serve
the role of CaCC) will be described briefly here, with further discussion of TMEM16A below. In
the human TMEM16 family, TMEM16A (ANO1) and TMEM16B (ANO2) are considered to be
the bona fide anion (chloride) channels, with no lipid scrambling reported(50), and are the most
closely related to each other in the family(43). TMEM16A is one of the best-studied members of
the family. It is broadly expressed at mucosal surfaces and in smooth muscle cells(51-57), and
conducts both chloride and bicarbonate ions(58). TMEM16B is primarily expressed in neuronal
cells (olfactory neurons(59, 60), hippocampal neurons(61), photoreceptors(62)) and also
conducts chloride ions(42, 60, 62, 63). Intriguingly, TMEM16F (ANO6) has been shown to
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conduct both chloride (64-67) and cations(68), and also displayed lipid scrambling activity (50,
69). It is broadly expressed at high levels throughout the body(43, 66, 70). Mutations in
TMEM16F are notably associated with Scott syndrome(69), a rare congenital bleeding disorder
due to impaired platelet coagulation, attributed to reduced Ca2+-dependent phospatidylserine
exposure(43).
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Table 1 Ion channel activity, scramblase activity, expression and disease associations of the
TMEM16 family
Gene

Ion Channel

Scramblase

Expression

TMEM16A
(ANO1)

Cl– (40-42)
HCO3– (58)

Not detected (50, 69)

TMEM16B
(ANO2)

Cl– (42, 60, 62,
63)

Not detected (50, 69)

TMEM16C
(ANO3)

Regulates Na+activated K+
channel (Slack)
(75)

PC, GalCer (50)
Not PS (50)

Epithelial cells of airway and
intestine, SMCs of airway and
reproductive tracts, ICCs (51-57),
nociceptive neurons, pancreas,
retina, kidney, DRG,
submandibular glands, Leydig
cells(41)
Olfactory neurons(59, 60),
photoreceptors(62), hippocampal
neurons(61)
Neurons of spinal cord, brainstem,
cerebellum (CNS, PNS) (70, 76),
DRG (75)

TMEM16D
(ANO4)
TMEM16E
(ANO5)

Not detected (50)

PS, PC, GalCer (50)

Outwardly
rectifying,
nonselective ion
channel (78) Not
detected (50)

PS (78, 79)
Not detected (50)

TMEM16F
(ANO6)

Cl– (as an
ORCC) (67)
Cl– (as a CaCC)
(64-66)
Cations (Ca2+,
Ba2+, Na+, K+,
Li+, Rb+, Cs+)
(68) (SCAN)
Not detected (50)

PS, PC, GalCer (50,
69)

Broadly expressed (43, 66, 70)

PS, PC, GalCer (50)

Prostate(44, 84)

Not detected (50)

Not detected (50)

Broadly expressed (43, 66, 70)

Cation (85)
Not detected (50)
Not detected (50)

PS, PC, GalCer (50)

TMEM16G
(ANO7)
TMEM16H
(ANO8)
TMEM16J
(ANO9)
TMEM16K
(ANO10)

Neurons of spinal cord, brainstem,
cerebellum (CNS, PNS) (70, 76),
Cardiac and skeletal muscle,
growth plate chondrocytes,
osteoblasts, thyroid (70, 80)

Not detected (50)

Broadly expression (43, 66, 70),
cerebral cortex, cerebellum(86)

Disease
Associations
Upregulated in
GIST(71), breast
cancers(72),
HNSCC (73),
asthma(61, 74),

Cervical dystonia
(mutation) (76),
MMR-vaccine
related febrile
seizure (77)
GDD(78, 81)
(GOF),
LGMD2L(82)
(LOF),
MMD3(82)
(LOF)
Scott Syndrome
(LOF) (69),
malignancy in
breast cancer
(83)

Upregulated in
prostate cancer
(84)

Cerebellar ataxia
(LOF) (86),
attention
disorders,
epilepsy,
porencephalic
cysts(49, 87, 88)

PS, phosphatidylserine. PC, phosphatidylcholine. GalCer, galactosylceramide. ORCC, outwardly-rectifying chloride channel.
CaCC, calcium-activated chloride channel. SCAN, small conductance Ca2+-activated cation channel. GIST, gastrointestinal
stromal tumors. HNSCC, head and neck squamous cell carcinoma. GDD, gnathodiaphyseal dysplasia type 1. LGMD2L, limbgirdle muscular dystrophy. MMD3, Myoshi myopathy type 3. CNS, central nervous system. PNS, peripheral nervous system.
DRG, dorsal root gangion. LOF, loss of function. GOF, gain of function. ICC, interstitial cells of Cajal. SMC, smooth muscle
cell. MMR, Measles, Mumps, Rubella.
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1.2.2 TMEM16A Function
TMEM16A is solely a channel that conducts both chloride(40-42) and bicarbonate
ions(58). It is expressed in secretory epithelial cells, particularly goblet cells, and submucosal
glands, of the airway and digestive tracts; smooth muscle cells of the airway and reproductive
tracts; nociceptive neurons; and interstitial cells of Cajal in the intestine (41, 51-57). TMEM16A
plays a role in gland secretion, intestinal motility, smooth muscle cell contraction and neuronal
excitability (43, 52, 55). TMEM16A has been implicated in airway disease (asthma (61, 74)) and
cancers (71-73). Particularly in mucosal epithelial cells, Th2 cytokines IL-4 and IL-13 can
induce the expression of TMEM16A (40, 89-91).
Of concern for mammalian studies regarding TMEM16A, mice appear to be more
dependent on TMEM16A for chloride secretion(92). Unlike in humans, deletion of CFTR in
mice does not produce the pulmonary aspects of disease (though the digestive impairments do
develop)(93), and this is thought to be due to the high expression and significant contribution
(compared to humans) of TMEM16A to epithelial transport in mice(92). Rather, TMEM16A –/–
mice also develop excessive mucus in the airways (56) and have impaired mucociliary transport
(94), much like human CF patients. In mice, TMEM16A appears to be required for tracheal
development, as whole body TMEM16A knockout in mice results in tracheomalacia, or collapse
of the trachea, which appears to be due to poorly developed ventral cartilaginous rings that keep
the trachea patent (95).
As a surface localized ion channel, TMEM16A must traffic through the cell to reach its
final destination at the cell surface. Indeed, work by our group suggests that TMEM16A
trafficking plays an important role in its regulation. The TMEM16A regulator CLCA1 (discussed
more below) prevents internalization of TMEM16A channels from the surface and treatment of
HEK293T cells with nocodazole, which inhibits internalization of plasma membrane proteins,
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increased endogenous TMEM16A surface localization (96). Though few studies have
investigated the trafficking of TMEM16A, a report by Hu et al. (97) demonstrates that
TMEM16F is trafficked to Rab7+ late endosomes, and this may be part of its functional
regulation. Likewise, TMEM16A may be regulated in this way. In unpublished preliminary
experiments, TMEM16A also localizes to Rab7 late endosomes with very little co-localization
with Rab5 early endosomes (data not shown).

1.2.3 Structure of TMEM16A
Until 2014, no structure of a TMEM16 family member was available. The Dützler group
produced the first structure of a TMEM16 member with the X-ray crystal structure of
nhTMEM16, a lipid scramblase from fungus Nectria haematococca, at 3.3 Å. The scramblase
crystallized as a dimer, and each monomer contained 10 transmembrane helices. Each subunit
contained a pore for scrambling. As expected for a lipid scramblase that must be in contact with
lipids in the bilayer, the pores were partially exposed to the membrane. Two sites of strong
density within the membrane correspond to the calcium binding sites that regulate the
scramblase.
In 2017, the Dützler (46, 47) and Jan (98) groups reported structures for mouse
TMEM16A (mTMEM16A) isoform abc (discussed further below), both determined by cryoelectron microscopy (cryo-EM) to 3-4 Å. The Düztler group used detergent solubilized
mTMEM16A, and the Jan group used both detergent solubilized and nanodisc-incorporated
mTMEM16A. In comparing the two structures, the transmembrane helices are in excellent
agreement. Like the fungal TMEM16, mTMEM16A is a homodimer consisting of 10
transmembrane helices with a dimerization interface formed by α-helix 10. Each subunit
contained a pore completely closed off from the membrane, and each subunit had two
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electronegative sites for calcium ion binding. However, there are some differences between the
two structures. The final 53 amino acids of the C-terminus of TMEM16A is missing in the
structure by the Jan group (because it improved stability for purification), and the extracellular
loops in both structures are in poor agreement, which might be expected given that these portions
may be less ordered. To date, human TMEM16A structure has yet to be published. Mouse and
human TMEM16A (abc) are 89.67% identical. Furthermore, the extracellular loops in
TMEM16A, which are in poor agreement or poorly defined in the mTMEM16A structures, will
be of particular importance for a regulator that binds to the extracellular face of the channel.

1.2.4 TMEM16A isoforms
Different isoforms of TMEM16A are known to be expressed in different tissues and cell
types, due to alternative splicing. The isoforms are distinguished by their inclusion of different
exons into the final transcript and the presence or absence of these segments imparts different
properties or regulation to the channel. Each of these segments is cytosolic(43, 54). Exon 1, or
segment a, specifies amino acids 1-116 (of the full protein TMEM16A abcd, consisting of 1008
amino acids). Skipping this exon may result in usage of a second start site at residue 117, but
non-canonical start codons may allow a portion of segment a to be included (40, 43, 99). The
alternative promoter is not evolutionarily conserved and is likely restricted to rare cell types or
developmental periods (100). Exon 6b, or segment b, specifies amino acids 268-289. When this
segment is missing, TMEM16A has decreased calcium sensitivity and is less likely to inactivate
at high Ca2+ concentrations (100, 101). This segment is also thought to mediate calmodulin
binding, due to a predicted non-canonical calmodulin binding site (102). It may also contain
some phosphorylation sites and is highly basic(43). However, there is debate about whether
TMEM16A is regulated by calmodulin (103). Exon 13 corresponds to segment c, a short
14

sequence of four amino acids from 470-473. It is well established that this sequence, along with
four preceding glutamates, regulates voltage dependence and calcium sensitivity (100, 104).
Exon 13 is rarely absent in endogenous TMEM16A transcripts(100). Exon 15, or segment d,
corresponds to amino acids 498-523. It is not clear what the role of this segment may be, but
TMEM16A without segment d is reported to have altered activation kinetics (105). Interestingly,
it appears that the presence of exon 6b is associated with the exclusion of exon 15 and vice versa:
if segment b is present, segment d is usually absent and vice versa (100, 106).
Tissues vary in their expression of TMEM16A isoforms. In mouse smooth muscle cells,
TMEM16A isoform abc (64.5%) and acd (25.8%) were most common, followed by ac (4.8%)
and abcd (4.8%) (107). Ferrera et al. (100) assessed the inclusion of segments b, c and d in
whole normal human tissue by RT-PCR. For the lung, exon 6b was nearly always present, but
missing in a minor amount; exon 13 is always present; and exon 15 was nearly always absent,
but with a minor amount present. Thus, TMEM16A isoform abc is most likely to be present in
the lung (as reported by Caputo et al. in the initial identification of TMEM16A from airway cells
(40)). However, minor amounts of isoforms ac, acd or abd (though this last option is unlikely)
may be present. As this was an assessment of whole tissue, it is unclear whether the different
lung cell types (airway epithelial cells, smooth muscle cells, goblet cells, etc) vary in their
isoform expression. Whether diseased tissue (such as CF airway) expresses different isoforms is
also unclear.

1.2.5 Attempts to activate TMEM16A in cystic fibrosis
Before the discovery of TMEM16A as a calcium activated chloride channel, attempts
were made to activate a CaCC in cystic fibrosis by increasing intracellular calcium influx with
denufosol and duramycin. These drugs nonspecifically activated TMEM16A(12), and
15

presumably a host of other calcium-dependent pathways. In clinical trials, these attempts failed
to resolve cystic fibrosis disease, likely because they were non-specific and had a short half-life
(36-39). With the identification of TMEM16A as a major CaCC, especially in the airway, others
have proposed activation of this source of alternate anion current to compensate for lack of
CFTR function in cystic fibrosis (12, 35). Some activators of TMEM16A have been published
(108) but not developed for use in treating CF disease. Indirectly, in a study by Romani et al.
(109), activation of TMEM16A via upregulation of its regulator CLCA1, itself upregulated by
the use of thymosin α1, was shown to be therapeutic in a CF mouse model and cells from CF
patients. More directly, blocking miRNA targeting TMEM16A has also been used to increase its
expression and total activity in human airway cultures (110). To date, TMEM16A activation via
direct modulation of its trafficking has not been published.

1.3 CLCA1
1.3.1 CLCA Family History and Identity
The calcium-activated chloride channel regulator (CLCA) family was originally thought
to be a family of chloride channels. Expression of these proteins in Xenopus oocytes (111) and
HEK293T cells(112) demonstrated anion currents, and their high sequence identity with putative
anion channels in bovine trachea (113) suggested that these proteins were themselves calcium
activated chloride channels. Flawed hydropathy analysis indicating transmembrane segments in
CLCA proteins (111, 112) seemed to further support the idea that this family was a class of ion
channels. This idea was later corrected with the recognition that the structural domains in CLCA
family members predicted a soluble von Willebrand type A domain within the predicted
transmembrane segments, with at most a single transmembrane segment at the C terminus (114).
Along with experiments demonstrating that human CLCA1 and mouse CLCA1 are indeed fully
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secreted proteins unattached to the membrane (115), the CLCA family was finally predicted to
be a family anion channel regulators and not the long sought after calcium activated chloride
channels themselves. Furthermore, Whittaker and Hynes (114)predicted that CLCA members
are likely to be very similar to the α2δ subunits of calcium channels. The α2δ proteins are
proteolytically processed into two subunits (like CLCA members, see next section on structural
domains) that remain attached by a disulfide bond and together regulate ion channel activity. Our
group went on to demonstrate that human CLCA1 is self-cleaving (116) and that it potentiates
chloride currents through the true calcium activated chloride channel (CaCC), TMEM16A (117).
To date, the CaCC targets for the remaining human CLCA members, hCLCA2 and hCLCA4,
have not been identified.

1.3.2 CLCA Structural Domains
CLCA proteins contain three major domains, from the N-terminus to the C-terminus: a
zincin metalloprotease-like (MMP-L) domain, a von Willebrand type A (vWA) domain and a
fibronectin III (FnIII) domain (Figure 1).

17

Figure 1 Domain architecture of the human CLCA family
Domain architecture schematic of full-length human CLCA1, CLCA2 and CLCA4. Labels
denote the following domains: CAT, matrix-metalloprotease-like catalytic domain; Cys, matrixmetalloprotease-like cysteine-rich region; vWA, von Willebrand factor type A domain; FnIII,
fibronectin type III domain; TM, transmembrane segment. GPI, glycosylphosphatidylinositol
anchor. Numbers above the domains indicate approximate domain boundaries. Dashed line
indicates cleavage site. Reproduced from Sala-Rabanal et al. 2015 (118).
Zincin Metalloprotease-Like Domain
CLCA proteins were suspected to carry a zincin metalloprotease based on a
bioinformatics approach of a cysteine-rich region within the N-terminus(119). This region
contains 8 invariant cysteines (Figure 1), 2 of which are in the catalytic domain and likely to be
disulfide bonded since these proteins are secreted, making it probable that they are related to the
ADAM family of zincin metalloproteases, which also contain disulfides in their catalytic
regions(116). Since it was known that CLCA proteins are proteolytically cleaved(114, 115), our
group demonstrated that this metalloprotease domain is active and responsible for self-cleavage
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of CLCA proteins between the vWA and FnIII domains into a ~70 kDa N-terminal CLCA1 (NCLCA1) fragment and a ~40 kDa C-terminal CLCA1 (C-CLCA1) fragment. Mutation of the
catalytic histidine (H156A) or of the catalytic glutamade (E157Q) renders the metalloprotease
inactive. Furthermore, our group also demonstrated that this cleavage regulates CLCA1
potentiation of chloride currents (116).
Von Willebrand Type A Domain
Von Willebrand type A (vWA) domains are protein-protein interaction domains found in
a wide variety of proteins including those that function in cell-cell adhesion (collagens,
integrins), ion channel regulation (α2δ subunits of voltage gated calcium channels), clotting (von
Willebrand Factor), complement, anthrax toxin receptors (TEM-8 and CMG2), intracellular
DNA-associated proteins (Ku10/80 DNA helicases, transcriptions factors), and others.
Structurally, vWA domains adopt a Rossman fold – a β-sheet surrounded by α helices. A
common feature of vWA domains is a metal-ion dependent adhesion site (MIDAS), a series of 5
residues consisting of a DXSXS motif, followed by a threonine and finally a second aspartate.
MIDAS residues chelate divalent cations, typically magnesium and sometimes calcium, and
together mediate the interaction of vWA domains with their ligands(114). It is proposed that the
presented divalent cation would bind to an acidic residue (glutamate or aspartate) within the
ligand. Based on crystal structures of vWA domain containing proteins with or without ion and
with or without ligand, some propose an additional step in which a basic residue would displace
the divalent cation in a final step of interaction with the ligand, a hypothesis which could explain
scenarios in which binding occurs in a cation-independent fashion (120). Additionally, some
vWA domains may bind in a MIDAS-independent fashion (121) (i.e., at a site other than the
MIDAS). Furthermore, not all vWA domain-containing proteins contain this exact sequence
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(often referred to as an imperfect MIDAS versus a perfect MIDAS), and a perfect MIDAS is not
required for ligand interaction and function (as is the case for von Willebrand Factor
proteins)(114). In cases where ligand interaction is MIDAS-independent, it is possible that other
nearby residues complete coordination of the divalent cation or could potentially substitute for it
altogether.
Most CLCA proteins contain a vWA domain, with the exception of the shorter CLCA
members (for example, hCLCA3 and mCLCA4C, considered to be pseudogenes since they are
truncated near the C-terminus of the MMP-L domain) (Figure 2). Most CLCA vWA domains
from human, mouse and pig contain perfect MIDAS motifs. CLCA2 proteins, however, have
only 2/5 MIDAS residues. Within CLCA vWA domains, there are three invariant cysteines. As
CLCA proteins are secreted, this would suggest that two of these are involved in a disulfide
bond, leaving one cysteine free. Disulfide bonds in vWA domain structures are exceedingly
rare(122-124), and the significance of a disulfide bond, and of the invariant cysteines in the
CLCA family in general, is unclear.
As hCLCA1 is a multidomain protein, any one or more of the domains could be
responsible for driving calcium activated chloride currents. Our group demonstrated that
CLCA1 potentiated chloride currents through CaCC TMEM16A (117) and also identified the
vWA domain of CLCA1 as necessary and sufficient to potentiate those currents (96). Using an
antibody against the extracellular α9- α10 loop of TMEM16A (the longest extracellular loop of
TMEM16A) prevented N-terminal CLCA1 from binding to cells endogenously expressing
TMEM16A(117). Because vWA domains are protein-protein interaction domains, this would
suggest that vWA domain of CLCA1 binds to TMEM16A to modulate chloride current.
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(Figure legend on the following page)
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Figure 2 Sequence alignment for human, mouse and pig CLCA vWA domains
Annotated sequence alignment for human, mouse and pig CLCA vWA domains. Numbering
corresponds to the sequence of human CLCA1. Secondary structure of human CLCA1 is labeled
above. A solid line indicates the disulfide bond observed in the crystal structure. Stars next to the
sequence indicate that the vWA domain contains an imperfect MIDAS (114). Sequences are
shown for hCLCA1 (NM_001285.3), pCLCA1 (NM_214148.1), mCLCA1 (NM_017474.2),
hCLCA4 (NM_012128.3), pCLCA4a (XM_001926978.5), pCLCA4b (XM_003125934.5),
mCLCA4a (NM_207208), mCLCA4b (NM_001033199), hCLCA2 (NM_006536.6), pCLCA2
(XM_003125930.4), mCLCA2 (NM_178697.5), mCLCA3b (NM_139148), mCLCA3a1
(NM_009899), and mCLCA3a2 (NM_030601) (where h = human; p = pig; m = mouse).
Sequence conservation is color coded as follows: magenta, invariant residues (with the exception
of cysteine and invariant MIDAS residues); green; invariant cysteines; yellow, residues with a
global similarity score of 0.75 or higher as determined by ESPript 3.0 software (125); blue,
perfect MIDAS residues; cyan, imperfect MIDAS residues. Black boxes indicate the most
strongly predicted sites of N-linked glycosylation by NetNGlyc 1.0 software (126). The
predicted α6 helix (JPRED4 (127)) of CLCA1 vWA domain is labeled above the alignment in
red. MIDAS residues are highlighted in purple. Invariant cysteines are labeled in yellow.
Reproduced from Berry KN, Brett TJ. 2020(128).
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However, no evidence of direct binding between CLCA1 and TMEM16A has been
demonstrated.
Fibronectin III Domain
Fibronectin III (FnIII) domains are also protein-protein interaction domains belonging to
the immunoglobulin superfamily, often found in cell surface and extracellular matrix
proteins(129). A well-known ligand of the fibronectin III domain 10 (for which this domain is
named) is β1 integrin(130). The role for this domain in the CLCA family has not been defined.
However, given that fibronectin domains often interact with integrins, which are well known for
their cell-surface signaling activities, it is possible that the FnIII domain in CLCA1 may bind to a
cell-surface receptor(s) to mediate signaling. In asthma and chronic obstructive pulmonary
disease (COPD), CLCA1 is thought to drive mucus hypersecretion via mucus cell metaplasia
(MCM) (131, 132). Therefore, the FnIII domain may be responsible for this activity.
Furthermore, as noted above, integrin vWA domains are some of the best studied in the
family(114). Thus, an interaction between a FnIII domain and a vWA domain is conceivable.
Our group hypothesizes that this FnIII domain in the full-length, uncleaved CLCA1 protein may
initially shield the vWA domain from interaction with TMEM16A. Full-length CLCA1 that is
proteolytically inactive (containing H156A or E157Q mutations) or that cannot be cleaved
(containing mutations to the cleavage sequence) is unable to potentiate TMEM16A currents. Yet,
an N-terminal CLCA1 that is proteolytically inactive is still capable of modulating chloride
current (116). Thus, 1) CLCA1 cleavage is necessary for potentiating TMEM16A currents, 2)
metalloprotease activity itself is likely not responsible for the chloride currents, and finally 3) the
FnIII domain may be blocking the vWA domain from accessing TMEM16A.
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Membrane Anchors
CLCA1 is a fully secreted protein. Yet, other CLCA proteins are associated with the
membrane. In the human CLCA family, CLCA4 is predicted to be anchored to the surface by a
glycosylphosphatidylinositol (GPI) anchor at the C-terminus. CLCA2 is predicted to have a
single transmembrane segment at the C-terminus, following the FnIII domain(129). Cleavage
between the vWA and FnIII domains, however, would release the N-terminal CLCA2 or CLCA4
fragments from the surface, while the C-terminus would remain attached to the membrane.

1.3.3 Function and Mechanism of CLCA1
CLCA1 was known to potentiate chloride currents in model systems (Xenopus,
HEK293Ts). As noted previously, it was thought that CLCA1 was itself a chloride channel (112,
113). However, a number of later predictions and experiments would follow that would show
this to be incorrect(114, 115), including a publication by our group identifying the true chloride
channel in that system to be TMEM16A(117). Our group then identified a mechanism by which
CLCA1 modulates TMEM16A currents. CLCA1 polypeptide is produced within the cell and the
metalloprotease domain within the N-terminus of CLCA1 cleaves full-length CLCA1 into NCLCA1 and C-CLCA1 by time CLCA1 is secreted into the extracellular milieu(116). The
cleavage of CLCA1 regulates its activity, but what governs the cleavage is unclear. The vWA
domain within N-CLCA1 is then free to interact in a paracrine fashion with TMEM16A on the
cell surface, likely binding to the α9- α10 extracellular loop of TMEM16A. This interaction
prevents the internalization of TMEM16A into the cell and increases the density of channels on
the surface, resulting in increased anion currents observed in cellular studies(96, 117). In
addition to its role as a calcium channel regulator, there have been a few reports that CLCA1 can
induce airway macrophages to release pro-inflammatory cytokines such as IL-1b, IL-6, TNFa
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and IL-8(133). These experiments were performed in cultured macrophage lines, and the in vivo
relevance is unclear. In humans, CLCA proteins are largely expressed at mucosal surfaces, and
some are expressed in neuronal tissue (129, 134) (Table 2).
Table 2 Tissue expression of the human CLCA family
Gene
hCLCA1
hCLCA2
hCLCA4

Expression
Small intestine, colon(134), airway mucus cells(131, 135), intestinal goblet cells,
basal crypt epithelial cells(136), uterus, stomach, testis, kidney, fetal spleen(137),
brain(138)
Airway epithelial cells(131, 134), trachea, breast, uterus, prostate, kidney, testis,
brain (134, 137, 139), conjunctival and corneal epithelium(140), nasal
epithelium(141), skin, vagina, esophagus, larynx(142, 143)
Airway epithelial cells(131, 134), brain, colon, bladder, uterus, prostate, stomach,
testis, salivary gland, breast, small intestine, appendix, trachea(134, 137), nasal
epithelium(141)

1.3.4 CLCA1 in human airway disease
In the human airway, CLCA1 is not endogeneously expressed, though it is expressed at
baseline in the small intestine and colon. In contrast, CLCA2 and CLCA4 are expressed in
normal human airway(131, 134). Instead, CLCA1 expression in the lung is known to be driven
by IL-13, whereas CLCA2 and CLCA4 expression are not induced by this Th2 cytokine(131).
Thus, it is not surprising that patients with asthma have increased CLCA1 expression in the
tissue (135) and increased CLCA1 protein in bronchoalveolar lavage fluid (BALF) (115).
CLCA1 is also found elevated in patients with chronic obstructive pulmonary disease
(COPD)(131). In asthma and COPD, CLCA1 is thought to drive mucus hypersecretion via
mucus cell metaplasia (MCM) (131, 132), and possibly also drives airway hyperreactivity (AHR,
smooth muscle contractions) (132). In patients with cystic fibrosis, CLCA1 single nucleotide
polymorphism (SNP) S357N has also been associated with aggravated meconium ileus(144)
lending evidence to the hypothesis that other genes may modify the cystic fibrosis phenotype.
The mechanisms behind these links have not been elucidated.
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1.4 Summary of the literature and goals of the project
1.4.1 Summary
Cystic fibrosis (CF) is a fatal genetic disorder resulting from loss of function mutations in
CFTR, an anion channel that conducts chloride and bicarbonate ions. The loss of these ions in
the mucus layer results in sticky mucus in the lungs that cannot be cleared and allows infection
to develop. Patients with CF therefore suffer from frequent pulmonary infections that can be lifethreatening. TMEM16A has long been proposed as a therapeutic target for cystic fibrosis. Its
ability to conduct chloride and bicarbonate ions makes it an ideal surrogate for inadequate CFTR
activity in cystic fibrosis. This approach would make it possible to treat CF patients regardless of
the mutation present (of which thousands exist) or regardless of a patient’s response to available
CFTR specific therapies. For those CF patients whom CFTR specific therapies are effective, this
approach could provide an additional means of improving disease outcomes.
Our lab has identified CLCA1 as a secreted regulator of TMEM16A chloride currents.
CLCA1 is a multi-domain protein that cleaves itself into two fragments as a means of regulating
its activity. Its vWA domain interacts with an extracellular loop on TMEM16A channels that
arrive at the cell surface and prevents the channels from being internalized into the cell. This
increases the density of TMEM16A on the surface and results in increased anion currents
through the cell. A detailed molecular understanding of this interaction may inform therapies
based on the TMEM16A-CLCA1 interaction but has yet to be established. To date, mouse
TMEM16A cryo-EM structures have been published. No structure of the CLCA family has been
reported. Furthermore, the effects of CLCA1 on CF airway has not yet been demonstrated. Thus,
the following two goals were outlined for this dissertation.
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1.4.2 Goals
1) Structural model of CLCA1 and TMEM16A
The first goal of this project is to determine a structure of human CLCA1, TMEM16A
and the two in complex to better understand the molecular determinants of the interaction. This
understanding will be important if a therapy based on the CLCA1-TMEM16A interaction were
to be developed for cystic fibrosis. In addition, a biophysical characterization of this interaction
will shed light on the thermodynamics and kinetics of this interaction.
2) Effects of CLCA1 on TMEM16A currents and mucociliary properties of cystic fibrosis airway
The second goal of this project is to determine whether CLCA1 could potentiate
TMEM16A currents in cystic fibrosis airway, and, if so, whether healthy mucus properties could
be restored. A determination of the expression and localization of TMEM16A in cystic fibrosis
airway was also pursued to demonstrate the feasibility of such an approach.
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Chapter 2: Expression, purification,
crystallization and structure of CLCA1
vWA domain
Portions of this chapter are taken from a manuscript published in Cell Reports: Berry KN and
Brett TJ. “Structural and Biophysical Analysis of the CLCA1 VWA Domain Suggests Mode of
TMEM16A Engagement.” Cell Rep 30(4): 1141-1151.e1143.
I would like to acknowledge Monica Sala-Rabanal, who performed the whole cell patch clamp
experiments that made many of the experiments included in this chapter possible.
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2.1 CLCA1 vWA potentiates TMEM16A currents through
the MIDAS
2.1.1 CLCA1 vWA domain is necessary and sufficient to potentiate
TMEM16A currents
As CLCA1 is a multi-domain protein, a number of mechanisms could be postulated for
how it drives calcium activated chloride currents through TMEM16A. In order to narrow down
potential mechanisms, CLCA1 constructs containing various combinations of the domains were
developed. The results of these experiments demonstrated that the vWA domain alone of CLCA1
was necessary and sufficient to potentiate TMEM16A currents and drive surface localization of
TMEM16A (1).

2.1.2 CLCA1 vWA domain potentiates TMEM16A currents within minutes
Previous experiments with CLCA1 demonstrated that currents could be potentiated with
overnight exposure of HEK293T cells to CLCA1(1-3). In order to identify a potential
mechanism by which CLCA1 potentiated TMEM16A currents and to determine the minimum
timescale by which it has its effect, the follow experiment was pursued.
Purified CLCA1 vWA domain (297-478) was used to treat HEK293T cells in a whole
cell patch clamp ramp protocol. Expi293 cells were cultured at 37 ºC and 8% CO2 in serum-free
Expi293 Expression Media (ThermoFisher Scientific) supplemented with 0.5%
penicillin/streptomycin (Pen/Strep, Gibco) WT human CLCA1 vWA domain (297-478) was
expressed in Expi293 cells via transient transfection with either Hype-5 or Hype-293 (OZ
Biosciences, San Diego, CA) at a 1:1.5 ratio (μg of DNA: μL of transfection reagent) using 1 μg
of plasmid per 1 million cells, similar to our previous reports (4). Media from supernatants were
harvested after 72-120 hours by centrifugation, concentrated to 1/10 of the original volume using
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a 10 kDa cutoff membrane (Ultracel Ultrafiltration Discs, EMD Millipore) and adjusted to pH
8.5 and 5 mM imidazole. The concentrated protein was purified using Ni-NTA Superflow resin
(Qiagen, Hilden, Germany) and eluted in 5 mL of buffer containing 50 mM K2HPO4 (pH 8), 300
mM NaCl, and 250 mM imidazole. The eluted protein was concentrated and purified by size
exclusion chromatography using the Superdex75 Increase 10/300 GL (GE Healthcare) in 20 mM
Tris pH 8.0 and 150 mM NaCl. Purified CLCA1 vWA was dialyzed into buffer containing 20
mM HEPES (pH 7.4) and 150 mM NaCl and concentrated in a 10 kDA cutoff centrifuge
concentrator (Vivaspin 500, Sartorius) to 1 mM as calculated from absorbance at 280 nm.
Dialysis buffer was used as the control treatment.
Purified CLCA1 vWA domain (5 μM) or buffer control was a applied to untransfected
HEK293T cells and a descending ramp protocol applied after establishment of whole cell
configuration, and currents recorded every 10 seconds by Monica Sala-Rabanal. Exposure to
CLCA1 vWA domain potentiated currents on the order of minutes compared to buffer control
(Figure 3). This suggested that CLCA1 likely does not have its effect by increasing TMEM16A
expression (also shown in Yurtsever et al. 2015(3)). Instead, this lent support to the hypothesis
that CLCA1 affected TMEM16A trafficking. Furthermore, in potentially applying CLCA1 in a
translational context, it is likely to have a quick effect on a tissue of interest.
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Figure 3 Purified vWA domain activates TMEM16A currents minutes after application
Purified vWA domain (5 μM) or buffer was applied to untransfected HEK293T cells, a
descending voltage ramp protocol applied after establishment of whole cell configuration, and
currents recorded every 10 seconds. Current density at +80 mV at 0, 1, 3, 5, 7, and 9 minutes are
shown here. Performed in conditions of symmetric chloride and 10 μM intracellular Ca2+.
Reproduced from Sala-Rabanal, Yurtsever, Berry et al. JBC 2017 (1).

2.1.3 CLCA1 potentiation of TMEM16A currents is MIDAS and Mg2+
dependent
The minimal domain of CLCA1 necessary to potentiate currents through TMEM16A is
the vWA domain (1). Most vWA domains mediate their effects through a metal ion dependent
adhesion site (MIDAS). The five residues that make up the MIDAS (DXSXS motif, threonine
and aspartate) chelate a divalent cation that binds to an acidic residue in the ligand. Mutation of
these residues or chelation of the divalent cation impedes the binding and function of many vWA
domains (5). To determine whether CLCA1 vWA domain is dependent upon the MIDAS,
mutations to CLCA1 vWA MIDAS residues were developed and Mg2+ chelation also employed.
The following mutants were generated using QuikChange Lightning (Agilent) of the
CLCA1 vWA domain: D312A/S314A, D312A/S314A/S316A, D312A/S314A/D412A,
D312A/S314A/S316A/T383A, D312A/S314A/S316A/D412A. As many of these mutants were
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not efficiently expressed and secreted, transfection conditions were optimized to ensure that all
mutants were expressed at levels similar to WT conditions. Conditioned media was generated by
expressing human CLCA1 vWA domain WT (297-478), mutants, (D312A/S314A,
D312A/S314A/S316A, D312A/S314A/D412A, D312A/S314A/S316A/T383A,
D312A/S314A/S316A/D412A) or vector control (pHLsec) in HEK293T cells. In chelation
experiments, conditioned media was generated using WT CLCA1 vWA domain (297-478) or
vector control (pHLsec). Cells were cultured in DMEM (Gibco) supplemented with 1%
penicillin/streptomycin (Gibco), 1% non-essential amino acids (NEAA) (Gibco), 1% glutamine
(Gibco) and 10% fetal bovine serum (FBS). Expression was achieved by transfection using
293Fectin at a ratio of 1:2 (μg of DNA: μL of transfection reagent, using 1 or 2 μg of DNA) on
cells plated to 70-90% confluency in 6 well plates for 48 hours. After expression, media was
cleared by centrifugation. Another set of HEK293T cells were then plated to 5-10% confluency
in cleared conditioned media overnight onto 8 mm cover glass (Electron Microscopy Sciences).
Currents were measured by whole cell patch clamp electrophysiology performed by Monica
Sala-Rabanal. For chelation experiments, Mg2+ was chelated using EDTA.
For immunofluorescence, cells were either transfected or exposed to conditioned medium
as described above. Cells were fixed for 5 minutes on glass slides with 4% paraformaldehyde
and blocked for 1 hour at room temperature with 1% blocking solution (Life Technologies).
Cells were incubated in goat anti-human- TMEM16A antibody S-20 (Santa Cruz) at 4 ºC
overnight followed by donkey anti-goat IgG-Alexa Fluor 594 (1:200, Life Technologies)).
Washed slides were then mounted in Vectashield H-1200 mounting medium with DAPI (Vector
Laboratories). Confocal microscopy was carried out using a Zeiss LSM 880 confocal laserscanning microscope with Airyscan (Carl Zeiss Microscopy). The images were acquired and
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batch-processed with Zen software (Carl Zeiss Microscopy). For each experiment, all cells were
treated on the same day and fixed, stained and imaged in parallel using the same acquisition and
display settings.
Chelation of Mg2+ abrogated the potentiation of TMEM16A by CLCA1 (Figure 4). In
addition, mutations to the MIDAS, and in particular mutants D312A/S314A/S316A,
D312A/S314A/S316A/D412A and D312A/S314A/S316A/T383A, also abrogated these currents
and reduced TMEM16A surface localization. Based on these observations, T383 and S316 are
likely key CLCA1 MIDAS residues contributing to the interaction with TMEM16A. Together
these experiments indicate that CLCA1 mediates potentiation of TMEM16A via its MIDAS.
These experiments showed that the MIDAS motif residues and the divalent cation that
these residues chelate within the vWA domain were important in driving TMEM16A currents
and surface localization of the channel (Figure 4). These experiments demonstrated the
importance of the vWA domain as important to the CLCA1-TMEM16A interaction. In order to
simplify attempts to determine the structure of CLCA1, the vWA domain was cloned and
expressed for structure determination studies.
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Figure 4 CLCA1 vWA potentiation of TMEM16A currents in MIDAS-dependent
A) Phyre2 model of the CLCA1 MIDAS. B,C) Currents in HEK293T cells in media from cells
expressing CLCA1 vWA domain (vWA) or vector control (pHLsec) measured by whole-cell
patch clamp in 1 mM Mg2+ or Mg2+ conditions. Example traces are shown in (B). (C) Current
density at +100 mV in HEK293T cells from (B). D,E) Currents in HEK293T cells in media from
cells expressing CLCA1 vWA domain mutants, WT vWA domain or vector control (pHLsec)
measured by whole-cell patch clamp. Example traces are shown in (E). Current density at +100
mV in HEK293T cells from (D). F) Confocal microscopy of TMEM16A (red) in vector, WT or
MIDAS mutant vWA conditioned medium. Reproduced from Sala-Rabanal, Yurtsever, Berry et
al. JBC 2017 (1).
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2.2 Expression and purification
2.2.1 Expression of CLCA1 vWA domain in bacterial systems
Cloning human CLCA1 vWA domain for bacterial expression
Human CLCA1 vWA domain (302-476) was amplified from pHLsec constructs
containing the full CLCA1 gene and subcloned into pet23b vectors using NheI and XhoI for
expression in E. coli. No tag was included. Unless indicated, all CLCA1 constructs contained the
S357 variant (and are referred to as the wild-type variant). The predicted molecular weight of
this domain in this vector is 18.547 kDa.
Expression and purification of CLCA1 vWA domain from bacteria
CLCA1 is a secreted protein with many cysteines that are likely to form disulfide bonds.
Thus, Human CLCA1 vWA domain was expressed as inclusion bodies in Rosetta2 (DE3) cells.
After transformation, single colonies were selected and starter cultures grown overnight under
antibiotic selection (25 μg/mL chloramphenicol and 100 μg/mL carbenicillin). Starter cultures
were used to inoculate 4-12 L of Luria Broth (LB) media. Cultures were grown to an OD600 of
~1.0 and induced with 0.5 mM Isopropyl β-D-1-thiogalactopyranoside (IPTG) at 37 ºC for 4
hours.
After pelleting cultures, insoluble were harvested. Cell pellets were resuspended in Lysis
Buffer containing 50 mM Tris pH 8.0, 12.5% sucrose, 50 mM NaCl, and 0.5 mM
ethylenediaminetetraacetic acid (EDTA), 1.0 % Triton X-100, fresh 10 mM dithiothreitol (DTT),
0.5 mg/mL lysozyme and 2 mg DNAse. Cells were lysed by sonication for 30 seconds at power
8 on ice, centrifuged at 10,000 rpm (in a Sorvall RC 6 plus centrifuge, 6x250 fiberlite rotor) for
10 min at 4 ºC, and inclusion bodies subjected to three washes in 50 mM Tris pH 8.0, 100 mM
NaCl, 1 mM EDTA, 1 mM DTT and 0.5% Triton X-100 before a final wash in the same buffer
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without Triton X-100 and without EDTA (to avoid divalent cation chelation from vWA domain
in later steps).
Refolding CLCA1 vWA domain from inclusion bodies
To refold, inclusion bodies were solubilized in 6 M guanidine hydrochloride (GuHCl), 20
mM β-mercaptoethanol (β -ME), and 10 mM Tris pH 8.0. Inclusion bodies were added over 4
hours to filtered, pre-chilled buffer of 100 mM Tris pH 8.5, 400 mM arginine, 10 mM CaCl2, 20
mM phenylmethylsufonyl fluoride (PMSF), 2.5 mM reduced glutathione and 0.25 mM oxidized
glutathione, and allowed to refold overnight at 4 ºC. After refolding, the solution was
concentrated over a 10 kDa filter (Amicon and EMD Millipore) and insoluble aggregates were
removed by filtration through a 0.22 μm filter and properly folded CLCA1 vWA domain
retrieved by size exclusion chromatography using a Superdex75 16/600 column (GE Healthcare)
in 20 mM Tris pH 8.0 and 150 mM NaCl. The peak eluted at ~12.4 mL, which corresponded to
an approximate size of 19 kDa (Figure 5). This peak was diluted to 10 mM NaCl in 20 mM Tris
pH 8 and purified on a MonoQ type column (GE Healthcare) with a gradient of 500 mM NaCl in
40 mL. Two peaks eluted around 25.2 and 31.9 mS/cm conductivity, the first peak being much
larger than the second. Both peaks appear identical by SDS-PAGE. The significance of two
peaks from one size exclusion peak is not clear but could potentially be one vWA domain
species bound to metal and one species not bound to metal (Figure 5). The first peak was
concentrated in a 10 kDa centrifuge concentrator and dialyzed in 20 mM HEPES pH 7.5 and 150
mM NaCl. Yields were typically ~5-7 mg of protein per 2 L expression.
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Figure 5 Purification of CLCA1 vWA domain from bacterial system
A) Inclusion body preparation of CLCA1 vWA refold. Pre-induction, E. coli sample before
induction. Post-induction, E. coli sample after induction. Lysate, E. coli sample after expression
and lysis. W1-W4, washes 1-4. Inclusion body, inclusion body sample after washes. B) SDSPAGE of size exclusion chromatography (s75) of CLCA1 vWA expressed in E. coli after
refolding. Input, sample of refolded CLCA1 vWA loaded onto the size exclusion column,
followed by fractions of the size exclusion chromatography. Asterisk above the lanes
corresponds to the fractions from the size exclusion column in (C). C) Size exclusion
chromatography of refolded CLCA1 vWA domain. Asterisk above the peak corresponds to the
fractions of SDS-PAGE. D) MonoQ ion exchange chromatography of refolded CLCA1 vWA
domain after size exclusion chromatography. Two peaks were observed, with the second peak
being the minor peak. Numbers above the peaks correspond to the lanes on SDS-PAGE in (E).
E) SDS-PAGE of peaks from MonoQ ion exchange chromatography. Numbers above the lanes
correspond to the peaks from the MonoQ column in (D).
Expression and purification of 15N CLCA1 vWA domain from bacteria
The hCLCA1 vWA domain is small (~18.5 kDa) and amenable to structure determination by
NMR. Thus, before crystals of the vWA domain were obtained, initial NMR studies were
pursued. Refolded CLCA1 vWA domain was examined by 1H-15N NMR. Human CLCA1 vWA
domain was expressed as inclusion bodies in Rosetta2 (DE3) cells. After transformation, single
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colonies were selected and 50 mL of start culture grown in LB overnight under antibiotic
selection (25 μg/mL chloramphenicol and 100 μg/mL carbenicillin). Starter cultures (50 mL)
were used to inoculate 2 L of M9 culture media: 48 mM Na2HPO4, 22 mM KH2PO4, 8.5 mM
NaCl, 18 mM 15NH4Cl, 0.1 mM CaCl2, 1 mM MgSO4., carbenicillin, chloramphenicol, 10 mL
vitamin/L, and 0.3 % (w/v) glucose. Cultures were grown to an OD600 of ~0.8 and induced
with 0.5 mM Isopropyl β-D-1-thiogalactopyranoside (IPTG) at 37 ºC for 5 hours.
After pelleting cultures, insoluble were harvested. Cell pellets were resuspended in Lysis
Buffer containing 50 mM Tris pH 8.0, 12.5% sucrose, 50 mM NaCl, and 0.5 mM
ethylenediaminetetraacetic acid (EDTA), 1.0 % Triton X-100, fresh 10 mM dithiothreitol (DTT),
0.5 mg/mL lysozyme and 2 mg DNAse. Cells were lysed by sonication for 30 seconds at power
8 on ice, centrifuged at 10,000 rpm (in a Sorvall RC 6 plus centrifuge, 6x250 fiberlite rotor) for
10 min at 4 ºC, and inclusion bodies subjected to three washes in 50 mM Tris pH 8.0, 100 mM
NaCl, 1 mM EDTA, 1 mM DTT and 0.5% Triton X-100 before a final wash in the same buffer
without Triton X-100 and without EDTA (to avoid divalent cation chelation from vWA domain
in later steps).
Refolding 15N CLCA1 vWA domain from inclusion bodies
To refold, inclusion bodies were solubilized in 6 M guanidine hydrochloride (GuHCl), 20
mM β-mercaptoethanol (β -ME), and 10 mM Tris pH 8.0. Inclusion bodies were added over 4
hours to filtered, pre-chilled buffer of 100 mM Tris pH 8.5, 400 mM arginine, 10 mM CaCl2, 20
mM phenylmethylsufonyl fluoride (PMSF), 2.5 mM reduced glutathione and 0.25 mM oxidized
glutathione, and allowed to refold overnight at 4 ºC. After refolding, the solution was
concentrated over a 10 kDa filter (Amicon and EMD Millipore) and insoluble aggregates were
removed by filtration through a 0.22 μm filter and properly folded CLCA1 vWA domain
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retrieved by size exclusion chromatography using a Superdex75 16/600 column (GE Healthcare)
in 20 mM Tris pH 8.0 and 150 mM NaCl. The peak eluted at ~12.5 mL (Figure 6). This peak
was diluted to 10 mM NaCl in 20 mM Tris pH 8 and purified on a MonoQ type column (GE
Healthcare) with a gradient of 500 mM NaCl in 40 mL. Two peaks eluted around 29 and 34.9
mS/cm conductivity, the first peak being much larger than the second. The first peak was
concentrated in a 10 kDa centrifuge concentrator and dialyzed in 20 mM HEPES pH 7.5 and 150
mM NaCl. Yields were typically 1.5 mg/L of culture.
1

H-15N NMR of refolded hCLCA1 vWA domain
15

N-labeled and refolded CLCA1 vWA domain was diluted to 0.3 mM in 10% D2O and

examined by nuclear magnetic resonance (NMR) with the help of Dr. Chao Wu from the Gaya
Amarasinghe lab. A 2D HSQC experiment was performed at 700 MHz at 25 ºC (Figure 6).
CCPNmr was used to analyze the results. The spectrum revealed a well-folded vWA domain.
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Figure 6 Refolded CLCA1 vWA forms a well-folded domain by 2D NMR
A) Inclusion body preparation of 15N CLCA1 vWA refold. Pre-induction, E. coli sample before
induction of 15N CLCA1 vWA. Post-induction, E. coli sample after induction of 15N CLCA1
vWA. B) Size exclusion chromatography of refolded 15N CLCA1 vWA domain. C) MonoQ ion
exchange chromatography of refolded CLCA1 vWA domain after size exclusion
chromatography. Two peaks were observed, with the second peak being the minor peak. (D).
HSQC spectrum of CLCA1 vWA domain obtained at 700 MHz at 25 ºC.

2.2.2 Expression of CLCA1 vWA domain in mammalian systems
Cloning
Human CLCA1 vWA domain constructs (302-476 and 302-478) were amplified from
pHLsec constructs containing the full CLCA1 gene and subcloned into pHLsec vectors using
AgeI-KpnI restriction site cloning. The pHLsec vector contains an optimized signal sequence
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and C-terminal 6-histidine tag for purification (6). The predicted molecular weight of this
domain in this construct is 19.785 kDa.
Expression and purification of CLCA1 vWA domain from mammalian culture
Expi293 cells used for high-level protein expression were cultured at 37 ºC and 8% CO2
in serum-free Expi293 Expression Media (ThermoFisher Scientific) supplemented with 0.5%
penicillin/streptomycin (Pen/Strep, Gibco) WT human CLCA1 vWA domains (302-476 and 302478) were expressed in Expi293 cells via transient transfection with either Hype-5 or Hype-293
(OZ Biosciences, San Diego, CA) at a 1:1.5 ratio (μg of DNA: μL of transfection reagent) using
1 μg of plasmid per 1 million cells, similar to our previous reports (4). Media from supernatants
were harvested after 72-96 hours by centrifugation, concentrated to 1/10 of the original volume
using a 10 kDa cutoff membrane (Ultracel Ultrafiltration Discs, EMD Millipore) and adjusted to
pH 8.5 and 5 mM imidazole. The concentrated protein was purified using Ni-NTA Superflow
resin (Qiagen, Hilden, Germany) and eluted in 5 mL of buffer containing 50 mM K2HPO4 (pH
8), 300 mM NaCl, and 250 mM imidazole. The eluted protein was concentrated and purified by
size exclusion chromatography using the Superdex75 Increase 10/300 GL (GE Healthcare) in 20
mM Tris pH 8.0 and 150 mM NaCl (Figure 7). Purified CLCA1 vWA was dialyzed into buffer
containing 20 mM HEPES (pH 7.4) and 150 mM NaCl and concentrated in a 10 kDA cutoff
centrifuge concentrator (Vivaspin 500, Sartorius) to 12 mg ml-1, as calculated from absorbance at
280 nm, for crystallization. Yields were typically 7 mg/L culture.
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Figure 7 Purification of CLCA1 vWA domain for crystallization
A,B). Left panels, SDS-PAGE of nickel purification (Ni NTA) and size exclusion
chromatography (s75 increase) of CLCA1 vWA domain (A) residues 302-476 and (B) 302-478.
FT, flow-through. W, wash. E, elution. Asterisks above the lanes correspond to the fractions
from the size exclusion column. Right panels, size exclusion chromatography of CLCA1 vWA
domain nickel elutions. Asterisks above the peaks correspond to the fractions of SDS-PAGE. In
(A), concentrated vWA, concentrated fractions from size exclusion column used for
crystallization screens.

52

2.3 Crystallization of CLCA1 vWA Domain
2.3.1 Obtaining and optimizing CLCA1 vWA domain crystals
Crystallization screens JCSG I-IV, PEG I and II screens (Qiagen) and HR2-130 and
HR2-134 (Hampton Research) of CLCA1 vWA 302-476 were set by hanging drop using a TTP
Mosquito robot using the 100 nL protein + 100 nL well solution. Crystals were grown at 17 ºC
by hanging drop vapor diffusion. In 6 days, crystals were observed in a condition containing 0.2
M HEPES pH 7.5, 0.1 M CaCl2, 28% PEG 400 (Figure 8). Repeater trays produced the same
crystals and drops containing no protein did not produce crystals. As many microcrystals were
observed, crystal growth was controlled by streak seeding crystals into the aforementioned
condition containing 5% glycerol. Fewer, larger crystals were obtained by this method, though
crystals remained small (~100 μm). Though crystal conditions were refined, crystals grew largest
in the original crystal hit. Crystals were flash frozen under a nitrogen stream at -160 ºC. Data
were collected at the Advanced Light Source, beamline 4.2.2 (Berkeley, CA).

2.3.2 Determining CLCA1 vWA structure
Molecular Replacement
Diffraction data was scaled and processed to 2.0 Å using XDS (7) (Table 3). The space
group was C2. As a plethora of vWA domains structures are available, a molecular replacement
solution was sought initially. A Phyre2 search of the CLCA1 vWA domain provided an initial set
of potential probes for a molecular replacement solution, including vWA from Catenulispora
acidiphila (PDB: 4FXA), complement Factor B (PDB: 2OK5) and integrin αI domains (PDB:
1SHU). CCP4 programs Chainsaw and Ensemble were used to create poly-Ala models. A
molecular replacement solution was found with PHASER (TFZ = 10.2, rigid body Rwork and Rfree
of 0.2091 and 0.2462) using uncharacterized membrane spanning protein from Vibrio fischeri
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(PDB ID: 4RCK, with 28% sequence identity) as the probe, locating two molecules in the
asymmetric unit (ASU) for a solvent content of 61%.

2.3.3 Refining CLCA1 vWA structure
Refinement strategies
The initial solution was refined by rigid body refinement in PHENIX (8) and initially
built using AUTOBUILD in PHENIX (Table 3). The model was improved by iterative rounds of
manual rebuilding in COOT (9) and refinement using PHENIX. Secondary structure restraints
were used during refinement and hydrogens were added as a riding model in the final rounds.
Simulated annealing was used early in refinement, and optimization of X-ray and ADP or
stereochemistry weight was applied in later rounds. The final model is 94% complete with 17 Cterminal residues (460-476) in both chains and the first N- terminal residue (302) in chain B not
visible in the electron density. Chain A contained three N-terminal residues (ETG 299-301) that
are a remnant of the vector-encoded signal sequence (6). The model was of high quality, with an
Rwork/Rfree of 0.1987/0.2251, Molprobity score of 1.74 and clash score of 3.41. Ramachandran
statistics were 96.82% favored, 3.18% allowed and 0% outliers. The model and data were
deposited in the RCSB protein data bank (PDB ID 6PYO).
Crystallization and structure of CLCA1 vWA 302-478
In the structure building of CLCA1 302-476, it became clear that the α6 helix of the
CLCA1 vWA domain was not present in the crystal, though secondary structure predictions
using JPRED4 (10) indicates that an α6 helix should be present and those residues are present in
the construct. However, to ensure that the C-terminal boundary of the initial construct was not
preventing formation of the α6 helix, a slightly longer construct (302-478) was developed
(Figure 7). Crystals of CLCA1 vWA (302-478) were grown under similar conditions as CLCA1
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vWA 302-476 and diffracted to 2.6 Å (Table 3). The structure of CLCA1 vWA 302-478 was
solved by isostructural replacement of CLCA1 vWA (302-476), and iteratively refined and
rebuilt as for CLCA1 vWA 302-476. The final model of this longer construct consisted of
residues 302-461 (chain A) and 303-459 (chain B), but yet again, the α6 helix was not present.
Further studies by small-angle x-ray scattering were pursued to examine the peculiarity of the
missing α6 helix. For the resolution, the structure was of high quality, with an Rwork/Rfree of
0.2182/0.2787, Molprobity score of 1.86 and clash score of 8.91. Ramachandran statistics were
94.3% favored, 5.7% allowed and 0% outliers. The model and data were deposited in the RCSB
protein data bank (PDB ID 6PYX).
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Table 3 Crystallographic refinement statistics for human CLCA1 vWA proteins
Reproduced from Berry KN, Brett TJ. 2020(11).
Table 3. Crystallographic statistics for human CLCA1 vWA proteins
Construct
302-476
302-478
Data collection statistics
Space Group
C2
C2
Unit Cell (Å and °)
a=104.9
= 90
a=103.4
= 90
b=71.8
= 109.8
b=74.5
= 109.4
c=74.8
= 90
c=75.4
= 90
Source
ALS 4.2.2
ALS 4.2.2
Wavelength(Å)
1.0000
1.0000
Resolution(Å)
59.79 – 2.60 (2.72-2.60)
58.05 - 2.00 (2.05-2.00)
Rmerge
0.266 (1.734)
0.090 (1.814)
CC1/2
0.977 (0.328)
0.998 (0.507)
Completeness(%)
99.6 (98.1)
98.3 (86.3)
Redundancy
3.6 (3.3)
6.4 (4.2)
I/σ(I)
4.6 (0.6)
10.7(0.6)
Refinement statistics
Rwork (%)
21.82
19.87
Rfree (%)
27.87
22.51
Amino Acid Residues(#)
320
318
Waters (#)
82
148
RMSD bond length (Å)/angles(°)
0.008/0.906
0.011/1.181
Wilson B (Å2)
36.7
40.5
Ave. B protein (Å2)
42.32
44.57
Ave. B water (Å2)
40.62
47.51
Ave. B Ca2+ (Å2)
40.12
37.50
Ramachandran
%Favored
94.3
96.82
%Allowed
5.7
3.18
%Outliers
0
0
Rotamer outliers (%)
0
3.53
Clashscore (score / percentile)
8.91
3.41
Molprobity (score / percentile)
1.86
1.74
Luzzati Error
0.393
0.284
PDB ID
6PYX
6PYO
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2.4 Results of CLCA1 vWA Crystal Structure
2.4.1 Crystal Structure of the CLCA1 vWA domain
Human CLCA1 vWA was purified from a mammalian cell expression system and was
previously shown to be functional in potentiating TMEM16A when exogenously applied to
HEK293 cells (1). The structure was determined by molecular replacement at 2.0 Å resolution
(Table 3). There are two molecules in the asymmetric unit (ASU) that are highly similar (Cα
RMSD of 0.3 Å, Figure 9). Therefore, our analysis of CLCA1 vWA will refer to chain B, unless
otherwise noted. The general structural features are similar to other vWA domain folds: a core
composed of 6 β strands sandwiched between α helical bundles (Figure 8B). A DALI structure
comparison revealed that the CLCA1 vWA shares the most three-dimensional similarity to
anthrax toxin receptors CMG2 (12) and TEM8 (13), and to the voltage dependent L-type calcium
channel Cav1.1 subunit α2δ (14, 15) (Figure 8C-E) with RMSDs ranging from 1.9-2.3 Å (16).
However, there are three notable exceptions in comparison to these vWA domains from other
families. First, the β-sheet core is usually encompassed by 6 α helices. Though the last α helix,
α6 (using the nomenclature of von Willebrand factor A2 domain (17)), is predicted by secondary
structure predictions (JPRED4 (10), see Figure 14) and is present in this construct (302-476), we
did not observe defined electron density for it. Neither did a slightly longer construct (302-478)
yield a map with α6 clearly present (Figure 10). The absence of α6 places the N- and C-termini
of the CLCA1 vWA domain on opposite ends, much like the arrangement reported in the
structure of a collagen VI vWA domain (Figure 8F) (18). If in solution α6 is not packed against
the domain (see later discussion), this could have implications for how the domains of CLCA1
are oriented relative to one another or may facilitate cleavage of the N-CLCA1 from C-CLCA1.
Secondly, there is a disulfide bond in proximity of the MIDAS residues, linking α3 and η2 of
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α4 (Figure 8B). This disulfide linkage is unique to the CLCA family of vWA domains. Most
vWA domains do not contain a disulfide bond, and if one is present, it usually connects the Nand C-terminal boundaries of the domain (Figure 8C). Third, there is a 310 helix (η2) at the Nterminus of α4 that ends with one of the disulfide-bonded cysteines (Figure 8B-E). Beyond
secondary structure, CLCA1 vWA domain differs most in the loops surrounding the MIDAS, as
would be expected, since these loops usually dictate ligand-binding specificities of vWA
domains (19).
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Figure 8 Crystal structure of the human CLCA1 vWA domain
A) Crystal of human CLCA1 vWA domain. B) Ribbon diagram of the human CLCA1 vWA
domain structure obtained by X-ray crystallography. β strands and α and η helices of the vWA
domain are labeled according to the vWFA2 nomenclature(17). A calcium ion (Ca2+)
coordinated by the vWA MIDAS motif is shown as a gray sphere. MIDAS motif residues
surrounding the divalent cation are highlighted. The three invariant cysteines and location of the
disease-associated variant S357 are also labeled. N = N-terminus; C = C-terminus. C-F) Human
CLCA1 vWA domain is superpositioned to anthrax toxin receptors C) CMG2 (PDB: 1SHU) and
D) TEM8 (PDB: 3N2N), E) CD11b aI domain (PDB: 1IDO), and F) collagen (PDB: 4IGI) vWA
domains. MIDAS motifs are indicated for all alignments. The η2 helix of CLCA1 vWA domain
and the α6 helices of the published vWA domain structures are labeled in (C-E). For all
structures, the CLCA1 disulfide is annotated by solid lines. For (A), the natural disulfide in
CMG2 is annotated by dashed lines. For (F), the N-termini (N) and C-termini (C) are labeled.
Adapter from Berry KN, Brett TJ. 2020(11) .
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Figure 9 Superposition of hCLCA1 vWA domain Chains A and B within the asymmetric
unit
A) Alignment of hCLCA1 vWA domain chains A (cyan) and B (green) within the asymmetric
unit, with a Cα RMSD of 0.3 Å. MIDAS residues, invariant disulfides and S357 are highlighted.
Pseudoligand residue from chain A (E299) and chain B (D403) are also shown. The N-termini
(N) and C-termini (C) of each chain are labeled. Reproduced from Berry KN, Brett TJ. 2020(11).
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Figure 10 Superposition of crystal structures of CLCA1 vWA domain 302-476 and 302-478
The structures are extremely similar (Cα RMSD of 0.33 Å). A) Alignment of chain B from
CLCA1 vWA domain constructs containing residues 302-476 (green) and residues 302-478
(orange). B) Alignment of chain A from hCLCA1 vWA domain constructs containing residues
302-476 (cyan) and residues 302-478 (yellow). MIDAS residues, invariant disulfides and S357
are highlighted. Pseudo-ligand residue from chain A (E299) and chain B (D403) are also shown.
The N-termini (N) and C-termini (C) of each chain are labeled. Reproduced from Berry KN,
Brett TJ. 2020 (11).

2.4.2 MIDAS Motif within CLCA1 vWA domain
CLCA1 vWA domain crystallizes with MIDAS in the open conformation
Most vWA domains mediate protein-protein interactions via a MIDAS motif, which
partially coordinates a divalent cation in a manner which encourages completion of the
coordination sphere via an acidic residue (Asp or Glu) contributed by the ligand (20-24).
MIDAS motifs have been observed to exist in two conformations that correspond to the affinity
of the vWA domain for its ligand: an open, high-affinity configuration and a closed, low-affinity
configuration (22). The closed conformation is defined by MIDAS D5 serving as a direct
chelator of the divalent cation, through which the motif partially satisfies its electrophilic nature
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(Figure 11D). In contrast, the open configuration is hallmarked by all the direct MIDAS
chelators of the divalent cation being uncharged (Thr, Ser or waters), creating an electrophilic
divalent cation whose coordination is best satisfied by an acidic residue contributed by the
engaging ligand (Figure 11C). The human CLCA1 vWA domain contains a perfectly conserved
MIDAS motif (5): a DXSXS sequence followed several residues later by a threonine (T383) and
a final aspartate (D412) (Figure 11A). Strong density corresponding to an ion was observed at
the center of this site for both molecules in the ASU (Figure 12). As the CLCA1 vWA domain
was crystallized in conditions containing high CaCl2 concentrations, we modeled a Ca2+ into the
MIDAS site. Very few vWA domains have been crystallized in the presence of Ca2+, and instead
usually contain Mg2+ or Mn2+ which bind at a higher affinity. Most vWA MIDAS motifs favor
occupancy by Mg2+ rather than Ca2+, and Mg2+ coordination usually results in higher affinity
binding to ligand or greater functional capability (25-28). However, attempts to obtain CLCA1
vWA crystals in the presence of excess MgCl2 were not successful.
For both molecules in the ASU, the structure reveals the MIDAS in the open, highaffinity conformation, with S314, S316 and T383 directly coordinating a calcium ion, and D312
and D412 indirectly coordinating through a water molecule (Figure 11A-B). This coordinating
geometry is consistent with our functional studies that showed: 1) mutation of MIDAS residues,
particularly T383 and S316 which both directly coordinate the divalent cation in the open
conformation, and 2) chelation of extracellular Mg2+ by EDTA both abrogated CLCA1 vWAmediated potentiation of TMEM16A in whole cell patch clamp experiments (1). An acidic
residue from an adjacent molecule in the crystal, either a glutamate from chain A (E299) or
aspartate (D403) from chain B, completes the coordination of the calcium ion. This arrangement
is identical to the open conformation observed for the CD11b αI domain (Figure 11C), with the
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exception that, unlike the CD11b structure (29), the acidic residue appears to mediate a
monodentate interaction with calcium, rather than a bidentate interaction. Such crystal contact
“pseudoligand” interactions are commonly observed in crystal structures of vWA domains,
which utilize the MIDAS motif to mediate interactions (12, 30-32). The presence of the open
conformation in our structures implies that the CLCA1 vWA likely adopts this configuration for
a high affinity interaction with TMEM16A, and also suggests that the binding is primarily
mediated by a critical acidic residue within TMEM16A.
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Figure 11 CLCA1 vWA MIDAS crystallizes in an open conformation
A-D) MIDAS regions of human CLCA1 chain B (A, in green) and chain A (B, in cyan) of the
asymmetric unit and of the open (C) and closed (D) MIDAS configurations of the CD11b αI
domain (PDB: 1IDO and 1JLM, respectively). For (A-C), the pseudoligand residue is shown in
the color of the appropriate chain. Waters are depicted as red spheres. Bonds coordinating
divalent cations are shown as blue dashes (for direct side chain interactions) and yellow dashes
(for indirect or water-mediated interactions). Reproduced from Berry KN, Brett TJ. 2020(11).
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Figure 12 Difference electron density for the MIDAS and Ca2+ ion.
Difference electron density (2mFo-DFc contoured at 2s) for the CLCA1 vWA MIDAS residues
of chain B (green), including E299 from chain A (cyan) and calcium ion (grey). Reproduced
from Berry KN, Brett TJ. 2020(11).
Support for Ca2+ in the crystal structure
As Mg2+ appears to be the preferred divalent cation for vWA domains, it could be argued
that trace Mg2+ or another divalent cation is present in the crystal structure rather than Ca2+,
although Ca2+ is in excess in the crystallization conditions. To probe and verify this further,
additional refinements were pursued replacing the Ca2+ in the final model with Mg2+.
Temperature (B) factors and distances from the MIDAS residues and coordinating waters in the
first coordination sphere to the divalent cation were recorded (Table 4 and Table 5).
Coordination sphere distances to the Mg2+ in the CD11b structure (PDB: 1IDO) are also included
for comparison.
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Typically in coordination of Ca2+ and Mg2+, the average distance from the divalent cation
to the atoms in the first coordination sphere is 2.4 Å and 2.1 Å, respectively (33). In observing
the distances from the divalent cation to the atoms in the first coordination sphere of CLCA1
vWA, the average coordination distance is 2.32 Å for Chain B and 2.30 Å for Chain A (Table 4
and Figure 13), suggesting that Ca2+ is likely coordinated. For comparison, in the CD11b
structure in which Mg2+ is recorded as the MIDAS cation, the average coordination distance is
2.10 Å. In comparing the Fo-Fc difference electron density maps in the refinement with versus
Mg2+ (Figure 13), the map with Mg2+ shows positive density in the cation site while the map
refined against Ca2+ is largely neutral. This suggests that Ca2+ is best modeled into the MIDAS.
Temperature (B) factors may also inform the identity of the divalent cation in the MIDAS. In
comparing B factors between a refinement including Ca2+ versus Mg2+, the B factor of Ca2+ (~37
Å2) more closely resembles the B factors of the surrounding MIDAS residues (~35 Å2) whereas
the B factor of Mg2+ (~22 Å2), is quite different from the coordinating atoms (Table 5).
Altogether, this lends support to Ca2+ being the divalent cation in the MIDAS of the CLCA1
structure.
Functionally, we believe that the CLCA1 vWA coordinates a Mg2+ ion in its interaction
with TMEM16A (see the next section). Yet, we observe a Ca2+ ion in the crystal structure, and
we were unable to grow crystals in the presence of 0.2 M MgCl2. It is possible that the unnatural
crystal packing environment made it more favorable for Ca2+ to bind and encourage packing
rather than Mg2+. However, the experiments below suggest that Mg2+ is the physiologically
relevant cation coordinated within the CLCA1 vWA MIDAS.
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Table 4 MIDAS first coordination sphere distances to divalent cation
CLCA1 vWA Distances (Å)
Chain B MIDAS
Thr-Oγ1
2.2
Ser-Oγ
2.3
Ser-Oγ
2.5
H2O (1)
2.3
H2O (2)
2.3
Pseudoligand- 2.3
Oxygen

CD11b (PDB: 1IDO)
Distances (Å)

Chain A MIDAS
2.2
2.3
2.2
2.4
2.4
2.3

2.1
2.2
2.2
2.0
2.0
2.1

Table 5 Temperature (B) factors of divalent cations and atoms in the first coordination
sphere of the MIDAS of CLCA1 vWA structure refined with Ca2+ versus Mg2+
Residue
Ca2+or Mg2+
Thr383-Oγ1
Ser314-Oγ
Ser316-Oγ
H2O (1)
H2O (2)
PseudoligandOxygen

Ca2+ Refinement (Å2)
Chain A
Chain B
39.13
35.62
33.54
30.67
36.41
34.55
36.42
32.01
48.35
30.97
34.59
31.14
41.77
31.54
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Mg2+ Refinement (Å2)
Chain A
Chain B
25.27
18.00
33.59
31.36
37.65
34.90
35.33
33.40
48.64
34.31
34.45
31.75
42.49
31.60

Figure 13 Comparison of Ca2+ versus Mg2+ in the CLCA1 vWA crystal
A,B) MIDAS of human CLCA1 chain B (A, in green) and of the open MIDAS configurations of
the CD11b αI domain (B, in teal, PDB: 1IDO). C,D) CLCA1 vWA domain refined with Ca2+ or
Mg2+ with the difference electron density maps 2mFo-DFc (contoured at 2s, blue) and Fo-Fc
(contoured at 3s, with positive densities in green and negative densities in red). For (A-D), the
pseudoligand residue is shown in the color of the appropriate chain. Waters are depicted as red
spheres. For (A, B), bonds coordinating divalent cations Ca2+ (grey sphere) or Mg2+ (green
sphere) are shown as blue dashes (for direct side chain interactions) and yellow dashes (for
indirect or water-mediated interactions) with bond distances of the first coordination sphere in Å
labeled. MIDAS residues are also labeled in (A,B). For (C,D), both cations are in grey.
CLCA1 vWA is stabilized by 1 mM Mg2+, but not Ca2+
Our crystallization studies seemed to indicate that CLCA1 vWA might not preferentially
bind Mg2+, as we were unable to obtain crystals in the presence of Mg2+. This would be unusual,
since vWA domains normally bind Mg2+ with affinities in the low micromolar range, with
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affinities for Ca2+ about 100-fold worse, in the range of hundreds of micromolar (25-28). In order
to relatively rank binding affinities of CLCA1 vWA for the divalent cations, we assessed
whether Ca2+ or Mg2+ impacted thermal stability using circular dichroism (CD) and differential
scanning fluorimetry (DSF, or thermal denaturation) experiments. Thermal stability was assessed
by DSF on protein purified by size exclusion chromatography. The Protein Thermal Shift kit
(Applied Biosystems) was used according to manufacturer’s instructions. Briefly, protein was
concentrated to 0.5 mg/mL after buffer exchange into 20 mM HEPES pH 7.5, 150 mM NaCl and
1-1000 mM of either EDTA, MgCl2, CaCl2 or DTT. 5 µL of reaction buffer and 2.5 µL 8x
fluorescent dye were added to 12.5 uL protein on ice. Melt-curve experiments were performed
using Fast7500 qPCR machine (Applied Biosystems) starting at 25 ºC and with continuous 1%
ramp to 95 ºC (roughly at 1 ºC/min). The data were analyzed using Protein Thermal Shift
software (Applied Biosystems). CD spectroscopy measurements were performed using an
Applied Photophysics Chirascan spectropolarimeter equipped with a Peltier temperature
controller. A 1 cm path length cuvette was used and the protein concentration was 50 ug/mL.
Thermal denaturation experiments were carried out in 20 mM Tris pH 8.0, 100 mM NaCl and 1
mM of either EDTA, MgCl2, or CaCl2. For reducing conditions, the buffer contained 1 mM
DTT. Ellipticity was measured at 222 nm in 1 ºC steps from 20 to 90 ºC at a rate of 1 ºC/min.
Data was analyzed using ProScan software.
Both analyses were consistent: Mg2+ significantly stabilizes the vWA domain over Ca2+
or cation-free conditions (+EDTA), increasing TM of CLCA1 vWA by 1.0-1.2 ºC by CD and 8.69.8 °C by DSF (Figure 14D). In addition, Mg2+ even stabilized CLCA1 vWA under reducing
conditions ( TM = +2.1 or +6.9 °C, by CD and DSF, respectively). In contrast, addition of 1 mM
Ca2+ was unable to shift the TM of CLCA1 vWA compared to cation-free conditions. In addition,
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increasing concentrations of Mg2+ continue to further stabilize CLCA1 vWA while increasing
concentrations of Ca2+ do not. In the presence of both 1 mM of Mg2+ and Ca2+, the melting
temperature resembles that of 1 mM Mg2+ alone (Figure 15). These results are consistent with
previous investigations of vWA domain affinities for divalent cations (25-28) and indicate that
CLCA1 vWA preferentially binds Mg2+ over Ca2+.
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(Figure legend on the following page)
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Figure 14 Biophysical analysis of CLCA family vWA domain invariant cysteines
A) Annotated sequence alignment for human, mouse and pig CLCA vWA domains. Numbering
corresponds to the sequence of human CLCA1. Secondary structure of human CLCA1 is labeled
above. A solid line indicates the disulfide bond observed in the crystal structure. Stars next to the
sequence indicate that the vWA domain contains an imperfect MIDAS (5). Sequences are shown
for hCLCA1 (NM_001285.3), pCLCA1 (NM_214148.1), mCLCA1 (NM_017474.2), hCLCA4
(NM_012128.3), pCLCA4a (XM_001926978.5), pCLCA4b (XM_003125934.5), mCLCA4a
(NM_207208), mCLCA4b (NM_001033199), hCLCA2 (NM_006536.6), pCLCA2
(XM_003125930.4), mCLCA2 (NM_178697.5), mCLCA3b (NM_139148), mCLCA3a1
(NM_009899), and mCLCA3a2 (NM_030601) (where h = human; p = pig; m = mouse).
Sequence conservation is color coded as follows: magenta, invariant residues (with the exception
of cysteine and invariant MIDAS residues); green; invariant cysteines; yellow, residues with a
global similarity score of 0.75 or higher as determined by ESPript 3.0 software (34); blue, perfect
MIDAS residues; cyan, imperfect MIDAS residues. Black boxes indicate the most strongly
predicted sites of N-linked glycosylation by NetNGlyc 1.0 software (35). The predicted α6 helix
(JPRED4 (10)) of CLCA1 vWA domain is labeled above the alignment in red. MIDAS residues
are highlighted in purple. Invariant cysteines are labeled in yellow. B) WT CLCA1 vWA
domain, and cysteine-to-serine mutants of the invariant disulfides (single mutants C308S,
C386S, and C421S, and double mutant C386S/C421S) were expressed in 293T cells.
Supernatants and lysates were analyzed by western blot (anti-6-His). Pos. control, = 6-histidine
tagged MAM domain from receptor tyrosine phosphatase µ (SDS-PAGE MW = 30 kDa). C)
Circular dichroism spectra of human CLCA1 vWA domain in the presence of EDTA (blue),
magnesium (green) and calcium (orange), with (dashed line) or without (solid line) reducing
agent (DTT). Spectra are plotted as mean ellipticity per residue ± SD of triplicate recordings.
Representative spectra of three independent experiments. D) Thermal denaturation of human
CLCA1 vWA domain by determination of melting temperatures (TM) by monitoring circular
dichroism at 222 nm (upper panel) or differential scanning fluorimetry (lower panel) in the
presence of EDTA (blue), magnesium (green) and calcium (orange), with (squares) and without
(diamonds) reducing agent (DTT). Representative melting temperatures of three independent
experiments. For circular dichroism, data are represented as mean ± SEM. For differential
scanning fluorimetry, data are represented as mean ± SEM of triplicate samples. Reproduced
from Berry KN, Brett TJ. 2020(11).
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Figure 15 Mg2+ but not Ca2+ increases the stability of the CLCA1 vWA domain
Thermal denaturation of human CLCA1 vWA domain by determination of melting temperatures
(TM) by differential scanning fluorimetry in the presence of EDTA (blue), magnesium (Mg,
green), calcium (Ca, orange), or magnesium and calcium (Mg+Ca, purple) with (squares) and
without (diamonds) reducing agent (DTT). For differential scanning fluorimetry, data are
represented as mean ± SEM of triplicate samples.

2.4.3 Unique structural features of the CLCA1 vWA Domain
An Invariant Disulfide Bond is Required for Folding and Secretion of CLCA1 vWA
Our high-resolution crystal structure of CLCA1 vWA revealed a disulfide bond between
C386 and C421, connecting α3 and the η2 segment of α4 (Figure 8B). This disulfide bond is
unique in that: 1) natural disulfide bonds in vWA domains are not common; and 2) unlike CMG2
(12), MIC2 (36) and TRAP (37) vWA domains in which a disulfide bond is found linking the N73

and C- termini, the disulfide bridge in the CLCA1 vWA domain is found in close proximity to
the MIDAS. Interestingly, sequence analysis indicates that CLCA proteins have three invariant
cysteines within the vWA domain (Figure 14A) (38). The free cysteine, C308, is packed within
the core of CLCA1 vWA (0% sidechain solvent accessibility as calculated by NACCESS (39))
(Figure 8B). This likely negates the possibility that CLCA1 vWA domain may
covalently bind to itself or to other proteins, as is the case for some vWA domains, such as the
Cav-1 and -2 calcium channel α2 subunits, which remain covalently link to the δ subunit via a
disulfide bond (14, 15) after proteolytic cleavage.
In order to investigate the structural importance of invariant cysteines in the CLCA1
vWA, we carried out mutations to serine (C308S, C386S, C421S and C386S/C421S) with
QuikChange Lightning and expressed them in HEK293T cells. HEK293T cells were grown to
70-90% confluency and transfected with CLCA1 vWA domain constructs and 293Fectin at a 1:2
ratio (μg of DNA: μL of transfection reagent) using 1 μg of plasmid DNA per 1 million cells.
After 24 hours, supernatants were mixed with 2x SDS containing 2-mercaptoethanol sample
buffer. Cells were pelleted and lysed in PBS-1% Triton X-100, then diluted in 2x SDS
containing 2-mercaptoethanol sample buffer and sonicated. Samples were boiled for 5 minutes,
then loaded on a 4-12% Bis-Tris NuPage gel (Life Technologies). Proteins were transferred to
nitrocellulose membranes using an iBlot Gel transfer device (Life Technologies). Membranes
were blocked with 0.5% blotting-grade blocker nonfat milk (Bio-Rad) in PBS with 0.1% Tween20. HRP-conjugated anti-6-histidine antibody (Bethyl Laboratories) diluted 1:5000 in blocking
buffer was incubated on the membrane for 10 minutes at room temperature. Following three
washes with PBS-Tween-20, signal was detected using Pierce ECL Western Blotting Substrate
(Thermo Fisher Scientific, Rockford, IL).

74

Though all proteins were expressed, only the C308S mutant was secreted (Figure 14B),
indicating that mutations preventing disulfide bond formation were misfolded and retained in the
secretory pathway. Further supporting this observation, for the mutants that were not secreted, a
band at approximately twice the monomer size of CLCA1 vWA (2 X 20kDa) was observed in
cell lysates, suggesting that aberrant disulfide bonds between molecules may have been formed
during misfolding and not sufficiently reduced in SDS-PAGE (Figure 14B). In order to assess
the role of this disulfide in CLCA1 vWA stability, we carried out circular dichroism (CD) and
differential scanning fluorimetry (DSF) experiments.
CD spectra of CLCA1 vWA in the absence of divalent cations (+EDTA) varied greatly
with the addition of DTT, especially at wavelengths < 215 nm, indicating partial unfolding upon
reduction of the disulfide bond (Figure 14C). In addition, thermal denaturation studies by CD
and DSF in the presence or absence of DTT showed that reduction of the disulfide bond
decreased the melting temperature (TM) by 2.6 and 6.5 °C, respectively (Figure 14D). Altogether,
these results suggest that CLCA family vWA domains contain an invariant disulfide that is
required for folding and stability. The role of the invariant free cysteine (C308) is unclear at this
time. However, it should be noted that the sidechain sulfhydryl does hydrogen bond to the
backbone carbonyl of L309, so this sidechain likely contributes to stability of the fold.
Interestingly, the Toxoplasma gondii motility and invasion protein MIC2 also has a cysteine in
this position of b1 which, in contrast, engages in a disulfide linkage with a4 (C164) in its vWA
domain (37). This is not the case in CLCA vWAs, as the structurally corresponding position
(A392 located in a3 of CLCA1) is either an alanine or glycine (Figure 14A). It is unclear at this
time what its functional role is and why it is invariant at this position.
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Solution Structures of CLCA1 Suggest vWA

6 Extends From the Core Fold

Since we were unable to observe definitive electron density for the CLCA1 vWA α6 in
our high resolution crystal structure, we utilized small angle X-ray scattering (SAXS) to develop
a low resolution envelope structure of the vWA domain (Figure 16A-D) as well as CLCA1
containing the catalytic and vWA domains with an inactivating mutation in the MMP-L domain
(CAT-CYS-vWA E157Q) (Figure 16E-H). SAXS data was obtained at the Advanced Light
Source on the SIBYLS beamline 12.3.1 (40). Thirty-three exposures of 0.3 seconds were
obtained for each protein at 1-10 mg/mL and scattering from the dialysis buffer (20 mM HEPES
pH 7.4, 150 mM NaCl, and 2% glycerol) was subtracted. Data were inspected for quality and
scale-merged in scÅtter 3.0g (41). Data was subsequently analyzed in the ATSAS 2.8.4 suite
(42) using PRIMUS (43). Guinier analysis showed no radiation damage, aggregation or
concentration effects. I(0) and the pair distance distribution function P(r) were calculated in
GNOM (44) within PRIMUS. Ten low-resolution ab initio models from DAMMIF (45) were
automatically averaged using DAMAVER (46) and converted to a surface map using SITUS
(47).
The CLCA1 vWA structure was docked into these envelopes using SITUS. Both
envelopes display globular regions consistent with one domain (vWA; Figure 16D) or three
domain (CAT-CYS-vWA E157Q, Figure 16H) proteins. However, both also included a tubular
tail extending from the sphere in both envelopes. In light of the missing α6 helix in our crystal
structure, we speculate that this tail may represent the

6 helix that cannot be resolved in the

crystal structure because it does not pack tightly against the rest of the domain. Analysis of
packing in the CLCA1 vWA crystal shows that the C-terminus for the built structure is located
adjacent to large solvent channels that would allow for multiple positions for an α6 helix that
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extends from the core vWA. Thus, solution structural studies by SAXS suggest that CLCA1
vWA α6 extends from the vWA core fold, in contrast to other structurally characterized vWA
domains.

Figure 16 Solution structures of CLCA1 vWA and CAT-CYS-vWA proteins from SAXS
analysis
Solution SAXS for human CLCA1 vWA (302-476) (A-D) and CLCA1 E157Q (22-477)
encompassing the MMP-L catalytic domain (CAT), cysteine rich region (Cys) and vWA. (E-H)..
A, E) Raw SAXS data. B, F) Upper panel, Guinier regions with SAXS data points (open circles)
and fits (solid red line). Radius of gyration (Rg) is labeled above the line of fit. Lower panel,
residual data points (open circles) of Guinier region with fits (solid red line). C, G) Distance
distribution functions. Dmax is indicated next to the distribution. D, H) Ab initio SAXS envelope
models. Models are the average of 10 independent DAMMIN predictions averaged in
DAMAVER. CLCA1 vWA domain was docked into the envelope using SITUS. Domain
architecture schematics and cartoons are labeled above the SAXS envelopes. in (D) and (H). The
N-termini (N) and C-termini (C) are labeled. Reproduced from Berry KN, Brett TJ. 2020(11).

2.4.4 Structural Insights Into the Disease-Associated CLCA1 Variant S357N
In genomic analyses, S357N has been identified as a mutation modifying the severity of
intestinal disease occurring in cystic fibrosis patients, as it was associated with aggravated
meconium ileus (48). In order to gain mechanistic insight into how this mutation might manifest
in disease, we analyzed the structural environment of S357 in our CLCA1 vWA structure. S357
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is found distal to the MIDAS motif, and the sidechain hydroxyl donates a hydrogen bond to the
backbone carbonyl of the adjacent residue (E358) (Figure 17). This results in the S357 sidechain
being mostly buried (4.8% side chain solvent accessibility by NACCESS). Given the tightly
packed environment, it is highly unlikely that an Asn at this position would be able to engage in
the same hydrogen bond, which might disrupt folding or folding kinetics and could result in
reduced expression levels. This would result in decreased potentiation of calcium activated
chloride currents, reducing hydration and resulting in thick mucus plugging of the intestine. This
would be consistent with our published functional studies in overexpression systems in which
S357N does not affect the ability of CLCA1 vWA to potentiate chloride currents via TMEM16A
(1). This is also consistent with studies in CFTR knockout mice that show that mouse CLCA1
expression is decreased in mice with aggravated meconium ileus, which is rescued by
overexpression of mouse CLCA1 (49).

Figure 17 Disease-associated residue S357 sidechain engages in an intramolecular hydrogen
bond
The sidechain of S357 and the backbone and sidechain of E358 are highlighted. The sidechain
hydroxyl of S357 forms a hydrogen bond to the backbone carbonyl of E358 (indicated by the
dashed yellow line). Reproduced from Berry KN, Brett TJ. 2020. (11).
78

2.5 References
1. Sala-Rabanal, M., et al. (2017). "Modulation of TMEM16A channel activity by the von
Willebrand factor type A (VWA) domain of the calcium-activated chloride channel regulator 1
(CLCA1)." J Biol Chem 292(22): 9164-9174.
2. Yurtsever, Z., et al. (2012). "Self-cleavage of human CLCA1 protein by a novel internal
metalloprotease domain controls calcium-activated chloride channel activation." J Biol Chem
287(50): 42138-42149.
3. Sala-Rabanal, M., et al. (2015). "Secreted CLCA1 modulates TMEM16A to activate Ca(2+)dependent chloride currents in human cells." Elife 4.
4. Kober, D. L., et al. (2015). "Efficient Mammalian Cell Expression and Single-step Purification
of Extracellular Glycoproteins for Crystallization." J Vis Exp(106): e53445.
5. Whittaker, C. A. and R. O. Hynes (2002). "Distribution and evolution of von
Willebrand/integrin A domains: widely dispersed domains with roles in cell adhesion and
elsewhere." Mol Biol Cell 13(10): 3369-3387.
6. Aricescu, A. R., et al. (2006). "A time- and cost-efficient system for high-level protein
production in mammalian cells." Acta Crystallogr D Biol Crystallogr 62(Pt 10): 1243-1250.
7. Kabsch, W. (2010). "Xds." Acta Crystallogr D Biol Crystallogr 66(Pt 2): 125-132.
8. Adams, P. D., et al. (2010). "PHENIX: a comprehensive Python-based system for
macromolecular structure solution." Acta Crystallographica Section D 66(2): 213-221.
9. Emsley, P., et al. (2010). "Features and development of Coot." Acta Crystallographica Section
D 66(4): 486-501.
10. Drozdetskiy, A., et al. (2015). "JPred4: a protein secondary structure prediction server."
Nucleic Acids Res 43(W1): W389-394.
11. Berry, K. N. and T. J. Brett (2020). "Structural and Biophysical Analysis of the CLCA1
VWA Domain Suggests Mode of TMEM16A Engagement." Cell Rep 30(4): 1141-1151.e1143.
12. Lacy, D. B., et al. (2004). "Crystal structure of the von Willebrand factor A domain of human
capillary morphogenesis protein 2: an anthrax toxin receptor." Proc Natl Acad Sci U S A
101(17): 6367-6372.
13. Fu, S., et al. (2010). "The structure of tumor endothelial marker 8 (TEM8) extracellular
domain and implications for its receptor function for recognizing anthrax toxin." PLoS One 5(6):
e11203.

79

14. Wu, J., et al. (2015). "Structure of the voltage-gated calcium channel Cav1.1 complex."
Science 350(6267): aad2395.
15. Wu, J., et al. (2016). "Structure of the voltage-gated calcium channel Ca(v)1.1 at 3.6 Å
resolution." Nature 537(7619): 191-196.
16. Holm, L. and L. M. Laakso (2016). "Dali server update." Nucleic Acids Res 44(W1): W351355.
17. Zhang, Q., et al. (2009). "Structural specializations of A2, a force-sensing domain in the
ultralarge vascular protein von Willebrand factor." Proc Natl Acad Sci U S A 106(23): 92269231.
18. Becker, A. K., et al. (2014). "A structure of a collagen VI VWA domain displays N and C
termini at opposite sides of the protein." Structure 22(2): 199-208.
19. Luo, B. H., et al. (2007). "Structural basis of integrin regulation and signaling." Annu Rev
Immunol 25: 619-647.
20. Nolte, M., et al. (1999). "Crystal structure of the alpha1beta1 integrin I-domain: insights into
integrin I-domain function." FEBS Lett 452(3): 379-385.
21. McCleverty, C. J. and R. C. Liddington (2003). "Engineered allosteric mutants of the integrin
alphaMbeta2 I domain: structural and functional studies." Biochem J 372(Pt 1): 121-127.
22. Shimaoka, M., et al. (2003). "Structures of the alpha L I domain and its complex with ICAM1 reveal a shape-shifting pathway for integrin regulation." Cell 112(1): 99-111.
23. Vorup-Jensen, T., et al. (2003). "Structure and allosteric regulation of the alpha X beta 2
integrin I domain." Proc Natl Acad Sci U S A 100(4): 1873-1878.
24. Springer, T. A. (2006). "Complement and the multifaceted functions of VWA and integrin I
domains." Structure 14(11): 1611-1616.
25. Baldwin, E. T., et al. (1998). "Cation binding to the integrin CD11b I domain and activation
model assessment." Structure 6(7): 923-935.
26. Ajroud, K., et al. (2004). "Binding Affinity of Metal Ions to the CD11b A-domain Is
Regulated by Integrin Activation and Ligands." J Biol Chem 279(24): 25483-25488.
27. San Sebastian, E., et al. (2006). "On the affinity regulation of the metal-ion-dependent
adhesion sites in integrins." J Am Chem Soc 128(11): 3554-3563.
28. Vorup-Jensen, T., et al. (2007). "The connection between metal ion affinity and ligand
affinity in integrin I domains." Biochim Biophys Acta 1774(9): 1148-1155.
29. Mahalingam, B., et al. (2011). "Stable coordination of the inhibitory Ca2+ ion at the metal
ion-dependent adhesion site in integrin CD11b/CD18 by an antibody-derived ligand aspartate:
80

implications for integrin regulation and structure-based drug design." J Immunol 187(12): 63936401.
30. Bhattacharya, A. A., et al. (2004). "Crystal structure of the A domain from complement
factor B reveals an integrin-like open conformation." Structure 12(3): 371-378.
31. Lee, J. O., et al. (1995). "Crystal structure of the A domain from the alpha subunit of integrin
CR3 (CD11b/CD18)." Cell 80(4): 631-638.
32. Li, R., et al. (1998). "Two functional states of the CD11b A-domain: correlations with key
features of two Mn2+-complexed crystal structures." J Cell Biol 143(6): 1523-1534.
33. Zheng, H., et al. (2017). "CheckMyMetal: a macromolecular metal-binding validation tool."
Acta Crystallogr D Struct Biol 73(Pt 3): 223-233.
34. Robert, X. and P. Gouet (2014). "Deciphering key features in protein structures with the new
ENDscript server." Nucleic Acids Res 42(Web Server issue): W320-324.
35. Blom, N., et al. (2004). "Prediction of post-translational glycosylation and phosphorylation
of proteins from the amino acid sequence." Proteomics 4(6): 1633-1649.
36. Song, G., et al. (2012). "Shape change in the receptor for gliding motility in Plasmodium
sporozoites." Proc Natl Acad Sci U S A 109(52): 21420-21425.
37. Song, G. and T. A. Springer (2014). "Structures of the Toxoplasma gliding motility adhesin."
Proc Natl Acad Sci U S A 111(13): 4862-4867.
38. Patel, A. C., et al. (2009). "The role of CLCA proteins in inflammatory airway disease."
Annu Rev Physiol 71: 425-449.
39. Hubbard, S. and J. Thornton (1993). NACCESS, Computer Program, Department of
Biochemistry and Molecular Biology, University College London.
40. Dyer, K. N., et al. (2014). "High-throughput SAXS for the characterization of biomolecules
in solution: a practical approach." Methods Mol Biol 1091: 245-258.
41. Rambo, R. P. (2015). "Resolving Individual Components in Protein-RNA Complexes Using
Small-Angle X-ray Scattering Experiments." Methods Enzymol 558: 363-390.
42. Franke, D., et al. (2017). "ATSAS 2.8: a comprehensive data analysis suite for small-angle
scattering from macromolecular solutions." J Appl Crystallogr 50(Pt 4): 1212-1225.
43. Konarev, P. V., et al. (2003). "PRIMUS: a Windows PC-based system for small-angle
scattering data analysis." Journal of Applied Crystallography 36: 1277-1282.
44. Svergun, D. I. (1992). "Determination of the Regularization Parameter in Indirect-Transform
Methods Using Perceptual Criteria." Journal of Applied Crystallography 25: 495-503.

81

45. Franke, D. and D. I. Svergun (2009). "DAMMIF, a program for rapid ab-initio shape
determination in small-angle scattering." J Appl Crystallogr 42(Pt 2): 342-346.
46. Volkov, V. V. and D. I. Svergun (2003). "Uniqueness of ab initio shape determination in
small-angle scattering." Journal of Applied Crystallography 36: 860-864.
47. Wriggers, W. and P. Chacon (2001). "Using Situs for the registration of protein structures
with low-resolution bead models from X-ray solution scattering." Journal of Applied
Crystallography 34: 773-776.
48. van der Doef, H. P., et al. (2010). "Association of the CLCA1 p.S357N variant with
meconium ileus in European patients with cystic fibrosis." J Pediatr Gastroenterol Nutr 50(3):
347-349.
49. Young, F. D., et al. (2007). "Amelioration of cystic fibrosis intestinal mucous disease in mice
by restoration of mCLCA3." Gastroenterology 133(6): 1928-1937.

82

Chapter 3: Expression, purification, and
structure of the TMEM16A-CLCA1
complex
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3.1 Cloning, expression and purification of human
TMEM16A
3.1.1 Cloning human TMEM16A from cystic fibrosis airway cells
TMEM16A is known to express different isoforms dependent upon the cell type, and
these isoforms confer different properties to the channel (1). The isoforms differ based on the
alternative splicing of four exons: exon 1 (segment a, 348 base pairs), exon 6b (segment b, 66
base pairs), exon 13 (segment c, 12 base pairs) and exon 15 (segment d, 78 base pairs). These
segments can be independently present or absent in the channel, though some combinations are
more common than others. The most common TMEM16A isoforms are abc, acd and ac. To
maintain relevance to translational work for this thesis (see Chapter 5), the particular isoform(s)
expressed in the cystic fibrosis (CF) airway epithelial cells were subcloned into expression
vectors.
Human airway epithelial cells from CF lung explant tissue were a kindly isolated and
grown by the Alexander-Brett lab. These cells were used to develop cDNA that could be used as
a template for PCR amplification. DNA was extracted using the TriZol solution (Thermo-Fisher)
according to manufacturers instruction. For PCR amplification, 5 μL of cDNA template was used
in the first round of amplification. A weak band was obtained, purified using QIAquick PCR
Purification kit and then gel extracted. This gel-extracted segment was then used as a template in
a second round of amplification. The PCR product from the second amplification was then
subcloned into pcDNA 3.1 vector using NheI and KpnI and into pHLsec vector using EcoRI and
KpnI. For pcDNA TMEM16A, a Kozak sequence was included in the primers and the construct
was tagless. For pHLsec, a Kozak sequence was included in the primers, and the digest site
EcoRI chosen to remove the signal sequence in the vector. The KpnI site was left intact to
include a 6-histidine tag at the C-terminus of TMEM16A. A similar construct was developed by
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Terashima et al. (2) to express and purify human TMEM16A into liposomes for
electrophysiology experiments. Once cloned into pcDNA and pHLsec, the templates were
sequenced and the isoform present determined to be isoform acd. Additionally, primers flanking
exons 6b, 13 and 15 were used to amplify this template (see Figure 39). Amplicons containing
the exon migrate at a higher molecular weight than if the exon is absent. Single bands were
observed, indicating that only one isoform of TMEM16A was expressed in these CF airway
epithelial cells. The predicted molecular weight of this construct in pcDNA is 114.078 kDa and
in pHLsec is 115.187 kDa. As TMEM16A is expected to form a dimer, the dimer molecular
weight is expected to be 228.156 kDa and 230.375 kDa, respectively.

3.1.2 Expression and purification of human TMEM16A acd in mammalian
system
Expression and purification of solubilized human TMEM16A
Full-length human TMEM16A acd cloned from CF airway epithelial cells into the
pHLsec vector was expressed in Expi293F cultured at 37 ºC and 8% CO2 in serum-free Expi293
Expression Media (ThermoFisher Scientific) supplemented with 0.5% penicillin/streptomycin
(Pen/Strep, Gibco). The channel was expressed via transient transfection with either Hype-5 or
Hype-293 (OZ Biosciences, San Diego, CA) at a 1:1.5 ratio (μg of DNA: μL of transfection
reagent) using 1 μg of plasmid per 1 million cells, similar to our previous reports (3). Cell pellets
were harvested by centrifugation after 96 hours by centrifugation, and resuspended in buffer A
(20 mM HEPES pH 7.5, 150 mM NaCl, 0.5 mM CaCl2) with 1x protease inhibitors (Sigma) and
2 mM phenylmethylsufonyl fluoride (PMSF) at 10 mL buffer A per gram of cells. Digitonin
(Sigma-Aldrich) was added to 1% and TMEM16A extracted by gentle agitation for 2 hours at 4
ºC. Insoluble material was removed by centrifugation at 22,000 x g for 40 minutes and the
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supernatant filtered through a 0.45 um vacuum filter. TMEM16A was affinity purified by batch
binding method for 2 hours at 4 ºC with Ni-NTA Superflow resin (Qiagen, Hilden, Germany)
after adjusting to pH 8.5 and 20 mM imidazole in 0.12% digitonin. Resin was washed with 20
column volumes (CV) of buffer containing 50 mM K2HPO4 (pH 8), 300 mM NaCl, and 50 mM
imidazole and eluted in 5 column volumes of buffer containing 50 mM K2HPO4 (pH 8), 300 mM
NaCl, and 300 mM imidazole. The eluate was concentrated in a 100 kDa centrifuge concentrator
at 4 ºC, resuspending after 5 minutes each time. TMEM16A was further purified by size
exclusion chromatography on a Superose 6 GL 10/300 column in buffer A supplemented with
0.12% digitonin. A peak eluting at ~14 mL was concentrated in a 10 kDa centrifuge concentrator
to 1 mg/mL for examination by negative stain transmission electron microscopy (Figure 18).
Yields were typically 0.3 mg/L mammalian culture.

86

Figure 18 Purification of human TMEM16A in detergent conditions
A) Flow-chart diagram of TMEM16A purification in detergent. Human TMEM16A isoform acd
with a C-terminal 6-histidine tag was expressed in Expi293 cells. Membrane protein was
extracted in 1% digitonin and TMEM16A purified by Nickel affinity chromatography in batch
binding method in detergent conditions. The nickel elution was then further purified by size
exclusion chromatography on a Superose 6 column. B) SDS-PAGE of nickel purification. FT,
flow-through. W1-W4, washes 1-4. E1-E2, elutions 1 and 2. A band near 98 kDa can be
observed in E1. C) Left panel, SDS-PAGE of size exclusion chromatography of TMEM16A in
detergent conditions. Input, elution from nickel affinity chromatography in (B). Right panel, size
exclusion chromatogram of TMEM16A purification. Bands above the peaks correspond to the
fractions of SDS-PAGE. Fractions in peak 1, 2 and 3 of the chromatogram were assessed by
SDS-PAGE. Peak 2 contains TMEM16A, eluting around 14 mL, which corresponds to a size of
about 200 kDa, the size of a TMEM16A dimer.
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Size exclusion chromatography co-elutions of TMEM16A and CLCA1 in detergent
Expi293 cells were cultured at 37 ºC and 8% CO2 in serum-free Expi293 Expression
Media (ThermoFisher Scientific) supplemented with 0.5% penicillin/streptomycin (Pen/Strep,
Gibco). N-CLCA1 E157Q (residues 22-695, excluding the signal sequence residues 1-21, 75.031
kDa), CAT-CYS-CLCA1 (residues 11-477, excluding signal sequence residues 1-21, 51.659
kDa) and CLCA1 vWA (residues 297-478) (Figure 19) were expressed in Expi293 cells via
transient transfection with either Hype-5 or Hype-293 (OZ Biosciences, San Diego, CA) at a
1:1.5 ratio (μg of DNA: μL of transfection reagent) using 1 μg of plasmid per 1 million cells,
similar to our previous reports (3). Media from supernatants were harvested after 72-96 hours by
centrifugation, concentrated to 1/10 of the original volume using a 30 kDa cutoff membrane for
N-E157Q and CAT-CYS-CLCA1 (Ultracel Ultrafiltration Discs, EMD Millipore) or 10 kDA
cutoff membrane for CLCA1 vWA and adjusted to pH 8.5 and 5 mM imidazole. The
concentrated protein was purified using Ni-NTA Superflow resin (Qiagen, Hilden, Germany)
and eluted in 5 mL of buffer containing 50 mM K2HPO4 (pH 8), 300 mM NaCl, and 250 mM
imidazole. Purified CLCA1 constructs were concentrated in a 10 or 30 kDa cutoff centrifuge
concentrator (as noted above) and exchanged into buffer containing 20 mM HEPES pH 7.5, 150
mM NaCl, 0.5 mM CaCl2 and 0.5 mM MgCl2.
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Figure 19 CLCA1 constructs used in co-elutions with TMEM16A
Domain architecture schematic of full-length human CLCA1. Labels denote the following
domains: CAT, matrix-metalloprotease-like catalytic domain; Cys, matrix-metalloprotease-like
cysteine-rich region; vWA, von Willebrand factor type A domain; FnIII, fibronectin type III
domain. Numbers above the domains indicate approximate domain boundaries. Dashed line
indicates cleavage site. Lines below the schematic indicate the boundaries of the constructs used
in co-elutions with TMEM16A. The red star indicates the presence of an inactivating mutation in
the metalloprotease domain within the construct. Schematic reproduced from Sala-Rabanal et al.
2015 (4).
Detergent purified TMEM16A was mixed with the CLCA1 constructs (adjusting the
digitonin concentration to 0.12%) and allowed to bind for 30 minutes on ice. In each case,
CLCA1 proteins were added in molar excess (and peaks corresponding to CLCA1 protein alone
is observed). Samples were loaded onto a Superose 6 GL 10/300 column in buffer A
supplemented with 0.12% digitonin. Fractions containing both TMEM16A and the CLCA1
construct were pooled and concentrated in a 100 kDa cutoff centrifuge concentrator. Negative
stain EM grids were prepared from concentrated co-elutions at 10-30 μg/ml as calculated by
absorbance at 280 nm. For one sample, TMEM16A and CLCA1 vWA were simply mixed (with
CLCA1 vWA in roughly 10X excess) just before negative stain grids were prepared (and not
purified on the Superose 6 column).
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Figure 20 Co-elutions of TMEM16A and CLCA1 constructs in detergent conditions
A-C) Left panels, western blots of nickel affinity chromatography of CLCA1 construct A) vWA
domain. B) CLCA1 NV E157Q and C) Nterm E157Q, followed by size exclusion
chromatography of TMEM16A and CLCA1 construct co-elutions. FT, flow-through. W, wash.
E, elution. Input, input sample of size exclusion chromatography after TMEM16A and CLCA1
construct were bound on ice for 30 minutes. To the left, dashed lines indicate TMEM16A and the
CLCA1 bands. Middle panels, size exclusion chromatograms of TMEM16A and CLCA1 coelutions. Lines above the peaks correspond to the fractions of the western blot. Right panels,
negative stain transmission electron microscopy (TEM) of the co-elutions. For (A), the upper
panel represents TMEM16A and CLCA1 vWA mixed together just before preparation of the
negative stain grid. The lower panel represents the pooled co-elution fractions (peak 2) used to
prepare the negative stain grid.
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Expression and purification of human TMEM16A in nanodiscs
Nanodisc Choice and Formation
In order to facilitate the interaction of CLCA1 and TMEM16A in an environment that
was detergent-free, and to mimic the environment of TMEM16A in a lipid bilayer, a nanodisc
preparation of TMEM16A was developed. Nanodiscs are composed of phospholipids that are
stabilized in solution by amphipathic alpha-helical proteins that wrap around the phospholipids
to shield the hydrophobic regions from water. These alpha helical proteins, termed membrane
spanning proteins (MSPs), are derived from apolipoprotein A-1, and over the years have been
modified to include different tags and yield different size discs. The sizes of these discs have
been determined by size exclusion chromatography and/or SAXS (5). The choice of the MSP is
important as different membrane proteins will require a disc size large enough to envelope the
protein and the lipids surrounding it. One cryo-EM structure of mouse TMEM16A
(mTMEM16A) provided a starting point to determine an appropriate MSP (6). As the diameter
of mTMEM16A dimer was about 117 Å at its widest point in the cryo-EM structures (6-8), the
most appropriate available MSP was MSP2N2 or MSP2N3, at diameters of 15.0/16.5 nm or
15.2/17.0 nm respectively (size exclusion/SAXS) (5). MSP1E3 may potentially have been
appropriate, but there is a concern that a diameter of 12.0 nm may be too small to contain the ion
channel and lipids surrounding it. Additionally, as MSP2N2 was available as a kind gift from the
Yuan lab, this MSP was chosen to generate TMEM16A in nanodiscs.
More experimental detail will be described below. In brief, to generate these nanodiscs,
TMEM16A is purified in detergent conditions with n-dodecyl b-D-maltoside (DDM) and then
combined with purified MSP2N2, lipids and protease inhibitors. The ideal ratio of membrane
protein to MSP to lipid must be determined empirically for each membrane protein. The slow
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removal of detergent using adsorbent beads encourages the assembly of the ion channel into the
lipid bilayer surrounded by the MSP. Stable nanodiscs, i.e. fractions containing both membrane
protein and MSP, are retrieved after size exclusion chromatography to separate the aggregate,
properly formed nanodiscs, empty nanodiscs (i.e. nanodisc containing no membrane protein) and
other impurities (Figure 22A).
Expression and purification of MSP2N2
MSP2N2 plasmid was a kind gift from the Yuan Lab. Plasmid was transformed into
Rosetta2 (DE3) BL21 under kanamycin selection. An overnight starter culture was used to
inoculate 6 L of Terrific Broth (6 g tryptone, 12 g yeast extract and 2 mL glycerol in 500 L,
autoclaved, cooled and 50 mL of 0.17 M KH2PO4, 0.72 M K2HPO4 buffer added) supplemented
with kanamycin and chloramphenicol in 2.8L glass flasks. Cultures were grown at 37 ºC shaking
to an OD600 of ~2.5-3, and induced with 1 mM IPTG at 30 ºC for 3 hours. Cells were harvested
by centrifugation and resuspended in lysis buffer (50 mM Tris pH 8.0, 150 mM NaCl) with
protease inhibitors (Sigma-Aldrich), 2 mM PMSF, 1 mg DNAse and 50 mg lysozyme. Cells
were sonicated on ice three times for 1 minute at a power of 8.0 with 3 minute rests. Insoluble
material was removed by centrifugation at 10,000 rpm and 4 ºC for 30 minutes. MSP2N2 was
purified using nickel beads (GoldBio) in the column setting. Beads were washed with 50 mL of
buffer 1 (20 mM Tris pH 8.0, 150 mM NaCl), 10 mL of buffer 2 (20 mM Tris pH 8.0, 150 mM
NaCl, 5 mM imidazole), 10 mL of buffer 3 (20 mM Tris pH 8.0, 150 mM NaCl, 10 mM
imidazole), and 10 mL of buffer 4 (20 mM Tris pH 8.0, 150 mM NaCl, 30 mM imidazole).
Protein was eluted with 10 mL of buffer 5 (20 mM Tris pH 8.0, 150 mM NaCl, 300 mM
imidazole) (Figure 21). The sample was concentrated to 6.9 mg/mL (152 μM) as calculated from
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absorbance at 280 nm and stored at -80 ºC. The expected molecular weight of MSP2N2 is 45.541
kDa (5).

Figure 21 Purification of MSP2N2
Nickel affinity chromatography of MSP2N2 expressed in E. coli. FT, flow-through. W1-W4,
washes 1-4. E, elution. The MSP2N2 bands is observed around 49 kDa. Lower bands are likely
degradation products.
Preparation of lipids
Soybean or soy phosphatidylcholine (PC) lipids were dissolved in chloroform using glass
vials and glass pipets at a concentration of 10 mg/mL and stored at -20 ºC in glass vials. Aliquots
were vacuum dessicated in the Michael Holtzman lab after initial instruction by Artie Romero.
Chloroform was removed using a rotary evaporator, spinning at an angle to evenly coat the vial
in the lipid. Lipids were further dried on a high vacuum line for 3-5 hours. Just before preparing
the nanodisc solution, 5 mg of lipids were dissolved 654 μL of buffer (20 mM HEPES pH 7.5,
150 mM NaCl, 0.5 mM CaCl2 and 14 mM DDM) for a final concentration of 10 mM lipids. This
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solution was vortexed for 45 seconds and sonicated for 3 minutes until the solution was clear.
Dissolved lipids were chilled on ice.
Preparation of adsorbent beads
Dry BioBeads SM-2 Resin (Bio-Rad) was loaded onto a simple column. Beads were
washed with 3 mL of methanol and further washed 3 times with 15 mL of MilliQ water. Beads
were then washed with buffer (20 mM HEPES pH 7.5, 150 mM NaCl) and transferred to a 50
mL conical forming a 50% slurry using the same buffer. Washed beads were stored at 4 ºC until
use.
Formation of TMEM16A nanodiscs
Full-length human TMEM16A acd cloned from CF airway epithelial cells into the
pHLsec vector was expressed in Expi293F cultured at 37 ºC and 8% CO2 in serum-free Expi293
Expression Media (ThermoFisher Scientific) supplemented with 0.5% penicillin/streptomycin
(Pen/Strep, Gibco). The channel was expressed via transient transfection with either Hype-5 or
Hype-293 (OZ Biosciences, San Diego, CA) at a 1:1.5 ratio (μg of DNA: μL of transfection
reagent) using 1 μg of plasmid per 1 million cells, similar to our previous reports (3). Cell pellets
were harvested by centrifugation after 96 hours by centrifugation, and resuspended in buffer A
(20 mM HEPES pH 7.5, 150 mM NaCl, 0.5 mM CaCl2) with 1x protease inhibitors (Sigma) and
2 mM PMSF at 10 mL buffer A per gram of cells. DDM (Sigma-Aldrich) was added to 0.5% and
TMEM16A extracted by gentle agitation for 2 hours at 4 ºC. Insoluble material was removed by
centrifugation at 22,000 x g for 40 minutes and the supernatant filtered through a 0.45 μm
vacuum filter. TMEM16A was affinity purified by batch binding method for 2 hours at 4 ºC with
Ni-NTA Superflow resin (Qiagen, Hilden, Germany) after adjusting to pH 8.5 and 20 mM
imidazole in 0.12% digitonin. Protein was washed with 20 column volumes (CV) of buffer
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containing 50 mM K2HPO4 (pH 8), 300 mM NaCl, and 50 mM imidazole and eluted in 5 CV of
buffer containing 50 mM K2HPO4 (pH 8), 300 mM NaCl, and 300 mM imidazole. The eluate
was concentrated in a 100 kDa centrifuge concentrator at 4 ºC, resuspending after 5 minutes each
time.
As mouse TMEM16A was found to be a dimer in cryo-EM structures, and 2 molecules of
MSP are required to form one nanodisc, an initial ratio of 2:2 TMEM16A:MSP2N2 was
determined. From there, the ratio of lipids was determined, testing ratios of 2:2:100, 2:2:150 and
2:2:200 TMEM16A:MSP2N2:lipids. A ratio of 2:8:200 was also tried based on the mouse cryoEM structure by Dang et al. (6). Both soy PC and soybean lipids were tested. A ratio of 2:8:200
soy PC appeared to work best. Concentrated TMEM16A, thawed MSP2N2 and freshly prepared
soy PC were mixed at a ratio of 2:8:200, adjusting the final DDM concentration to 3 mM. This
mixture was incubated for 30 minutes on ice, aiming for a volume of 500 μL or less to facilitate
loading onto a size exclusion column. After the 30 minute incubation, BioBeads were added at a
3:1 v/v ratio. BioBeads were added in two batches to slowly remove detergent, once after the 30
minute incubation and once after an overnight incubation at 4 ºC on a rotator. After 2-4 hours
incubation with the second batch of BioBeads, beads were removed after centrifugation at
14,000 rpm for 5 minutes and filtration through a 0.22 um syringe filter. The sample was loaded
onto a Superose 6 GL 10/300 size exclusion column (GE Healthcare) and run in buffer A (20
mM HEPES pH 7.5, 150 mM NaCl, 0.5 mM CaCl2) (Figure 22B). Purified nanodiscs were
concentrated on a 100 kDa centrifuge concentrator to at least 1 mg/mL as calculated from
absorbance at 280 nm for electron microscopy and co-elution with CLCA1. Yields were
typically 0.3 mg/L culture.
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Figure 22 TMEM16A nanodisc formation and co-elution with N-terminal CLCA1 E157Q
A) Flow-chart diagram of TMEM16A purification and nanodisc formation. Human TMEM16A
isoform acd with a C-terminal 6-histidine tag was expressed in Expi293 cells. Membrane protein
was extracted in 1% digitonin or 0.5% DDM and TMEM16A purified by Nickel affinity
chromatography in batch binding method in detergent conditions. The nickel elution was
concentrated and mixed with MSP2N2 and lipids. Detergent was slowly removed with the
addition of adsorbent beads (SM2 biobeads) and stably formed nanodiscs (determined by
fractions containing TMEM16A and MSPN2) isolated by size exclusion chromatography. B)
Left panel, western blot of size exclusion chromatography of TMEM16A nanodiscs. Right panel,
negative stain transmission electron microscopy (TEM) of TMEM16A in nanodiscs. Input, input
to size exclusion chromatography column. C) Left panel, western blot of the co-elution of
TMEM16A nanodiscs and N-terminal CLCA1 E157Q. Right panel, negative stain transmission
electron microscopy (TEM) of TMEM16A nanodiscs and N-terminal CLCA1 E157Q co-elution.
Input, input to size exclusion chromatography column.
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Expression and purification of CLCA1 for nanodiscs preparations
Rationale
Though we know the minimal region of CLCA1 to potentiate TMEM16A is the vWA
domain, in order to enhance the success of structure determination of CLCA1-TMEM16A by
cryo-EM by generating a larger complex, the full N-terminal CLCA1 fragment (N-CLCA1) that
would normally engage TMEM16A in a cellular context was used. The N-terminal CLCA1
fragment in pHLsec is about 75 kDa. In the case that one molecule of CLCA1 binds the
TMEM16A dimer, this would generate a 305 kDa complex; in the case that two molecules of
CLCA1 bind the dimer, this would generate a 380 kDa complex. Both would be ideal sizes for
structure determination by cryo-EM. Furthermore, to reduce potential proteolysis of either
protein by the metalloprotease of domain of CLCA1, which is present in the N-terminal
fragment, an inactivating mutation in the metalloprotease domain was constructed in the Nterminal fragment used in these preparations. This construct (N-CLCA1 E157Q) is inactive as a
metalloprotease but still capable of potentiating currents through TMEM16A (9). Thus, NCLCA1 E157Q subcloned into the pHLsec vector was used for expression in mammalian
culture.
Expression and purification
Expi293 cells were cultured at 37 ºC and 8% CO2 in serum-free Expi293 Expression
Media (ThermoFisher Scientific) supplemented with 0.5% penicillin/streptomycin (Pen/Strep,
Gibco). N-CLCA1 E157Q (residues 22-695, excluding the signal sequence residues 1-21) was
expressed in Expi293 cells via transient transfection with either Hype-5 or Hype-293 (OZ
Biosciences, San Diego, CA) at a 1:1.5 ratio (μg of DNA: μL of transfection reagent) using 1 μg
of plasmid per 1 million cells, similar to our previous reports (3). Media from supernatants were
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harvested after 72-96 hours by centrifugation, concentrated to 1/10 of the original volume using
a 30 kDa cutoff membrane (Ultracel Ultrafiltration Discs, EMD Millipore) and adjusted to pH
8.5 and 5 mM imidazole. The concentrated protein was purified using Ni-NTA Superflow resin
(Qiagen, Hilden, Germany) and eluted in 5 mL of buffer containing 50 mM K2HPO4 (pH 8), 300
mM NaCl, and 250 mM imidazole. Purified N-CLCA1 E157Q was concentrated in a 30 kDa
cutoff centrifuge concentrator and exchanged into buffer containing 20 mM HEPES pH 7.5, 150
mM NaCl, 0.5 mM CaCl2 and 0.5 mM MgCl2.
Size exclusion chromatography co-elution of TMEM16A nanodiscs and N-CLCA1.
Complexes of TMEM16A and CLCA1 were generated as follows. Concentrated NCLCA1 was mixed in excess with purified and concentrated TMEM16A nanodiscs on ice for 30
minutes in buffer containing 20 mM HEPES pH 7.5, 150 mM NaCl, 0.5 mM CaCl2 and 0.5 mM
MgCl2 (since we know that the interaction is dependent upon divalent cation, most likely Mg2+).
The complex was then purified by size exclusion chromatography using a Superose 6 10/300 GL
(GE Healthcare) in 20 mM HEPES pH 7.5, 150 mM NaCl, 0.5 mM CaCl2 and 0.5 mM MgCl2. A
slightly left-shifted peak was observed, indicating that a higher molecular weight complex was
formed. These fractions contained TMEM16A (115 kDa monomer band), N-CLCA1 (75 kDa
monomer band) and MSP2N2 (45 kDa monomer band) by western blot (Figure 22C). The
complex was concentrated using a 100 kDa cutoff centrifuge concentrator to at least 1 mg/mL as
calculated from absorbance at 280 nm for electron microscopy.

3.2 Cryo-EM Structure of TMEM16A and CLCA1
3.2.1 Negative stain of TMEM16A and TMEM16A/N-CLCA1
Negative stain grids of TMEM16A alone and TMEM16A/N-CLCA1 complexes were
prepared for imaging by transmission electron microscopy (TEM). Carbon coated 200 mesh
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copper grids (Ted Pella 0184-F) were glow discharged (Leica) at 12 mA, 2 mbar, 50 mm, 0º tilt.
Fresh preparations of TMEM16A alone and TMEM16A/N-CLCA1 complexes at 10-20 μg/mL
were stained onto glow-discharged copper grids for 1 minute, washed in 5 droplets of MilliQ
water and stained in 0.75% (w/v) uranyl formate (UF) or 2% (w/v) uranyl acetate (UA), both
freshly filtered, for 3 minutes. Excess UF or UA was blotted away using a Kimwipe and dried
for 15 minutes. Prepared grids were imaged on a 120 kV JEOL JEM-1400Plus TEM.
Detergent solubilized TMEM16A particles appeared homogenous save for some
aggregate. TMEM16A nanodiscs alone showed greater heterogeneity, which could be due to a
number of factors, including nanodiscs that are unstable. N-CLCA1/TMEM16A nanodiscs
showed even greater heterogeneity, which could be due to additional N-CLCA1 that is not bound
to TMEM16A and contributing to background noise (N-CLCA1 is roughly 75 kDa as a
monomer). However, co-elutions of N-CLCA1/TMEM16A appeared much more homogenous
than samples in which N-CLCA1 and TMEM16A nanodiscs were simply mixed before grid
preparation (a technique used by Scapin et al. (10) for the insulin-insulin receptor complex),
likely because excess N-CLCA1 was removed. Thus, only co-elutions were used to make
cryogrids.

3.2.2 Cryo-EM Structure of TMEM16A nanodiscs
Imaging
Cryogrids were prepared as follows. TMEM16A nanodiscs at 500 μg/mL (as calculated
from absorbance at 280 nm) in a 3 μL volume were pipetted onto gold Quantifoil R 300 2/2
holey mesh copper carbon grids that were plasma cleaned for 20 seconds. Grids were blotted
once for 2 seconds with a blotting force of -2 at 4 ºC and 100% humidity and flash-frozen in
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liquid ethane using a Vitribot (Thermoscientific). Cryo-EM data were collected on a 300 kV FEI
Titan Krios electron microscope.

3.3 CLCA1-TMEM16A binding Interaction
3.3.1 Expression, purification and biotinylation of Avitag TMEM16A acd in
mammalian system
Human TMEM16A acd was cloned into the pHLsec Avitag vector (11) that, when cloned
using KpnI sites has a BirA sequence at the C-terminus, allowing for the specific biotinylation of
this sequence at the C-terminus (Figure 23A). This construct was expressed and purified in
Expi293 and prepared in nanodiscs using the same protocol as for cryo-EM sample preparation
for TMEM16A nanodiscs alone (Figure 23B). Fractions from size exclusion chromatography
were concentrated in a 100 kDa centrifuge concentrator to a volume of 400 μL and exchanged
into biotinylation buffer containing 100 mM Tris pH 7.5, 5 mM MgCl2, 200 mM NaCl and 0.5
mM CaCl2. To the protein was added the following: 40 μL BioA buffer (0.5 M bicine pH 8.3),
40 μL BioB buffer (100 mM ATP, 100 μM MgOAc), biotin to 50 μM and BirA enzyme (~10
μL). TMEM16A nanodiscs were specifically biotinylated on a rotator at 4 ºC overnight.
Biotinylation was confirmed by streptavidin-HRP western blot (Figure 23C). Biotinylated
TMEM16A nanodiscs were concentrated on a 100 kDa centrifuge concentrator and exchanged
into buffer containing 20 mM HEPES pH 7.5, 150 mM NaCl, and 0.5 mM CaCl2.

3.3.2 Expression and purification of CLCA1 vWA for binding experiments
Expi293 cells were cultured at 37 ºC and 8% CO2 in serum-free Expi293 Expression
Media (ThermoFisher Scientific) supplemented with 0.5% penicillin/streptomycin (Pen/Strep,
Gibco) WT human CLCA1 vWA domain (297-478) was expressed in Expi293 cells via transient
transfection with either Hype-5 or Hype-293 (OZ Biosciences, San Diego, CA) at a 1:1.5 ratio
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(μg of DNA: μL of transfection reagent) using 1 μg of plasmid per 1 million cells, similar to our
previous reports (3). Media from supernatants were harvested after 72-96 hours by
centrifugation, concentrated to 1/10 of the original volume using a 10 kDa cutoff membrane
(Ultracel Ultrafiltration Discs, EMD Millipore) and adjusted to pH 8.5 and 5 mM imidazole. The
concentrated protein was purified using Ni-NTA Superflow resin (Qiagen, Hilden, Germany)
and eluted in 5 mL of buffer containing 50 mM K2HPO4 (pH 8), 300 mM NaCl, and 250 mM
imidazole. The eluted protein was concentrated and purified by size exclusion chromatography
using the Superdex75 Increase 10/300 GL (GE Healthcare) in 20 mM Tris pH 8.0 and 150 mM
NaCl. Purified CLCA1 vWA was dialyzed into buffer containing 20 mM HEPES (pH 7.4) and
150 mM NaCl and concentrated in a 10 kDA cutoff centrifuge concentrator (Vivaspin 500,
Sartorius) to 1 mM as calculated from absorbance at 280 nm.
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Figure 23 Biolayer interferometry experiments with TMEM16A and CLCA1
A) Schematic of biolayer interferometry experiment (BLI). Human TMEM16A in nanodiscs
with a C-terminal biotinylation tag binds to a streptavidin pin as ligand. CLCA1 vWA domain in
the well is the analyte. B) TMEM16A with a C-terminal biotinylation and 6-histidine tag is
purified by nickel affinity chromatography. A faint band is present at ~100 kDa corresponding to
monomer TMEM16A. FT, flow-through. W1-W4, washes 1-4. E1 and E2, elutions 1 and 2. C)
Specific biotinylation of the TMEM16A construct using BirA enzyme is assessed by western
blot with streptavidin-HRP. Pre-BirA, before biotinylation. Post-BirA, after biotinylation. After
desalting, TMEM16A nanodiscs samples desalted to remove excess reaction components (biotin,
salts, etc). A monomer TMEM16A band is observed as biotinylated ~100 kDa. D) Example BLI
experiment. Blue line, TMEM16A nanodiscs with CLCA1 vWA domain. Red line, TMEM16A
nanodiscs in buffer. Cyan line, Free pin with CLCA1 vWA domain. Green line, Free pin in
buffer.
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3.3.3 CLCA1-TMEM16A direct binding interaction by biolayer
interferometry
Biotinylated TMEM16A nanodiscs were bound to superstreptavidin (SSA) pins (Pall
ForteBio), either for 10 minutes or overnight since 10 minute loading did not result in saturated
binding. Experiments were carried out using CLCA1 vWA (297-478) as the analyte at 78 nM to
10 μM at 25 ºC or 10 ºC, in buffer containing 20 mM HEPES pH 7.5, 150 mM NaCl, 0.5 mM
CaCl2, 0.5 mM MgCl2, and 0.1% bovine serum albumin (BSA). No Tween-20 or other detergent
was used, to limit destruction of nanodiscs. In both cases, it appears that vWA is binding to the
pin at high concentrations (2.5-10 μM). Strong binding between CLCA1 vWA and TMEM16A
was not observed (Figure 23D). This could be due to insufficient loading to the pin, or
TMEM16A nanodiscs that are not properly oriented or not intact on the pin.
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Chapter 4: CLCA2 and CLCA4
I would like to acknowledge Monica Sala-Rabanal, as well as Conor McClenaghan and Alex
Hanson from the Nichols Lab, who performed the whole cell patch clamp experiments that made
many of the experiments included in this chapter possible.
Portions of CLCA4 experiments in this chapter are included in a manuscript in preparation:
Sala-Rabanal, Berry, et al. Modulation of TMEM16B Channel Activity by the CalciumActivated Chloride Channel Regulator 4 (CLCA4) in Human Cells. Manuscript in preparation.
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4.1 CLCA2 and CLCA4 increase endogenous calcium
activated chloride current (CaCC)
In unpublished experiments performed by Zeynep Yurtsever and Monica Sala-Rabanal,
expression of full-length WT human CLCA2 and full-length WT human CLCA4 (hCLCA4) in
HEK293T cells elicited calcium activated chloride currents compared to control vector (Figure
24). As hCLCA1, hCLCA2 and hCLCA4 belong to the same family, and mouse CLCA family
members appear to be redundant in their activities in the airway (1), it was unclear whether
CLCA2 and CLCA4 also potentiated calcium activated chloride currents through TMEM16A.
Further experiments described below suggest that human CLCA2 and CLCA4 likely have their
effects on distinct TMEM16 channels.
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Figure 24 CLCA2 and CLCA4 potentiate calcium-activated chloride currents
A) Schematic of the experimental protocol. Currents in HEK293T cells expressing wild-type
full-length human CLCA2 or CLCA4 or vector control (mock) were measured by whole-cell
patch clamp in the presence of intracellular 10 μM Ca2+. Example traces are shown below the
protocol schematic. B) Left, current-voltage relationships of HEK293T cells expressing vector
control (mock), CLCA2 and CLCA4. Right, currents at +100 mV are shown. From Monica SalaRabanal.

4.2 Studies of CLCA4
4.2.1 CLCA4 vWA domain potentiates TMEM16B
CLCA4 does not increase surface localization of TMEM16A unlike CLCA1
As one step towards determining the specificity amongst the CLCA family for CaCC targets,
conditioned media was generated by expressing full-length WT human CLCA4, CLCA1 or
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vector control (pHLsec) in HEK293T. Cells were cultured in DMEM (Gibco) supplemented with
1% penicillin/streptomycin (Gibco), 1% non-essential amino acids (NEAA) (Gibco), 1%
glutamine (Gibco) and 10% fetal bovine serum (FBS). Expression was achieved by transient
transfection using 293Fectin at a ratio of 1:2 (μg of DNA: μL of transfection reagent) on cells
plated to 70-90% confluency on poly-L-lysine (Sigma-Aldrich) coated #1-1/2 Micro Coverglass
coverslips 12 mm diameter (Electron Microscopy Sciences) coated according to manufacturer’s
instructions for 48 hours. After expression, media was cleared by centrifugation and applied to
naïve HEK293T cells plated to 70% confluency. After 48 hours of exposure, cells were washed 3
times with cold phosphate buffered saline (PBS), fixed with 4% paraformaldehyde for 5 minutes
on ice, left non-permeabilized, washed with phosphate buffered saline, blocked with 1% BSA in
PBS for 1 hour at room temperature, and stained overnight at 4 ºC with goat anti-TMEM16A
antibody S20 (Santa Cruz) diluted 1:50. Antibody S20 targets the extracellular epitope of the α9α10 loop of TMEM16A. Coverslips were then washed and stained with donkey anti-goat
AlexaFluor 488 (Invitrogen) diluted 1:200 for 1 hour at room temperature. Coverslips were
washed, mounted onto glass slides with Vectashield Mounting Medium with DAPI (Vector
Labs) and polymerized with clear nail polish. Cells were imaged using a Zeiss LSM 880
confocal laser-scanning microscope with Airyscan (Carl Zeiss Microscopy). The images were
acquired and batch-processed with Zen software (Carl Zeiss Microscopy). For each experiment,
all cells were treated on the same day and fixed, stained and imaged in parallel using the same
acquisition and display settings.
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Figure 25 CLCA4 does not increase TMEM16A surface localization
Confocal microscopy of non-permeabilized 293T cells expressing human CLCA1, CLCA4 or
vector control (pHL) and stained with and anti-TMEM16A antibody (green) targeted against the
α9- α10 loop of TMEM16A. Nuclear staining with DAPI is shown (blue).
As expected, CLCA1 increased surface localization of TMEM16A as evidenced by
increased TMEM16A signal in these non-permeabilized cells (Figure 25). However, the signal
from CLCA4-conditioned cells was the same as vector control if not even slightly reduced. This
experiment was the first indication that CLCA4 does not elevate calcium activated chloride
current through increased TMEM16A surface localization (though it does not rule out the
possibility that CLCA4 functions through TMEM16A via an alternative mechanism).
CLCA4 potentiates CaCC specifically through TMEM16B
To further identify the calcium-activated chloride channel through which CLCA4 may
act, electrophysiology experiments utilizing siRNA were performed. Because TMEM16B is the
other known calcium-activated chloride channel in the TMEM16 family with no other confirmed
activity (such as lipid scrambling or in transporting cations), we decided to target this channel
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with siRNA in addition to TMEM16A. Conditioned media was generated by expressing fulllength wild-type human CLCA4 or vector control (pHLsec) in HEK293T cells. Cells were
cultured in DMEM (Gibco) supplemented with 1% penicillin/streptomycin (Gibco), 1% nonessential amino acids (NEAA) (Gibco), 1% glutamine (Gibco) and 10% fetal bovine serum
(FBS). Expression was achieved by transfection using 293Fectin at a ratio of 1:2 (μg of DNA:
μL of transfection reagent) on cells plated to 70-90% confluency in 6 well plates for 48 hours.
After expression, media was cleared by centrifugation. At the same time, another set of
HEK293T cells plated to 70% confluency were transfected with 20 nM medium GC scramble
siRNA control (Stealth RNAi siRNA Negative Control Medium GC Duplex, Invitrogen),
TMEM16A siRNA (Stealth siRNA ANO1 HSS123904, ThermoFisher) or TMEM16B siRNA
(Stealth siRNA ANO2 HSS125973, Thermofisher) with Lipofectamine 2000 (Invitrogen) at a
ratio of 20 nM: 20 μL (nM siRNA: μL of transfection reagent) for 48 hours. Cells transfected
with siRNA were then plated to 5-10% confluency in cleared conditioned media overnight onto 8
mm cover glass (Electron Microscopy Sciences). Currents were measured by whole cell patch
clamp electrophysiology performed by Monica Sala-Rabanal. In a previous publication, siRNA
knockdown of TMEM16A was shown to be effective at reducing TMEM16A mRNA and
protein. However, available antibodies to TMEM16B have not successfully detected endogenous
or exogenous TMEM16B (of which the exogenous expression has been confirmed by 6-histidine
tags).
In mock-conditioned media, calcium activated chloride current was not elevated for any
siRNA condition. However, with CLCA4-conditioned media, control siRNA cells demonstrated
elevated current. Knockdown of TMEM16A did not have an effect on elevated current produced
by CLCA4-conditioned media, but TMEM16B knockdown did abrogate CLCA4-mediated
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potentiation of CaCC. Together with previous data, this suggests that CLCA4 potentiates
currents through TMEM16B and not through TMEM16A.
CLCA4 vWA is the minimal domain required to potentiate CaCC through TMEM16B
In a similar siRNA experiment, and based on the observation that the minimal domain of
CLCA1 that potentiates TMEM16A is the vWA domain, likewise the minimal domain of
CLCA4 was identified. The same protocol was executed but using the wild-type human CLCA4
vWA domain (297-479).
Much like WT full-length CLCA4, its vWA domain elevates currents in cells receiving
scramble siRNA compared to mock conditioned media. Similarly, the vWA domain potentiated
currents when TMEM16A was knocked down. However, TMEM16B knockdown abrogated the
potentiation (Figure 26). Thus, the minimal domain of CLCA4 required to potentiate TMEM16B
is the vWA domain.
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Figure 26 CLCA4 potentiates CaCC through TMEM16B and not through TMEM16A
A) Schematic of the experimental protocol. Media from cells expressing CLCA4 (full-length or
vWA domain) or vector control (pHL) is applied to HEK293T cells receiving either scrambled
siRNA (siControl) or siRNA targeting TMEM16A or TMEM16B overnight. Currents were
measured by whole-cell patch clamp. B,C) Whole cell patch clamp of cells receiving scrambled
siRNA (siControl), or TMEM16A or TMEM16B siRNA and cultured in media harvested from
cells expressing CLCA4 full-length (B) or vWA domain (C). Currents at +100 mV are shown.
Reproduced from Sala-Rabanal, Berry et al. Manuscript in preparation.
CLCA4 potentiation of TMEM16B is MIDAS dependent
Human CLCA4 vWA domain also contains a perfect metal ion dependent adhesion site
(MIDAS): a DXSXS motif followed by a Thr and then followed by an Asp (Figure 27). Since
CLCA1 vWA and many vWA domains in other proteins depend on the MIDAS and a divalent
cation to bind to a ligand (2, 3), the same dependency was investigated for CLCA4. In our
investigations with CLCA1, it was discovered that mutating S316 and T383 to Ala nearly
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completely blocked potentiation of TMEM16A by CLCA1. Thus, we chose to focus on these
residues in CLCA4.

Figure 27 Phyre2 model of CLCA4 vWA domain superimposed on CLCA1 vWA domain
structure
Human CLCA4 vWA domain (purple) sequence was threaded onto the human CLCA1 vWA
domain structure (green) using Phyre2 one-to-one threading mode. MIDAS residues for both
CLCA4 model and CLCA1 structure are labeled. The residue glycosylated in CLCA4 (N340) is
also labeled. It is in a reasonably exposed position to be glycosylated.
QuikChange Lightning (Agilent) was used to generate the mutations S316A, T383A, and
T383+S316A in full length CLCA4 vWA domain within the pHLsec construct. Conditioned
media was generated by expressing these mutants or vector control (pHLsec) in HEK293T cells.
Cells were cultured in DMEM (Gibco) supplemented with 1% penicillin/streptomycin (Gibco),
1% non-essential amino acids (NEAA) (Gibco), 1% glutamine (Gibco) and 10% fetal bovine
serum (FBS). Expression was achieved by transient transfection using 293Fectin at a ratio of 1:2
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(μg of DNA: μL of transfection reagent) on cells plated to 70-90% confluency in 6 well plates
for 48 hours. After expression, media was cleared by centrifugation. At the same time, another
set of HEK293T cells were then plated to 5-10% confluency in cleared conditioned media
overnight. Currents were measured by whole cell patch clamp electrophysiology performed by
Monica Sala-Rabanal, Conor McClenaghan or Alex Hanson. Protein expression was confirmed
by western blot.
As before, CLCA4 vWA domain potentiated currents in HEK293T cells, but the double
T383+S316A mutant could not and current levels remained similar to vector control (Figure 28).
Though further experiments will be needed to confirm dependence on the cation itself, based on
these experiments, the CLCA4 vWA domain appears to depend on its MIDAS to potentiate
currents through TMEM16B.

Figure 28 CLCA4 potentiation of calcium-activated chloride currents is MIDAS dependent
Currents in HEK293T cells expressing wild-type full-length human CLCA4 (black), wild-type
CLCA4 vWA domain (purple) or MIDAS mutant T383+S316A (green) or vector control (pHL,
grey) were measured by whole-cell patch clamp in the presence of intracellular 10 μM Ca2+.
Example traces are shown below the protocol schematic. Currents at +100 mV are shown.
Reproduced from Sala-Rabanal, Berry et al. Manuscript in preparation.
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4.2.2 Expression, purification, and crystallization trials of the CLCA4 vWA
domain
Expression, purification, and crystallization trials of WT CLCA4 vWA domain
Rationale and Cloning
To facilitate success in structure determination by X-ray crystallography based on the
success of CLCA1, and because the minimal domain of CLCA4 required to potentiate
TMEM16B is the vWA domain, crystallization trials with human CLCA4 vWA domain were
pursued. Human CLCA1 and CLCA4 vWA domains are 63.5% identical, and CLCA4 vWA may
produce crystals in conditions similar to CLCA1. Thus, CLCA1 crystallization steps were used
as a template for CLCA4 crystallization. Similar constructs of CLCA4 vWA were generated:
encompassing residues 302-477 and 302-479 by subcloning into pHLsec from a full length
CLCA4 gene using the AgeI and KpnI sites to include an optimized secretion signal and a 6histidine tag (4) for purification. The predicted molecular weight of this domain, residues 302477 and 302-479, in this construct without post-translational modification is 20.270 and 20.414
kDa, respectively.
Expression and purification of WT CLCA4 vWA domain from mammalian culture
Expi293 cells used for high-level protein expression were cultured at 37 ºC and 8% CO2
in serum-free Expi293 Expression Media (ThermoFisher Scientific) supplemented with 0.5%
penicillin/streptomycin (Pen/Strep, Gibco) WT human CLCA1 vWA domains (302-476 and 302478) were expressed in Expi293 cells via transient transfection with either Hype-5 or Hype-293
(OZ Biosciences, San Diego, CA) at a 1:1.5 ratio (μg of DNA: μL of transfection reagent) using
1 μg of plasmid per 1 million cells, similar to our previous reports (5). Media from supernatants
were harvested after 72-96 hours by centrifugation, concentrated to 1/10 of the original volume
using a 10 kDa cutoff membrane (Ultracel Ultrafiltration Discs, EMD Millipore) and adjusted to
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pH 8.5 and 5 mM imidazole. The concentrated protein was purified using Ni-NTA Superflow
resin (Qiagen, Hilden, Germany) and eluted in 5 mL of buffer containing 50 mM K2HPO4 (pH
8), 300 mM NaCl, and 250 mM imidazole. The eluted protein was concentrated and purified by
size exclusion chromatography using the Superdex75 Increase 10/300 GL (GE Healthcare) in 20
mM Tris pH 8.0 and 150 mM NaCl. Purified CLCA4 vWA was dialyzed into buffer containing
20 mM HEPES (pH 7.4) and 150 mM NaCl and concentrated in a 10 kDa cutoff centrifuge
concentrator (Vivaspin 500, Sartorius) to 5 mg ml-1, as calculated from absorbance at 280 nm,
for crystallization. Protein quality was assessed by Coomassie stain and western blot. Two bands
were observed around 20-30 kDa by both western blot and protein stain (Figure 29), indicating
that CLCA4 vWA is post-translationally modified or proteolyzed.
Crystallization trials of WT CLCA4 vWA domain
Crystallization screens Qiagen PEG I and II screens were chosen based on the success of
CLCA1 crystallization and the high sequence identity between CLCA1 and CLCA4. Trials were
set by hanging drop using a TTP Mosquito robot using the 100 nL protein + 100 nL well
solution. Crystals were grown at 17 ºC by hanging drop vapor diffusion. Crystal-like species
were observed in conditions similar to CLCA1, but no crystals could be reproduced.
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Figure 29 WT CLCA4 vWA domain purification
A-C). Left panels, western blot of nickel purification of CLCA4 vWA domain constructs, (A)
vWA short (residues 302-477), (B) vWA short-long (residues 302-479) and (C) vWA long
(residues 297-479). Two bands near 20-30 kDa are observed, with the higher molecular weight
band often stronger in intensity. FT, flow-through. W, wash. E, elution. Middle panels, SDSPAGE of nickel purification and size exclusion chromatography (s75 increase) of CLCA4 vWA
domain constructs. Lines above the lanes correspond to the fractions from the size exclusion
column. Right panels, size exclusion chromatography of CLCA4 vWA domain nickel elutions.
Lines above the peaks correspond to the fractions of SDS-PAGE.
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Predicted glycosylation in CLCA4 vWA domain
As the CLCA proteins are processed in the secretory pathway, post-translational
modifications such as glycosylations are possible. To determine whether CLCA4 may contain a
glycosylation site, the NetNGlyc 1.0 server (6) was employed. The CLCA4 sequence from 297479 was submitted (Figure 30). One site, was predicted, N340 (sequence NGSW), with a score
of 0.53. To determine whether this residue may be accessible for glycosylation, the CLCA4
sequence was modeled onto the CLCA1 crystal structure using the one-to-one threading mode in
Phyre2 (7). Residue N340 is found at the C-terminus of β2, and is very likely exposed for
glycosylation. Thus, further steps focused on the verification and removal of this glycosylation to
facilitate crystal packing in crystallization trials.
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Figure 30 Results from N-glycosylation prediction server NetNGlyc 1.0
CLCA4 vWA domain (residues 297-479) sequence was submitted to the NetNGlyc 1.0 server
(6). One position, N340, was predicted to likely be glycosylated.
Expression, purification and crystallization trials of deglycosylated CLCA4 vWA domain
To confirm the presence of a glycosylation, confirm that the glycosylation was producing
the two observed bands by western blot and protein stain, and produce deglycosylated protein
suitable for crystallization trials, a number of methods were employed to generate deglycosylated
CLCA4 vWA domain: 1) kifunensine treatment and EndoHf cleavage, 2) expression of a
CLCA4 glycosylation mutant and 3) expression of CLCA4 from a GnTI– system followed by
EndoHf cleavage.
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Kifunensine and EndoHf cleavage
Expi293 cells used for high-level protein expression were cultured at 37 ºC and 8% CO2
in serum-free Expi293 Expression Media (ThermoFisher Scientific) supplemented with 0.5%
penicillin/streptomycin (Pen/Strep, Gibco) WT human CLCA1 vWA domains (302-476 and 302478) were expressed in Expi293 cells via transient transfection with either Hype-5 or Hype-293
(OZ Biosciences, San Diego, CA) at a 1:1.5 ratio (μg of DNA: μL of transfection reagent) using
1 μg of plasmid per 1 million cells, similar to our previous reports (5). Originally, kifunensine
was added to a concentration of 1 μg/mL at the time of transfection. Kifunensine will limit
maturation of glycosylation, which will allow removal of the glycosylation with EndoHf at a
later step. Media from supernatants were harvested after 72-96 hours by centrifugation,
concentrated to 1/10 of the original volume using a 10 kDa cutoff membrane (Ultracel
Ultrafiltration Discs, EMD Millipore) and adjusted to pH 8.5 and 5 mM imidazole. The
concentrated protein was purified using Ni-NTA Superflow resin (Qiagen, Hilden, Germany)
and eluted in 5 mL of buffer containing 50 mM K2HPO4 (pH 8), 300 mM NaCl, and 250 mM
imidazole. The eluted protein was concentrated to a volume of 400 μL. Glycobuffer 3 (acetic
acid, supplied with the EndoHf enzyme by NEB) was added to 1x from a 10x stock and 10 μL of
EndoHf was added, and incubated at 4 ºC or room temperature on a rotator. To assess the extent
of deglycosylation, samples were taken at 0, and 4 hours and after an overnight incubation
(Figure 31), and assessed by western blot. While glycosylation removal was observed (by the
appearance of a more intense band at lower molecular weight and a less intense band at higher
molecular weight), the reaction was far from complete. To ensure that sufficient kifunensine was
added, the same protocol was attempted but using kifunensine at twice the typical concentration
(results not shown). Yet again, even an overnight incubation at room temperature did not
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completely remove the glycosylation. Thus, other methods were subsequently pursued, though
these samples were further purified and set in crystallization trials.
After EndoHf treatment, CLCA4 vWA was purified by size exclusion chromatography
using the Superdex75 Increase 10/300 GL (GE Healthcare) in 20 mM Tris pH 8.0 and 150 mM
NaCl. Purified CLCA4 vWA was dialyzed into buffer containing 20 mM HEPES (pH 7.4) and
150 mM NaCl and concentrated in a 10 kDa cutoff centrifuge concentrator (Vivaspin 500,
Sartorius) to 8 mg ml-1, as calculated from absorbance at 280 nm, for crystallization in Qiagen
PEG I and II screens. Trials were set by hanging drop using a TTP Mosquito robot using the 100
nL protein + 100 nL well solution. Crystals were grown at 17 ºC by hanging drop vapor
diffusion. To date, no crystal hits have been observed.
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Figure 31 Deglycoslyation of WT CLCA4 vWA domain by kifunensine treatment and
EndoHf cleavage
A-C). Panels from left to right: First panel, SDS-PAGE of nickel purification of CLCA4 vWA
domain constructs, (A) vWA short (residues 302-477), (B) vWA short-long (residues 302-479)
and (C) vWA long (residues 297-479) deglycosylated by kifunensine treatment during
expression in mammalian culture followed by EndoHf cleavage. FT, flow-through. W, wash. E,
elution. Second panels, SDS-PAGE of EndoHf cleavage before (0 hours) and after overnight
(O/N) cleavage. Third panels, western blots of EndoHf cleavage before (0 hours), and after 4
hours or overnight (O/N) cleavage. Deglycosylation is observed (by a more intense lower
molecular weight band) but is not complete. Fourth panels, size exclusion chromatography (s75
increase) of CLCA4 vWA domain constructs. Lines above the peaks correspond to the fractions
on SDS-PAGE. Fifth panel, size exclusion chromatography of CLCA4 vWA domain 302-477
after EndoHf cleavage. Lines above the lanes correspond to the fractions from the size exclusion
column.
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Cloning, expression, purification and crystallization trials of CLCA4 vWA N340Q
The N340Q glycosylation mutant was generated using QuikChange Lightning (Agilent)
in the WT CLCA4 vWA (302-477) construct within the pHLsec vector. The mutation was
confirmed by sequencing. The CLCA4 vWA N340Q mutant was expressed in Expi293 cells
cultured at 37 ºC and 8% CO2 in serum-free Expi293 Expression Media (ThermoFisher
Scientific) supplemented with 0.5% penicillin/streptomycin (Pen/Strep, Gibco) via transient
transfection with either Hype-5 or Hype-293 (OZ Biosciences, San Diego, CA) at a 1:1.5 ratio
(μg of DNA: μL of transfection reagent) using 1 μg of plasmid per 1 million cells, similar to our
previous reports (5). Media from supernatants were harvested after 72-96 hours by
centrifugation, concentrated to 1/10 of the original volume using a 10 kDa cutoff membrane
(Ultracel Ultrafiltration Discs, EMD Millipore) and adjusted to pH 8.5 and 5 mM imidazole. The
concentrated protein was purified using Ni-NTA Superflow resin (Qiagen, Hilden, Germany)
and eluted in 5 mL of buffer containing 50 mM K2HPO4 (pH 8), 300 mM NaCl, and 250 mM
imidazole. The eluted protein was concentrated and purified by size exclusion chromatography
using the Superdex75 Increase 10/300 GL (GE Healthcare) in 20 mM Tris pH 8.0 and 150 mM
NaCl. Purified CLCA4 vWA was dialyzed into buffer containing 20 mM HEPES (pH 7.4) and
150 mM NaCl and concentrated in a 10 kDA cutoff centrifuge concentrator (Vivaspin 500,
Sartorius) to 3 mg ml-1, as calculated from absorbance at 280 nm, for crystallization. Protein
quality was assessed by Coomassie stain and western blot. Only one band at the lower molecular
weight was observed (Figure 32). However, compared to WT CLCA4 vWA domain and
CLCA1, CLCA4 vWA N340Q expressed at much lower levels. Crystallization trials of the
N340Q mutant were set using the Qiagen PEG I and II screens. Trials were set by hanging drop
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using a TTP Mosquito robot using the 100 nL protein + 100 nL well solution. Crystals were
grown at 17 ºC by hanging drop vapor diffusion. To date, no crystals hits have been obtained.

Figure 32 Purification of CLCA4 vWA domain N340Q
A-C). Left panel, western blot of CLCA4 vWA domain WT and N340Q expressions in Expi293
cells. Right panel, size exclusion chromatography (s75 increase) of purified CLCA4 vWA
domain N340Q. Expression and yields of the mutant were low.
Expression and purification of CLCA4 vWA domain from GnTI– mammalian culture
Soon after pursuing the aforementioned methods, an Expi293 GnTI– line (Gibco) became
available. This would allow for the high level expression of protein (due to the high densities that
Expi293 cells can grow) that leaves glycosylations unprocessed. Given the poor success with
kifunensine and EndoHf treatment and low expression of the N340Q mutant, the Expi293 GnTI–
line seemed to be an ideal system for expression and removal (with EndoHf) of the glycosylation
in the CLCA4 vWA domain.
Expi293 GnTI– cells were cultured at 37 ºC and 8% CO2 in serum-free Expi293
Expression Media (no additional or specialized media is required for this line) (ThermoFisher
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Scientific) supplemented with 0.5% penicillin/streptomycin (Pen/Strep, Gibco). WT human
CLCA4 vWA domains (302-477 and 302-479) were expressed in Expi293 cells via transient
transfection with either Hype-5 or Hype-293 (OZ Biosciences, San Diego, CA) at a 1:1.5 ratio
(μg of DNA: μL of transfection reagent) using 1 μg of plasmid per 1 million cells, similar to our
previous reports (5). Media from supernatants were harvested after 72-96 hours by
centrifugation, concentrated to 1/10 of the original volume using a 10 kDa cutoff membrane
(Ultracel Ultrafiltration Discs, EMD Millipore) and adjusted to pH 8.5 and 5 mM imidazole. The
concentrated protein was purified using Ni-NTA Superflow resin (Qiagen, Hilden, Germany)
and eluted in 5 mL of buffer containing 50 mM K2HPO4 (pH 8), 300 mM NaCl, and 250 mM
imidazole. The eluted protein was concentrated to a volume of 400 μL. Glycobuffer 3 (acetic
acid, supplied with the EndoHf enzyme by NEB) was added to 2x from a 10x stock and 20 μL of
EndoHf was added, and incubated at room temperature on a rotator. The extent of
deglycosylation was assessed by western blot and protein stain. In nickel purification, two bands
can be observed. After glycosylation removal, only the lower molecular weight band is observed
(Figure 33).
After EndoHf treatment, CLCA4 vWA was purified by size exclusion chromatography
using the Superdex75 Increase 10/300 GL (GE Healthcare) in 20 mM Tris pH 8.0 and 150 mM
NaCl. Purified CLCA1 vWA was dialyzed into buffer containing 20 mM HEPES (pH 7.4) and
150 mM NaCl and concentrated in a 10 kDa cutoff centrifuge concentrator (Vivaspin 500,
Sartorius) to 5-8 mg ml-1, as calculated from absorbance at 280 nm, for crystallization in Qiagen
PEG I and II screens. Trials were set by hanging drop using a TTP Mosquito robot using the 100
nL protein + 100 nL well solution. Crystals were grown at 17 ºC by hanging drop vapor
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diffusion. Crystal-like species were observed in conditions similar to CLCA1, but no crystals
could be reproduced.

Figure 33 Purification of CLCA4 vWA domain from GnTI– mammalian culture
A,B). Left panels, SDS-PAGE of nickel purification and EndoHf cleavage of CLCA4 vWA
domain constructs, (A) vWA short (residues 302-477), and (B) vWA short-long (residues 302479) expressed in Expi293 GnTI– cells. FT, flow-through. W, wash. E, elution. Pre-EndoHf,
sample before cleavage with EndoHf. Post-EndoHf, sample after overnight EndoHf cleavage.
Middle panels, SDS-PAGE of size exclusion chromatography (s75 increase) of CLCA4 vWA
domain constructs after EndoHf cleavage. Asterisk above the lanes correspond to the fractions
from the size exclusion column. Right panels, size exclusion chromatography of CLCA4 vWA
domain after EndoHf cleavage. Asterisks above the peaks correspond to the fractions of SDSPAGE.
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4.3 Studies of CLCA2
4.3.1 Expression, purification and crystallization trials of CLCA2 vWA
domain
An imperfect MIDAS motif is present in the CLCA2 vWA domain
Though it is known that CLCA2 also potentiates a calcium-activated chloride current, the
minimal domain of CLCA2 required to carry out this activity has yet to be determined. However,
given the precedent of CLCA1 and CLCA4, the vWA domain of CLCA2 likely drives
potentiation of calcium-activated chloride current. Thus, elucidating the structure of CLCA2
vWA domain will be important towards uncovering the mechanism by which CLCA2 does this.
Furthermore, in carefully comparing the CLCA family vWA domains, it becomes apparent that
CLCA2 is most different in sequence. CLCA1 and CLCA2 vWA domains are 45% identical,
while CLCA1 and CLCA4 are 63.5% identical. While human CLCA1 and CLCA4 contain
perfect MIDAS residues (DXSXS followed by a threonine and then an aspartate), human
CLCA2 appears to only match 2 out of 5 of these residues (and 2 or 3 of these residues match for
mouse and pig CLCA2s). Instead, for human CLCA2, the second serine in the DXSXS motif is a
lysine (K321), the expected threonine is an isoleucine (I390) and the expected aspartate is a
serine (S420) (Figure 34). If the vWA domain of CLCA2 does potentiate CaCC, it is unclear
whether the potentiation is MIDAS dependent. There are reports of vWA domain interactions
being MIDAS- independent; in the case of EMS16, the ligand binds adjacent to the MIDAS (8).
If the mechanism is dependent upon these atypical residues in CLCA2, the mode of engagement
will be unique for the human CLCA family. Either neighboring residues will be responsible for
presenting the divalent cation, or the lysine, isoleucine, and serine will coordinate the interaction
in unexpected ways. Thus, it is of critical importance to elucidate the structure of the CLCA2
vWA domain as it is the most different in the human CLCA family.
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Figure 34 Phyre2 model of CLCA2 vWA domain superimposed on CLCA1 vWA domain
structure
Human CLCA2 vWA domain (cyan) sequence was threaded onto the human CLCA1 vWA
domain structure (green) using Phyre2 one-to-one threading mode. MIDAS residues for both
CLCA2 model and CLCA1 structure (in parenthesis) are labeled. One 2/5 MIDAS residues are
identical between CLCA1 and CLCA2 (S314 and S319 respectively, and D312 and D317,
respectively).
Expression, purification and crystallization trials of CLCA2 vWA domain
Cloning
CLCA2 vWA domain was amplified (like CLCA1 encompassing residues 307-483 and
307-485) from WT full-length human CLCA2 and subcloned into pHLsec using the AgeI and
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KpnI sites to include an optimized secretion signal and a 6-histidine tag (4) for purification. The
predicted molecular weight of this domain, residues 307-483 and 307-485, in this construct
without post-translational modification is 20.451 and 20.595 kDa, respectively.
Expression and purification
Expi293 cells used for high-level protein expression were cultured at 37 ºC and 8% CO2
in serum-free Expi293 Expression Media (ThermoFisher Scientific) supplemented with 0.5%
penicillin/streptomycin (Pen/Strep, Gibco) WT human CLCA2 vWA domains (307-483 and 307485) were expressed in Expi293 cells via transient transfection with either Hype-5 or Hype-293
(OZ Biosciences, San Diego, CA) at a 1:1.5 ratio (μg of DNA: μL of transfection reagent) using
1 μg of plasmid per 1 million cells, similar to our previous reports (5). Media from supernatants
were harvested after 72-96 hours by centrifugation, concentrated to 1/10 of the original volume
using a 10 kDa cutoff membrane (Ultracel Ultrafiltration Discs, EMD Millipore) and adjusted to
pH 8.5 and 5 mM imidazole. The concentrated protein was purified using Ni-NTA Superflow
resin (Qiagen, Hilden, Germany) and eluted in 5 mL of buffer containing 50 mM K2HPO4 (pH
8), 300 mM NaCl, and 250 mM imidazole. The eluted protein was concentrated and purified by
size exclusion chromatography using the Superdex75 Increase 10/300 GL (GE Healthcare) in 20
mM Tris pH 8.0 and 150 mM NaCl. Purified CLCA2 vWA was dialyzed into buffer containing
20 mM HEPES (pH 7.4) and 150 mM NaCl and concentrated in a 10 kDa cutoff centrifuge
concentrator (Vivaspin 500, Sartorius) to 5 mg ml-1, as calculated from absorbance at 280 nm,
for crystallization. Protein quality was assessed by Coomassie stain and western blot (Figure
35). Only a single band was detected by both methods indicating no further post-translational
modification to the CLCA2 vWA domain.
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Crystallization trials of WT CLCA2 vWA domain
Crystallization screens (Qiagen PEG I and II screens) were set by hanging drop using a
TTP Mosquito robot using the 100 nL protein + 100 nL well solution. Crystals were grown at 17
ºC by hanging drop vapor diffusion. To date, no crystal hits have been obtained.

Figure 35 Purification of CLCA2 vWA domain
A,B). Left panels, SDS-PAGE of nickel purification of CLCA2 vWA domain constructs, (A)
residues 307-483, and (B) residues 307-485. FT, flow-through. W, wash. E, elution. Middle
panels, SDS-PAGE of size exclusion chromatography (s75 increase) of CLCA2 vWA domain
constructs. Asterisk above the lanes correspond to the fractions from the size exclusion column.
Right panels, size exclusion chromatography of CLCA2 vWA domain. Asterisks above the peaks
correspond to the fractions of SDS-PAGE.
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Chapter 5: CLCA1 Potentiation of TMEM16A
in Human Cystic Fibrosis Airway
I would like to thank Jen Alexander-Brett and Ella Katz in the Alexander-Brett lab for processing
lung explants and establishing airway cultures. I would like to acknowledge Monica Sala-Rabanal,
who performed the whole cell patch clamp and Ussing chamber experiments that made many of the
experiments included in this chapter possible. I also acknowledge Mark Miller and his team at the
In Vivo Imaging Core who imaged and analyzed the data from the mucociliary transport assays of
the airway tissues.
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5.1 Expression and localization of TMEM16A in human cystic
fibrosis airway
Experiments in HEK293Ts suggested that applying CLCA1 to TMEM16A expressing cells
would potentiate calcium-activated chloride currents. Thus, we hypothesized that treating airway
epithelial cells, which were reported to express TMEM16A (1-5), with CLCA1 may increase
chloride currents. Furthermore, as TMEM16A has long been a target for therapy in cystic fibrosis
(CF), we hypothesized that CLCA1 may compensate for lack of CFTR function in CF airway
epithelial cells. In order for the latter to be possible, TMEM16A would need to be expressed and
accessible to exogenous and apical CLCA1 applied to cystic fibrosis airways. Thus, TMEM16A
expression and localization was examined in cystic fibrosis airway.

5.1.1 Development of submerged and air-liquid-interface (ALI) cultures from
primary human airway epithelial cells
Cystic Fibrosis Lungs
Primary human airway tracheobronchial epithelial cells were obtained from lung explants of
cystic fibrosis (CF) patients undergoing transplantation and from lung transplant donors without
lung disease at the Barnes Jewish Hospital in St Louis, MO. A table of cystic fibrosis lungs used in
these experiments, along with the associated genotypes (if known) and CF mutation class, are
recorded (Table 6). CFTR mutations from each class are represented in the set, with a
preponderance of ΔF508 alleles present – 88% of the samples have at least one ΔF508 mutation
(~88% within the US population(6)). About 33% of the samples are of the ΔF508/ΔF508 genotype
(compared to 50% in the US population(7)). Because these are lung explants, presumably patients
undergoing transplant have severe disease. It is important to be aware that the lung explants we
receive are likely biased towards the most severe disease.
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Table 6 CF lung explants acquired throughout this study
CF Lung
Genotype
Class
Comments
1
ΔF508*/2789+5G>A
II/V
2
Q493X/L1077P*
I/III
3
ΔF508/ΔF508
II/II
4
ΔF508/2184insA
II/I
5
ΔF508/ΔF508
II/II
6
ΔF508/N1303K*
II/II
7
ΔF508/ΔF508
II/II
8
ΔF508/ΔF508
II/II
9
ΔF508/ΔF508
II/II
10
ΔF508/621+1G>T**
II/I
11
ΔF508/2789+5G>A
II/V
12
Unknown
13
ΔF508/ΔF508
II/II
14
ΔF508/N1303K
II/II
15
Unknown
16
Unknown
17
Unknown
18
Unknown
19
Unknown
20
ΔF508/G542X
II/I
21
ΔF508/G542X
II/I
African-American
22
S434X/L467P
I/II
23
ΔF508/G542X
II/I
*Under the “refined classification”, which recognizes that individual mutants may display
dysfunctional characteristics from multiple classes and therefore may benefit from CFTR therapies
that target multiple classes (i.e. benefit from combinatorial therapy), these mutants are classified as
II-III-VI (8)
**Though categorized as Class I, this is also a splicing mutant (9, 10)
Submerged and Air-Liquid-Interface Cultures
The Alexander-Brett lab kindly harvested and established the air-liquid-interface cultures
according to published methods (Tyner 2006, Alevy 2012). Briefly, epithelial cells were isolated by
enzymatic digestion from tracheobronchial tissue excised from explanted lungs, seeded onto
permeable filter supports (either transwells or Snapwells), and grown in DMEM-Ham’s F12
medium supplemented with 2% NuSerum, primocin, and retinoic acid, with or without IL-13 (25
ng/mL, Peprotech) under submerged conditions and then air-liquid-interface conditions (by
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removing the apical media) for 3-4 weeks. Transepithelial electrical resistance (TEER) was
monitored using an EVOM voltohmmeter for Ussing chamber experiments. Typical measurements
were greater than 700 mOhm/cm2.
For submerged cultures, cells were seeded onto plates coated with collagen in the same
media and grown in submerged culture. No IL-13 treatment was applied.

5.1.2 TMEM16A mRNA expression is not significantly different between
normal and cystic fibrosis airway epithelium
Transcript levels of TMEM16A in normal and cystic fibrosis airway epithelial cells were
assessed by quantitative polymerase chain reaction (qPCR). For experiments in Figure 36A, mRNA
transcript levels were assessed from airway epithelial cells grown in culture, from the same seed of
cells analyzed in whole cell patch clamp experiments in Figure 40 (CF genotypes and
ΔF508/ΔF508 and ΔF508/2789+5G>A). These cells were harvested in TriZol (ThermoFisher)
according to manufacturures directions and RNA was isolated by phenol-chloroform extraction
with isopropanol precipitation (25:24:1 phenol:chloroform:isopropanol). Chloroform was added to
cells harvested in TriZol. Samples were vortexed and phases were separated by centrifugation
14,000 rpm for 15 minutes. The phenol layer was removed and to it, isopropanol was added and
Glycoblue (ThermoFisher) for RNA visualization. RNA was pelleted by centrifugation at 14,000
rpm for 10 minutes. The supernatant was removed and the pellet dried. RNA was reconstituted in
DEPC-treated water and 50 ng used in cDNA preparation using high-capacity reverse transcriptase
kit (ThermoFisher) for 2 hours at 37 ºC (4 μL 10X reverse transcriptase buffer, 1.6 μL 25X dNTP, 4
μL 10X random primer, 2 μL Multiscribe reverse transcriptase, 0.2 μL RNase inhibitor, 8.2 μL
water + 50 ng RNA).
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The qPCR reaction was carried out using a KAPA Probe Fast qPCR Kit (KAPA Biosystems
KK4702) using primer/probe combinations for hCLCA1 vWA domain, hTMEM16A, hMUC5AC
(IDT, Table 7) and hGAPDH (4352934-1010033, Applied Biosystems). The TMEM16A
primer/probe combination was designed to detect all isoforms of TMEM16A. An Applied
Biosystems 7500 Fast Analyzer was used to measure fluorescence levels. Standards for CLCA1
vWA, TMEM16A and GAPDH were used and levels were standardized to level of GAPDH (1 x
105 copies). A MUC5AC standard was not available and not generated, but levels were
standardized to GAPDH. Figure 36 was generated in GraphPad Prism 8.
Table 7 Primer-probe sequences used in qPCR of airway cultures
mRNA Transcript
hCLCA1 (vWA
domain)
Probe
Forward Primer
Reverse Primer
hCLCA1
Probe
Forward Primer
Reverse Primer
hTMEM16A (exon 1011)
Probe
Forward Primer
Reverse Primer
hMUC5AC
Probe

Primer/Probe Sequences (5’ à 3’)
5’6-FAM/CCCATCCGT/ZEN/CAGCAGCACAATTTC/3’IABkFQ
GGCTTCGATCGGCATTTACT
CCTCGTTAAAGCACCCACTTAT
5’6FAM/TGGCTGGAT/ZEN/TGAGAATATGAAATACAAT/3’IABk
FQ
AGCAGAGTGGAGCACTGTACA
CACACTTGCTTGTGTTGAACATCAT
5’6-FAM/ATGCTCATC/ZEN/CCTGCCTCCATCG/3’IABkFQ
GCATCCGTACAGGAAGACA
CTATAAGTACCAGCCCATCGAC

Forward Primer

5’6FAM/TGCAACACC/ZEN/TGCACCTGTGACAGCAGGAT/3’IA
BkFQ
GTCCCCGTACACGGCGCAGGTGGCCAGGCA

Reverse Primer

AGGCCAGCTACCGGGCCGGCCAGACCAT

136

Given the response of cystic fibrosis cells but not normal airway cells to CLCA1 treatment
in later experiments, it could be argued that CF airway expresses more TMEM16A than normal
airway. However, these results suggest that TMEM16A transcript levels seem to be variable
amongst the human samples, whether from normal or CF airway (Figure 36). Thus, the response to
CLCA1 treatment by the CF epithelial cells is not likely to be due to increased TMEM16A
expression there.

Figure 36 hTMEM16A levels are not elevated in CF airway compared to normal airway
A) Expression of human TMEM16A in normal airway, and CF airway epithelial cells of genotype
ΔF508/ΔF508 and ΔF508/2789+5G>A analyzed in Figure 40. Copies are standardized to hGAPDH
levels. B) Expression of human TMEM16A in normal donor airway, and CF ALI cultures. Donor
cultures were left untreated; CF airway cultures were treated with buffer or purified CLCA1 vWA
(for electrophysiology experiments) and analyzed by qPCR. Copies are standardized to hGAPDH
levels.
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5.1.3 TMEM16A is expressed in smooth muscle and secretory epithelial cells
but not ciliated cells
Our model suggests that CLCA1 acts on TMEM16A by interacting with the channel on the
apical surface of the cell and stabilizing its presence at the cell surface. Additionally, if CLCA1
activity on TMEM16A were to compensate for CFTR activity, TMEM16A would ideally be present
at the epithelial surface. Thus, cellular and subcellular localization of TMEM16A was examined by
immunostaining.
Tissue staining of cystic fibrosis lung
Sections of small airway were obtained from cystic fibrosis lung explants with the help of
the Alexander-Brett lab. Tissue sections were fixed in 10% formalin for 24 hours at room
temperature and transferred to 70% ethanol at 4 ºC until tissue blocks and slides were prepared at
the Pulmonary Morphology Core at Washington University School of Medicine. Tissue slides were
de-paraffinized in citrisolve (Decon Laboratories) for 8 minutes and rehydrated in an ethanol-water
series (100%, 95%, 90%, 70%, 50% and 30%) for 30 seconds each. A DAB Detection IHC kit
(Abcam, ab80436) was then used for staining. H2O2 block was applied for 10 minutes followed by
a wash (3 times for 3 minutes each in PBS). Tissue slides were boiled in 1X Antigen Unmasking
Solution (Vector Labs, H-3301) for 3 minutes at power 100 then 5 minutes at power 30 and cooled
to room temperature. Slides were washed, and blocked in 1X Animal-Free Blocker (Vector Labs,
SP-5030) supplemented with 0.1 % (v/v) Triton. Anti-TMEM16A antibody SP31 (Abcam,
ab64085) at a 1:25 dilution was applied for 1 hour at room temperature. Tissue slides were then
washed, complement added for 10 minutes, washed and HRP conjugate added for 15 minutes. After
a wash, DAB chromogen and substrate was added for 1-10 minutes until the slide was sufficiently
but not over- developed. After a wash, slides were stained with hematoxylin (Abcam, ab128990)
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for 15-30 seconds and washed in water. Slides were mounted in Aqueous Mounting Medium
(Abcam, ab64230) and a coverslip applied.
In the cystic fibrosis tissue, from a patient with a ΔF508/ΔF508 genotype, strong
TMEM16A signal is observed in the apical regions of airway epithelial cells. These cells appear to
adopt a rounded shape at the apical surface, suggesting that TMEM16A is present secretory
epithelial cells (such as goblet cells or club cells). TMEM16A was also observed in the apical
region of submucosal glands, as well as in the myoepithelial smooth muscle cells of these glands.
Visually, tissue staining with the DAB chromogen system was not sensitive enough to detect more
moderate levels of TMEM16A signal (anything less than the strong, concentrated signal observed at
the apical surfaces of the submucosal glands or epithelial cells). However, the staining did imply
that TMEM16A would be accessible to CLCA1 applied exogenously to the apical surface of the
airway.
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Figure 37 TMEM16A localization in cystic fibrosis lung tissue
Expression of TMEM16A in cystic fibrosis lung tissue (genotype ΔF508/ΔF508). Upper panel,
submucosal glands show evidence of TMEM16A expression in the myoepithelial cells and apical
secretory cells of the gland. Lower panel, airways show evidence of TMEM16A expression in the
apical regions of airway cells (likely secretory by their rounded shape).
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Staining of airway liquid interface cultures
Airway liquid interface (ALI) cultures developed for electrophysiology experiments were
also immunostained to compare TMEM16A expression with TMEM16A activity in the
electrophysiology experiments. ALI cultures with and without CLCA1 vWA treatment were
stained. The cultures were rinsed twice in cold phosphate buffered saline (PBS), fixed with 4%
(w/v) paraformaldehyde for 10 minutes, washed three times with cold PBS and permeabilized with
PBS plus 0.3% (v/v) Tween-20 (PBST) for 5 minutes. Samples were blocked with 1% (w/v) BSA
in PBST for 2 hours at room temperature and stained with primary antibodies, goat anti-TMEM16A
antibody S20 (Santa Cruz), anti-CC10 (for club cells), anti-acetylated alpha-tubulin (for ciliated
cells) and anti-MUC5AC (for goblet cells), and in the blocking solution overnight at 4 ºC. After
overnight staining, samples were washed with PBST, stained with the appropriate fluorescent
secondary antibody in blocking solution for 1 hour at room temperature and subsequently washed
with PBST. The fixed and stained cultures were removed from the transwell or Snapwell inserts and
mounted onto a slide with a coverslip with vectashield +DAPI (Vector Labs, H-1200). Images
were obtained on a Zeiss LSM 880 confocal laser-scanning microscope with Airyscan (Carl Zeiss
Microscopy), including a Z-stack. The images were acquired, batch-processed and Z-stacks
reconstructed with Zen software (Carl Zeiss Microscopy).
Normal and CF airway was examined (genotype ΔF508/ΔF508 shown in Figure 38).
TMEM16A was found apically and internally in airway epithelial cells, again suggesting that
TMEM16A is expressed and could be accessible to exogenous CLCA1. Two patterns for
TMEM16A were observed: punctate staining, which co-localizes well with the CC10-positive cells,
as well as strong TMEM16A signal in some cells appearing in clusters, which overlaps well with
the MUC5AC-positive cells. In contrast, TMEM16A signal did not overlap well with acetylated
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alpha-tubulin. There is much debate regarding whether TMEM16A and CFTR interact or impact
the other’s expression and/or activity and whether they co-localize. Broadly, in our cystic fibrosis
(and normal) airway epithelial cultures, it appears that TMEM16A is expressed in secretory cells
and that its expression is not limited to goblet cells.

Figure 38 TMEM16A localizes with secretory epithelial cells of the airway
Air-liquid-interface (ALI) cultures of primary CF airway cells (genotype ΔF508/ΔF508) were
treated with buffer control (upper panels) or purified CLCA1 vWA domain (lower panels) for two
hours. Cultures were fixed, permeabilized and stained for TMEM16A, MUC5AC (goblet cells),
acetylated alpha tubulin (ciliated cells), and CC10 (club cells). DAPI nuclear stain is also included.
Confocal z-stacks were obtained. Below and to the right of each example z-slice is an XZ and YZ
orthogonal view, respectively.
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5.1.4 Normal airway epithelial cells express TMEM16A isoform abc while cystic
fibrosis airways express isoform acd or ac
To determine whether the isoform of TMEM16A could explain any discrepancies and
because the different TMEM16A splicing isoforms impart different properties to the channel, the
particular isoform expressed in the normal and cystic fibrosis airway epithelial cells was examined
by reverse transcriptase polymerase chain reaction (RT-PCR) adapted from a protocol from Ferrera
et al (11). CF airway cDNA obtained in the same manner as in section 5.1.2 was used as the
template. Primers flanking exons 6b (variant b), 13 (variant c) and 15 (variant d) in the transcript
were designed (Table 8). The PCR protocol was as follows. PCR products for segments b and d
were separated by DNA gel electrophoresis on 1.5% agarose in Tris-Acetic Acid-EDTA (TAE) and
ethidium bromide (EtBr), while amplicons for segment c were separated on 3% agarose in TAE and
EtBr. If the exon is present in the mRNA transcript, the amplicon will migrate at a higher
molecular weight than if the exon were absent (Figure 39A). A TMEM16A standard of isoform acd
was included for comparison.
Table 8 Primers used in isoform RT-PCR
Exon
6b
Forward
Reverse
13
Forward
Reverse
15
Forward
Reverse

Segment
b

Boundary
802-867

Primers (5’ à 3’, Forward above, Reverse below)
736F: CGGAGCACGATTGTCTATGAGATCTTGAAGAG
1318R: GGGCCATGAAGACAGAGAAGAAGACCG

c

1408-1419
1301F: CTCTGTCTTCATGGCCCTCTGGGCTG
1458R: CTCCAAGACTCTGGCTTCGTATTCAGCTC

d

1492-1569
1439F: CGAAGCCAGAGTCTTGGAGAAGTCTCTG
1912R: CAAACTTCAGCAGGAAAGCCTTGAAGATCAGC

*Numbered according to abcd isoform
Airway epithelial cells grown in culture (in other words, smooth muscle cells and other
TMEM16A expressing cells outside of the epithelium are not present) of CF genotypes
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Q493X/L1077P and ΔF508/ΔF508 and a normal CFTR sufficient donor were analyzed. The normal
donor airway epithelial cells expressed a TMEM16A isoform with variant segments a, b and c
present; variant d was absent. For the CF airway epithelial cells, variant segments a and c were
present, segment d was variably present, and b was absent. Thus, the CF cells are expressing
isoform ac and/or acd. This difference in isoform expression could explain why CF airway
epithelial cells responds to CLCA1 while normal airway epithelial cells do not, despite having
similar TMEM16A mRNA transcript levels.

Figure 39 Normal airway cells Express TMEM16A isoform abc while CF airway cells express
isoform ac or acd
A) Schematic of the isoform RT-PCR experiment. Primers flanking the exon of interest are used in
PCR amplification, and PCR products separated by DNA gel electrophoresis. If the exon is present,
the amplicon will migrate at a higher molecular weight than if the exon were absent. B)
Amplification of variant segments b, c and d in CF airway epithelial cells of genotype
Q493X/L1077P and ΔF508/ΔF508. A control plasmid containing TMEM16A isoform acd is
included for comparison. C) Amplification of variant segments b, c and d in normal airway
epithelial cells treated with IL-13. A control plasmid containing TMEM16A isoform acd is
included for comparison.

144

5.2 Electrophysiologic effects of CLCA1 on TMEM16A in
normal and cystic fibrosis human airway
TMEM16A was found to be expressed apically in the airway epithelium. To determine
whether CLCA1 could potentiate currents in human airway from normal individuals and cystic
fibrosis patients, whole cell patch clamp and Ussing chamber experiments were performed.

5.2.1 CLCA1 potentiates TMEM16A currents in cystic fibrosis but not normal
airway by whole cell patch clamp
Generation of conditioned media and treatment of submerged cultures
The lung adenocarcinoma line NCI-H292 was used to generated conditioned media for the
treatment of airway epithelial cells. Cells were maintained in RPMI 1640 media (Gibco)
supplemented with 10% FBS, penicillin/streptomycin (Gibco), and 1% glutamine (Gibco).
Conditioned media was generated by expressing full length WT human CLCA1 (in pcDNA 3.1
vector), CLCA1 vWA domain (297-478) or vector control (pcDNA 3.1) in NCI-H292 cells by
transient transfection using FuGene6 at a ratio of 2:3 (μg of DNA: μL of transfection reagent) on
cells plated to 70-90% confluency in 6 well plates for 48 hours. Transfection reagent was removed
after 6 hours and fresh media was applied. After expression, media was cleared of cellular material
by centrifugation.
Normal and cystic fibrosis airway epithelial cells grown as described in section 5.1.1.2 were
seeded to 5-10% confluency on irradiated collagen-coated coverslips (Neuvitro, H-12-Collagen).
After cells were allowed to adhere for 24 hours, media was removed and conditioned media was
applied for 24 hours. Currents were measured by whole cell patch clamp electrophysiology
performed by Monica Sala-Rabanal.
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Results of whole cell patch clamp experiments
CF genotypes ΔF508/ΔF508, ΔF508/2789+5G>A and ΔF508/2184insA, and normal airway
epithelial cells, were tested (Figure 40). For normal airway epithelium, mock CLCA1 conditioned
cells responded similarly – little potentiation was observed. However, for all CF genotypes tested,
full-length CLCA1 potentiated chloride currents. This potentiation was sensitive to TMEM16A
specific inhibitor T16Ainh-A01, suggesting that CLCA1 acted on TMEM16A. Furthermore, for
genotype ΔF508/2184insA, CLCA1 vWA domain was also able to potentiate TMEM16A similar to
full-length CLCA1, mirroring results we had observed in the HEK293T model system (12).
It was remarkable that the normal airway cells did not respond to CLCA1 treatment. Given
that the TMEM16A expression levels appear to be similar across normal and CF airway cells
(Figure 36), and that normal airway seems to express TMEM16A isoform abc while CF airway
expresses isoform acd or ac, differential isoform expression may be one variable that could explain
the lack of response from normal airway epithelial cells to CLCA1 exposure. Because we
hypothesize that CLCA1 affects TMEM16A trafficking, it is possible that the b or d segments,
which are cytosolic segments, may be determinants of TMEM16A response to CLCA1.
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(Figure legend on following page)
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Figure 40 Human CLCA1 potentiates currents in CF airway cells but not normal donor
airway cells
A) Calcium-activated chloride currents in normal donor and CF airway cells (genotypes
ΔF508/ΔF508, ΔF508/2789+5G>A) in submerged culture with and without full-length CLCA1
were measured by whole cell patch clamp. TMEM16A inhibitor T16Ainh-A01 was used to
demonstrate the specificity of the elicited currents. Example traces are shown. B) Calcium-activated
chloride currents in CF airway cells (genotype ΔF508/2184insA) in submerged culture with and
without full-length CLCA1 or vWA domain were measured by whole cell patch clamp. TMEM16A
inhibitor T16Ainh-A01 was used to demonstrate the specificity of the elicited currents. Example
traces are shown. C) Currents at +100 mV in normal donor and CF airways cells from (A).
ANOVA. From Monica Sala-Rabanal.
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5.2.2 CLCA1 potentiates UTP-dependent currents in differentiated cystic
fibrosis airway monolayers by Ussing chamber analysis
Purified CLCA1 vWA domain (297-478) was used to treat air-liquid interface (ALI)
cultures before Ussing chamber experiments. Expi293 cells were cultured at 37 ºC and 8% CO2 in
serum-free Expi293 Expression Media (ThermoFisher Scientific) supplemented with 0.5%
penicillin/streptomycin (Pen/Strep, Gibco) WT human CLCA1 vWA domain (297-478) was
expressed in Expi293 cells via transient transfection with either Hype-5 or Hype-293 (OZ
Biosciences, San Diego, CA) at a 1:1.5 ratio (μg of DNA: μL of transfection reagent) using 1 μg of
plasmid per 1 million cells, similar to our previous reports (13). Media from supernatants were
harvested after 72-120 hours by centrifugation, concentrated to 1/10 of the original volume using a
10 kDa cutoff membrane (Ultracel Ultrafiltration Discs, EMD Millipore) and adjusted to pH 8.5
and 5 mM imidazole. The concentrated protein was purified using Ni-NTA Superflow resin
(Qiagen, Hilden, Germany) and eluted in 5 mL of buffer containing 50 mM K2HPO4 (pH 8), 300
mM NaCl, and 250 mM imidazole. The eluted protein was concentrated and purified by size
exclusion chromatography using the Superdex75 Increase 10/300 GL (GE Healthcare) in 20 mM
Tris pH 8.0 and 150 mM NaCl. Purified CLCA1 vWA was dialyzed into buffer containing 20 mM
HEPES (pH 7.4) and 150 mM NaCl and concentrated in a 10 kDa cutoff centrifuge concentrator
(Vivaspin 500, Sartorius) to 1 mM as calculated from absorbance at 280 nm. Dialysis buffer was
used as the control treatment.
ALI cultures were prepared as in section 5.1.1. One week before Ussing chamber
experiments, cultures were treated with IL-13 to boost TMEM16A expression and develop goblet
cells in the culture. As cystic fibrosis lungs are under inflammatory conditions due to infection, this
treatment also mirrors the inflammatory environment of those lungs. Experiments were performed
on cultures treated with IL-13 no longer than one week because CLCA1 expression by qPCR
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begins to increase significantly by day 11 and endogenous CLCA1 expression may interfere with
the interpretation from exogenous CLCA1 vWA treatment (data not shown). Purified CLCA1 vWA
at 5 μM concentration or buffer control (dialysis buffer) was applied to ALI cultures 24 hours
before the experiment, and the morning the assay was performed. Additionally, 1 μM CLCA1 vWA
was present in the Ussing chamber during the experiment. Just before analysis, transepithelial
electrical resistance (TEER) recordings were performed and only cultures with resistances above
700 mOhm/cm2 were used. Ussing chamber experiments and analysis were conducted by Monica
Sala-Rabanal. Amiloride was used to block epithelial sodium channel (ENaC) currents and
CFTRinh-172 to block CFTR currents as these currents will interfere with the TMEM16A signal.
TMEM16A was activated with UTP (which will result in an intracellular influx of calcium to
activate the calcium-activated chloride current) and the inhibitor T16Ainh-A01 was used to
specifically block TMEM16A current. MONNA is another calcium-activated chloride channel
inhibitor used in the experiment.
Ussing chamber experiments for CF genotypes ΔF508/ΔF508 and ΔF508/621+1G>T are
shown. Treatment with CLCA1 vWA appeared to have little effect on normal airway ALI cultures.
However, treatment of CF ALI cultures with CLCA1 vWA appeared to increase the baseline
current as well as the UTP dependent current. An observable response in both the baseline currents
suggests that TMEM16A may contribute to currents apart from an influx in intracellular calcium.
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Figure 41 CLCA1 potentiates UTP-dependent currents in differentiated cystic fibrosis airway
monolayers
A) Ussing chamber recordings of normal donor and CF (genotype ΔF508/621+1G>T) airway airliquid interface cultures with (blue trace) and without (black trace) purified CLCA1 vWA
treatment. Amiloride, ENaC blocker. CFTRinh-172, CFTR inhibitor. UTP, P2Y2 agonist (to activate
CaCC). T16Ainh-A01, TMEM16A inhibitor. MONNA, CaCC inhibitor. IL-13 was used to enhance
TMEM16A expression. B) Ussing chamber recordings of CF airway (genotype ΔF508/ΔF508) airliquid interface cultures with buffer control or purified CLCA1 vWA treatment. Amiloride, ENaC
blocker. CFTRinh-172, CFTR inhibitor. UTP, P2Y2 agonist (to activate CaCC). C) Baseline current,
UTP-current peak and timescale of UTP current decay were measured from multiple samples of this
genotype. From Sala-Rabanal.

5.3 Effects of CLCA1 on mucus properties in human airway
5.3.1 CLCA1 drives MUC5AC expression independently of the MIDAS motif
CLCA1 has been associated with driving mucus, and specifically MUC5AC, hypersecretion
in inflammatory lung diseases such as asthma and chronic obstructive pulmonary disease (14, 15).
A potential concern with using CLCA1 potentiation of TMEM16A as compensation for CFTR
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activity in CF airway is that CLCA1 may drive mucus overexpression in a disease that is already
plagued with excessively sticky mucus. To address this concern, it should be noted that CLCA1 is
a multi-domain protein, and that each domain is likely involved in a different activity of the protein.
For example, our experiments show that the vWA domain is necessary and sufficient for
potentiation of TMEM16A chloride currents. If CLCA1 does drive mucus hypersecretion, another
domain, possibly the fibronectin III (FnIII) domain, may be responsible for driving mucus
overexpression. To rule out the possibility that the CLCA1 vWA domain is the responsible domain,
a MIDAS mutant of the full-length CLCA1 protein, mutant D312A/S314A/S316A/T383A that is
unable to potentiate TMEM16A currents in HEK293T cells (12), was cloned into pcDNA 3.1. The
expression, secretion and proteolytic processing of this mutant was confirmed by western blot using
anti-CLCA1 antibody 8D3, with the N-terminal fragment (~70 kDa) of both mutant and wild-type
observed.
Conditioned media was generated by expressing full length wild-type human CLCA1 (WT
FL CLCA1), full-length human CLCA1 D312A/S314A/S316A/T383A MIDAS mutant or vector
control (pcDNA 3.1) in NCI-H292 cells by transient transfection using FuGene6 at a ratio of 2:3
(μg of DNA: μL of transfection reagent) on cells plated to 70-90% confluency in 6 well plates for
48 hours. Transfection reagent was removed after 6 hours and fresh media was applied. After
expression, media was cleared of cellular material by centrifugation. This conditioned media was
applied for 2 hours to normal primary human tracheobronchial epithelial cells cultured under ALI
conditions for 7 days, in the presence and absence of IL-13. Cultures were harvest in TriZol
(ThermoFisher) according to manufacturers’ instructions and cDNA prepared as in section 5.1.2.
Transcript levels for hMUC5AC, hCLCA1 and hTMEM16A were determined by qPCR. An Applied
Biosystems 7500 Fast Analyzer was used to measure fluorescence levels. Standards for CLCA1
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vWA, TMEM16A and GAPDH were used and levels were standardized to level of GAPDH (1 x
105 copies). A MUC5AC standard was not available and not generated, but levels were
standardized to GAPDH. Primer/probe combinations are in Table 7.
For cultures not treated with IL-13, MUC5AC, TMEM16A and CLCA1 transcript levels were
similar for control, WT FL CLCA1 and MIDAS mutant (Figure 42). With IL-13 treatment,
TMEM16A and CLCA1 transcripts increase as expected. However, MUC5AC transcripts increase
only for CLCA1 WT and MIDAS mutant treated cultures. If the vWA domain acting on
TMEM16A were responsible for driving MUC5AC overexpression, then mutation of the critical
MIDAS residues should abrogate the overexpression. While CLCA1 could drive mucus
overexpression independent of the MIDAS, this experiment suggests that another domain within
CLCA1 may induce MUC5AC expression. A possible candidate is the fibronectin III domain.
Fibronectin III domains are known to interact with integrins, which are well-known for their
signaling activities (16). Thus, the CLCA1 FnIII domain may interact with a cell-surface receptor
to induce signaling resulting in MUC5AC expression.

Figure 42 CLCA1 drives MUC5AC expression independently of vWA domain MIDAS
motif
A) Western blot of medium from NCI-H292 cells expressing mock vector, wild-type full-length
CLCA1 or full-length CLCA1 MIDAS mutant (D312A/S314A/S316A/T383A). Secretion of WT
and MIDAS mutant CLCA1 were detected, and proteolytic processing to the N-terminal fragment
(~70 kDa) was observed for each. B) Medium from (A) was applied daily for two hours to normal
primary hTECs cultured under ALI conditions for 7 days, in the presence and absence of IL-13.
hMUC5AC, hTMEM16A and hCLCA1 mRNA levels were determined by real-time qPCR.
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5.3.2 CLCA1 vWA enhances mucociliary transport in normal and cystic
fibrosis tissue
Whole cell patch clamp and Ussing chamber experiments demonstrated that CLCA1
potentiated currents through TMEM16A in cystic fibrosis airway epithelia. Whether CLCA1
potentiation of TMEM16A could affect mucociliary properties in cystic fibrosis epithelium
remained an open question. One way to assess the mucociliary property of mucociliary clearance is
by fluorescent nanosphere bead tracking assays (17-19). Fluorescent spheres, typically ~1 μm
(mimicking the size of a bacterium), are applied to air liquid interface airway cultures or whole
airway sections and the movement of the spheres tracked by fluorescence microscopy. Distance
traveled and/or velocity of the beads can be an indication of mucociliary transport properties of the
epithelium. These types of assays had been performed with human or mouse airway ALI cultures or
whole tissue from mouse, pig or other model systems (17-19). However, to our knowledge, the
experiments that follow were the first to be conducted on whole explanted human trachea and
bronchi, either from normal or cystic fibrosis airways.
The Alexander-Brett lab prepared sections of trachea and bronchi from normal and cystic
fibrosis airway (genotypes ΔF508/ΔF508, ΔF508/G542X, and S434X/L467P from an African
American patient). Excess connective tissue and cartilage were removed and the posterior face of
the tissue (away from the airway) was scored to facilitate mounting onto a microscope stage.
Tissues were maintained in transwell plates in culture media and used as soon as possible after
sectioning. CLCA1 vWA domain was purified as in section 5.2 and applied at 5 μM concentration
to the normal and cystic fibrosis tissues 12-24 hours before analysis. Dialysis buffer was used as
control. Carboxyfluorescein succinimidyl ester (CFSE) at 5 μM final concentration was added to
the protein and buffer control to ensure that regions of tissue imaged received treatment. Addition
of CFSE also assisted in choosing healthy tissue to image. Treated tissues were placed in a 37 ºC
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incubator when not in use to maintain freshness while other samples were processed. Images were
obtained with the help of Mark Miller in the In Vitro Imaging Core at Washington University
School of Medicine. Tissues were adhered to a coverslip and placed on a heated (to 37 ºC)
microscope stage flooded with DMEM. Red or green beads of 1 or 4 μm size were applied to the
tissue and video images were recorded just above the epithelium. Beads were tracked using Imaris
9.3. For each sample image, 2-3 tissues were imaged and bead velocities aggregated for each
sample.
In early preliminary experiments of CF airway (ΔF508/G542X), vWA treatment increased
mucociliary transport (Figure 43A). As a negative control, application of hydrogen peroxide to
vWA treated cultures nearly eliminated mucociliary transport (Figure 43B). Normal airway tissue
treated with either control or CLCA1 vWA, bead movement is quite fast at ~10 μm/second on
average (Figure 43E). However, in CF tissue treated with control, bead movement is sluggish to
absent, ~8 μm/second or less on average. In CF tissue treated with CLCA1 vWA, bead movement is
restored, almost to the level of normal tissue in many cases. This appears to be consistent regardless
of the genotype analyzed. These striking results were observed after just a 12-24 hour treatment of
cystic fibrosis tissues with protein. It is likely that after much longer treatment, say after a week or
more of CLCA1 vWA treatment, that mucus properties could be further restored as hydration of the
sticky mucus network in cystic fibrosis could be further reorganized at periods longer than 24
hours. Overall, these promising results suggest that CLCA1 vWA not only potentiates TMEM16A
chloride currents in cystic fibrosis lungs, but also that doing so may restore healthy mucus
properties in the absence of CFTR activity, regardless of CF genotype. Future experiments could
explore whether CLCA1 vWA treatment matches the effects seen with CFTR drugs ivacaftor and
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lumacaftor, and whether there may be additive or synergestic effects when CLCA1 vWA and CFTR
specific drugs are used in combination.

Figure 43 CLCA1 vWA enhances mucociliary transport in CF airway tissue
A-D) Mucociliary bead transport assays. Normal and cystic fibrosis tissues were resected from
explanted lung and treated with buffer or purified CLCA1 vWA domain overnight. Fluorescent
bead of 1 μm size were applied to the tissue and imaged by microscopy. Bead velocity above the
epithelium was tracked. A, B) CF genotype ΔF508/G542X treated with buffer, CLCA1 vWA or
CLCA1 vWA followed by H2O2 before image acquisition (green bar) as negative control. C,D)
Bead velocity of representative samples from normal airway tissue (C), CF genotype ΔF508/G542X
(D, left) or CF genotype S434X/L467P (D, right) treated with buffer or CLCA1 vWA. E)
Quantification of bead velocity over N=3-4 tissues for donor and CF airway, by one-way ANOVA
(p<0.05). Groups with similar letters are statistically similar. Groups not sharing any letters are
statistically different.
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Chapter 6: Implications for CLCA and
TMEM16 Families and for Cystic Fibrosis
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6.1 Contributions from this study
The goal of this study was to 1) determine a structure of human CLCA1, TMEM16A and
the two in complex to understand the molecular determinants of the interaction and 2) examine
the effects of CLCA1 on cystic fibrosis airway. The contributions of this study are manifold,
having implications for the structure and function of 1) CLCA family, 2) TMEM16 family and 3)
CLCA1 and TMEM16A interactions. This study also represents a path towards exploring
therapeutic options for cystic fibrosis based on the CLCA1-TMEM16A interaction and
mechanism.
CLCA1
– CLCA1 vWA Domain Structure
This study reveals the 2.0 Å X-ray crystal structure of human CLCA1 vWA domain, the
first structure of any CLCA family member. The structure provided the first look at the metal ion
dependent adhesion site (MIDAS) in CLCA1, residues which we had previously found were
critical to the potentiation of TMEM16A currents and increase in TMEM16A surface channel
density (results published in the Journal of Biological Chemistry (1)). In the crystal structure, the
MIDAS is in an open conformation, indicating that CLCA1 is capable of adopting high affinity
interactions with its ligand. Furthermore, the MIDAS conformation and the presence of a
pseudoligand interaction in the crystal offered insight into how CLCA1 might engage
TMEM16A on the cell surface: in an open MIDAS configuration bound to Mg2+ and
coordinating to an acidic residue (glutamate or aspartate) in TMEM16A. This study also
revealed a disulfide bond uncommon to vWA domains but ostensibly unique to the CLCA family
since the cysteines in this disulfide bond are invariant in the family. This prompted further study
into the stability of the CLCA1 vWA domain with this disulfide bond, and these experiments
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revealed that the CLCA1 vWA domain is most stable with this disulfide bond in the presence of
Mg2+. These observations were published in Cell Reports in 2020(2).
– Advancing Our Understanding of the Cellular Mechanism by which CLCA1 Potentiates
TMEM16A
The experiments in this study also give further insight into the mechanism by which
CLCA1 potentiates TMEM16A. Specifically, time course experiments with purified CLCA1
vWA domain demonstrated that CLCA1 could have its effect within minutes, indicating that
CLCA1 vWA domain likely regulates TMEM16A trafficking, akin to the α2δ subunit regulation
of voltage gated calcium channels which inhibit endocytosis (3). At the molecular level, these
effects are mediated by the MIDAS within the vWA domain of CLCA1. These observations
were published in the Journal of Biological Chemistry in 2017(1).
CLCA1-TMEM16A Structure
To date, mouse TMEM16A structures have been published(4-6), both of the abc isoform.
In this study, I report the purification and nanodisc preparation of human TMEM16A, isoform
acd (which was the isoform found in our cystic fibrosis airway epithelial cells), and initial
negative stain images of this species. I also report the purification and nanodisc preparation of
human TMEM16A isoform acd in complex with human N-CLCA1 for cryo-electron microscopy
structure determination, and initial negative stain images of this complex.
Human CLCA Family – CLCA2 and CLCA4
CLCA4 Specifically Potentiates TMEM16B
Before this study, it was known that CLCA2 and CLCA4 potentiated calcium activated
chloride currents, but the channel targets had not been identified, though TMEM16B was
suggested recently as the target for CLCA4 (7). Cellular experiments presented in this study
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demonstrated for the first time that CLCA4 specifically potentiates TMEM16B while CLCA1
specifically potentiates TMEM16A. Furthermore, like CLCA1, the vWA domain is necessary
and sufficient for channel potentiation and is MIDAS-dependent. These results are included in a
manuscript for submission. Given the specificity observed between CLCA1 and TMEM16A, and
CLCA4 and TMEM16B, it will be important to examine the molecular determinants of this
specificity.
Purification of CLCA2 and CLCA4
This study contributed the first purification of human CLCA2 and CLCA4 vWA domain
for crystallization studies. During the course of the CLCA4 purification, a glycosylation site was
confirmed and removed for crystallization.
CLCA1 and TMEM16A in Cystic Fibrosis and Normal Airway
Expression and Localization of TMEM16A in Cystic Fibrosis Airway
The precise cellular localization of TMEM16A in the airway has been a matter of debate.
Thus, in this study, the expression and cellular localization of TMEM16A in cystic fibrosis
airway was examined. TMEM16A was observed intracellularly and apically in secretory cells,
including goblet and club cells of the small airways, and in myoepithelial cells and apical regions
of secretory cells of submucosal glands. The mRNA expression of TMEM16A between normal
and cystic fibrosis airway was not observed to be different. However, CF airway epithelial cells
appear to express TMEM16A isoform acd or ac, while normal airway expresses isoform abc,
which could explain why CLCA1 affects CF airway epithelial cells but not normal airway in
electrophysiology experiments.
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CLCA1 Potentiates TMEM16A Currents in Cystic Fibrosis Airway
This study also reveals for the first time the effects of potentiating TMEM16A currents in
human CF airway with CLCA1. Treating airway epithelial cells with CLCA1 (either full-length
or vWA domain) potentiated TMEM16A currents by whole cell patch clamp and Ussing
chamber electrophysiology. In particular, Ussing chamber experiments demonstrated that
CLCA1 could increase baseline currents, without the need for stimulating an influx of
intracellular calcium. Furthermore, this study demonstrated that CLCA1 vWA did not drive
MUC5AC expression; rather another domain within CLCA1 may be responsible for stimulating
mucus expression.
CLCA1 Enhances Mucociliary Transport in Cystic Fibrosis Airway
Finally, electrophysiology experiments established that CLCA1 could target TMEM16A
in cystic fibrosis airway, and mucus bead transport assays showed for the first time that CLCA1
vWA could improve mucociliary transport in cystic fibrosis tissue, even to the point of restoring
it to normal airway transport levels. This study also gave us the first look at mucociliary bead
transport rates in human airway tissue. These effects were evident for a range of CF genotypes,
including the Class I alleles which produce no CFTR protein. Overall, this thesis provided the
first evidence that CLCA1 vWA treatment of CF airway of a myriad of genotypes could improve
mucus properties via potentiation of TMEM16A.

6.2 Proposed model of CLCA1-TMEM16A interaction
6.2.1 Structural implications
CLCA Family vWA Domains
Unique vWA domain of the CLCA Family
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The overall CLCA1 structure suggests that like other vWA domain, the CLCA family of
vWA domains adopts a classic vWA fold – a β sheet surrounded by α helices. Though the α6
helix is missing for CLCA1, it will be interesting to discover whether this is similar for other
CLCA vWA crystal structures. Most strikingly in the CLCA1 structure, the arrangement of the
three invariant cysteines in the vWA domain was finally answered. The uncommon presence and
unique location of the disulfide bond involving two of the invariant cysteines is likely to be a
feature of the CLCA1 vWA family. It appears that this disulfide is important for the stability of
the vWA domain, though other vWA domains do not require a disulfide linkage in this position
to maintain the fold. This disulfide bond may have other functions that are yet unknown, such as
stabilizing an open configuration that allows it to interact with its binding partner.
Metal Ion Dependent Adhesion Sites (MIDAS) in the CLCA Family
The CLCA1 vWA domain contains a perfect MIDAS and is dependent upon this site and
Mg2+ to potentiate TMEM16A currents. The CLCA1 vWA structure revealed an open MIDAS
configuration including a pseudoligand interaction. Because hCLCA1 and hCLCA4 are most
similar in sequence, and hCLCA4 contains a perfect MIDAS, one would expect the MIDAS of
CLCA4 to adopt an open conformation like CLCA1 given that a divalent cation is present. For
CLCA2, however, a different configuration will likely be observed since only 2/5 MIDAS
residues are present. In addition, CLCA2 is two residues longer than CLCA1 and CLCA4,
between α2 and α3, where the threonine in the MIDAS motif (T383 in CLCA1) resides.
Interestingly, just before the isoleucine that resides in the MIDAS threonine position is an
aspartate (D389) and a threonine (T388) (Figure 44). It is possible that the additional residues in
that loop may reposition one of those residues to chelate a divalent cation. Furthermore, in
CLCA2 there is a lysine in place of the second serine of the MIDAS DXSXS motif, K321,
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whose positive charge could obviate the need for a divalent cation. These lingering hypotheses
make it even more necessary to determine the structure of CLCA2 and the remainder of the
CLCA family to observe whether alternate MIDAS modes are possible and how they could
mediate ligand interaction.

Figure 44 Phyre2 model of CLCA2 vWA domain and potential MIDAS residues
Human CLCA2 vWA domain (cyan) sequence was threaded onto the human CLCA1 vWA
domain structure (green) using Phyre2 one-to-one threading mode. MIDAS residues for both
CLCA2 model and CLCA1 structure (in parenthesis) are labeled. One 2/5 MIDAS residues are
identical between CLCA1 and CLCA2 (S314 and S319 respectively, and D312 and D317,
respectively).
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CLCA-TMEM16 Interactions
An Acidic Residue in an Extracellular Loop of TMEM16A Binds to the MIDAS of CLCA1
The presence of a pseudoligand interaction in the hCLCA1 crystal structure provided a
glimpse into the binding interaction between CLCA1 and TMEM16A: the CLCA1 MIDAS
likely binds in an open, high affinity conformation to an acidic residue (aspartate or glutamate) in
TMEM16A. How this binding interaction translates into preventing TMEM16A internalization is
still unclear, especially given that CLCA1 is not anchored to the membrane (by a transmembrane
segment of phospholipid anchor) like the α2δ subunits(3, 8).
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Figure 45 Most probable sites of CLCA1-TMEM16A interaction suggested by structural
and functional studies
The cryo-EM model of mouse TMEM16A (mTMEM16A) dimer (PDB: 5OYB, (4)) (purple)
with the α9-α10 loop (blue) and labeled acidic residues in this loop shown in either yellow
(<60% solvent accessible surface for sidechain) or cyan (>60% solvent accessible surface for
sidechain). CLCA1 vWA (green) is poised on the extracellular face of mTMEM16A, as our
structural data suggest that interaction with CLCA1 vWA MIDAS is likely mediated by one of
these residues. Divalent cations (Ca2+) are shown in grey. Reproduced from Berry KN, Brett TJ.
2020(2).

6.2.2 Specificity of CLCA Family Members for TMEM16 Family Members
– CLCA4 and TMEM16B
Because CLCA1 and CLCA4 vWA domains are highly similar and both potentiate
calcium activated chloride currents, there was a possibility that CLCA4 may also redundantly
potentiate TMEM16A. Confocal and siRNA experiments demonstrated, however, that CLCA4
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vWA domain specifically potentiates TMEM16B. This suggests that, although CLCA4 and
CLCA1 have identical MIDAS residues, that other residues are responsible for mediating the
specific pairing between CLCA4 to TMEM16B and CLCA1 to TMEM16A. Cellular
experiments show that CLCA4 is also MIDAS dependent, and it would be expected that CLCA4
also binds to an acidic residue in TMEM16B.
– CLCA2 and TMEM16F?
The target of CLCA2 potentiation has yet to be identified. If the hypothesis is correct that
CLCA family members interact with specific TMEM16 proteins, then CLCA2 likely potentiates
TMEM16F, thus far the only other TMEM16 family member besides TMEM16A and
TMEM16B reported to conduct anion current. However, the possibility remains that CLCA2
may redundantly potentiate TMEM16A or TMEM16B, though less likely since it is most
different in sequence from CLCA1 and CLCA4. Given that CLCA2 is most different from
CLCA1 and CLCA4 in protein sequence, and does not contain a perfect MIDAS, the molecular
mechanism by which it potentiates currents is unclear.
– CLCA Members and TMEM16 Scramblases
Finally, potentiation of calcium activated chloride currents by the CLCA family has been
well-established, but no group has investigated whether CLCA members may have an effect on
TMEM16 lipid scrambling. Thus, a thorough exploration of the CLCA family members effect on
TMEM16 family members activity, either channel or scramblase activity, is warranted.
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6.3 The CLCA family as modulators of specific TMEM16
members
6.3.1 CLCA proteins are secreted regulators of ion channel trafficking
The mechanism of CLCA potentiation of TMEM16 channels is highly similar to that of
the α2δ subunits of voltage gated calcium channels. The α2δ subunit is generated by the
synthesis of a single α2δ polypeptide chain. During processing, the two become linked internally
by a disulfide bond between a cysteine in the vWA domain within α2 and a cysteine in δ (9). The
α2δ polypeptide chain is then cleaved but the subunits remains attached due to the disulfide
bond. The α2δ subunit remains anchored to the membrane by the δ subunit and localizes to the
cell surface (3, 8). The MIDAS in its vWA domain binds the calcium channel assisting in its
trafficking to the surface and maintaining there. The expression of the α2δ subunit dramatically
increases calcium channel activity, especially as the channel seems to be highly dependent on the
subunit for trafficking to the surface (3, 9, 10). In contrast to the α2δ subunits, CLCA vWA
domains mediate their effects on TMEM16 channels without being anchored to the membrane,
and it appears that CLCA1 is not necessary to get TMEM16A to the surface. Thus, there is a
likelihood that the mechanism by which CLCA proteins maintain TMEM16 channels at the
surface is slightly different than how α2δ subunits traffic or maintain voltage gated calcium
channels at the surface.
CLCA proteins may induce a conformational change in TMEM16A that prevents it from
being internalized into the cell. Hu et al. (11) published that TMEM16F rapidly traffics from the
plasma membrane to Rab7 late endosomes to be routed to lysosomes for proteosomal
degradation. In preliminary confocal experiments, I also found that TMEM16A localizes to Rab7
late endosomes, and that CLCA1 may result in less frequent colocalization with those endosomes
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(data not shown). TMEM16A may likewise be quickly trafficked from the plasma membrane to
late endosomes after reaching the cell surface.
In sum, this is consistent with a model in which CLCA1 can bind TMEM16A, induce a
conformational change that prevents its internalization, and on a minute timescale enrich
TMEM16A on the surface to result in increased chloride currents through the cell. CLCA1
appeared to be ineffective at potentiating currents in normal airway epithelial cells, which
express TMEM16A isoform abc, while being able to potentiate currents in cystic fibrosis airway,
which express isoform ac or acd. Because these variant segments are intracellular, it is tempting
to speculate that CLCA1 may have an effect on either segment b or d that allows TMEM16A to
remain at the cell surface, perhaps by exposing the segment during a conformational change to
trafficking proteins. Further experiments will be required to identify the mechanism by which
these non-anchored CLCA vWA domains maintain TMEM16 channels at the cell surface.
Given that TMEM16A and TMEM16F appear to traffic through the endosomal pathway,
it is possible that this is part of the regulation of the TMEM16 family. Indeed, many TMEM16
proteins are localized intracellularly (12-17). They may require assistance in trafficking to the
cell surface. Given that our group has identified the specific regulation of CLCA1 with
TMEM16A, and CLCA4 with TMEM16B, and from our experiments with CLCA1, the
mechanism involves altering the trafficking of the TMEM16 channel, we may be able to view
the CLCA family as a family of secreted proteins that regulate TMEM16 channel trafficking to
the surface.
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6.3.2 Implications for CLCA and TMEM16 members in the airway and
beyond
Thus far, our data suggests that CLCA members regulate specific TMEM16 members. In
the human families, we have demonstrated that CLCA1-TMEM16A (18) and CLCA4TMEM16B are pairs. TMEM16F is the remaining candidate calcium-activated chloride channel.
Thus, we further speculate that CLCA2-TMEM16F is a pair. CLCA proteins have a paracrine
effect on their cellular targets(18). In order to elicit CaCC current, the CLCA and TMEM16 pair
must be expressed in similar locations. CLCA2 and CLCA4 are reported to be expressed at
baseline in the lung by airway epithelial cells (19-21), though other cell types in the lung could
express them. TMEM16B seems to be primarily expressed in neuronal tissue (22). In the airway,
it is possible that CLCA4 is expressed in neuronal cell types of the lung and could potentiate
TMEM16B, but no studies have expressly searched for CLCA4 in neurons of the airway. As for
CLCA2, TMEM16F seems to be expressed very broadly (22), so CLCA2 could have its effect on
TMEM16F in many settings in the lung.
Outside the lung, there are a number of interactions where CLCA proteins could
influence TMEM16 channel activity. Particularly, many TMEM16 proteins were thought to have
no or scant scrambling or ion channel activity, but noted to be primarily localized intracellularly
(12-17). Thus, detection of phosphatidylserine scrambling activity by annexin V staining or of
ion channel activity by whole cell patch clamp would not demonstrate any activity. This apparent
lack of activity could be attributed to lack of CLCA family expression in those systems, which
could be responsible for localizing TMEM16 proteins to the surface. For these interactions
between the families to be possible, the CLCA protein and its TMEM16 target(s) would ideally
be co-localized. CLCA4 is expressed in the small intestine, colon, brain, reproductive tissues (19,
20) and more (see Table 2). It appears that TMEM16B is broadly expressed in neuronal tissue.
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Thus, it is possible that CLCA4 in concert with TMEM16B could have roles in modulating
neuronal excitability, intestinal motility, reproduction and more. Besides the lung, CLCA2 is
expressed throughout the body, including in the brain, reproductive tract, cornea, and skin (20,
21) (see Table 2). As TMEM16F is expressed broadly, CLCA2 and TMEM16F could have roles
in many tissue processes. TMEM16F mutations are associated with Scott syndrome, a bleeding
disorder(23); whether CLCA2 could have a role in clotting remains unclear. Finally, CLCA
protein regulation of TMEM16 lipid scramblases is unexplored. Thus, CLCA and TMEM16
interactions could reach far beyond its originally discovered role as a regulator of calcium
activated chloride channel activity.

6.4 Implications of the CLCA1-TMEM16A Interaction for
Cystic Fibrosis
In this study, CLCA1 treatment potentiated TMEM16A currents in cystic fibrosis airway
of multiple genotypes and also improved mucociliary transport properties. A study targeting
TMEM16A miRNA had similar effects (24). Thus, targeting TMEM16A in cystic fibrosis may
be a viable strategy. This approach has the advantage of being effective regardless of the CF
genotype of the patient. In particular, it would be helpful for those patients with a Class I
mutation, for whom CFTR specific therapies (such as ivacaftor, lumacaftor, etc.) would not be
effective, could help those who do not respond well to CFTR specific therapies and could be a
supplement for those who can receive CFTR specific therapies. In addition, knowledge of the
mechanism and the molecular determinants of the CLCA1-TMEM16A interaction would allow
for the development of the specific and potent induction of TMEM16A currents and an
assessment and limitation of off-target effects. Because CLCA1 alters TMEM16A trafficking
and this occurs on a fast timescale (within minutes), a therapy based on this particular
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mechanism would take effect quickly. Indeed, in treatment of the CF tissue sections with CLCA1
vWA domain, significant improvement to near normal levels of mucociliary transport was
observed with less than 24 hours of exposure. Longer treatment could result in more improved
outcomes.
Given the positive outcomes in the airway, it is possible that using CLCA1 vWA protein or
a small molecule mimicking it, in the digestive system may also help patients with cystic fibrosis
disease or other diseases in which mucosal hydration is impaired. TMEM16A is expressed in the
epithelium of the intestine and in smooth muscle cells (22). In humans, CLCA1 is also expressed
in the small intestine and colon (20). Additional CLCA1 vWA in the intestine could trigger fluid
secretion to hydrate sticky mucus in CF, and if possible to target it to the pancreas, could also
improve digestive enzyme secretions from that organ as well. A number of factors would need to
be considered for using of CLCA1 in the digestive system, including whether CLCA1 could
rehydrate the particular mucus network in the intestine as it does in the lung the lifetime of the
protein in the gut, whether it could have an effect on intestinal motility, among others.

6.5 Future Directions
6.5.1 Human CLCA Family
CLCA1 - Avenues to explore based on the CLCA1 structure
The human CLCA1 vWA crystal structure is the first of the family, and it gave us the
first look at the structure of the CLCA1 family. However, many avenues remain to be explored.
The significance of the invariant cysteines, especially the free invariant cysteine, in this domain
is still unclear. The C308S mutant could be purified and tested for functionality in whole cell
patch clamp experiments. Additionally, testing the functionality of a reduced and alkylated WT
vWA domain may offer insight into the stability and significance of the disulfide bond in the
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CLCA1 vWA domain. During the course of this study this approach was attempted, but correct
alkylation was not definitively confirmed.
The human CLCA1 vWA domain crystallized in conditions of Ca2+ but not in Mg2+.
However, CLCA1 vWA is most stable in magnesium and magnesium chelation abrogated
potentiation of TMEM16A. In solution, Mg2+ is likely the ion bound to CLCA1 vWA domain.
However, identification of the ion in the MIDAS site presented for interaction with TMEM16A
could be pursued by ICP-mass spectrometry and binding affinities determined by isothermal
titration calorimetry (ITC). Large amounts of protein would be required for ITC since the
expected affinity is in the micromolar range, but this is feasible given yields for crystallography.
Finally, the CLCA1 variant S357N was identified to be a modifier of meconium ileus in
cystic fibrosis (25). Our group did not find a functional defect with this mutant (1). S357 is
somewhat solvent exposed but far from the MIDAS. It is possible that the S357N mutation may
be less stable. Both TMEM16A and CLCA1 being expressed in the intestine, reduced CLCA1
output may produce reduced hydration of the mucus layer, resulting in the symptoms of
meconium ileus.
CLCA2
As CLCA2 vWA expresses well and is stable, crystallization screens should be
continued. The structure of CLCA2, and especially of the MIDAS, will be of particular
importance as it is most different than the other two members of the human CLCA family. It is
paramount to identify the CaCC target of CLCA2. TMEM16F siRNA has been acquired, and
TMEM16F knockdown may be attempted first. If TMEM16F is not the target of CLCA2, siRNA
knockdown of other members of the family, including TMEM16A and TMEM16B, should be
explored. Once the target(s) of CLCA2 has been identified, a complex structure of CLCA2 and
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its target by cryo-EM will reveal whether and how CLCA2 engages its target with an imperfect
MIDAS. Finally, CLCA2 is expressed at baseline in the airway. Its role in the airway, in terms of
its potentiation of calcium activated chloride currents (CaCC) and significance of the C-terminal
fragment (especially being anchored to the membrane by a transmembrane segment), will need
to be clarified. The CaCC target of CLCA2 will factor into understanding CLCA2 role in the
airway. This also applies to its role in other tissues such as the brain and reproductive system.
CLCA4
CLCA4 vWA crystallization screens should be continued to develop a crystal and
determine a structure for CLCA4 vWA domain. The structure will begin to reveal the differences
in how CLCA1 and CLCA4 engage different TMEM16 channels. Now that it is known that the
CLCA4 vWA is glycosylated, whole cell patch clamp experiments should be performed with
WT and deglycosylated vWA to determine whether the glycosylation is important for the
function of CLCA4 vWA. Lastly, like CLCA2, CLCA4 is also expressed in the lung at baseline,
and its role in the airway is unclear. The significance of the C-terminal fragment, also being
membrane anchored but through a GPI anchor, is unknown. In addition, the importance of
potentiation of CaCC by CLCA4 in the airway has also not been clarified. Interestingly,
TMEM16B is not thought to be highly expressed there based on whole lung mRNA expression
(20). However, staining of the airway is warranted to examine to what extent and in what cell
type TMEM16B may be expressed in the lung, and whether CLCA4 is also found in those
locations.

6.5.2 TMEM16 Family
Exploration of TMEM16A isoforms
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Thus far, the published mouse cryo-EM structures were both of TMEM16A isoform abc.
Yet, it is known that other isoforms are expressed and lend different properties to the channel.
Structures of other TMEM16A isoforms may reveal what these differences are on a molecular
level and aid in explaining how the various segments impart these different properties to the
channel. In this study, isoform acd was purified and examined as it was the isoform expressed in
the cystic fibrosis lung samples studied. Isoform ac was also found in other CF lung epithelial
cells, and it is also expressed in other cell types (26). In addition, how and whether CLCA1 has
differential effects on these isoforms must be examined more thoroughly. Expression of these
isoforms in HEK293T cells, possibly in a TMEM16A knockout line that has been transduced
with a low level expression of the different TMEM16A isoforms or with the TMEM16A isoform
under the control of the endogenous promoter, with and without CLCA1 present, might offer an
answer to this question.
TMEM16A Trafficking
TMEM16A trafficking is altered by the presence of CLCA1, yet very little is known
about TMEM16A trafficking in general. In the course of these studies, TMEM16A
colocalization with Rab7 was discovered (data not shown) like TMEM16F (11), suggesting that
regular trafficking to the lysosome is part of the path of TMEM16A through the cell. The
structural elements within TMEM16A involved in this trafficking are unknown. Airway
experiments in this study suggest that the alternatively spliced segments b and/or d may be
responsible. However, phosphorylation is also known to regulate trafficking and other trafficking
elements, such as tyrosine-based and dileucine sorting motifs (27, 28), which may play a role in
TMEM16A trafficking. Potential phosphorylation sites could be identified by mass spectrometry
and mutations to potential tyrosine-based and dileucine sorting motifs may reveal aspects of
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TMEM16A trafficking. As other TMEM16 members appear to be regulated by trafficking (11)
and many of them are located intracellularly (12-17), these elements may be a feature of the
family.
TMEM16A expression in the airway
There is much controversy over the cellular localization of TMEM16A in the airway; this
may be due to different antibodies and staining procedures used to observe TMEM16A protein
expression. Analysis of single cell sequencing may assist in answering in what cell type and
where in the cell TMEM16A is expressed and localized in normal and CF airway. Additionally,
in situ hybridization using probes against the various exon segments, particularly segments b and
d since these are most variably spliced into the TMEM16A transcript (29, 30), may assist in
observing what isoforms are expressed in which cell types. Being certain of where TMEM16A
is expressed will better inform where CLCA1 may have its effect in the lung.

6.5.3 CLCA-TMEM16 Interactions
CLCA1 and TMEM16A
CLCA1 effect on TMEM16A trafficking
The mechanism of TMEM16A trafficking, and how CLCA1 affects its trafficking, has
been poorly explored. To what extent CLCA1 redirects TMEM16A from Rab7 late endosomes
and lysosomes is not known. Exposure of HEK293Ts and airway epithelial cells to CLCA1,
staining for TMEM16A and Rab proteins, and examining localization microscopically and
quantitatively may clarify this. If a TMEM16A-GFP and Rab7-GFP line could be established,
this could be observed in real-time by confocal or TIRF microscopy. Mutations to sorting motifs
may also establish if and how trafficking elements in TMEM16A play a role in the CLCA1TMEM16A interaction.
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A binding affinity for TMEM16A and CLCA1
A binding affinity for TMEM16A and CLCA1 has not yet been determined. Doing so
will provide the quantitative basis towards establishing, by mutational analysis, which residues
are important for this interaction and also for improving the potency and specificity of the
interaction between the CLCA and TMEM16 partners. It was difficult to bind specifically
biotinylated TMEM16A nanodiscs to biolayer interferometry (BLI) streptavidin (or super
streptavidin) pins; saturation could not be achieved. Either a return to detergent solubilized
TMEM16A or use of biotinylated lipids (either manually generated or acquired) used in the
nanodiscs may make BLI experiments feasible. As we believe exposed acidic residues in
TMEM16A will be important for the interaction with CLCA1, to date, I have generated 3/9 of
these mutants to be expressed and purified for use in BLI experiments. These constructs could
also potentially be used in flow cytometry experiments to observe which mutants disrupt
(fluorescently-tagged) CLCA1 binding to cells expressing those mutants.
Effect of CLCA1 on smooth muscle cells
TMEM16A is known to be expressed in smooth muscle cells in the lung (22, 31) though
CLCA1 is not reported in that cell type (19). Whether or not CLCA1 could be induced there is
not known. However, since CLCA1 is secreted, it could have an effect there. In order to
determine whether CLCA1 could affect smooth muscle cell activity, CLCA1 could be applied to
isolated smooth muscle cells from the airway and TMEM16A currents and smooth muscle cell
contraction observed. As smooth muscle cells were not examined in this study, noting the
particular isoform expressed in these smooth muscle cells will be of importance. If CLCA1 does
have an effect on smooth muscle cells, it could potentially be a factor in airway hyperreactivity
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(AHR) observed in asthma. Testing purified CLCA1 in an animal model (pig or mouse) may
offer insight into the effect on smooth muscle cells is biologically relevant.
CLCA and TMEM16 Partners
The discovery that CLCA4 specifically potentiates TMEM16B set up the paradigm that
CLCA proteins modulate specific TMEM16 members. As mentioned in section 6.5.1, the target
of CLCA2 has yet to be identified. TMEM16F is a likely target. Thus, TMEM16F siRNA
knockdown experiments akin to the CLCA4-TMEM16B experiments would be a direct way to
test this. Otherwise, a TMEM16 siRNA knockdown “screen” may help identify the TMEM16
target of CLCA2. Knockdown of TMEM16A and TMEM16B in experiments with CLCA2
should also be performed to rule out redundancy. In terms of tissue function, a thorough
examination of CLCA1/TMEM16A, CLCA2/CLCA2-target and CLCA4/TMEM16B expression
will be important to determine where the pairs will act in concert. An initial survey of CLCA1, –
2, and –4 and TMEM16A –B, and –F mRNA expression in normal and CF airway liquid
interface cultures was performed. qPCR Primer/probe combinations are included in (Table 9).
Largely, the pairs’ expression co-vary: hCLCA2 and hTMEM16F are the highest expressed and
at similar levels, followed by hCLCA1 and hTMEM16A, with hCLCA4 and hTMEM16B being
the lowest-expressed pair (Figure 46). A more thorough analysis of CLCA and TMEM16
expression in various cell types will provide clues as to their function in that tissue. In addition,
cryo-EM structures of these pairs will inform the molecular determinants of the interactions and
how specificity is achieved.
Whether CLCA proteins also regulate TMEM16 family scrambling activity remains to be
investigated. The TMEM16 family scramblases move phosphatidylcholine, phosphatidylserine
and galactosylceramide across the plasma membrane (22). Fluorescence-based scrambling
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assays, such as Annexin V staining (coupled with flow cytometry), would be an appropriate
readout to screen for whether CLCA proteins also alter scrambling activity. If CLCA proteins
can regulate TMEM16 scramblases, another survey for co-expression of the two families may
help inform the function of CLCA-TMEM16 interactions in those cell types. Additionally,
whether CLCA proteins would also regulate the scramblases by trafficking would need to be
determined. If interactions between CLCA proteins and TMEM16 scramblases did exist, the
molecular complexes formed by these partners would be of particular importance to determine,
likely by cryo-EM.
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Table 9 CLCA and TMEM16 primer-probe combinations used in qPCR of ALI cultures
mRNA Transcript
hCLCA1 (vWA
domain)
Probe
Forward Primer
Reverse Primer
hCLCA2 (vWA
domain)
Probe
Forward Primer
Reverse Primer
hCLCA4 (vWA
domain)
Probe
Forward Primer
Reverse Primer
hTMEM16A
(hANO1, exon 1011)
Probe
Forward Primer
Reverse Primer
hTMEM16B
(hANO2)
Probe
Forward Primer
Reverse Primer
hTMEM16F
(hANO6)
Probe

Primer/Probe Sequences (5’ à 3’)

5’6-FAM/CCCATCCGT/ZEN/CAGCAGCACAATTTC/3’IABkFQ
GGCTTCGATCGGCATTTACT
CCTCGTTAAAGCACCCACTTAT
5’6FAM/TCCTTCAAC/ZEN/TACAACAAGCCGCAGA/3’IABkFQ
TGGATGTGTCCAGCAAGATG
CAATGCCCACGAAGGTATGA
5’6FAM/TCTGGGAGG/ZEN/AACTTCCATCTGCTCT/3’IABkFQ
ACACACTCATGGCAGGATTAC
CGAGTTGGGAATGTAGCTCTC

5’6-FAM/ATGCTCATC/ZEN/CCTGCCTCCATCG/3’IABkFQ
GCATCCGTACAGGAAGACA
CTATAAGTACCAGCCCATCGAC
5’6-FAM/ATGGGCAGA/ZEN/GTCAGTTTCTCCAGC
/3’IABkFQ
GATTGGAGTCCCGAAGCTAAA
CCCACTGCTCTGGATGTTT

5’6-FAM/ TGCTTGGCT/ZEN/
GGGCTATTACACTCA/3’IABkFQ
Forward Primer
AAGCAGCCCTTGGATCTTATC
Reverse Primer
GAAAGCAAGCCACTCCTACA
IABKFQ (Iowa Black FQ)
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Figure 46 Expression of CLCA and TMEM16 family members in normal and CF airway
A-F) Expression of human (A) CLCA1, (B) CLCA2, (C) CLCA4, (D) TMEM16A, (E) TMEM16F
and (F) TMEM16B in normal airway, and CF airway ALI cultures by qPCR. Donor cultures were
left untreated; CF airway cultures were treated with buffer or purified CLCA1 vWA for
electrophysiology experiments. Copies are standardized to hGAPDH levels.

6.5.4 CLCA1 and TMEM16A in Cystic Fibrosis
The results in this study demonstrate that CLCA1 can potentiate TMEM16A in cystic
fibrosis airway of multiple CFTR genotypes, including Class I CFTR mutants that produce no
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protein, and alter mucus properties of the CF tissues. Many experiments remain to be pursued.
The duration of the effect of CLCA1 vWA domain is unknown. It appears to have an effect with
overnight treatment, but its lifetime on airway tissue is not known. Dose-response experiments
may also be pursued. If CLCA1 can have additive effects with ivacaftor, lumacaftor and
tezacaftor also remains to be explored. Because CLCA1 works through an alternate anion
channel, and because it appears that TMEM16A and CFTR are largely expressed in different cell
types (32, 33), its effect may be additive. The question of whether CF airway expresses different
isoforms than normal airways will need to be more thoroughly explored. In situ hybridization
and a more detailed look at available RNA-sequencing data (32, 33) may inform what isoforms
are expressed in which cell types (since these differences are due to alternative splicing) in CF
versus normal donor tissue.
In examining mucus properties after treatment with CLCA1 vWA domain, only
mucociliary transport by fluorescent bead tracking was performed. However, there are other
mucus property characteristics that may be examined. Periciliary and airway surface liquid
heights may be determined by using fluorescent beads of increasing diameters and observing
where those beads no longer penetrate the mucus layers. These heights are thought to be reduced
in CF due to poor hydration (34). Thus, CLCA1 vWA treatment may restore these heights to
more normal levels. Ciliary beat frequency (CBF) is known to be reduced in CF due to thick
mucus, infection and inflammation(35, 36). CLCA1 may restore a normal CBF. Finally, whether
CLCA1 could reverse mucus acidification in CF may also be examined. Pezzulo et al. noted that
normal airway mucus is more quickly able to kill Psueudomonas than CF airway (37). Testing an
infection model with these tissues (although the CF tissue is typically already infected) may
demonstrate whether CLCA1 vWA treatment may have an effect on bacterial burden in CF.
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Lastly, while the experiments in this study only included human models, testing in an animal CF
model, such as in pigs or possibly ferrets, will be important moving forward for reproducibly
testing the effects of using CLCA1 vWA and improving its potency. Thus far, experiments on
human tissue suggest that using CLCA1 vWA may be a viable option for CF treatment.
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Chloride transport proteins play critical roles in inflammatory airway diseases, contributing to the detrimental aspects of mucus
overproduction, mucus secretion, and airway constriction. However, they also play crucial roles in contributing to the innate
immune properties of mucus and mucociliary clearance. In this review, we focus on the emerging novel roles for a chloride
channel regulator (CLCA1), a calcium-activated chloride channel (TMEM16A), and two chloride exchangers (SLC26A4/pendrin
and SLC26A9) in chronic inflammatory airway diseases.

1. Introduction
The chronic inflammatory airway disease, asthma, and chronic
obstructive pulmonary disease (COPD) are significant causes
of morbidity and mortality in children and adults. Asthma
affects over 300 million people worldwide, and the prevalence
is increasing among all demographics. COPD is currently
the third leading cause of death in USA. These diseases
are hallmarked by a Th2-mediated inflammatory response
which drives the three pathologies that contribute to airway
obstruction in these diseases: chronic inflammation; airway
muscle constriction due to airway hyperreactivity (AHR);
and mucus overproduction due to mucous cell metaplasia
(MCM). A central feature of these diseases is production
of the inflammatory cytokines IL-4 and IL-13, which drive
MCM and contribute to AHR.
The inflammatory signaling upregulates the expression
of hundreds of proteins in the airway epithelia. A number

of these proteins have roles in anion transport across membranes, including chloride channels, channel regulators, and
transporters. The identity, function, and elucidated mechanism of action of these proteins have lagged behind their
cation channel counterparts. However, recent advances in
several technologies, including high throughput screening,
have made it possible to consider the development of specific
inhibitors and activators for these classes of proteins [1].
The development of such therapeutics, however, requires an
intimate knowledge of the roles these proteins play in airway
homeostasis and mucociliary clearance. Anion channels play
very crucial roles in mucus function. Mucus is composed of
97% water and 3% solids, with the main solid component
being the mucin proteins [2]. Mucin proteins are secreted in a
dehydrated form and require anion channel activity to instill
chloride and bicarbonate ions that ensure proper salination,
hydration, and pH of the mucus gel layer. Proper control of
this is crucial as is exemplified by the disease cystic fibrosis

2
(CF), which is caused by loss of function mutations to the
chloride channel cystic fibrosis transmembrane conductance
regulator (CFTR) that produces thick, sticky mucus deficient
in mucociliary clearance or innate antimicrobial properties
[3].
Here we discuss what is currently known about the
function of four exciting, new, and emerging proteins affecting anion channel activity in inflammatory airway epithelia:
a chloride channel regulator (CLCA1), a calcium-activated
chloride channel (TMEM16A), and two chloride exchangers
(SLC26A4/pendrin and SLC26A9). In particular, we focus
on recently uncovered contributions to airway diseases and
mucus function, in order to answer whether they can be
targeted by inhibitors or activators and whether they should
be.

2. The CLCA Family of Chloride
Channel Regulators
The CLCA family of proteins was originally misidentified
as calcium-activated chloride channels and has long been
associated with chronic inflammatory airway diseases. Their
evolving functional identity and the possible role they play in
these diseases have only recently been elucidated.
2.1. CLCAs: Association with Chronic Inflammatory Airway Diseases. Asthmatic inflammation results from a Th2mediated mechanism, where the cytokines IL-4 and IL-13
bind their receptors and activate the transcription factor
STAT6 to drive inflammation and mucus overproduction in
the airways [4, 5]. In mouse models of both allergic and
respiratory virus induced-asthma, CLCA1 (previously known
as mCLCA3 or gob-5) expression has been solidly linked to
IL-13 driven MCM [6, 7] and controversially linked to AHR
[6], both hallmarks of asthma and COPD. Similar results were
observed in vitro with the human pulmonary mucoepidermoid cell line NCI-H292, in which expression of the protein
significantly increased mucin gene MUC5AC expression and
subsequent mucus production [8, 9], implying that CLCA1
can drive MCM. Studies using Clca1−/− mice, however, have
failed to show reduced response to IL-13 stimulation, as these
mice showed the same phenotype as wild-type (WT) mice
[7, 10]. Other members of the family, particularly CLCA2 and
potentially CLCA4A and CLCA4B, have also been observed
to be upregulated and to induce and colocalize with the
inflammatory mucin protein, MUC5AC [7]. These results
indicate a possible functional redundancy between members
of the mouse CLCA family, which is unlikely to translate to
human biology, as there are only three human CLCA proteins,
compared to the seven mouse CLCA proteins [11] (Figure 1).
Of the three human CLCA proteins, CLCA1 has been
identified as a potential biomarker of inflammation and
MCM in the airways [12] and suggested as a potential drug
target for treatment of asthma and COPD. Similar to mouse
CLCA1, overexpression of human CLCA1 in NCI-H292 cells
increases MUC5AC expression and mucus levels [6, 8, 9].
Its expression is upregulated in primary cell models of IL13 driven MCM and siRNA-mediated knockdown of CLCA1
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prevents IL-13-driven mucus overproduction [9]. These
experimental observations suggest a central role for CLCA1
function in IL-13-mediated MCM (Figure 2). Additionally, it
is highly overexpressed in the airway epithelia of asthmatic
patients [8] and can be found in the bronchoalveolar lavage
fluid (BALF) at high levels [13]. In contrast, other members of
the human CLCA family are not upregulated in response to
IL-13 [8, 9], suggesting that CLCA1 is the sole family member
with an essential role in MCM in human airways.
2.2. The Conceptual Evolution of CLCA Proteins from “Channels” into “Channel Regulators”. The family of CLCA proteins
were first cloned from bovine and murine samples, where
overexpression of these proteins increased Ca2+ -sensitive Cl−
conductance, which led to their initial misannotation as
Ca2+ -activated Cl− channels (CaCCs) [14–16]. In addition,
observations that nonspecific chloride channel blockers, such
as niflumic acid and DIDS, seemed to reduce both currents
and the mucus production [17] erroneously supported this
hypothesis. However, modern bioinformatics algorithms and
experimental approaches have definitively demonstrated that
CLCA proteins are soluble, secreted proteins that do not
constitute ion channels themselves [13, 18], and subsequent
studies demonstrated that CLCA proteins activate currents
through an endogenous CaCC [18–20]. As a consequence,
the CLCA nomenclature has been updated and the family
is now recognized as Ca2+ -activated Cl− channel regulator
proteins. All members of this family (with the exception of the
likely pseudogenes human CLCA3 and mouse CLCA4C) are
synthesized as full-length proteins and proteolytically cleaved
into two fragments. It has been demonstrated that, for some
of the family members, the cleavage is carried out by a zincdependent matrix metalloprotease-like (MMP-like) domain
located in the N-terminus of the protein [18, 21] (Figure 1).
However, sequence analysis has revealed that all CLCA family
members contain the required MMP active site motif [18];
thus self-cleavage is likely a conserved feature of all CLCAs.
Self-cleavage is required to unmask the N-terminal fragment
of CLCA1, which then interacts with the CaCC [18] (Figure 2).
The molecular identity of this previously unknown CaCC
has been shown to be TMEM16A and the direct interaction
between the channel and the N-terminal fragment stabilizes
and increases the cell surface expression of the channel,
thereby increasing currents [20].
2.3. CLCA1 as a Potential Regulator of Cytokine Expression.
Upstream of CLCA1 expression, the involvement of Th2cytokines IL-4 and IL-13 has been shown in cellular and
animal models as discussed above. The relationship between
CLCA1 and downstream cytokine signaling, however, is still
under investigation. The few articles that do exist report
contradictory observations regarding the role of CLCA1 as
a signaling molecule for cytokine expression. Challenging
Clca1−/− mice with lipopolysaccharide (LPS), Long et al.
observed increased KC (keratinocyte-chemoattractant) levels
in BALF, but no change in MIP-2 (macrophage inflammatory
protein 2) or IL-17 levels in the knockout mice compared
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Figure 1: Domain architecture schematic for human and mouse CLCA proteins. Each row contains the corresponding human and mouse
homologs. Mouse CLCA proteins are labeled according to the recently updated naming commissioned by the Mouse Gene Nomenclature
Committee (MGNC) in order to align the numbering established by the Human Gene Nomenclature Committee and the Rat Genome
Database. The previously used names for the mouse proteins are shown below the current names and are in italics. Scissors denote
the experimentally determined location of proteolytic cleavage sites [18]. Human CLCA3 and mouse CLCA4C are likely pseudogenes
because they contain premature stop codons. Labels denote the following domains: CAT: matrix-metalloprotease-like catalytic domain;
CYS: matrix-metalloprotease-like cysteine rich domain; vWA: von Willebrand factor type A domain; FnIII: fibronectin type III domain;
TM: transmembrane domain; GPI: glycosylphosphatidylinositol anchor.
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to WT mice [22]. In contrast, Dietert et al. observed significantly decreased levels of IL-17 and CXCL-1 in BALF
from the Clca1−/− mice infected with Staphylococcus aureus
[23]. Using a cellular model of inflammation, Ching et al.
showed that CLCA1-conditioned media increased proinflammatory cytokine (IL-6, IL-8, IL-1𝛽, and TNF 𝛼) mRNA
levels in monocyte cell line U-937 and primary porcine
alveolar macrophages. Immunopurified CLCA1 protein only
increased IL-8 and IL-1𝛽 levels significantly [24]. If such a
regulatory mechanism exists for cytokine expression, modulation of CLCA1 function with small molecules to treat mucus
cell metaplasia might also alter the inflammatory response in
the airways.

3. TMEM16: The First Family of CaCCs
While CaCC conductance was a long-observed phenomenon
in the airways and could be separated from CFTR currents, the molecular identity of the channels responsible for
these currents remained elusive until the late 2000s. The
TMEM16/Anoctamin family was identified in 2008 as the
first bona fide CaCCs [25–27]. However, based on their
electrical and pharmacological characterization, only two
of the ten family members, TMEM16A and TMEM16B,
displayed properties previously observed for CaCCs in the
airways [28, 29], whereas most of the other members function
as lipid scramblases. Of these two, TMEM16A expression has
been verified in airway epithelium and airway smooth muscle
cells [30].

3.1. TMEM16A Is Linked to Chronic Inflammatory Airway Diseases. The predicted topology for TMEM16 family members
is based on the recent landmark crystal structure of the fungal
Nectria haematococca TMEM16 (nhTMEM16) which has 10
transmembrane domains instead of the previously predicted
8 (Figure 3) [31]. The purified and reconstituted protein,
which was shown to be a homodimer [32], constitutes a
channel on its own and does not require other proteins to be
active [33]. While the Ca2+ sensitivity of the channel is well
documented [31, 34, 35] and the protein directly binds Ca2+ ,
the possible involvement and mechanism of interaction with
calmodulin as a calcium sensor and binding partner are still
controversial [35–37].
Much like CLCA1, expression of TMEM16A is upregulated by IL-4/IL-13 stimulation [38–41]. Upon upregulation,
TMEM16A colocalizes to the apical plasma membrane of
goblet cells along with the mucin MUC5AC [41–43]. It
is expressed in airway smooth muscle cells and has been
shown to play a role in AHR [42]. Additionally, inhibitors
of TMEM16A have been shown to block mucus secretion
[42, 44] whereas small molecule activators increase secretion
[45].
3.2. The Potential for Targeting CLCA1 and TMEM16A in
Chronic Inflammatory Airway Diseases. CLCA1 is a promising therapeutic target for asthma and COPD, as it is the only
member of its family to be upregulated in models of IL-13
mediated mucus overproduction [9], is a secreted protein
[18], is expressed in goblet cells [7, 9, 16], and associates with
mucin granules [46, 47]. Overexpression of CLCA1 in airway
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epithelium induces MUC5AC expression via a signaling cascade involving the kinase MAPK13, and siRNA-knockdown
of CLCA1 blocks mucus production in these models [9],
implying a critical role for CLCA1 function in inflammatory mucus production. Consistent with these observations,
DNA vaccines [48] and antibodies targeting mouse CLCA1
[49] have displayed some effectiveness in reducing airway
inflammation and MUC5AC levels in mouse asthma models.
Similarly, as mentioned above, TMEM16A inhibitors block
ATP-dependent mucus secretion, suggesting a central role for
this pair in inflammatory mucus overproduction. However, it
should be noted that these small molecules have relatively low
potency and questionable selectivity and these findings need
to be supported by additional experiments to determine the
role TMEM16A plays in mucus secretion [50]. An important
question that currently remains unanswered is what role this
pair of molecules plays in mucociliary clearance. It is well
known that anion channel activity is required for secreted
mucins (MUC5AC and MUC5B) to function properly in a
mucosal immunity and mucociliary clearance capacity [51].
Mucin proteins are secreted in dense, dehydrated granules
and require anion channel passage of chloride and bicarbonate ions to ensure proper hydration, salination, and pH
control [2]. Thus, any therapy targeting anion channel activity
in airway diseases should proceed with caution to avoid
any potential detrimental impacts to mucociliary clearance
and innate mucosal immunological properties. Along these
lines, exploiting the mechanism CLCA1-mediated regulation
of TMEM16A action might be a possible therapeutic route
for CF, utilizing a potential compensatory channel to make
up for loss of CFTR activity [52]. Further along these lines,
TMEM16A has been shown to carry not only chloride ions
but also bicarbonate ions [36]; thus activation of TMEM16A
in the setting of CF could be beneficial to adjust mucus
hydration and pH.

4. SLC26: An Ancient Family with
Unexpected New Roles
Over the last decade the anion exchanger pendrin (PDS,
SLC26A4), once thought to be limited mainly to the inner
ear, kidney, and thyroid, has been found to be upregulated by
inflammatory cytokines in the bronchial epithelium, where
it contributes to the pathogenesis of inflammatory airway
diseases [53–55] and also to the host response to bacterial
infections [56, 57]. Another member of the family, SLC26A9,
is prominently expressed in the airway epithelia, where it
interacts with CFTR to modulate mucus production [58].
The discovery of these crucial roles in lung physiology and
pathophysiology makes these anion transporters intriguing
new biomarkers for airway disease and promising novel
pharmacological targets.
4.1. Pendrin: An Anion Exchanger with Critical Roles in Ear,
Kidney, and Lung Physiology. Pendrin (PDS, SLC26A4) is
a member of the SLC26 family of multifunctional anion
transporters and channels [59, 60]. The eleven mammalian
SLC26 genes encode proteins with cytoplasmic N-termini
and C-termini flanking a transmembrane core of unknown

5
structure, predicted to span the lipid bilayer 10 to 14 times
(Figure 4). Mutagenesis, homology modeling, and molecular
dynamics simulation data are consistent with the hypothesis
that the SLC26 transmembrane fold consists of two nesting,
inverted repeats of 5–7 helices, resembling that of the CLC
Cl− /H+ antiporter channel proteins [61, 62] and the recently
solved three-dimensional structure of SLC26Dg, a bacterial
H+ -coupled fumarate symporter, has clarified this [63]. It has
been suggested that SLC26 proteins organize in functional
homodimers or homotetramers [64], though each subunit is
thought to constitute an independent translocation pathway.
The C-terminal cytoplasmic region of all SLC26 proteins
includes a sulfate transporter and antisigma factor antagonist
(STAS) domain (Figure 4), which has been implicated in
nucleotide binding and hydrolysis [65]. SLC26A4, or pendrin, functions as an electroneutral exchanger of Cl− , HCO3 − ,
I− , NO3 − , formate, SCN− , and other monovalent anions. It is
expressed in cochlear epithelial cells of the spiral prominence,
in root cells, in spindle cells of the stria vascularis, in
epithelial cells of the endolymphatic sac, and in epithelial
cells surrounding the hair cells of the saccule, utricle, and
ampulla [66]. Additionally, pendrin is expressed in the apical
membrane of thyrocytes [67, 68], renal collecting duct Type
B intercalated cells [69], salivary gland cells [70], and airway
epithelia [53].
Pendrin function is important in several settings. In the
inner ear, pendrin helps maintain Cl− and HCO3 − homeostasis, which is crucial for normal hearing and for the development of bony structures such as the cochlea and the vestibular
aqueduct [71]. In the thyroid gland, pendrin contributes I−
to the follicle for thyroxine biosynthesis [72], and in the
cortical collecting duct the transporter is implicated in Cl−
reabsorption through functional coupling with the epithelial
Na+ channel ENaC and the Na+ -dependent Cl− /HCO3 −
exchanger NDCBE/SLC4A8 [73]. Most interestingly, it has
been shown that in the bronchial epithelium pendrin mediates an increase in Cl− /SCN− exchange in response to IL-4
stimulation [74] to provide SCN− substrate to lactoperoxidase
for the synthesis of hypothiocyanite (OSCN− ), a molecule
with antimicrobial properties [75], and this underscores the
emerging role of pendrin in innate airway defense mechanisms (Figure 5).
4.2. Pendrin and the Pathogenesis of Inflammatory Lung
Disease: Too Much of a Good Thing? Pendrin was first identified by positional cloning as the disease gene for Pendred
syndrome (OMIM number 247600), an autosomal recessive
condition characterized by deafness with enlargement of
the vestibular aqueduct, complex abnormalities in cochlear
structure, and variably penetrant euthyroid goiter [76–78].
Pendrin is also implicated in DFNB4, an autosomal recessive
form of nonsyndromic deafness [79]. SLC26A4 mutations
that are clinically associated with Pendred syndrome cause
complete loss of transport function when studied in heterologous expression systems, mostly due to retention in various intracellular compartments, whereas those exclusively
associated with DFNB4 have residual transport activity [80].
In recent years, pendrin gain of function, mainly due to
increased surface expression, has been linked to respiratory
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diseases including bronchial asthma, COPD, and rhinovirus
infection, rhinitis, and chronic rhinosinusitis [54, 55, 81–86].
The association between pendrin and inflammatory airway disease was first proposed in 2005, when it was observed
that pendrin expression was upregulated in three different
murine asthma models, including transgenic overexpression
of IL-13 in lung [83]. Later, it was reported that induction
of asthma or COPD in mice by inhalation of ovalbumin or
elastase, respectively, resulted in increased pendrin expression; direct overexpression of pendrin in the lung led to
increased mucus production and secretion and neutrophilic
infiltration [86]. In subsequent works, the link between
inflammatory cytokines, in particular IL-4 and IL-13, and
pendrin overexpression has been cemented [81, 85, 87],
and in a recent study SLC26A4 was identified as the most
upregulated gene in human asthmatic bronchi [88]. A major
downstream effect of IL-4 and IL-13 signaling is the activation of the signal transducer and activator of transcription
6 (STAT6). Following ligand-receptor binding, associated
Janus kinases (JAKs) activate the receptor, allowing STAT6
to then be recruited and activated by phosphorylation. Once
phosphorylated, STAT6 homodimerizes and translocates to
the nucleus where it regulates the transcription of target genes
via binding to N4 interferon-𝛾 activated sequences (N4 GAS)
in the promoter region [89]. The pendrin promoter contains
at least one N4 GAS motif, and STAT6 has been shown to
bind this sequence in vitro, thus suggesting that increases in

pendrin promoter activity via STAT6 represent at least one
mechanism by which IL-4 and IL-13 increase pendrin activity
[87]. Cytokines other than IL-4 and IL-13 may be responsible
for increases in pendrin expression; IL-1𝛽, a macrophagesecreted cytokine involved in the immunopathogenesis of
asthma and COPD, has also been shown to increase pendrin
levels in rodent and human bronchial epithelial cells [74, 90].
Signaling through IL-4/IL-13 mediates airway hyperresponsiveness, eosinophilic inflammation, mucus cell metaplasia and mucus overproduction, subepithelial fibrosis, and
increased viscosity of the airway surface liquid (ASL), all of
which are common to bronchial asthma and COPD [91].
Pendrin may play a major role in the pathogenesis of asthma
or COPD by regulating some of these responses, in particular
ASL thickness and mucus production (Figure 5). In lung
epithelial cells, reabsorptive Na+ transport through ENaC is
suppressed whereas secretory Cl− transport through CFTR
and CaCCs is stimulated, which collectively results in a
net secretory phenotype whereby water osmotically flows
into the lumen and ASL viscosity decreases. On the other
hand, pendrin imports Cl− in exchange for other anions,
and thus an IL-4/IL-13-mediated increase in pendrin activity
may shift the equilibrium towards a reabsorptive phenotype,
resulting in the osmotic flow of water into the interstitium
and the thinning of the ASL [85]. In asthmatic mice, mucus
overproduction is accompanied by an increased pendrin
expression at the apical surface of bronchial epithelial cells,
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and in pendrin overexpression cell models, production of
MUC5AC, a major mucus protein in asthma and COPD
patients, is increased [86]. In mice, pendrin overexpression
is also accompanied by neutrophil-dominant inflammation,
suggesting that, in this system, mucus production may be
induced not only by a direct effect of pendrin on airway
epithelial cells, but also by an indirect effect of pendrin by
recruiting inflammatory neutrophils [86].
In bronchial epithelial cells, IL-4/IL-13 signaling upregulates the expression of CLCA1 [9], CFTR [92], and pendrin
[87], whereas it downregulates the expression of the 𝛽
and 𝛾 subunits of ENaC. Because upregulation of certain
proteins, such as pendrin, might aggravate asthma or COPD
symptoms, whereas the downregulation of ENaC and the
downregulation of CLCA1 might be protective (Figure 5), it
is unsurprising that pharmacological strategies aimed at the
blocking of the IL-4/IL-13 pathway are not as successful as
they were anticipated to be [93]. Selective inhibition of pendrin could be an intriguing new strategy for asthma/COPD

therapy, but as noted above, pendrin contributes to the
secretion of SCN− , a substrate of lactoperoxidase for the
production of the protective, antimicrobial OSCN− [74], and
this should be taken into account when exploring novel
treatment avenues.
4.3. The Next Frontier: Pendrin and Infectious Lung Disease.
Most recently, pendrin has been implicated in the IL-17Adependent host inflammatory response to bacterial airway
infections (Figure 5) [56, 57]. IL-17A is critical for the
immune response of the lung to infectious bacteria, for example, Haemophilus influenzae, Staphylococcus aureus, Klebsiella
pneumoniae, and Bordetella pertussis [94]. The latter is the etiologic agent of whooping cough, or pertussis disease, which
is a resurgent condition of great clinical concern as it can
progress to pulmonary inflammation and death in infants and
for which there is no effective treatment [95]. Pertussis toxin
(PT), the virulence factor of B. pertussis, undermines the host
immune system by inhibiting macrophage and neutrophil
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responses, suppressing the production of antibodies against
the bacteria, and inducing proinflammatory cytokines, in
particular IL-17A [96]. One of the most highly upregulated
genes in association with PT activity is SLC26A4 [97, 98], and
pendrin is upregulated in human bronchial epithelial cells
exposed to IL-17A [56]. In the lungs of B. pertussis-infected
mice there is an increase in pendrin levels that is concomitant
with an increase in IL-17A but not in IL-4/IL-13 levels, and
pendrin upregulation is significantly hampered in Il-17anull mice [57]. Other host factors may be involved in PTdependent upregulation of pendrin, such as IL-1𝛽 and IFN-𝛾,
as both are upregulated during B. pertussis infection and have
been linked with pendrin upregulation [85, 98, 99]. Taken
together, these recent advances suggest that the upregulation
of pendrin, with its associated inflammatory pathology, is a
major mechanism of virulence for the pertussis toxin and
position pendrin as a potential novel therapeutic target for
the treatment of whooping cough.
4.4. SLC26A9: A Novel CFTR Regulator. SLC26A9 is another
member of the SLC26 family of anion exchangers and
channels. It is robustly expressed in apical airway epithelia
[100] and gastric parietal cells [101] and to a lesser extent in
the kidney, brain, and reproductive tracts [59, 102–104]. The
function of SLC26A9 is still unclear: it has been described as
a Cl− channel with a small degree of bicarbonate transport
[104], a Cl− channel or a Cl− /HCO3 − exchanger [105, 106].
One group reported increased Cl− conductance particularly
in high bicarbonate conditions [107], and others have found
that SLC26A9 activity is coupled to Na+ transport [58, 103,
108]. Like other members of the family, SLC26A9 is predicted
to span the membrane 14 times, and it contains a STAS
domain followed by a PSD95-Dlg1-Zo-1 (PDZ) domain in
the C-terminal cytoplasmic region (Figure 4) [59, 109]. Two
groups propose that SLC26 proteins, including SLC26A9,
interact with CFTR initially via their PDZ domains [110,
111]. This is followed by a stronger interaction between
the CFTR R domain and the SLC26 STAS domain, which
is enhanced by PKA-dependent phosphorylation of the R
domain [111–113]. The interaction between SLC26A9 and
CFTR has been described in multiple studies. However,
whether the interaction is stimulatory or inhibitory is still
controversial and may be cell type-dependent [108, 114].
Not much is known about the regulation of SLC26A9, but
WNK kinases, also known to regulate other transporters
and channels involved in osmoregulation, have been shown
to inhibit SLC26A9 activity via interaction with the STAS
domain [109]. Though the influence of SLC26A9 on CFTR
has been reported, the reciprocal interaction is less clear.
Multiple groups have described CFTR regulation of SLC26A9
activity and expression, but the results are not consistent
[58, 114–118]. Evidence of CFTR and SLC26A9 coexpression
has been found in the lung, trachea, stomach, and sweat gland
[119].
Due to its high expression in the lung, numerous studies
have investigated the role of SLC26A9 in lung disease.
Anagnostopoulou and colleagues [120] first reported that
SLC26A9 activity is responsible for increased constitutive
Cl− current under Th2 inflammatory conditions, but not in
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normal physiology. The authors also found that SLC26A9
prevents airway mucous obstruction after stimulation with
IL-13. These changes were due to increased SLC26A9 activity, which may be due to changes in regulation by WNK
kinases [104]. Unlike CFTR and TMEM16A, SLC26A9 is
downregulated in patients with allergic asthma (Figure 4).
Further investigation revealed that a SNP in the 3 UTR of
the SLC26A9 gene likely reduced expression levels in these
patients, possibly through enhanced binding of hsa-miR-632
[120].
SLC26A9 has also been implicated in the pathogenesis
of bronchiectasis, the widening of airways frequently due
to mucous obstruction, a condition often seen in patients
with cystic fibrosis. A recent report [119] identified two
patients with diffuse idiopathic bronchiectasis who also had
mutations in the SLC26A9 gene. One patient presented with a
mutation in a transmembrane domain of SLC26A9 (V486I);
the patient’s brother was asymptomatic, though he had the
same mutation. The second patient presented with a mutation
in the STAS domain of SLC26A9 (R575W) in addition to the
Fdel508 mutation in CFTR. Coexpression of both mutants in
Xenopus oocytes provided evidence of a decreased interaction
between the SLC26A9 STAS domain and the R domain of
CFTR. It is thought that wild-type SLC26A9, in conjunction
with CFTR loss, may enhance ion conductance and fluid
secretion [121]. Thus, loss of SLC26A9, in the setting of
CFTR loss, may result in reduced airway surface liquid
hydration, mucous blockage, and consequent bronchiectasis.
The authors of the study further narrow the CFTR-SLC26A9
interaction region to a peptide within the STAS domain but
do not confirm that the R575W mutation in this peptide
disrupts the interaction and activation [119]. In contrast, a
second group did not report changes in Cl− transport with
the R575W mutation [122]. As the second patient’s daughter
only carried the Fdel508 mutation and was asymptomatic, the
authors speculate that one mutation in CFTR is not sufficient
to produce the CF phenotype [119]. However, mutations in
modifier genes, such as SLC26A9, may contribute to CF in
those heterozygous for CFTR mutations. Thus, SLC26A9 may
influence phenotypic expression of heterozygous mutations
in ion channels (CFTR, ENaC, and others) involved in airway
surface liquid hydration [119].
Further supporting the modifier gene hypothesis, some
SLC26A9 mutations have been shown to increase the risk
of meconium ileus in patients with CF [123], as well as CFrelated diabetes onset [124] and pancreatic disease severity
[108, 125]. In the case of CFTR and SLC26A9 double mutations, the exact mechanism causing the phenotype must be
further investigated as Cl− transport could be due to altered
CFTR and/or SLC26A9 function or to impaired regulation of
CFTR by SLC26A9 or vice versa [119, 124]. Understanding the
various mechanisms of SLC26A9 mutations will be important
towards developing therapies that can improve lung diseases
such as asthma, CF, and bronchiectasis.

5. Conclusions
Chloride transport proteins play crucial roles in airway
health and disease. On one hand, they contribute to proper
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mucus function by controlling mucus hydration and pH via
controlling chloride and bicarbonate ion transport. On the
other hand, they may play a direct role in mucus synthesis,
secretion, and AHR. Recent animal model studies have
emphasized the crucial role that mucus and mucin proteins
play in innate mucosal immunology. Deletion of MUC5B (the
main secreted mucin protein produced in the airway under
homeostatic conditions) results in impaired mucociliary
clearance and increased microbial infection [126]. Knockout
of CFTR in pig results in airway mucus that is more acidic
and deficient in antimicrobial activity due to loss of defensin
function at low pH [3, 127] and is also deficient in mucociliary
clearance as it remains tethered to secreting cells [128]. This
could be due to improper proteolytic processing of mucin
proteins, since loss of CFTR function in the intestine impairs
𝛽-meprin processing and release of secreted mucins in that
setting [129]. Thus a complete understanding of how these
channels contribute to mucus synthesis, secretion, function,
and mucociliary clearance is required to understand the
impact of modulating their activity.
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Journal of Physiology, vol. 467, no. 6, pp. 1261–1275, 2015.
[109] M. A. Mall and L. J. Galietta, “Targeting ion channels in cystic
fibrosis,” Journal of Cystic Fibrosis, vol. 14, no. 5, pp. 561–570,
2015.
[110] M. N. Chernova, L. Jiang, B. E. Shmukler et al., “Acute regulation
of the SLC26A3 congenital chloride diarrhoea anion exchanger
(DRA) expressed in Xenopus oocytes,” The Journal of Physiology,
vol. 549, no. 1, pp. 3–19, 2003.
[111] S. B. Ko, W. Zeng, M. R. Dorwart et al., “Gating of CFTR by the
STAS domain of SLC26 transporters,” Nature Cell Biology, vol.
6, no. 4, pp. 343–350, 2004.
[112] S. B. H. Ko, N. Shcheynikov, J. Y. Choi et al., “A molecular
mechanism for aberrant CFTR-dependent HCO−3 transport in
cystic fibrosis,” The EMBO Journal, vol. 21, no. 21, pp. 5662–5672,
2002.
[113] N. Shcheynikov, S. B. H. Ko, W. Zeng et al., “Regulatory interaction between CFTR and the SLC26 transporters,” Novartis
Foundation Symposium, vol. 273, pp. 177–186, 2006.
[114] J. Ousingsawat, R. Schreiber, and K. Kunzelmann, “Differential
contribution of SLC26A9 to Cl− conductance in polarized and
non-polarized epithelial cells,” Journal of Cellular Physiology,
vol. 227, no. 6, pp. 2323–2329, 2012.
[115] M. Avella, C. Loriol, K. Boulukos, F. Borgese, and J. Ehrenfeld,
“SLC26A9 stimulates CFTR expression and function in human
bronchial cell lines,” Journal of Cellular Physiology, vol. 226, no.
1, pp. 212–223, 2011.

Mediators of Inflammation
[116] C. A. Bertrand, R. Zhang, J. M. Pilewski, and R. A. Frizzell,
“SLC26A9 is a constitutively active, CFTR-regulated anion
conductance in human bronchial epithelia,” Journal of General
Physiology, vol. 133, no. 4, pp. 421–438, 2009.
[117] J. Braun, L. Mundhenk, F. Range, and A. D. Gruber, “Quantitative expression analyses of candidates for alternative anion
conductance in cystic fibrosis mouse models,” Journal of Cystic
Fibrosis, vol. 9, no. 5, pp. 351–364, 2010.
[118] M.-H. Chang, C. Plata, A. Sindic et al., “Slc26a9 is inhibited by
the R-region of the cystic fibrosis transmembrane conductance
regulator via the STAS domain,” The Journal of Biological
Chemistry, vol. 284, no. 41, pp. 28306–28318, 2009.
[119] N. Bakouh, T. Bienvenu, A. Thomas et al., “Characterization
of SLC26A9 in patients with CF-like lung disease,” Human
Mutation, vol. 34, no. 10, pp. 1404–1414, 2013.
[120] P. Anagnostopoulou, B. Riederer, J. Duerr et al., “SLC26A9mediated chloride secretion prevents mucus obstruction in
airway inflammation,” Journal of Clinical Investigation, vol. 122,
no. 10, pp. 3629–3634, 2012.
[121] M. R. Miller, D. Soave, W. Li et al., “Variants in solute carrier
SLC26A9 modify prenatal exocrine pancreatic damage in cystic
fibrosis,” Journal of Pediatrics, vol. 166, no. 5, pp. 1152–1157.e6,
2015.
[122] A.-P. Chen, M.-H. Chang, and M. F. Romero, “Functional
analysis of nonsynonymous single nucleotide polymorphisms
in human SLC26A9,” Human Mutation, vol. 33, no. 8, pp. 1275–
1284, 2012.
[123] L. Sun, J. M. Rommens, H. Corvol et al., “Multiple apical plasma
membrane constituents are associated with susceptibility to
meconium ileus in individuals with cystic fibrosis,” Nature
Genetics, vol. 44, no. 5, pp. 562–569, 2012.
[124] S. M. Blackman, C. W. Commander, C. Watson et al., “Genetic
modifiers of cystic fibrosis-related diabetes,” Diabetes, vol. 62,
no. 10, pp. 3627–3635, 2013.
[125] W. Li, D. Soave, M. R. Miller et al., “Unraveling the complex
genetic model for cystic fibrosis: pleiotropic effects of modifier
genes on early cystic fibrosis-related morbidities,” Human
Genetics, vol. 133, no. 2, pp. 151–161, 2014.
[126] M. G. Roy, A. Livraghi-Butrico, A. A. Fletcher et al., “Muc5b is
required for airway defence,” Nature, vol. 505, no. 7483, pp. 412–
416, 2014.
[127] M. H. Abou Alaiwa, L. R. Reznikov, N. D. Gansemer et al.,
“pH modulates the activity and synergism of the airway surface
liquid antimicrobials beta-defensin-3 and LL-37,” Proceedings of
the National Academy of Sciences, vol. 111, no. 52, pp. 18703–
18708, 2014.
[128] M. J. Hoegger, A. J. Fischer, J. D. McMenimen et al., “Impaired
mucus detachment disrupts mucociliary transport in a piglet
model of cystic fibrosis,” Science, vol. 345, no. 6198, pp. 818–822,
2014.
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selective activation of TMEM16A by the CLCA1 VWA
domain in loss-of-function chloride channelopathies such as
cystic fibrosis.

Calcium-activated chloride channels (CaCCs)4 are key players in transepithelial ion transport and fluid secretion, smooth
muscle constriction, neuronal excitability, and cell proliferation (1, 2). The first member of the family to be identified,
TMEM16A/Anoctamin 1 (ANO1) (3–5), is found in airway
epithelia, submucosal glands, and smooth muscle, and increased TMEM16A activity has been associated with chronic
obstructive pulmonary disease and asthma manifestations such
as mucus cell metaplasia and mucus hypersecretion (3, 6, 7).
Conversely, targeted potentiation of TMEM16A has been suggested as a mechanism to treat certain channelopathies, such as
cystic fibrosis (CF) (8). Calcium-activated chloride channel regulator (CLCA) proteins are self-cleaving metalloproteases that
activate calcium-dependent chloride currents (ICaCC) in mammalian cells (9). Initially annotated as CaCCs (10), further studies have shown that CLCAs are not channels but secreted,
soluble proteins that modulate CaCCs endogenous to cells
(11–14). CLCA1 is expressed in lung epithelia, where it plays
a role in mucus homeostasis (15), and it has been linked to
some of the same airway disease traits associated with
TMEM16A (16). Overexpression of CLCA1 alleviates the
intestinal disease meconium ileus in Cftr-deficient mice (17),
and the CLCA1 variant S357N is found with high frequency in
CF patients with aggravated intestinal disease (18), all of which
suggests that CLCA1 might act as a modifier in the context of
CF.
Recently, we uncovered a functional link between CLCA1
and TMEM16A (13, 14). Specifically, we demonstrated that the
N-terminal fragment resulting from the self-proteolysis of
CLCA1 (N-CLCA1) can activate ICaCC in mammalian cells (14)
4

The abbreviations used are: CaCC, calcium-activated chloride channel; CF,
cystic fibrosis; CLCA, calcium-activated chloride channel regulator; ICaCC,
calcium-dependent chloride current; VWA, von Willebrand factor type A;
MIDAS, metal ion-dependent adhesion site; CaV, voltage-gated Ca2! channel; GPI, glycosylphosphatidylinositol; FnIII, fibronectin type III; CFTR, cystic
fibrosis transmembrane conductance regulator; WGA, wheat germ agglutinin; pF, picofarad; ANOVA, analysis of variance; CAT, metalloprotease catalytic domain; F, F test statistic.
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Calcium-activated chloride channels (CaCCs) are key players
in transepithelial ion transport and fluid secretion, smooth
muscle constriction, neuronal excitability, and cell proliferation. The CaCC regulator 1 (CLCA1) modulates the activity of
the CaCC TMEM16A/Anoctamin 1 (ANO1) by directly engaging the channel at the cell surface, but the exact mechanism is
unknown. Here we demonstrate that the von Willebrand factor
type A (VWA) domain within the cleaved CLCA1 N-terminal
fragment is necessary and sufficient for this interaction.
TMEM16A protein levels on the cell surface were increased in
HEK293T cells transfected with CLCA1 constructs containing
the VWA domain, and TMEM16A-like currents were activated.
Similar currents were evoked in cells exposed to secreted VWA
domain alone, and these currents were significantly knocked
down by TMEM16A siRNA. VWA-dependent TMEM16A modulation was not modified by the S357N mutation, a VWA
domain polymorphism associated with more severe meconium
ileus in cystic fibrosis patients. VWA-activated currents were
significantly reduced in the absence of extracellular Mg2!, and
mutation of residues within the conserved metal ion-dependent
adhesion site motif impaired the ability of VWA to potentiate
TMEM16A activity, suggesting that CLCA1-TMEM16A interactions are Mg2!- and metal ion-dependent adhesion site-dependent. Increase in TMEM16A activity occurred within
minutes of exposure to CLCA1 or after a short treatment with
nocodazole, consistent with the hypothesis that CLCA1 stabilizes TMEM16A at the cell surface by preventing its internalization. Our study hints at the therapeutic potential of the

The VWA domain of CLCA1 activates TMEM16A

Results
The VWA domain of CLCA1 is necessary and sufficient to
up-regulate TMEM16A activity
We demonstrated previously that N-CLCA1 binds to
TMEM16A and that this interaction can increase the surface
density of TMEM16A, thereby increasing TMEM16A currents
(13, 14). Because N-CLCA1 contains several discrete protein
domains (Fig. 1A), we set out to identify the minimal region
required for interaction with TMEM16A. First, we transfected
HEK293T cells with expression constructs composed of one or
more N-CLCA1 structural domains (Fig. 1A) and tested them
for TMEM16A activity by means of patch clamp electrophysiology and confocal microscopy-based immunofluorescence
(Fig. 1, B–E). Robust, modestly outward-rectifying currents
were activated in cells expressing full-length (CLCA1) or
N-CLCA1 (Fig. 1, C and D), and we have demonstrated that
these currents are carried by TMEM16A (13). Substantially
smaller currents were measured in cells transfected with the
empty pHLsec vector, consistent with the low endogenous levels of TMEM16A at the membrane of these cells (19, 20). In
cells transfected with constructs containing the VWA domain,
currents with the same biophysical characteristics and comparable density as those evoked in CLCA1- or N-CLCA1-transfected cells were activated (Fig. 1, C and D), and this was not
affected by the absence of the ! sheet-rich domain in the
CAT ! VWA construct, suggesting that this domain is not
required for CLCA1-dependent TMEM16A regulation. In cells
transfected with a construct containing only the metalloprotease domain (CAT), the currents were indistinguishable from
those measured in mock-transfected cells (Fig. 1, C and D),
suggesting that proteolytic cleavage of a downstream target is
not part of the TMEM16A modulation mechanism, in agreement with our previous results (14). In immunofluorescence
experiments, fixed and non-permeabilized cells transfected
with constructs that included the VWA domain (CLCA1,
N-CLCA1, CAT ! VWA, or VWA alone) stained strongly for
TMEM16A surface expression, whereas cells transfected with
CAT or pHLsec displayed little or no TMEM16A staining (Fig.

1E), further suggesting that N-CLCA1 interactions with
TMEM16A are mediated by the VWA domain. Thus, we conclude that the VWA domain contained within N-CLCA1 is
required and sufficient to stabilize TMEM16A at the cell
surface.
Secreted CLCA1 VWA can activate TMEM16A-mediated
currents and increase TMEM16A surface levels
In our previous studies, we showed that N-CLCA1 can be
applied exogenously to potentiate the functional expression of
TMEM16A in HEK293T cells (13). We therefore investigated
whether the isolated VWA domain can elicit the same
responses, and we also examined the cellular phenotype of
S357N, a common human polymorphism within the CLCA1
VWA domain that has been associated with more severe meconium ileus in CF patients (18) (Fig. 2). We cultured untransfected cells or cells transfected with negative control scrambled
RNAi (siControl) or TMEM16A siRNA overnight in medium
obtained from cells transfected with either empty pHLsec vector or wild-type or S357N VWA and then assayed them for
TMEM16A protein and activity as above (Fig. 2A). Typical
CLCA1-dependent currents were activated in untransfected
cells exposed to secreted WT or S357N VWA (Fig. 2B); the
current density was similar in both cases (Fig. 2C) and comparable with that observed in VWA-transfected cells (Fig. 1D).
Conversely, only small background currents were measured
in mock-conditioned untransfected cells (Fig. 2, B and C).
TMEM16A staining was noticeably increased in untransfected
cells conditioned with either WT or S357N VWA (Fig. 2D), and
currents were knocked down to near background levels in WT
or mutant VWA-conditioned cells transfected with TMEM16A
siRNA but remained unchanged in cells transfected with
siControl (Fig. 2, B and C). These results further support the
hypothesis that the VWA domain of CLCA1 is critical for
CLCA1-TMEM16A interactions and suggest that external
application of the CLCA1 VWA domain may be an effective
means of potentiating TMEM16A activity. Finally, VWA
activity was not modified by the S357N mutation, suggesting
that the association of CLCA1 S357N with the etiology of
meconium ileus, if any, is unrelated to TMEM16A channel
regulation.
CLCA1 VWA-mediated current activation is dependent on
extracellular Mg2! and is impacted by mutations within the
MIDAS motif
VWA domains, commonly found in extracellular adhesion
proteins, are implicated in extracellular protein-protein interactions, largely via a MIDAS motif consisting of up to five polar
or negatively charged residues that coordinate a divalent cation,
usually Mg2! (21). Sequence alignments and structure prediction (Fig. 3A) indicate that the CLCA1 VWA domain contains a
five-residue (“perfect”) MIDAS motif (21), corresponding to
Asp-312, Ser-314, Ser-316, Thr-383, and Asp-412 (Fig. 3A), and
we investigated whether CLCA1-TMEM16A interactions are
mediated by this motif (Fig. 3, B–F). We observed that CLCA1
VWA-dependent current activation requires extracellular
Mg2!; thus, the current density in cells incubated overnight
with CLCA1 VWA-conditioned medium dropped to backJ. Biol. Chem. (2017) 292(22) 9164 –9174
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and that these currents are carried by TMEM16A, which interacts directly with secreted N-CLCA1 at the cell surface (13). In
this study, we apply electrophysiological and imaging methods
to further investigate the mechanisms underlying CLCA1TMEM16A interactions. We report that the von Willebrand
factor type A (VWA) domain within N-CLCA1 is sufficient to
increase TMEM16A at the cell surface and TMEM16A-mediated current density and that the mechanism is dependent
upon the metal ion-dependent adhesion site (MIDAS) motif
within N-CLCA1 VWA. Up-regulation of TMEM16A activity by CLCA1 occurs in minutes and can be mimicked by
treatment with the endocytosis inhibitor nocodazole, in support of our hypothesis that CLCA1 stabilizes TMEM16A at
the cell surface by preventing its internalization (13). Our
findings provide novel insights into CLCA1 and TMEM16A
as a cooperative pair and have direct implications for the
targeting of CLCA1-TMEM16A interactions in airway
disease.

The VWA domain of CLCA1 activates TMEM16A

ground levels when experiments were performed in Mg2!-free
extracellular solution (Fig. 3, B and C). More conclusively, disruption of the MIDAS motif, in particular mutation of Ser-316
or Thr-383 to Ala, reduced the ability of CLCA1 VWA to modulate surface protein levels and activity of TMEM16A (Fig. 3,
D–F). The current density in cells treated with D312A/S314A
or D312A/S314A/D412 VWA-conditioned medium was comparable with that measured in cells exposed to wild-type VWA
but decreased "30% in cells conditioned with D312A/S314A/
S316A or D312A/S314A/S316A/D412A VWA and to back-
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ground levels in cells conditioned with D312A/S314A/S316A/
T383A VWA (Fig. 3, D and E). Compared with cells conditioned with WT, D312A/S314A, or D312A/S314A/D412
VWA, the increase in TMEM16A surface staining was also
attenuated in cells exposed to D312A/S314A/S316A, D312A/
S314A/S316A/D412A, and D312A/S314A/S316A/T383A (Fig.
3F). These findings suggest that CLCA1 VWA interacts with
TMEM16A in a Mg2!- and MIDAS-dependent manner and
that residues Ser-316 and Thr-383 within the MIDAS motif are
critical for these interactions.
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Figure 1. The VWA domain of CLCA1 is necessary and sufficient to activate TMEM16A-like currents and to increase TMEM16A protein at the cell
surface. A, top panel, CLCA1 is a self-cleaving zincin metalloprotease. The dashed line indicates the proteolytic cleavage site. Cat, metalloprotease catalytic
domain; Cys, cysteine-rich domain; VWA, von Willebrand factor type A domain; BSR, ! sheet-rich domain; FnIII, fibronectin type III domain. Bottom panel,
schematic of constructs used to experimentally determine the minimal domain within CLCA1 required to modulate TMEM16A. B, HEK293T cells were transfected with empty pHLsec vector or with CLCA1 constructs as in A and assayed for TMEM16A functional expression by patch clamp electrophysiology and
confocal microscopy imaging. C and D, whole-cell currents measured in cells superfused with standard extracellular solution and in the presence of 10 "M free
Ca2! in the pipette. C, representative current traces. The pulse protocol is shown at the top left. Outward currents are represented by upward deflections, and
dotted lines indicate zero current. Membrane capacitance was similar in all cases at "25 pF. D, current density at !100 mV, measured at the end of the 600-ms
voltage step. Symbols represent data from individual cells (n # 19 – 45); error bars indicate the means $ S.E. of all experiments. Statistical differences are
indicated by different lowercase letters; i.e. a group labeled with a given letter is statistically similar to any other group labeled with the same letter but
significantly different from any other group labeled differently (p % 0.05, one-way ANOVA, F # 16 and p # 4 & 10'13, followed by the Tukey test). E,
immunofluorescence staining of TMEM16A (green) and the cell surface marker WGA (blue).

The VWA domain of CLCA1 activates TMEM16A

CLCA1-dependent modulation of TMEM16A activity occurs
within minutes and is mimicked by treatment with the
internalization inhibitor nocodazole
We demonstrated previously that application of exogenous
CLCA1 to HEK293T cells increases TMEM16A-mediated current density and TMEM16A surface staining without changing
total TMEM16A protein levels. Because we found that CLCA1
directly binds TMEM16A at the cell surface, we hypothesize
that this interaction may prevent recycling of the channel (13).
The effects of CLCA1 on TMEM16A surface levels and func-

tion are relatively rapid (Fig. 4), consistent with a mechanism
that is independent of protein synthesis. Strong TMEM16A
staining was detected and maximized after just 30 min of incubation in CLCA1-conditioned medium (Fig. 4A). In patch
clamp assays (Fig. 4, B–E), robust, slightly outward-rectifying
currents were activated "1–3 min after application of purified
CLCA1 VWA protein to the extracellular solution and
approached steady state "5–7 min later (Fig. 4, C and D); the
maximum current density in VWA-treated cells was up to
7-fold higher than in cells exposed to protein-free buffer (Fig.
J. Biol. Chem. (2017) 292(22) 9164 –9174
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Figure 2. Secreted CLCA1 VWA domain up-regulates TMEM16A. A, untransfected cells or cells transfected with negative control RNAi (siControl) or
TMEM16A siRNA were cultured in medium from pHLsec-transfected cells or from cells expressing CLCA1 VWA, either WT or cystic fibrosis-associated variant
S357N, and subsequently assayed for TMEM16A currents and surface staining. B and C, whole-cell currents measured under standard extracellular and pipette
conditions. B, representative current traces, displayed as in Fig. 1C. The pulse protocol is shown at the bottom right. Membrane capacitance was similar in all
cases at "25 pF. C, current density at !100 mV. Symbols represent data from individual cells (n # 9 –31); error bars indicate the means $ S.E. of all experiments.
The results of the statistical analysis are indicated by lowercase letters; i.e. groups sharing letters are statistically similar (for example, groups labeled a and ab),
whereas those not sharing any letters are significantly different (for example, groups labeled a and bc) (p % 0.05, one-way ANOVA, F # 11 and p # 2 & 10'9,
followed by the Tukey test). D, immunofluorescence staining of TMEM16A (green), CLCA1 (red, anti-human CLCA1 antibody 2F4), and the cell surface marker
WGA (blue) in untransfected cells incubated in pHLsec-, WT, or S357N VWA-conditioned medium.

The VWA domain of CLCA1 activates TMEM16A

4E). The microtubule destabilizer nocodazole disrupts microtubule-dependent internalization of channels and other membrane proteins (22–24), thus preventing the recycling of these
proteins from the cell surface. In cells treated with nocodazole,
but not in those treated with vehicle (0.5% DMSO), currents
with properties similar to those observed in cells transfected or
conditioned with CLCA1 (see, for example, Refs. 13, 14 and
Figs. 1–3) were activated (Fig. 5). The current density was
significantly knocked down in nocodazole-treated cells
transfected with TMEM16A siRNA in contrast to those transfected with siControl (Fig. 5). Together, these data support the
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hypothesis that CLCA1 stabilizes TMEM16A at the cell surface
by impeding its reinternalization.

Discussion
The VWA domain in N-CLCA1 is the minimal requirement for
interaction with TMEM16A
Here we demonstrate that the CLCA1 VWA domain is
responsible for mediating the interaction with TMEM16A,
resulting in increased TMEM16A at the cell surface and
increased ICaCC density (Figs. 1– 4). VWA domains mediate
protein-protein interactions important for cell adhesion and
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Figure 3. A MIDAS motif within the CLCA1 VWA domain is implicated in the CLCA1-TMEM16A interactions. A, homology model of the CLCA1 VWA
domain based on the VWA domain of C. acidiphila (PDB code 4FX5). Inset, the MIDAS pocket with an Mg2! ion within. The critical residues Ser-316 and Thr-383
are highlighted in red. B and C, whole-cell currents measured in wild-type CLCA1 VWA- (WT VWA) or mock-conditioned (pHLsec) cells superfused with standard
([1 mM Mg2!]out) or Mg2!-free ([0 mM Mg2!]out) extracellular solution. D and E, whole-cell currents measured in mock-conditioned cells and in cells conditioned
with WT or MIDAS motif mutant VWA superfused with standard extracellular solution. B and D, representative current traces displayed as in Fig. 1C. The pulse
protocol is the same as in Figs. 1 and 2. The membrane capacitance was similar in all cases at "25 pF. C and E, current density at !100 mV. Symbols are data from
individual cells (C, n # 6 –25; E, n # 18 –30); error bars indicate the means $ S.E. of all experiments. The results of the statistical analysis are indicated by lowercase
letters; i.e. groups sharing letters are statistically similar (for example, groups labeled a and ab or groups labeled ab and bc), whereas those not sharing any
letters are significantly different (for example, groups labeled a and b or groups labeled ab and c) (p % 0.05, one-way ANOVA; C, F # 13 and p # 3 & 10'9; E, F #
12 and p # 1 & 10'10; followed by Tukey test). F, immunofluorescence staining of TMEM16A (red) in pHLsec-, WT, or MIDAS motif mutant VWA-conditioned
medium.

The VWA domain of CLCA1 activates TMEM16A

signaling in extracellular matrix proteins, such as integrins and
collagens, but are also found in auxiliary subunits of voltagegated Ca2! (CaV) channels (21). A common mechanism of
VWA domain-dependent protein-protein interactions involves
the coordination of a divalent cation, usually Mg2!, by a
MIDAS motif at the binding interface (21). However, there are
examples of VWA-mediated interactions in which surfaces
other than the MIDAS are implicated (25–27). Our results indicate that the CLCA1 VWA-TMEM16A interaction is, at least in
part, dependent on both Mg2! and the perfect MIDAS motif
within the VWA domain of CLCA1 (Fig. 3). These observations
draw intriguing comparisons with the #2$ subunits of CaV
channels, in particular CaV1 and CaV2 (28). Like CLCAs, #2$
proteins are posttranslationally cleaved into two fragments, #2

and $ (29), and modulate Ca2! currents through functional and
structural association with #1 pore-forming subunits (30, 31).
Both #2$-1 and #2$-2 contain VWA domains with a perfect
MIDAS motif that is required for increasing Ca2! current density and CaV channel complex surface expression (30, 32, 33).
However, unlike N- and C-CLCA1, the #2 and the $ fragments
remain linked by a disulfide bond after cleavage (34) and are
likely associated with the plasma membrane though a predicted
glycosylphosphatidylinositol (GPI) anchor site at the C terminus of $ (35, 36). CaV#1-#2$ interactions seem to occur during
the intracellular protein maturation process (32), whereas
CLCA1 can interact with TMEM16A after it has been secreted,
either by the same cell or by neighboring cells (13). Similar to
CLCA1, a major mechanism for #2$ subunit-dependent modJ. Biol. Chem. (2017) 292(22) 9164 –9174
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Figure 4. CLCA1-dependent modulation of TMEM16A activity occurs within minutes. A, immunofluorescence staining of TMEM16A (red), CLCA1 (green,
anti-human CLCA1 antibody 1228), and the cell surface marker WGA (blue) in untransfected cells incubated in CLCA1-conditioned medium for a few seconds
(0 min) or 30 or 120 min. B–E, time course of whole-cell current activation by purified CLCA1 VWA protein. B, experiments were performed under standard
extracellular and pipette conditions. A descending voltage ramp was applied every 10 s for the duration of the experiment. C, current density at !80 mV
measured over time in two example cells (membrane capacitance "20 pF). After stable conditions were achieved, 5 "l of purified CLCA1 VWA protein (final
concentration, 5 "M) or dialysis buffer B was added to the bath (arrow); currents immediately before addition of protein or buffer (a) and at the post-application
steady state (b) are shown in color. D, current/voltage relationships at a and at b for the examples shown in C. E, current density at !80 mV in three individual
buffer-treated cells and in three individual VWA-treated cells measured at selected time points, immediately before (0 min) or up to 9 min after addition of
protein or buffer. Each cell is represented with unique symbols; the colored symbols are the same as in C.

The VWA domain of CLCA1 activates TMEM16A

ulation of Ca2! currents is the increase of #1 subunit and CaV
channel complex surface expression (28), but, unlike CLCA1,
there is substantial evidence that #2$ subunits also inform the
biophysical and pharmacological properties of CaV channels
(37).
Mechanism of TMEM16A stabilization by CLCA1
Our data indicate that exogenously applied CLCA1 increases
TMEM16A surface levels and, thus, ICaCC through the channel.
This up-regulation occurs within minutes (Fig. 4), suggesting
that it is not dependent on protein synthesis but, rather, draws
from the existing pool of TMEM16A protein in the cell.
TMEM16A channels are functional oligomeric homodimers,
i.e. each of the two identical subunits defines its own conduction pore (38 – 40), but oligomerization is required for channel
assembly and surface expression (41, 42); TMEM16A likely
forms high-affinity dimers, as the purified protein elutes as a
dimer on gel filtration columns (43), and the first crystal structure of a fungal orthologue revealed a dimer (44). Thus, it
is unlikely that CLCA1 engages monomeric TMEM16A and
drives dimerization, but it may stabilize the dimer at the cell
surface, perhaps through a conformational change that masks a
reinternalization signal. Treatment with nocodazole, an inhibitor of microtubule-dependent internalization, recapitulates
the effect of exogenous application of CLCA1 (Fig. 5), suggesting that CLCA1 may prevent the recycling of TMEM16A channels. Interestingly, although the #2$ subunits of CaV channels
are thought to act mostly by enhancing forward trafficking of
the channel complexes (45, 46), there is evidence that they may
also delay their turnover (47), but the mechanisms involved
remain unclear.
A model for CLCA1-TMEM16A interactions
Based on our previous findings (13, 14) and the results
reported here, we propose the following model for the up-reg-
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ulation of TMEM16A-mediated ICaCC by secreted CLCA1 (Fig.
6). CLCA1 is synthesized as a full-length protein, and, in this
form, the VWA domain of CLCA1 is prevented from interacting with TMEM16A by the C-terminal region of the protein
(Fig. 6A); accordingly, disruption of the catalytic or cleavage
sites impairs the ability of CLCA1 to activate ICaCC (14). This
masking of the VWA domain might be achieved through interaction with the fibronectin III (FnIII) domain found in the
C-terminal fragment (Fig. 1A), as FnIII domains are known
ligands for VWA domains (21). Upon proteolytic self-cleavage,
the CLCA1 VWA domain is exposed and free to engage
TMEM16A, likely via the last extracellular (#9-#10) loop of the
channel (Fig. 6A); thus, an antibody raised against this region of
TMEM16A blocks the binding of N-CLCA1 to TMEM16Aexpressing cells (13). The VWA domain of secreted N-CLCA1
binds and stabilizes TMEM16A at the cell surface, likely by
preventing its reinternalization (Fig. 6B), thereby leading to
increased TMEM16A surface expression and TMEM16A-mediated ICaCC density.
Implications for airway disease
CLCA1 has been proposed as a modifier gene in the context
of CF. Cftr'/' mice, which mostly die from severe meconium
ileus, show decreased expression of Clca1 in the intestine, but
up-regulation of Clca1 in these mice ameliorates the intestinal
phenotype and improves survival (17). One report linked the
S357N variant within the CLCA1 VWA domain to increased
risk of developing meconium ileus in a subset of CF patients
(18). However, this variant had no effect on VWA; neither
TMEM16A current activation (Fig. 2, B and C) nor TMEM16A
surface staining (Fig. 2D) were altered by S357N, suggesting
that any potential contribution of this mutation to the development of meconium ileus is not linked to decreased ability of the
VWA domain to engage TMEM16A.
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Figure 5. Nocodazole increases TMEM16A current density. HEK293T cells, untransfected or transfected with negative control RNAi (siControl) or TMEM16A
siRNA, were treated for 30 min with the microtubule polymerization inhibitor nocodazole (20 "g/ml) or with vehicle (DMSO). Whole-cell currents were
measured under standard extracellular and pipette conditions and using the same pulse protocol as for Figs. 1–3. A, representative current traces. B, current
density at !100 mV. Symbols are data from individual cells (n # 10 –20); error bars are the means $ S.E. of all experiments. Statistical differences are indicated
by different lowercase letters, i.e. a group labeled with a given letter is statistically similar to any other group labeled with the same letter but significantly
different from any other group labeled differently (p % 0.05, one-way ANOVA, F # 11 and p # 2 & 10'5, followed by the Tukey test).

The VWA domain of CLCA1 activates TMEM16A

A significant gap in our knowledge still exists regarding the
cooperative roles of CLCA1 and TMEM16A in physiology and
disease (48). For example, both proteins are up-regulated in
mucus cell metaplasia (7, 49), a hallmark of asthma and chronic
obstructive pulmonary disease, but no mechanistic link has yet
been established. Increased TMEM16A activity is associated
with pulmonary hypertension in a rat model of the disease (50),
but whether CLCA1 is involved remains to be addressed. Both
CLCA1 and TMEM16A have been proposed as therapeutic targets for airway disease (9), and our results suggest that they may
be used in tandem to selectively activate anion currents. This
may be advantageous in the case of certain channelopathies,
such as CF, which arises from impaired Cl' and HCO3' conductance in mucosal epithelia because of partial or total loss of
function of the cystic fibrosis transmembrane conductance regulator (CFTR). Therapeutic approaches have mostly focused on
the symptoms, but significant efforts are being made to target
the defective CFTR itself. Approximately 2000 mutations in the
CFTR gene have been found that disrupt CFTR function by one
of six general mechanisms, including defective trafficking, folding, and gating of the channel protein (51). Although a few
mutation-specific therapies are available (52), the activation of
an alternate anion channel, such as TMEM16A, would be
agnostic to the CFTR mutation and, thus, a potentially universal approach. We show that exogenously applied CLCA1, specifically the VWA domain including a classic protein-protein
interaction MIDAS motif, directly binds and stabilizes TMEM16A
at the cell surface, thereby increasing Cl' conductance. This
raises the intriguing possibility that CLCA1 VWA, or a peptide
derived from it, might be developed as a drug to compensate for
decreased or absent CFTR conductance in CF patients.

Cloning and mutagenesis
All human CLCA1 cDNAs were cloned into the pHLsec
vector, which contains an optimized secretion signal and a
C-terminal hexahistidine tag (53). Constructs with the cDNA
sequences for full-length CLCA1 (22–914), the CLCA1 N-terminal fragment (N-CLCA1, 22– 694), or the following CLCA1
domains were prepared (Fig. 1A): CAT (22–293), including the
metalloprotease catalytic domain; VWA (294 – 478), containing von Willebrand factor type A; and CAT ! VWA (22– 478).
Domain boundaries were predicted by means of the Phyre2
Protein Fold Recognition Server (54). Mutations were introduced by means of QuikChange Lightning (Agilent, Santa
Clara, CA). Constructs were verified by sequencing. Expression
and secretion of each of the different CLCA1 proteins were
confirmed by Western blotting (supplemental Fig. S1).
Heterologous expression of CLCA1
HEK293T cells were cultured in 6-well dishes in Dulbecco’s
modified Eagle’s medium (Life Technologies) supplemented
with 10% fetal bovine serum, 105 units/liter penicillin, 100
mg/liter streptomycin, 1% glutamine, and 1% non-essential
amino acids (Corning Inc., Corning, NY) at 37 °C and 5% CO2.
Cells were transfected at 80% confluency with 293fectin transfection reagent (Life Technologies) at a 1:2 ratio (micrograms of
DNA:microliters of 293fectin) using 1–2 "g of plasmid DNA
per 1 million cells. Experiments were conducted in cells that
were transiently transfected with the appropriate constructs or
in cells that were exposed to exogenous CLCA1 protein by
treatment with medium conditioned with CLCA1. For conditioned medium experiments, cells were transfected with either
CLCA1 constructs or empty pHLsec vector (pHLsec). After 6 h,
the transfection medium was removed, cells were washed with
sterile PBS, and fresh medium was applied. Following 24 – 48 h
of incubation, medium from these cells was harvested and
centrifuged gently (1500 rpm, 5 min) to remove non-adherent cells. Untransfected cells were plated at low density onto
UV-sterilized, 8-mm round German glass coverslips (ElecJ. Biol. Chem. (2017) 292(22) 9164 –9174
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Figure 6. Model for CLCA1-mediated activation of TMEM16A. A, in fulllength CLCA1, the VWA domain within the N-terminal region of the protein
(N-CLCA1) is unable to engage TMEM16A, possibly because of a self-interaction with the FnIII domain in the C-terminal portion (C-CLCA1) that masks the
VWA. Following self-cleavage, N-CLCA1 and C-CLCA1 likely dissociate, allowing the N-CLCA1 VWA domain to directly engage TMEM16A, likely via the
#9-#10 loop of the channel. B, N-CLCA1 secreted by the same cell (autocrine)
or by adjacent cells (paracrine) binds and stabilizes TMEM16A at the cell surface, likely by preventing its recycling, thereby increasing TMEM16A surface
expression and ICaCC density.

Experimental procedures
Reagents
Commercial antibodies were used according to the specifications of the manufacturer. Primary antibodies were as follows:
goat-anti-human-TMEM16A polyclonal antibody S-20 raised
against a 15- to 20-amino acid peptide within residues 820870, corresponding to the last (#9-#10) extracellular loop
(Santa Cruz Biotechnology, Santa Cruz, CA); rabbit anti-human CLCA1 polyclonal antibody 1228 (Biosystems, Rockford,
IL); and wheat germ agglutinin (WGA)-Alexa Fluor 633 conjugate (Life Technologies). Secondary antibodies were as follows:
donkey anti-goat IgG-Alexa Fluor 488, donkey anti-rabbit IgGAlexa Fluor 488, donkey anti-mouse IgG-Alexa Fluor 555, and
donkey anti-goat IgG-Alexa Fluor 594 conjugates (all from Life
Technologies). Mouse anti-human CLCA1 monoclonal antibody 2F4 was produced in-house and used as described previously (14, 16). Nocodazole (Sigma-Aldrich, St. Louis, MO) was
prepared as a 2 mg/ml stock solution in DMSO and was used at
a working concentration of 20 "g/ml.
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tron Microscopy Sciences, Hatfield, PA) and incubated for
up to 24 h in 2 ml of cleared CLCA1- or pHLsec-conditioned
medium supernatants.
siRNA knockdown of TMEM16A
Cells plated in 48-well plates were transfected with either 200
nM TMEM16A siRNA (HSS123904, 5(-AAG UUA GUG AGG
UAG GCU GGG AAC C-3(, Life Technologies) or 200 nM
medium GC content Stealth RNAi negative control (12935300,
5(-GGU UCC CAG CCU ACC UCA CUA ACU U-3(, Life
Technologies) using Lipofectamine 2000 (Life Technologies) at
a 20:2 ratio (picomoles of siRNA:microliters of Lipofectamine
2000). 24 h later, cells were plated onto round coverslips and
incubated for an additional 24 h in CLCA1- or pHLsec-conditioned medium as described above. TMEM16A knockdown
was estimated at 60 –70% as assayed by quantitative PCR.
The VWA domain of CLCA1 was expressed in 293F cells via
transient transfection with Hype-5 (OZ Biosciences, San Diego,
CA) at a 1:1.5 ratio (micrograms of DNA:microliters of Hype-5)
using 1 "g of plasmid per 1 million cells. Media from supernatants were harvested after 72 h. Protein was purified from
medium supernatant using nickel-nitrilotriacetic acid superflow resin (Qiagen, Hilden, Germany) and eluted in 5 ml of
buffer A containing 50 mM K2HPO4 (pH 8), 300 mM NaCl, and
250 mM imidazole. Purified CLCA1 VWA was dialyzed into
buffer B containing 20 mM HEPES and 150 mM NaCl (pH 7.4)
and concentrated in a centrifuge concentrator to 1 mM, calculated from absorbance at 280 nm.
Whole-cell patch clamp recordings
Experiments were performed at 25 °C up to 24 h after transfection or incubation in conditioned medium. Micropipettes
were prepared from non-heparinized hematocrit glass (KimbleChase, Vineland, NJ) on a horizontal puller (Sutter Instruments, Novato, CA) and filled to a typical electrode resistance
of 3 megohms with a pipette solution containing 150 mM
N-methyl-D-glucamine chloride, 10 mM Hepes, 2 mM MgCl2, 8
mM HEDTA, and 5.8 mM CaCl2 to attain 10 "M free Ca2!, as
calculated by means of the CaBuf program (available through
Katholieke Universiteit Leuven). The pH of the pipette solution
was adjusted to 7.1 with Tris. The standard bath solution was
150 mM NaCl, 10 mM Hepes, 1 mM CaCl2, and 1 mM MgCl2 and
adjusted to pH 7.4 with Tris. Selected experiments were performed in the absence of extracellular Mg2! with a bath solution composed of 150 mM NaCl, 10 mM Hepes, 1 mM Na-EDTA,
and 2 mM CaCl2 to maintain the extracellular free Ca2! at 1 mM
(Fig. 3, B and C). After formation of a gigaohm seal and establishment of the whole-cell configuration, cells were voltageclamped at 0 mV. For most experiments, a pulse protocol was
applied in which the membrane potential was held at 0 mV for
50 ms and stepped to a test value ('100 to !100 mV in 20-mV
increments) for 600 ms before returning to the holding potential for an additional 400 ms. For time course experiments (Fig.
4), a 400-ms descending voltage ramp protocol (!80 to '80
mV in 400 ms) was applied every 10 s, and were currents continuously recorded. Following a brief period of stabilization ("1
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Immunofluorescence
For staining experiments, cells were either transfected or
exposed to conditioned medium as described above. Cells were
fixed for 5 min on glass slides with 4% paraformaldehyde and
blocked for 1 h at room temperature with 1% blocking solution
(Life Technologies). For the experiments shown in Figs. 1E and
2D, cells were incubated with primary antibodies overnight at
4 °C, i.e. goat anti-human-TMEM16A polyclonal antibody S-20
at 1:50 dilution (Figs. 1E and 2D) and mouse anti-human
CLCA1 monoclonal antibody 2F4 at 1:100 dilution (Fig. 2D).
Slides were washed and incubated with WGA-Alexa Fluor 633
conjugate (5 "g/ml) for 30 min at room temperature, followed
by secondary antibodies for 2 h at room temperature; i.e. donkey anti-goat IgG-Alexa Fluor 488 conjugate at 1:200 dilution
(Figs. 1E and 2D) and donkey anti-mouse IgG-Alexa Fluor 555
conjugate at 1:250 dilution (Fig. 2D). For the experiments
shown in Fig. 3F, cells were incubated in goat anti-humanTMEM16A antibody S-20 as above, followed by donkey antigoat IgG-Alexa Fluor 594 (1:200). For the experiments shown in
Fig. 4A, cells were incubated with rabbit anti-human 1228 antibody at 1:100 dilution and goat anti-human-TMEM16A antibody S-20 and WGA-Alexa Fluor 633 conjugate as described
above, followed by donkey anti-goat IgG-Alexa Fluor 594 conjugate (1:200) and donkey anti-rabbit IgG-Alexa Fluor 488
conjugate (1:250). Washed slides were then mounted in
Vectashield H-1200 mounting medium with DAPI (Vector
Laboratories, Burlingame, CA). Confocal microscopy was carried out using a Zeiss LSM 880 confocal laser-scanning microscope with Airyscan (Carl Zeiss Microscopy, Thornwood, NY).
The images were acquired and batch-processed with Zen software (Carl Zeiss Microscopy). For each experiment, all cells
were treated on the same day and fixed, stained and imaged in
parallel using the same acquisition and display settings.
Homology modeling
The tertiary structure of the CLCA1 VWA domain was predicted using Phyre2 (54). The best template identified was the
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min after break-in), a 5 "M bolus of purified CLCA1 VWA
protein or the equivalent volume of buffer B (5 "l) was added to
the bath, and the response was monitored until a steady state
was reached. Membrane capacitance was calculated from the
integral of the current transient in response to 10-mV depolarizing pulses and monitored for stability throughout the experiments. Patch clamp data were filtered at 2 kHz, and signals
were digitized at 5 kHz with a Digidata 1322A (Molecular
Devices, Sunnyvale, CA). MultiClamp 700B Commander and
pClamp software (Molecular Devices) were used for pulse or
ramp protocol application and data acquisition. Data were analyzed using Clampfit 10.1 (Molecular Devices). Results are presented as mean $ S.E. Statistical differences between groups
were assessed by one-way ANOVA and post hoc all-pairwise
Tukey test (Prism 5.0c, GraphPad Software, San Diego, CA).
The results of the statistical analysis are indicated in the figures
by a lowercase letter system, whereby groups that share letters
are statistically similar (for example, “a” and “ab” or “ab” and
“bc”), whereas those not sharing any letters are significantly
different (for example, “a” and “b” or “a” and “bc”).

The VWA domain of CLCA1 activates TMEM16A
VWA domain from Catenulispora acidiphila (PDB code
4FX5), and the resulting model based on this template was built
with 99.9% confidence.
Author contributions—M. S. R., Z. Y., K. N. B., C. G. N., and T. J. B.
designed the experiments. M. S. R., Z. Y., and K. N. B. performed the
experiments and analyzed the data. M. S. R., Z. Y., and T. J. B. wrote
the manuscript. M. S. R., Z. Y., K. N. B., C. G. N., and T. J. B. revised
and edited the manuscript.
References

18.

19.
20.

21.
22.

23.

24.
25.
26.
27.
28.
29.

30.

31.
32.

33.
34.

35.

J. Biol. Chem. (2017) 292(22) 9164 –9174

9173

Downloaded from http://www.jbc.org/ at Washington University on October 16, 2017

1. Pedemonte, N., and Galietta, L. J. (2014) Structure and function of
TMEM16 proteins (anoctamins). Physiol. Rev. 94, 419 – 459
2. Picollo, A., Malvezzi, M., and Accardi, A. (2015) TMEM16 proteins: unknown structure and confusing functions. J. Mol. Biol. 427, 94 –105
3. Caputo, A., Caci, E., Ferrera, L., Pedemonte, N., Barsanti, C., Sondo, E.,
Pfeffer, U., Ravazzolo, R., Zegarra-Moran, O., and Galietta, L. J. (2008)
TMEM16A, a membrane protein associated with calcium-dependent
chloride channel activity. Science 322, 590 –594
4. Schroeder, B. C., Cheng, T., Jan, Y. N., and Jan, L. Y. (2008) Expression
cloning of TMEM16A as a calcium-activated chloride channel subunit.
Cell 134, 1019 –1029
5. Yang, Y. D., Cho, H., Koo, J. Y., Tak, M. H., Cho, Y., Shim, W. S., Park, S. P.,
Lee, J., Lee, B., Kim, B. M., Raouf, R., Shin, Y. K., and Oh, U. (2008)
TMEM16A confers receptor-activated calcium-dependent chloride conductance. Nature 455, 1210 –1215
6. Huang, F., Zhang, H., Wu, M., Yang, H., Kudo, M., Peters, C. J., Woodruff,
P. G., Solberg, O. D., Donne, M. L., Huang, X., Sheppard, D., Fahy, J. V.,
Wolters, P. J., Hogan, B. L., Finkbeiner, W. E., et al. (2012) Calciumactivated chloride channel TMEM16A modulates mucin secretion and
airway smooth muscle contraction. Proc. Natl. Acad. Sci. U.S.A. 109,
16354 –16359
7. Scudieri, P., Caci, E., Bruno, S., Ferrera, L., Schiavon, M., Sondo, E.,
Tomati, V., Gianotti, A., Zegarra-Moran, O., Pedemonte, N., Rea, F.,
Ravazzolo, R., and Galietta, L. J. (2012) Association of TMEM16A chloride
channel overexpression with airway goblet cell metaplasia. J. Physiol. 590,
6141– 6155
8. Mall, M. A., and Galietta, L. J. (2015) Targeting ion channels in cystic
fibrosis. J. Cyst. Fibros. 14, 561–570
9. Sala-Rabanal, M., Yurtsever, Z., Berry, K. N., and Brett, T. J. (2015) Novel
roles for chloride channels, exchangers, and regulators in chronic inflammatory airway diseases. Mediators Inflamm. 2015, 497387
10. Cunningham, S. A., Awayda, M. S., Bubien, J. K., Ismailov, I. I., Arrate,
M. P., Berdiev, B. K., Benos, D. J., and Fuller, C. M. (1995) Cloning of an
epithelial chloride channel from bovine trachea. J. Biol. Chem. 270,
31016 –31026
11. Gibson, A., Lewis, A. P., Affleck, K., Aitken, A. J., Meldrum, E., and
Thompson, N. (2005) hCLCA1 and mCLCA3 are secreted non-integral
membrane proteins and therefore are not ion channels. J. Biol. Chem. 280,
27205–27212
12. Hamann, M., Gibson, A., Davies, N., Jowett, A., Walhin, J. P., Partington,
L., Affleck, K., Trezise, D., and Main, M. (2009) Human ClCa1 modulates
anionic conduction of calcium-dependent chloride currents. J. Physiol.
587, 2255–2274
13. Sala-Rabanal, M., Yurtsever, Z., Nichols, C. G., and Brett, T. J. (2015)
Secreted CLCA1 modulates TMEM16A to activate Ca2!-dependent
chloride currents in human cells. eLife 4, e05875
14. Yurtsever, Z., Sala-Rabanal, M., Randolph, D. T., Scheaffer, S. M., Roswit,
W. T., Alevy, Y. G., Patel, A. C., Heier, R. F., Romero, A. G., Nichols, C. G.,
Holtzman, M. J., and Brett, T. J. (2012) Self-cleavage of human CLCA1
protein by a novel internal metalloprotease domain controls calcium-activated chloride channel activation. J. Biol. Chem. 287, 42138 – 42149
15. Patel, A. C., Brett, T. J., and Holtzman, M. J. (2009) The role of CLCA
proteins in inflammatory airway disease. Annu. Rev. Physiol. 71, 425– 449
16. Alevy, Y. G., Patel, A. C., Romero, A. G., Patel, D. A., Tucker, J., Roswit,
W. T., Miller, C. A., Heier, R. F., Byers, D. E., Brett, T. J., and Holtzman,

17.

M. J. (2012) IL-13-induced airway mucus production is attenuated by
MAPK13 inhibition. J. Clin. Invest. 122, 4555– 4568
Young, F. D., Newbigging, S., Choi, C., Keet, M., Kent, G., and Rozmahel,
R. F. (2007) Amelioration of cystic fibrosis intestinal mucous disease in
mice by restoration of mCLCA3. Gastroenterology 133, 1928 –1937
van der Doef, H. P., Slieker, M. G., Staab, D., Alizadeh, B. Z., Seia, M.,
Colombo, C., van der Ent, C. K., Nickel, R., Witt, H., and Houwen, R. H.
(2010) Association of the CLCA1 p.S357N variant with meconium ileus in
European patients with cystic fibrosis. J. Pediatr. Gastroenterol. Nutr. 50,
347–349
Kunzelmann, K., Kongsuphol, P., Aldehni, F., Tian, Y., Ousingsawat, J.,
Warth, R., and Schreiber, R. (2009) Bestrophin and TMEM16-Ca2! activated Cl' channels with different functions. Cell Calcium 46, 233–241
Pritchard, H. A., Leblanc, N., Albert, A. P., and Greenwood, I. A. (2014)
Inhibitory role of phosphatidylinositol 4,5-bisphosphate on TMEM16Aencoded calcium-activated chloride channels in rat pulmonary artery.
Br. J. Pharmacol. 171, 4311– 4321
Whittaker, C. A., and Hynes, R. O. (2002) Distribution and evolution of
von Willebrand/integrin A domains: widely dispersed domains with roles
in cell adhesion and elsewhere. Mol. Biol. Cell 13, 3369 –3387
Choi, W. S., Khurana, A., Mathur, R., Viswanathan, V., Steele, D. F., and
Fedida, D. (2005) Kv1.5 surface expression is modulated by retrograde
trafficking of newly endocytosed channels by the dynein motor. Circ. Res.
97, 363–371
Vossenkämper, A., Nedvetsky, P. I., Wiesner, B., Furkert, J., Rosenthal, W.,
and Klussmann, E. (2007) Microtubules are needed for the perinuclear
positioning of aquaporin-2 after its endocytic retrieval in renal principal
cells. Am. J. Physiol. Cell Physiol. 293, C1129 –1138
Zadeh, A. D., Xu, H., Loewen, M. E., Noble, G. P., Steele, D. F., and Fedida,
D. (2008) Internalized Kv1.5 traffics via Rab-dependent pathways.
J. Physiol. 586, 4793– 4813
Horii, K., Okuda, D., Morita, T., and Mizuno, H. (2004) Crystal structure
of EMS16 in complex with the integrin #2-I domain. J. Mol. Biol. 341,
519 –527
Kamata, T., and Takada, Y. (1994) Direct binding of collagen to the I
domain of integrin # 2 ! 1 (VLA-2, CD49b/CD29) in a divalent cationindependent manner. J. Biol. Chem. 269, 26006 –26010
Song, G., and Springer, T. A. (2014) Structures of the Toxoplasma gliding
motility adhesin. Proc. Natl. Acad. Sci. U.S.A. 111, 4862– 4867
Dolphin, A. C. (2016) Voltage-gated calcium channels and their auxiliary
subunits: physiology and pathophysiology and pharmacology. J. Physiol.
594, 5369 –5390
Jay, S. D., Sharp, A. H., Kahl, S. D., Vedvick, T. S., Harpold, M. M., and
Campbell, K. P. (1991) Structural characterization of the dihydropyridinesensitive calcium channel # 2-subunit and the associated $ peptides.
J. Biol. Chem. 266, 3287–3293
Cassidy, J. S., Ferron, L., Kadurin, I., Pratt, W. S., and Dolphin, A. C. (2014)
Functional exofacially tagged N-type calcium channels elucidate the interaction with auxiliary #2$-1 subunits. Proc. Natl. Acad. Sci. U.S.A. 111,
8979 – 8984
Wu, J., Yan, Z., Li, Z., Yan, C., Lu, S., Dong, M., and Yan, N. (2015) Structure of the voltage-gated calcium channel Cav1.1 complex. Science 350,
aad2395
Cantí, C., Nieto-Rostro, M., Foucault, I., Heblich, F., Wratten, J., Richards,
M. W., Hendrich, J., Douglas, L., Page, K. M., Davies, A., and Dolphin, A. C.
(2005) The metal-ion-dependent adhesion site in the von Willebrand factor-A domain of #2$ subunits is key to trafficking voltage-gated Ca2!
channels. Proc. Natl. Acad. Sci. U.S.A. 102, 11230 –11235
Hoppa, M. B., Lana, B., Margas, W., Dolphin, A. C., and Ryan, T. A. (2012)
#2$ expression sets presynaptic calcium channel abundance and release
probability. Nature 486, 122–125
Calderón-Rivera, A., Andrade, A., Hernández-Hernández, O., GonzálezRamírez, R., Sandoval, A., Rivera, M., Gomora, J. C., and Felix, R. (2012)
Identification of a disulfide bridge essential for structure and function of
the voltage-gated Ca2! channel #2$-1 auxiliary subunit. Cell Calcium 51,
22–30
Alvarez-Laviada, A., Kadurin, I., Senatore, A., Chiesa, R., and Dolphin,
A. C. (2014) The inhibition of functional expression of calcium channels

The VWA domain of CLCA1 activates TMEM16A

36.

37.
38.
39.
40.
41.

43.
44.

9174 J. Biol. Chem. (2017) 292(22) 9164 –9174

45. Dolphin, A. C. (2012) Calcium channel auxiliary #2$ and ! subunits:
trafficking and one step beyond. Nat. Rev. Neurosci. 13, 542–555
46. Macabuag, N., and Dolphin, A. C. (2015) Alternative splicing in Ca(V)2.2
regulates neuronal trafficking via adaptor protein complex-1 adaptor protein motifs. J. Neurosci. 35, 14636 –14652
47. Bernstein, G. M., and Jones, O. T. (2007) Kinetics of internalization and
degradation of N-type voltage-gated calcium channels: role of the #2/$
subunit. Cell Calcium 41, 27– 40
48. Brett, T. J. (2015) CLCA1 and TMEM16A: the link towards a potential
cure for airway diseases. Expert Rev. Respir. Med. 9, 503–506
49. Patel, A. C., Morton, J. D., Kim, E. Y., Alevy, Y., Swanson, S., Tucker, J.,
Huang, G., Agapov, E., Phillips, T. E., Fuentes, M. E., Iglesias, A., Aud, D.,
Allard, J. D., Dabbagh, K., Peltz, G., and Holtzman, M. J. (2006) Genetic
segregation of airway disease traits despite redundancy of calcium-activated chloride channel family members. Physiol. Genomics 25, 502–513
50. Forrest, A. S., Joyce, T. C., Huebner, M. L., Ayon, R. J., Wiwchar, M., Joyce,
J., Freitas, N., Davis, A. J., Ye, L., Duan, D. D., Singer, C. A., Valencik, M. L.,
Greenwood, I. A., and Leblanc, N. (2012) Increased TMEM16A-encoded
calcium-activated chloride channel activity is associated with pulmonary
hypertension. Am. J. Physiol. Cell Physiol. 303, C1229 –C1243
51. Carter, S. C., and McKone, E. F. (2016) Pharmacogenetics of cystic fibrosis
treatment. Pharmacogenomics 17, 1453–1463
52. Brodsky, J. L., and Frizzell, R. A. (2015) A combination therapy for cystic
fibrosis. Cell 163, 17
53. Aricescu, A. R., Lu, W., and Jones, E. Y. (2006) A time- and cost-efficient
system for high-level protein production in mammalian cells. Acta Crystallogr. D Biol. Crystallogr. 62, 1243–1250
54. Kelley, L. A., Mezulis, S., Yates, C. M., Wass, M. N., and Sternberg, M. J.
(2015) The Phyre2 web portal for protein modeling, prediction and analysis. Nat. Protoc. 10, 845– 858

Downloaded from http://www.jbc.org/ at Washington University on October 16, 2017

42.

by prion protein demonstrates competition with #2$ for GPI-anchoring
pathways. Biochem. J. 458, 365–374
Davies, A., Kadurin, I., Alvarez-Laviada, A., Douglas, L., Nieto-Rostro, M.,
Bauer, C. S., Pratt, W. S., and Dolphin, A. C. (2010) The #2$ subunits of
voltage-gated calcium channels form GPI-anchored proteins, a posttranslational modification essential for function. Proc. Natl. Acad. Sci. U.S.A.
107, 1654 –1659
Dolphin, A. C. (2013) The #2$ subunits of voltage-gated calcium channels. Biochim. Biophys. Acta 1828, 1541–1549
Lim, N. K., Lam, A. K., and Dutzler, R. (2016) Independent activation of
ion conduction pores in the double-barreled calcium-activated chloride
channel TMEM16A. J. Gen. Physiol. 148, 375–392
Jeng, G., Aggarwal, M., Yu, W. P., and Chen, T. Y. (2016) Independent
activation of distinct pores in dimeric TMEM16A channels. J. Gen.
Physiol. 148, 393– 404
Hartzell, H. C., and Whitlock, J. M. (2016) TMEM16 chloride channels are
two-faced. J. Gen. Physiol. 148, 367–373
Sheridan, J. T., Worthington, E. N., Yu, K., Gabriel, S. E., Hartzell, H. C.,
and Tarran, R. (2011) Characterization of the oligomeric structure of
the Ca2!-activated Cl' channel Ano1/TMEM16A. J. Biol. Chem. 286,
1381–1388
Tien, J., Lee, H. Y., Minor, D. L., Jr, Jan, Y. N., and Jan, L. Y. (2013) Identification of a dimerization domain in the TMEM16A calcium-activated
chloride channel (CaCC). Proc. Natl. Acad. Sci. U.S.A. 110, 6352– 6357
Terashima, H., Picollo, A., and Accardi, A. (2013) Purified TMEM16A is
sufficient to form Ca2!-activated Cl' channels. Proc. Natl. Acad. Sci.
U.S.A. 110, 19354 –19359
Brunner, J. D., Lim, N. K., Schenck, S., Duerst, A., and Dutzler, R. (2014)
X-ray structure of a calcium-activated TMEM16 lipid scramblase. Nature
516, 207–212

Modulation of TMEM16A channel activity by the von Willebrand factor type A
(VWA) domain of the calcium-activated chloride channel regulator 1 (CLCA1)
Monica Sala-Rabanal, Zeynep Yurtsever, Kayla N. Berry, Colin G. Nichols and Tom J.
Brett
J. Biol. Chem. 2017, 292:9164-9174.
doi: 10.1074/jbc.M117.788232 originally published online April 18, 2017

Access the most updated version of this article at doi: 10.1074/jbc.M117.788232

Click here to choose from all of JBC's e-mail alerts

Supplemental material:

http://www.jbc.org/content/suppl/2017/04/18/M117.788232.DC1
This article cites 54 references, 26 of which can be accessed free at
http://www.jbc.org/content/292/22/9164.full.html#ref-list-1

Downloaded from http://www.jbc.org/ at Washington University on October 16, 2017

Alerts:
• When this article is cited
• When a correction for this article is posted

REVIEW ESSAY
Prospects & Overviews

www.bioessays-journal.com

Limiting Respiratory Viral Infection by Targeting
Antiviral and Immunological Functions of BST-2/
Tetherin: Knowledge and Gaps
Kayla N. Berry, Daniel L. Kober, Alvin Su, and Tom J. Brett*
most deadly communicable diseases). Current options to prevent or clear respiratory
virus infections are limited and have
notable shortcomings. For example, the
effectiveness of vaccination against seasonal inﬂuenza A virus (IAV) usually
hovers around 50–60%,[1] and there is
often a 6-month delay between strain
identiﬁcation and vaccine production.[2]
There is currently no vaccine for respiratory syncytial virus (RSV). Few antiviral
drugs are presently approved for treating
respiratory virus infections and most are
IAV neuraminidase inhibitors.[3] For individuals suffering from the chronic airway
diseases asthma and chronic obstructive
pulmonary disease (COPD), respiratory
virus infections can cause debilitating,
and potentially deadly, exacerbations. In
addition to acute disease, frequent and
severe respiratory viral infections in youth have been implicated
in detrimental airway remodeling and in the development of
chronic diseases asthma and COPD in adulthood.[4] Thus, there
is a current unmet need to develop new antivirals to treat
respiratory virus infections.
The majority of respiratory viruses are RNA viruses,[5] which
initially infect epithelial cells of nasal passages and airways.
These viruses primarily infect with a minimal infectious dose,
then utilize host cell machinery to replicate and produce new
virions that then infect other cells, eventually causing epithelial
cell death and airway remodeling. Efﬁcient ampliﬁcation,
including virus release and infection of new cells, is obligatory
for virus survival and disease pathogenesis. To subvert this
process, host cells encode several interferon (IFN)-inducible
antiviral factors that constitute a potent battery of innate
immune defense. These antiviral factors interfere with various
steps in the viral replication pathway to aid in clearance.[6] A
comprehensive mechanistic understanding of how host antiviral
factors function could potentially be exploited to develop new
treatments to limit disease caused by respiratory viruses.
This essay will focus on the function of one particularly
proliﬁc host antiviral factor called bone marrow stromal antigen
2 (BST-2, also known as tetherin or CD317). We will examine
whether BST-2 could be targeted to inhibit the replication of
respiratory viruses and aid in their clearance. BST-2 has
demonstrated broad-spectrum antiviral activity against numerous enveloped viruses,[7] and in response, most viruses have
evolved functions to antagonize BST-2. BST-2 has not been

Recent findings regarding the cellular biology and immunology of BST-2 (also
known as tetherin) indicate that its function could be exploited as a universal
replication inhibitor of enveloped respiratory viruses (e.g., influenza, respiratory syncytial virus, etc.). BST-2 inhibits viral replication by preventing virus
budding from the plasma membrane and by inducing an antiviral state in
cells adjacent to infection via unique inflammatory signaling mechanisms.
This review presents the first comprehensive summary of what is currently
known about BST-2 anti-viral function against respiratory viruses, how these
viruses construct countermeasures to antagonize BST-2, and how BST-2
function might be targeted to develop therapies to treat respiratory virus
infections. The authors address the current gaps in knowledge, including the
need for mechanistic understanding of BST-2 antagonism by respiratory
viruses, that should be bridged to achieve that goal.

1. Introduction
Respiratory viruses represent an enormous worldwide health
burden. They are a common cause of respiratory tract infections,
which are the third leading cause of death worldwide (and the
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shown to restrict non-enveloped viruses. Thus, our discussion
will focus on common enveloped respiratory viruses that cause
disease in humans[5,8] (e.g., IAV; RSV; parainﬂuenza virus, PIV;
metapneumovirus, MPV; coronaviruses, CoV) and mouse
models (Sendai virus, SeV) but we will not discuss common
non-enveloped respiratory viruses (e.g., rhinovirus, RV; enterovirus 68, EV68). We will review what is known regarding the
regulation of BST-2 expression, the structure and function of
BST-2, the mechanism of BST-2 antiviral function, modes of
BST-2 antagonism by viral proteins, BST-2-mediated and
-modulated signaling, and other immunological and cellular
functions of BST-2, paying special attention to the settings of
airway epithelial cells and respiratory viruses.

2. Is BST-2 Expressed in Airway Epithelia
Following Viral Infection?
In order to most optimally inhibit respiratory virus replication,
BST-2 would need to be expressed in epithelial cells of the airway
and mucosal surfaces. A number of signaling pathways have
been demonstrated to induce expression of BST-2. The promoter
region contains consensus sites for the transcription factors
STAT3, IRF1, and ISGF1.[9] Accordingly, interferons (IFNs) from
all three classes (i.e., IFN-α, -β, -γ, -τ, -λ3, and -ω) induce the
expression of BST-2 in numerous cell types.[10,11] In naïve mice,
BST-2 expression appears to be limited to plasmacytoid dendritic
cells, but is upregulated on most cell types by interferons that are
induced and secreted in response to viral infection.[10] However,
upregulation is not limited to IFN signaling, as a number of IFNindependent stimulants have also been reported. For example,
IL-27 is a potent inducer,[12] and TLR3 and TLR8 stimulation
induce BST-2 expression in the absence of IFN.[13] In contrast,
despite the apparent presence of an IRF1 binding site in the BST2 promoter region, TNFα has little impact on BST-2 expression
levels.[10,14] Expression is downmodulated by TGFβ.[15]
Because the response to IFN-I is generally conserved in all
cells,[16] BST-2 expression should increase in the airway as part of
the antiviral response. However, there have been differing
observations as to whether or not BST-2 expression is induced in
airway epithelial cells. In cultured primary mouse airway
epithelial cells and mouse airway cell lines (LA-4), BST-2
expression is induced by IFN-α, but only modestly increases 24 h
after IAV infection.[17] In contrast, we have observed increased
BST-2 expression in vivo in mouse airway epithelial cells
following both SeV and IAV infection (unpublished data), and
BST-2 expression is upregulated in human airway cell lines
(A549, NCI-H196, NCI-H358) following viral infection[18–20] and
IFN-I production.[19,21] Overall, these observations suggest
BST-2 is expressed in airway and mucosal epithelia in response
to viral infection.

3. BST-2 Restricts Cellular Virion Release for a
Broad Range of Enveloped Viruses
The antiviral function of BST-2 was ﬁrst reported in 2008, when
it was demonstrated that it inhibited the release of HIV-1 viral
particles that were deﬁcient in the viral membrane protein
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Vpu.[22] BST-2 inhibits viral replication by preventing release of
viral progeny from infected cells, leading to their subsequent
internalization and degradation.[23] Since then, BST-2 has been
shown to potently inhibit several enveloped viruses that bud
from the plasma membrane.[7] Due to this pressure, most
viruses have developed antagonist strategies to block BST-2
function. Because of this, the BST-2 viral tethering function has
typically been demonstrated in assays using mutant viruses
deﬁcient in BST-2-antagonizing proteins (such as Vpu-deﬁcient
HIV-1) or virus-like particles (VLPs). These types of studies have
shown that BST-2 restricts the budding of VLPs or mutant
viruses from the following families: retroviruses (alpha-, beta-,
delta-, lenti-, and spuma-);[24,25] arenaviruses (Lassa and
Machupo);[26,27] herpesviruses (KSHV);[28] ﬁloviruses (Ebola
and Marburg);[24,27] rhabdoviruses (vesicular stomatitis);[29]
paramyxoviruses (Nipah);[26] and ﬂaviviruses (Hepatitis C).[30]
BST-2 has been shown to effectively inhibit budding of some
intact infectious viruses, including Lassa and Machupo
arenaviruses,[26] and vesicular stomatitis rhabdovirus,[29] but
does not restrict other infectious viruses such as Ebola, Marburg,
cowpox, or Rift Valley fever bunyavirus.[26]
These observations demonstrate that BST-2 inhibits the
budding of a broad spectrum of enveloped viruses and suggest
that it might inhibit release of enveloped respiratory viruses from
infected epithelial cells. More recent studies have investigated the
potential of BST-2 to restrict budding of respiratory viruses
(Table 1). For IAV, results appear to be dependent on virus strain
and cell type used. Some groups have reported that BST-2 does not
restrict IAV release,[17,19,31] while others report that BST-2 does
inhibit release of IAV VLPs[18,32,33] and partially restricts
infectious virus.[20,21,34] These observations appear to be dependent on IAV-encoded BST-2 antagonists, the identity and
effectiveness of which may be strain dependent (discussed in
section 6). BST-2 also partially restricts the human pathogens
PIV2,[35] hCoV-229E,[36] and SARS,[37] and this restriction is
enhanced by deletion of viral antagonists. It also restricts animal
model respiratory virus SeV,[38] but interestingly does not seem to
inhibit pRRSV.[39] Thus, BST-2 appears to restrict a number of
enveloped respiratory viruses in vitro, and this ability is hindered
by encoded viral antagonists (discussed in section 6).

4. Structural Features of BST-2 Optimally
Facilitate Tethering of Viruses
The structural organization of BST-2 is highly unique among
mammalian proteins. It is a type II transmembrane protein
consisting of a short N-terminal cytoplasmic tail (CT), a single
transmembrane region (TM), an ectodomain (ED), and a second
membrane anchor- a C-terminal glycosylphosphotidylinositol
(GPI) (Figure 1A). Sequence analysis suggests this dual-anchor
topology is only found in one other protein in the human
genome, a special form of the prion protein.[40] These structural
features are important for the antiviral function of BST-2.
Deletion of either one of the membrane anchors (TM or GPI)
ablates the ability of BST-2 to restrict viral budding.[22,41,42] In
addition to being a membrane anchor required for viral
tethering, the GPI-anchor is required for cellular trafﬁcking
as BST-2 is sequestered in the ER of cells that have defects in the
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Table 1. Summary of experimental observations for respiratory virus release inhibited by BST-2.
Virus
Influenza A

Family

Experimental observations

Orthomyxovirus

Observations have been strain-specific. Some report BST-2 does not inhibit IAV release.[17,19,31] Others report
BST-2 inhibits IAV VLP release; dependent on neuraminidase sequence.[18,20,21,32,33] Others report BST-2
inhibits infectious IAV and IAV VLPs, enhanced by loss of IAV M2.[34] NS1, which broadly targets ISG
expression at the RNA level, may partially inhibit BST-2 by lowering expression.[31,32]

PIV2

Paramyxovirus

BST-2 inhibits PIV2 release.[35]

Sendai (SeV)

Paramyxovirus

BST2 inhibits SeV release from PM.[38]

SARS CoV

Coronavirus

BST-2 inhibits SARS release from PM; more strongly inhibits SARS-ORF7abΔ release from PM.[37]

Human CoV 229E (hCoV-229E)

Coronavirus

BST-2 inhibits hCoV-229E release from the PM.[36]

Porcine reproductive and respiratory
syndrome virus (pRRSV)

Arterivirus

pRRSV E protein interacts with BST-2 by yeast two-hybrid and mislocalizes it from surface; BST-2 does not
inhibit pRRSV.[39]

CoV, coronavirus; PIV, parainﬂuenza virus; PM, plasma membrane; SARS, severe acute respiratory syndrome; SARS-ORF7abΔ, SARS with ORF7a and ORF7b deleted.

GPI-biosynthesis pathway.[42] The GPI-anchor enriches BST-2 to
lipid rafts to enhance its antiviral activity, since this is a preferred
site of budding for many enveloped viruses.[40] Mature BST-2
recycles between the plasma membrane, endosomes, and transGolgi network (TGN).[40,43] Despite localization to lipid rafts,
BST-2 is internalized via clathrin-dependent endocytosis,
mediated by an evolutionarily conserved YxY motif in the CT,
which recruits the adaptor AP-2.[43]

The BST-2 ectodomain has numerous structural features
required for optimal antiviral function (Figure 1A). The
ectodomain spans the two membrane anchors, forming a
coiled-coil parallel dimer containing three inter-dimer
disulﬁdes and resembles a molecular “rope” spanning roughly
150–170 Å .[44–46] The ectodomain coiled-coil is unique in that it
contains conserved patterns of residues at the dimer interface
that destabilize the packing, causing the ectodomain to act less

Figure 1. Structure of BST-2 and mechanisms of viral tethering. A) Crystal structure of mouse BST-2 ectodomain.[44] Structural features are highlighted:
N-linked glycosylation sites ¼ green boxes; disulfide bonds ¼ blue boxes. Transmembrane domains, GPI anchors, and N-terminal cytoplasmic tails are
shown as cartoons. Black labels correspond to mouse BST-2 sequence and features while the corresponding residues and values for human BST-2 are
shown in red italics. B) The direct tethering models of BST-2 mediated inhibition of viral budding. Parallel BST-2 dimers incorporate one set of
membrane anchors each into the viral membrane and host membrane. There is a three- to fivefold preference for incorporation of the GPI-anchor into
the viral membrane (left) versus the other orientation (right).[51] C) A dimeric assembly created by crystallographic symmetry in the mouse BST-2 crystal
structure. The dimer has a similar shape to BAR domains that bind membranes to generate or stabilize curvature. The N-terminal tail of BST-2 could bind
cytoplasmic BAR domain proteins (e.g., RICH2)[55] to enhance mechanical stability in the stabilized tabulation model. D) Stabilized tubulation and
prevention of scission model of BST-2 mediated inhibition of viral budding. BAR-like BST-2 oligomers stabilize the tubulating membrane and prevent
membrane scission. These tubules could be further stabilized by cytosolic BAR domain proteins that bind the cytoplasmic tail of BST-2 (e.g., RICH2).[55]
This hypothetical model is based on the observation of a BAR-like dimer in the mouse BST-2 ectodomain crystal structure[44] and the observation of long
tube-like structures longer than the ectodomain of BST-2 (>200 Å ) tethering HIV-1 VLPs to the plasma membrane by cryo-EM.[47]
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like a rigid rod and more like a ﬂexible rope in solution, which
likely aids its ability to adjust to the dynamics of virus assembly
at the plasma membrane.[44,45,47] The ectodomain also contains
two conserved N-linked glycosylation sites (Figure 1A), which
appear to be required for proper vesicular transport and
possibly folding of BST-2, but are not required for antiviral
activity.[42] Although isolated BST-2 ectodomains form parallel
homodimers, the transmembrane regions of BST-2 also form
parallel dimers in lipid environments and likely aid the
formation of the parallel dimer.[48] Collectively, these structural
features serve to inhibit viral budding from the plasma
membrane.

5. What Are the Mechanisms by Which BST-2
Restricts Viral Infection?
The bulk of evidence in the literature suggests that BST-2
restricts enveloped virus release by directly bridging the host and
viral membranes through simultaneous inclusion of the two
opposing membrane anchors (Figure 1B).[42,49] Cryo-EM and
cryo-ET studies have shown budding viruses and VLPs anchored
to cells by short tethers containing BST-2.[22,47,49,50] Two
orientations for viral tethering are possible (Figure 1B).
However, insertion of the GPI-anchor into the viral membrane
is favored three- to ﬁvefold.[51] This orientation would optimize
the ability of the N-terminal CT to interact with the cytoskeleton,
which likely aids in BST-2 clustering at the host membrane. BST2 accumulates at HIV budding sites, where it clusters at around
four to seven molecules per site.[52] Mutations to the BST-2
ectodomain prevent clustering and render it unable to restrict
the release of VLPs.[53] This orientation and clustering also likely
enhances the ability of BST-2 to form signaling complexes,
which will be discussed in Section 7.1.
Crystallographic and cryo-EM studies suggest a second
potential mechanism for BST-2-mediated inhibition of viral
budding. Analysis of the crystal structure of mouse BST-2
revealed a dimer-of dimers assembly that resembled those
formed by BAR domains (Figure 1C).[44] BAR domains are
α-helical bundles that dimerize to form crescent-shaped
structures that can bind to and stabilize curved membranes
that form during membrane trafﬁcking and budding events.[54]
Clustering BST-2 could form such assemblies, which could be
stabilized on the cytosolic side by the BAR-domain protein
RICH2, which binds BST-2 CT using a C-terminal domain.[55]
Such assemblies could stabilize tubulating membranes and
prevent viral scission (Figure 1D). Interestingly, cryo-EM studies
of HIV-infected cells have observed some tethers that span at
least 500 Å , much longer than a single BST-2 ectodomain,[47]
hence lending further support to this potential assembly.

6. Viruses Encode Antagonists That Inhibit
BST-2 Antiviral Function Via Diverse
Mechanisms
BST-2 is highly efﬁcient at trapping a wide variety of enveloped
viruses. Consequently, most viruses have developed countermeasures to evade BST-2 antiviral function. These viral

BioEssays 2018, 40, 1800086

antagonists impair BST-2 by a number of different mechanisms, including removal from or prevention of trafﬁcking to
the cell surface, and targeting of BST-2 for proteosomal
degradation.[7,56] For example, HIV-1 encodes Vpu, a small
membrane protein that interacts with BST-2 via transmembrane regions.[41,57,58] Vpu then facilitates recruitment of
ubiquitin ligases and AP-1 to enable targeting of BST-2 for
endolysosomal degradation.[59,60] KSHV uses a similar strategy,
encoding the protein K5 that is itself an E3 RING ubiquitin
ligase that recognizes the BST-2 CT, thus enabling ubiquitination of BST-2 and subsequent degradation[28,61] SIV Nef
protein directs removal from the cell surface by binding the
BST-2 CT and linking it to the endocytic adaptor AP-2 to remove
BST-2 from the plasma membrane.[62] HIV-2 Env protein
interacts with the BST-2 ectodomain and likewise facilitates
BST-2 internalization by (again via AP-2) via a GYXXΦ
internalization motif in the HIV-2 Env cytoplasmic tail.[63]
Ebola envelope glycoprotein (GP) also interacts with the BST-2
ectodomain. However, this interaction appears to be independent of protein sequence, also requires the GP transmembrane
domain, and does not lead to signiﬁcant surface removal of
BST-2.[64] Thus, viruses have developed a myriad of methods to
inhibit BST-2 antiviral function and are facilitated by
interactions involving various structural features of the protein.
The theme of viruses encoding BST-2 antagonists extends to
respiratory viruses (Figure 2). As mentioned earlier, IAV release
appears to be partially restricted by BST-2 in a strain-dependent
manner.[20] These differences appear to be mostly due to
variations in the sequence of the encoded neuraminidase.[20,21,32,33] Neuraminidase has been the most widely
reported IAV-encoded BST-2 antagonist, but little known about
its mechanism of action. Despite this lack of information,
differences of a single amino acid have been reported to switch
a restricted IAV VLP to one not inhibited by BST-2.[18]
Interactions appear to be mediated between the ectodomains
of the two proteins. However, this interaction does not appear to
promote surface removal of BST-2. A more recent study
suggests the IAV M2 channel protein is a BST-2 antagonist.[34]
In contrast to neuraminidase, this interaction promotes surface
removal of BST-2, ending in proteasomal degradation. In
addition, IAV encodes the general IFN-I antagonist NS1, which
can broadly inhibit expression of ISGs. NS1 may partially
inhibit BST-2 via this broadly targeted strategy.[31,32] PIV2
encodes the V protein, which targets BST-2 for surface removal,
but does not appear to catalyze proteasomal destruction of
BST-2.[35] PIV2V may also prevent viral-mediated induction of
BST-2.[65] SARS-CoV encodes ORF7a, which binds BST-2 via
interaction of their ectodomains.[37] This interaction appears to
inhibit maturation of BST-2 glycosylation, which prevents
surface expression. Infection of cells with hCoV-229E promotes
surface removal of BST-2, but the mechanism and viral protein
involved are unknown.[36] SeV infection promotes proteasomal
degradation of BST-2. This degradation appears to be mediated
by the fusion (F) and hemagluttanin-neuraminidase (HN)
proteins in concert, although further mechanistic details are
unknown.[38] In summary, respiratory viruses have also evolved
countermeasures to inhibit BST-2 viral tethering demonstrating evolutionary pressure to evade this potent viral restriction
factor.
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Figure 2. Respiratory virus antagonism of BST-2 and mode of action. Schematic summarizes what is currently understood about how various respiratory
viruses antagonize BST-2. Structural domains demonstrated to mediate direct interactions are indicated by solid red arrows. Implied interactions are
denoted by dashed red arrows. Antagonism of BST-2 by IAV is strain-dependent. In some strains, the neuraminidase protein partially inhibits IAV
release.[18,21,33] This antagonism is thought to be mediated by the ectodomains (ED) of neuraminidase and BST-2. Another study suggests IAV
antagonizes BST-2 using hemagglutinin, but the effect requires neuraminidase.[20] A more recent study suggests that the IAV M2 channel protein
antagonizes BST-2 targeting interactions with the ectodomain and/or transmembrane (TM), causing surface removal.[34] The cytoplasmic V protein of
PIV2 may antagonize BST-2 by two different mechanisms. It may bind and target BST-2 for surface removal[35,80] and it may also inhibit induction of BST2 expression.[65] How interaction is mediated is unknown. SeV F and HN proteins are required to degrade BST-2. However, it is unknown how interaction
is mediated or the mechanism.[38] SARS CoV ORF7a ectodomain mediates an interaction with BST-2, which leads to inhibited glycosylation of BST-2 and
its antagonism.[37] Human CoV-229E triggers surface removal of BST-2. The identity of the antagonist protein(s) is unknown.[36]

7. BST-2 Mediates and Modulates Immune
Signaling
7.1. Pro-Inflammatory Signaling
BST-2 is known to have roles in inﬂammatory signaling. In
addition to its function as a viral tethering protein, BST-2 also
acts as an innate immune viral sensor that signals and triggers
activation of NF-κB to elicit production of inﬂammatory
cytokines that alert neighboring cells, extending its protection
abilities to adjacent cells by inducing production of antiviral
proteins. Clustering of BST-2 captured in budding virions
initiates assembly of a signaling pathway that causes NF-κB
activation.[66,67] This clustering creates the formation of a
specialized signaling motif called a HemITAM including
residues Y6 and Y8 in the BST-2 CT, which recruit Src-family
kinases and become phosphorylated (Figure 3). The phosphorylation speciﬁcally recruits the kinase Syk, which then
assembles a signaling complex composed of adaptors TRAF2
and TRAF6, as well as TAK1, and culminates in downstream
activation of NF-κB.[68] BST-2 is coupled to the actin
cytoskeleton via interaction with the BAR and Rho-GAP
containing protein RICH2, which binds the BST-2 CT.
Mutations that inhibit this interaction prevent or reduce
phosphorylation of BST-2 and subsequent downstream NF-κB
activation.[68,69] Thus, it appears that pre-concentration of BST-2
on the cell surface is required for efﬁcient clustering by viruses.
This signaling can induce expression of inﬂammatory and
antiviral signaling cytokines IFN-β, CXCL10, and IL-6.[68] Virusencoded BST-2 antagonists have varying effects on BST-2mediated activation of NF-κB, which appears to be linked to the
ability to direct degradation of BST-2. HIV-1 Vpu, which targets
BST-2 for surface removal and destruction, also prevents BST-2mediated activation of NF-κB.[67,70] However, Ebola GP and
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HIV2 Env, which engage BST-2 to inhibit its viral tethering
ability but do not direct its degradation, do not inhibit this
signaling ability of BST-2.[71] The impact of antagonists
encoded by respiratory viruses on BST-2-mediated NF-κB
activation has not been investigated.
7.2. Anti-Inflammatory Signaling
BST-2 has also been implicated in inhibitory signaling in
plasmacytoid dendritic cells (pDCs), thereby dampening
inﬂammatory signaling. In this capacity, it serves as a ligand
for the inhibitory receptor ILT-7, which is exclusively expressed
on pDCs (Figure 3). Circulating pDCs produce IFN-I in response
to virus-derived TLR7/9 stimulation, which then initiates the
antiviral state in infected and surrounding cells, including
upregulation of BST-2 expression. The BST-2 expressed on
infected and neighboring cells can then engage ILT-7 on the
surface of pDCs, which signals through FcRγI to shut down
production of IFN-I in a negative-feedback manner to prevent
overstimulation.[72] HIV-1 Vpu appears to exploit this mechanism by speciﬁcally targeting BST-2 clustered to viral budding
sites for destruction, and enriching distribution of BST-2 outside
of the viral budding site, thus enhancing the probability of BST2/ILT7 interaction to suppress pDC antiviral response.[73] This
interaction has also been suggested to occur in cis between ILT7
and BST-2 both expressed on the surface of pDCs, possibly to
prevent premature maturation.[14]
BST-2 can also suppress virus-induced interferon production
by altering innate immune signaling. It was recently reported
that BST-2 can direct the degradation of the RIG-I-like receptor
MAVS to dampen IFN-I production.[74] In this scenario, BST-2
engages MAVS and recruits the ubiquitin E3 ligase MARCH8,
which directs K27-linked poly-Ub chains to K7 of MAVS. This
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Figure 3. Immune signaling functions of BST-2. IFN produced in response to viral infection stimulates a cellular antiviral state by inducing the
expression of hundreds of genes, including BST-2. IFN-induced BST-2 inhibits budding of newly forming virions, creating BST-2 clusters at the plasma
membrane. Clustered BST-2 is linked to the cortical actin cytoskeleton via RICH2, a BAR domain containing protein. This leads to phosphorylation of
tyrosines in the YDYCRV motif in the cytoplasmic tail by Src-family kinases followed by the recruitment and activation of Syk. Syk activation recruits
TRAF2, TRAF6, and TAK1 into a complex that leads to the activation of NF-kB and the induction of proinflammatory cytokines.[68] The upregulated BST-2
expressed on the surface of infected cells engages the plasmacytoid dendritic cell (pDC) receptor ILT7, resulting in inhibitory signaling that reduces the
expression of IFNs by pDCs.[72,73] BST-2 also negatively regulates RIG-I-like receptor innate immune signaling. RIG-I recognizes uncapped viral dsRNA
and induces MAVS, resulting in IFN-I expression and subsequently BST-2 expression. BST-2 then recruits the ubiquitin E3-ligase MARCH8 to catalyze
addition K27-linked polyUb chains to MAVS at K7. This chain is then recognized by NDP52, which recruits BST-2/MAVS to autophagosomes for
destruction, thereby dampening IFN-I production.[74]

polyubiquitination then engages NDP52, leading to autophagic
degradation (Figure 3). This function highlights the need for
tight regulation of IFN-I production to initiate proper antiviral
immune response while avoiding development of autoimmune
disorders.

7.3. Other Signaling Roles
In addition to these roles in signaling pathways, BST-2 may also
play a role in mediating intercellular signaling by tethering
exosomes.[75] Exosomes are small, secreted extracellular vesicles
that carry cargo such as growth factor cytokines and nutrients
between cells. BST-2 can trap exosomes on the surface of parent
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cells, thereby controlling whether exosomes are involved in
short- or long-range communication by cells.

8. Strategies to Harness BST-2 Antiviral
Function to Accelerate Clearance of
Respiratory Viruses
BST-2 was ﬁrst identiﬁed as a potent HIV-1 antiviral factor in
2008.[22] In the decade since, there has been much research
activity on the antiviral and immunological functions of BST-2:
these investigations have demonstrated that it can restrict a wide
variety of enveloped viruses. A number of recent studies indicate
that BST-2 can also restrict the budding of respiratory viruses.
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This is further exempliﬁed by the fact that these viruses have
developed BST-2 countermeasures against this signiﬁcant
pressure. So how could BST-2 function be exploited to clear
respiratory virus infections and what knowledge is needed to
design such treatments? In this section, we will discuss how this
could be achieved given the current state of knowledge and
examine what gaps need to be addressed.

activation and production of cytokines involved in inﬂammatory
and antiviral responses (Figure 3). Additionally, BST-2 serves as a
ligand for ILT-7 that dampens production of antiviral IFN-I.
Third, BST-2 can dampen innate immune signaling through
MAVS. Inhibition of some of these aspects may be needed to
create the optimal tuning of antiviral versus anti-inﬂammatory
response in the airway.

8.1. Pharmacological Inhibition of Viral BST-2 Antagonists

8.4. Gaps in Knowledge and How to Address Them

Nearly all enveloped viruses investigated to date encode an
antagonist that at least partially blocks BST-2 ability to prevent
virus release. In theory, inhibiting these antagonists (most
speciﬁcally by disrupting interaction with BST-2) would allow
BST-2 to exert its function at the cell surface and trap virion
release. This concept has been actualized, at least experimentally,
for HIV-1. BST-2 antiviral function against HIV-1 and how it is
antagonized by Vpu has been investigated comprehensively.
This understanding has allowed the design of unique
membrane-targeted peptides[76] as well as high-throughput
assays, which have identiﬁed compounds that prevent Vpumediated surface down-regulation of BST-2.[77] These small
molecules inhibit HIV-1 release and suppress replication.[78]
Similar pursuits could be engaged for respiratory viruses.
However, a similar level of comprehensive knowledge would
need to be obtained.

Although some mechanistic details are known for each of the
three pathways, detailed structural and biophysical information
regarding BST-2 interactions in these events have not been
reported (e.g., BST-2 engagement of RICH2, which is central to
NF-κB activation; BST-2 binding ILT-7 to signal for downregulation of IFN production). Such details are required to
develop methods to block or enhance these interactions. In
addition, it is currently unknown whether BST-2 antagonists
encoded by respiratory viruses alter any of these signaling
pathways.

8.2. Gaps in Knowledge and How to Address Them
The identity of BST-2 antagonists encoded by various respiratory
viruses as well as their mechanism of action is poorly
understood. The action of BST-2 against some established
(e.g., RSV) and emerging respiratory pathogens (e.g., metapneumovirus, bocavirus) has not been investigated. Additionally,
it is unknown whether BST-2 exerts inhibitory effects toward any
non-enveloped viruses. Within this class, rhinovirus and
enterovirus-68 are prominent respiratory pathogens, causing
severe acute disease and triggering asthma exacerbations. For
others that have been studied (Table 1), few details are known
about how the putative antagonists engage BST-2 or their
mechanism of action. In fact, the only virus for which structural
details of antagonist action have been elucidated is HIV-1
Vpu.[58,59] Detailed mechanistic and structural studies of BST-2
antagonist action and their interactions with BST-2 are required
to design inhibitors or develop screens to discover them. In
addition, mechanistic studies should be carried out in airway
epithelial cell lines and veriﬁed in primary airway epithelial cells
and animal models. Treatments would be virus-speciﬁc, as
current knowledge indicates that each respiratory virus employs
a unique antagonist mechanism.

8.3. Pharmacological Tuning of BST-2 Signaling
It is now understood that BST-2 plays a role in innate immune
and downstream inﬂammatory signaling. Viral clustering of
BST-2 initiates a signaling cascade that results in NF-κB
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8.5. Pharmacological Enhancement of BST-2 Cell Surface
Expression
BST-2 needs to be on the cell surface in order to restrict virus
release and suppress further infection. Its expression is
mostly controlled by interferon signaling. However, induction
of BST-2 has also been reported in the absence of IFN.[13] This
suggests that multiple transcription factors maybe be able to
regulate BST-2 expression and implies that pharmacological
induction, independent of the pleiotropic effects of IFN, is
likely possible.

8.6. Gaps in Knowledge and How to Address Them
Long-term BST-2 overexpression has been implicated in the
growth and progression of some cancers,[79] so methods to
enhance BST-2 surface expression should be approached with
caution. However, it is unclear whether enhanced surface
expression over a short term would be a signiﬁcant risk.

9. Conclusions and Prospects
In this essay, we present the ﬁrst comprehensive review of
BST-2 antiviral function and signaling with respect to
respiratory viruses. Emerging evidence indicates that BST-2
can restrict budding and replication of important respiratory
viruses, which is counteracted by encoded viral antagonists.
Detailed structural, biophysical, and cellular immunologic
studies utilizing airway cells are now needed to develop a
mechanistic understanding of how respiratory viruses antagonize BST-2 antiviral function and, potentially, immunologic
signaling. This understanding could lead to the development of
novel therapies that exploit BST-2 function to enhance recovery
from respiratory virus infections.
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SUMMARY

The secreted protein calcium-activated chloride channel regulator 1 (CLCA1) utilizes a von Willebrand factor
type A (VWA) domain to bind to and potentiate the calcium-activated chloride channel TMEM16A. To gain
insight into this unique potentiation mechanism, we
determined the 2.0-Å crystal structure of human
CLCA1 VWA bound to Ca2+. The structure reveals the
metal-ion-dependent adhesion site (MIDAS) in a
high-affinity ‘‘open’’ conformation, engaging in crystal
contacts that likely mimic how CLCA1 engages
TMEM16A. The CLCA1 VWA contains a disulfide
bond between a3 and a4 in close proximity to the
MIDAS that is invariant in the CLCA family and unique
in VWA structures. Further biophysical studies indicate
that CLCA1 VWA is preferably stabilized by Mg2+ over
Ca2+ and that a6 atypically extends from the VWA core.
Finally, an analysis of TMEM16A structures suggests
residues likely to mediate interaction with CLCA1 VWA.
INTRODUCTION
The calcium-activated chloride channel regulator 1 (CLCA1) is
emerging as an important channel-modifying protein with poorly
defined roles in health and disease (Patel et al., 2009; Sala-Rabanal
et al., 2015a). CLCA1 is a secreted protein that binds to and potentiates the calcium-activated chloride channel TMEM16A (Sala-Rabanal et al., 2015b). In the airways and digestive tracts, anion channels play important roles in mediating mucus hydration and pH
balance for protective and digestive purposes. CLCA1 and other
CLCA family members have often been associated with airway
and digestive manifestations. For example, animal models and
clinical studies suggest a compensatory role for CLCAs in the
context of cystic fibrosis (CF). The fatal intestinal disease meconium ileus that arises in cystic fibrosis transmembrane conductance regulator (CFTR)-deficient mice is corrected by overexpres-

sion of mouse CLCA1 (Young et al., 2007). Correspondingly,
variants of either CLCA1 (van der Doef et al., 2010) or CLCA4
(Kolbe et al., 2013) have been linked to more severe meconium
ileus in humans. In addition, the therapeutic peptide thymosin
alpha 1 (Ta1) has been observed to rectify multiple airway and intestinal defects in a mouse model of CF, which may be partially due
to increasing CLCA1 expression and, thus, potentiation of
TMEM16A (Romani et al., 2017). By similar arguments, TMEM16A
has emerged as a therapeutic target for CF and other mucoobstructive diseases (Li et al., 2017; Mall and Galietta, 2015; Sondo
et al., 2014). Inhibiting microRNA (miRNA)-mediated knockdown
of TMEM16A results in increased chloride flux and mucociliary
clearance in CF cell lines, primary CF cells, and mouse models
(Sonneville et al., 2017). Increased TMEM16A activity has also
been linked to other processes that are important to the resolution
of CF airway disease: cell migration and proliferation for wound
healing (Ruffin et al., 2013; Sonneville et al., 2017) and suppression
of inflammatory cytokine production (Veit et al., 2012). Based on
these and other observations, both CLCA1 and TMEM16A have
been suggested as targets for stimulation in muco-obstructive diseases—either to compensate or bypass dysfunctional CFTR in CF
or to stimulate secretion to solubilize obstructive mucus in asthma
and chronic obstructive pulmonary disease (COPD) (Mall et al.,
2018). Such efforts require a detailed molecular level understanding of the mechanism of potentiation.
The ability of CLCA1 to potentiate TMEM16A is regulated by
a matrix-metalloprotease-like (MMP-L) domain found in the N terminus of CLCA1. During secretion, CLCA1 MMP-L cleaves
CLCA1 into two fragments, allowing the N-terminal fragment of
CLCA1 (N-CLCA1) to engage TMEM16A (Yurtsever et al., 2012).
This engagement is mediated between the von Willebrand factor
type A (VWA) domain in CLCA1 and the a9-a10 loop in TMEM16A
and increases the surface expression of TMEM16A, thereby
increasing currents (Sala-Rabanal et al., 2015b, 2017). The
CLCA1 VWA domain (CLCA1 VWA) alone is necessary and sufficient to potentiate TMEM16A (Sala-Rabanal et al., 2017). VWA domains commonly mediate protein-protein interactions, within which
the integrin aI subfamily has been the most well-characterized
structurally and biophysically (Luo et al., 2007). Most contain a
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Figure 1. Structure of Human CLCA1 VWA Domain
(A) Domain architecture schematic of full-length human CLCA1. Labels denote the following domains: CAT, matrix-metalloprotease-like catalytic domain; Cys,
matrix-metalloprotease-like cysteine-rich region; FnIII, fibronectin type III domain; VWA, von Willebrand factor type A. Numbers above the domains indicate
approximate domain boundaries. Dashed line indicates cleavage site.
(B) Ribbon diagram of the human CLCA1 VWA domain structure obtained by X-ray crystallography. b strands and a and h helices of the VWA domain are labeled
according to the vWFA2 nomenclature (Zhang et al., 2009). A calcium ion (Ca2+) coordinated by the VWA MIDAS motif is shown as a gray sphere. MIDAS motif
residues surrounding the divalent cation are highlighted. The three invariant cysteines and location of the disease-associated variant S357 are also labeled. N, N
terminus; C, C terminus.
(C–F) Human CLCA1 VWA domain is superpositioned to anthrax toxin receptors CMG2 (PDB: 1SHU) (C) and TEM8 (PDB: 3N2N) (D), CD11b aI domain (PDB:
1IDO) (E), and collagen (PDB: 4IGI) (F) VWA domains. MIDAS motifs are indicated for all alignments. The h2 helix of the CLCA1 VWA domain and the a6 helices of
the published VWA domain structures are labeled in (C)–(E). For all structures, the CLCA1 disulfide is annotated by solid lines. For (A), the natural disulfide in CMG2
is annotated by dashed lines. For (F), the N and C termini are labeled.
See also Figures S1 and S2.

metal-ion-dependent adhesion site (MIDAS) motif to mediate protein-protein interactions (Springer, 2006; Whittaker and Hynes,
2002). MIDAS motifs consist of a loop containing a DXSXS
sequence, a second loop containing a threonine (T4), and a third
loop containing an aspartate (D5) that acts to chelate and present
a divalent cation (usually Mg2+) to ligands containing acidic residues
(Asp or Glu), which then complete the coordination sphere for the
divalent cation upon binding (Luo et al., 2007). Sequence analysis
indicates that these MIDAS residues are present in CLCA1 VWA
(Whittaker and Hynes, 2002), and we have shown that this motif
and the divalent cation are necessary for CLCA1 potentiation of
TMEM16A (Sala-Rabanal et al., 2017).
VWA domains are found in a functionally diverse range of
proteins, including blood coagulation factors (von Willebrand
factor), complement factors (Springer, 2006), signaling receptors
(a integrins; Shimaoka et al., 2002), toxin receptors (anthrax
toxin receptors; Lacy et al., 2004a, 2004b; Santelli et al., 2004),
extracellular matrix (collagen, Becker et al., 2014; and matrillin,
Paulsson and Wagener, 2018), ion channel regulators or subunits (CLCAs, Patel et al., 2009; and Cav1.1 a2d1, Dolphin,
2016), as well as in critical proteins in bacterial pathogens such
as Plasmodium (Song et al., 2012) and Toxoplasma (Song and
Springer, 2014). Structural and biophysical studies have been
carried out for several of these proteins, with those from a integ-
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rins, von Willebrand factor, and complement factors being the
best characterized (Springer, 2006). All adopt a Rossman fold
composed of a b sheet surrounded by amphipathic a helices
(Rossmann et al., 1974). However, there are often structural
and functional features that are unique to distinct families of
VWA domains (Becker et al., 2014; Song et al., 2012; Song
and Springer, 2014; Springer, 2006). To date, no high-resolution
structure has been determined for a VWA domain from the
CLCA phylogenetic branch. All CLCA proteins, with the exception of the CLCA3 pseudogenes (Mundhenk et al., 2018), contain
a central VWA domain (Figure 1). To gain insight into the unique
structural features of CLCA VWA domains, as well as how
CLCA1 VWA might engage TMEM16A, we determined the
high-resolution crystal structure of CLCA1 VWA. The structural
information suggests the mode by which CLCA1 engages
TMEM16A and the most likely sites on TMEM16A where engagement occurs.
RESULTS
Crystal Structure of the CLCA1 VWA
Human CLCA1 VWA (Figure 1A) was purified from a mammalian cell expression system and was previously shown to be
functional in potentiating TMEM16A when exogenously applied

Table 1. Crystallographic Statistics for Human CLCA1 VWA
Parameter

Data

Construct

302–476

Data collection statistics
Space group

C2

Unit cell
a, b, c (Å)

104.9, 71.8, 74.8

a, b, g ( )

90, 109.8, 90

Source

ALS 4.2.2

Wavelength (Å)

1.0000

Resolution (Å)

58.05–2.00 (2.05–2.00)

Rmerge

0.090 (1.814)

CC1/2

0.998 (0.507)

Completeness (%)

98.3 (86.3)

Redundancy

6.4 (4.2)

I/s (I)

10.7(0.6)

Refinement statistics
Rwork (%)

19.87

Rfree (%)

22.51

Amino acid residues (#)

318

Waters (#)

148

RMSD bond length (Å)/angles ( )

0.011/1.181

Wilson B (Å2)

36.7

Average B protein (Å2)

44.57

Average B water (Å2)

47.51

Average B Ca2+ (Å2)

37.50

Ramachandran
% Favored

96.82

% Allowed

3.18

% Outliers

0

Rotamer outliers (%)

3.53

Clashscore

3.41

Molprobity

1.74

Luzzati error

0.284

PDB ID

6PYO

Values shown in parantheses () represent the highest resolution shell. See
also Table S2.

to HEK293 cells (Sala-Rabanal et al., 2017). The structure was
determined by molecular replacement at a 2.0-Å resolution
(Table 1). There are two molecules in the asymmetric unit
(ASU) that are highly similar (Ca root-mean-square deviation
[RMSD] of 0.3 Å; Figure S1). Therefore, unless otherwise noted,
our analysis of CLCA1 VWA will refer to chain B. The general
structural features are similar to other VWA domain folds: a
core composed of 6 b strands sandwiched between a-helical
bundles (Figure 1B). A DALI structure comparison revealed that
the CLCA1 VWA shares the most three-dimensional similarity
to anthrax toxin receptors CMG2 (Lacy et al., 2004b) and
TEM8 (Fu et al., 2010) and to the voltage-dependent L-type
calcium channel Cav1.1 subunit a2d (Wu et al., 2015, 2016; Figures 1C–1E) with RMSDs ranging from 1.9–2.3 Å (Holm and
Laakso, 2016). However, there are three notable exceptions in

comparison to these VWA domains from other families. First,
the b sheet core is usually encompassed by 6 a helices. Although
the last a helix, a6 (using the nomenclature of the VWA2 domain;
Zhang et al., 2009), is predicted by secondary structure predictions (JPRED4; Drozdetskiy et al., 2015; see Figure 3A) and is
present in this construct (residues 302–476), we did not observe
defined electron density for it. Also, a slightly longer construct
(residues 302–478) did not yield a map with a6 clearly present
(Figure S2; Table S2). The absence of a6 places the N and C
termini of the CLCA1 VWA on opposite ends, much like the
arrangement reported in the structure of a collagen VI VWA
domain (Figure 1F; Becker et al., 2014). If in solution a6 is not
packed against the domain (see Discussion), this could have implications for how the domains of CLCA1 are oriented relative to
one another or may facilitate cleavage of the N-CLCA1 from CCLCA1. Second, there is a disulfide bond in proximity of the
MIDAS residues, linking a3 and h2 of a4 (Figure 1B). The cysteines in this disulfide linkage are unique to the CLCA family of
VWA domains. Most VWA domains do not contain a disulfide
bond, and if one is present, it usually connects the N- and C-terminal boundaries of the domain (Figure 1C). Third, there is a 310
helix (h2) at the N terminus of a4 that ends with one of the disulfide-bonded cysteines (Figures 1B–1E). Beyond the secondary
structure, CLCA1 VWA differs most in the loops surrounding
the MIDAS, as would be expected, because these loops usually
dictate ligand-binding specificities of VWA domains (Luo et al.,
2007).
CLCA1 VWA Crystallizes with MIDAS in the Open
Conformation
Most VWA domains mediate protein-protein interactions by a
MIDAS motif, which partially coordinates a divalent cation in a
manner that encourages completion of the coordination sphere
by an acidic residue (Asp or Glu) contributed by the ligand
(McCleverty and Liddington, 2003; Nolte et al., 1999; Shimaoka
et al., 2003; Springer, 2006; Vorup-Jensen et al., 2003). MIDAS
motifs have been observed to exist in two conformations that
correspond to the affinity of the VWA domain for its ligand: an
open, high-affinity configuration and a closed, low-affinity
configuration (Shimaoka et al., 2003). The closed conformation
is defined by MIDAS D5 serving as a direct chelator of the
divalent cation, through which the motif partially satisfies its
electrophilic nature (Figure 2D). In contrast, the open configuration is hallmarked by all the direct MIDAS chelators of the divalent cation being uncharged (threonine, serine, or waters),
creating an electrophilic divalent cation whose coordination is
best satisfied by an acidic residue contributed by the engaging
ligand (Figure 2C). The human CLCA1 VWA contains a perfectly
conserved MIDAS motif (Whittaker and Hynes, 2002): a DXSXS
sequence followed several residues later by a threonine (T383)
and a final aspartate (D412) (Figure 2A). Strong density corresponding to an ion was observed at the center of this site for
both molecules in the ASU (Figure S3). As the CLCA1 VWA
was crystallized in conditions containing high CaCl2 concentrations, we modeled a Ca2+ into the MIDAS site. Very few VWA
domains have been crystallized in the presence of Ca2+ and
instead usually contain Mg2+ or Mn2+ that bind at a higher affinity.
Most VWA MIDAS motifs favor occupancy by Mg2+ rather than
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Figure 2. CLCA1 VWA MIDAS Crystallizes in
an Open Conformation
(A–D) MIDAS regions of human CLCA1 chain B (A,
in green) and chain A (B, in cyan) of the asymmetric
unit and of the open (C) and closed (D) MIDAS
configurations of the CD11b aI domain (PDB: 1IDO
and 1JLM, respectively).
For (A)–(C), the pseudoligand residue is shown in
the color of the appropriate chain. Waters are
depicted as red spheres. Bonds coordinating
divalent cations are shown as blue dashes (for
direct side chain interactions) and yellow dashes
(for indirect or water-mediated interactions).
See also Figure S3.

the open conformation in our structures
implies that the CLCA1 VWA likely adopts
this configuration for a high-affinity interaction with TMEM16A and also suggests
that the binding is primarily mediated by a
critical acidic residue within TMEM16A.

Ca2+, and Mg2+ coordination usually results in higher-affinity
binding to ligand or greater functional capability (Ajroud et al.,
2004; Baldwin et al., 1998; San Sebastian et al., 2006; VorupJensen et al., 2007). However, attempts to obtain CLCA1 VWA
crystals in the presence of excess MgCl2 were not successful.
For both molecules in the ASU, the structure reveals the
MIDAS in the open, high-affinity conformation, with S314,
S316, and T383 directly coordinating a calcium ion and D312
and D412 indirectly coordinating through a water molecule (Figures 2A and 2B). This coordinating geometry is consistent with
our functional studies that showed (1) mutation of MIDAS residues, particularly T383 and S316, which both directly coordinate
the divalent cation in the open conformation; and (2) chelation of
extracellular Mg2+ by EDTA abrogated CLCA1 VWA-mediated
potentiation of TMEM16A in whole-cell patch clamp experiments (Sala-Rabanal et al., 2017). An acidic residue from an
adjacent molecule in the crystal, either a glutamate from chain
A (E299) or aspartate (D403) from chain B, completes the coordination of the calcium ion. This arrangement is identical to the
open conformation observed for the CD11b aI domain (Figure 2C) with the exception that, unlike the CD11b structure
reported by Mahalingam et al. (Mahalingam et al., 2011), the
acidic residue appears to mediate a monodentate interaction
with calcium rather than a bidentate interaction. Such crystal
contact ‘‘pseudoligand’’ interactions are commonly observed
in crystal structures of VWA domains that utilize their MIDAS
motif to mediate interactions (Bhattacharya et al., 2004; Lacy
et al., 2004b; Lee et al., 1995; Li et al., 1998). The presence of
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An Invariant Disulfide Bond Is
Required for Folding and Secretion
of CLCA1 VWA
Our high-resolution crystal structure of
CLCA1 VWA revealed a disulfide bond between C386 and C421, connecting a3 and
the h2 segment of a4 (Figure 1B). This disulfide bond is unique in that (1) natural disulfide bonds in VWA domains are not common; and (2) unlike
CMG2 (Lacy et al., 2004b), MIC2 (Song et al., 2012) and TRAP
(Song and Springer, 2014), VWA domains in which a disulfide
bond is found linking the N- and C-termini, the disulfide bridge
in the CLCA1 VWA is found in close proximity to the MIDAS. Interestingly, sequence analysis indicates that CLCA proteins have
three invariant cysteines within the VWA domain (Figure 3A;
Patel et al., 2009). The free cysteine C308 is packed within the
core of CLCA1 VWA (0% sidechain solvent accessibility as calculated by NACCESS; Hubbard and Thornton, 1993; Figure 1B). This
likely negates the possibility that CLCA1 VWA may covalently bind
to itself or to other proteins, as is the case for some VWA domains,
such as the Cav-1 and 2 calcium channel a2 subunits, which
remain covalently linked to the d subunit by a disulfide bond (Wu
et al., 2015, 2016) after proteolytic cleavage. To investigate the
structural importance of invariant cysteines in the CLCA1 VWA,
we carried out mutations to serine (C308S, C386S, C421S, and
C386S/C421S) and expressed them in HEK293T cells. Although
all proteins were expressed, only the C308S mutant was secreted
(Figure 3B), indicating that mutants with disrupted disulfide bond
formation were misfolded and retained in the secretory pathway.
Further supporting this observation, for the mutants that were not
secreted, a band at approximately twice the monomer size of
CLCA1 VWA (2 X 20kDa) was observed in cell lysates, suggesting
that aberrant disulfide bonds between molecules may have been
formed during misfolding and not sufficiently reduced in SDSPAGE (Figure 3B). To assess the role of this disulfide in CLCA1
VWA stability, we carried out circular dichroism (CD) and

Figure 3. Biophysical Analysis of CLCA Family VWA Domain Invariant Cysteines
(A) Annotated sequence alignment for human, mouse, and pig CLCA VWA domains. Numbering corresponds to the sequence of human CLCA1. Secondary
structure of human CLCA1 is labeled above. A solid line indicates the disulfide bond observed in the crystal structure. Stars next to the sequence indicate that the
VWA domain contains an imperfect MIDAS (Whittaker and Hynes, 2002). Sequences are shown for hCLCA1 (GenBank: NM_001285.3), pCLCA1 (NM_214148.1),
mCLCA1 (NM_017474.2), hCLCA4 (NM_012128.3), pCLCA4a (XM_001926978.5), pCLCA4b (XM_003125934.5), mCLCA4a (NM_207208), mCLCA4b
(NM_001033199), hCLCA2 (NM_006536.6), pCLCA2 (XM_003125930.4), mCLCA2 (NM_178697.5), mCLCA3b (NM_139148), mCLCA3a1 (NM_009899), and
mCLCA3a2 (NM_030601) (where h, human; p, pig; m, mouse). Sequence conservation is color coded as follows: invariant residues (with the exception of cysteine
and invariant MIDAS residues), magenta; invariant cysteines, green; residues with a global similarity score of 0.75 or higher as determined by ESPript 3.0 software
(Robert and Gouet, 2014a), yellow; perfect MIDAS residues, blue; and imperfect MIDAS residues, cyan. Black boxes indicate the most strongly predicted sites of
N-linked glycosylation by NetNGlyc 1.0 software (Blom et al., 2004). The predicted a6 helix (JPRED4; Drozdetskiy et al., 2015) of the CLCA1 VWA domain is
labeled above the alignment in red. MIDAS residues are highlighted in purple. Invariant cysteines are labeled in yellow.
(B) Wild-type (WT) CLCA1 VWA domain and cysteine-to-serine mutants of the invariant disulfides (single mutants C308S, C386S, and C421S, and double mutant
C386S/C421S) were expressed in 293T cells. Supernatants and lysates were analyzed by western blot (anti-6-His). Pos. control, 6-histidine tagged MAM domain
from receptor tyrosine phosphatase m (SDS-PAGE molecular weight [MW] = 30 kDa).
(C) Circular dichroism spectra of the human CLCA1 VWA domain in the presence of EDTA (blue), magnesium (green), and calcium (orange), with (dashed line) or
without (solid line) reducing agent (DTT). Spectra are plotted as mean ellipticity per residue ± SD of triplicate recordings. Representative spectra of three independent experiments.
(D) Thermal denaturation of human CLCA1 VWA domain by determination of melting temperatures (TM) by monitoring circular dichroism at 222 nm (top panel) or
differential scanning fluorimetry (bottom panel) in the presence of EDTA (blue), magnesium (green), and calcium (orange), with (squares) and without (diamonds)
reducing agent (DTT). Representative TMs of three independent experiments. For circular dichroism, data are represented as the calculated TM and estimated
error from the ProScan software. For differential scanning fluorimetry, data are represented as mean ± SEM of triplicate samples.
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Figure 4. Solution Structures of CLCA1 VWA and CAT-CYS-VWA Proteins from SAXS Analysis
Solution SAXS for human CLCA1 VWA (302–476) (A–D) and CLCA1 E157Q (22–477) encompassing the MMP-L catalytic domain (CAT), cysteine-rich region (Cys),
and VWA (E–H).
(A and E) Raw SAXS data.
(B and F) Top panel, Guinier regions with SAXS data points (open circles) and fits (solid red line). Radius of gyration (Rg) is labeled above the line of fit. Bottom
panel, residual data points (open circles) of Guinier region with fits (solid red line).
(C and G) Distance distribution functions. Dmax is indicated next to the distribution.
(D and H) Ab initio SAXS envelope models. Models are the average of 10 independent DAMMIN predictions averaged in DAMAVER. CLCA1 VWA domain was
docked into the envelope using SITUS. Domain architecture schematics and cartoons are labeled above the SAXS envelopes. in (D) and (H). N and C termini are
labeled.

differential scanning fluorimetry (DSF) experiments. CD spectra of
CLCA1 VWA in the absence of divalent cations (+EDTA) varied
greatly with the addition of DTT, especially at wavelengths of
<215 nm, indicating partial unfolding upon reduction of the
disulfide bond (Figure 3C). In addition, thermal denaturation
studies by CD and DSF in the presence or absence of DTT
showed that reduction of the disulfide bond decreased the melting
temperature (TM) by 2.6 C and 6.5 C, respectively (Figure 3D).
Altogether, these results suggest that CLCA family VWA domains
contain an invariant disulfide that is required for folding and stability. The role of the invariant free cysteine (C308) is unclear at this
time. However, it should be noted that the sidechain sulfhydryl
does hydrogen bond to the backbone carbonyl of L309, so this
sidechain likely contributes to the stability of the fold.
CLCA1 VWA Is Stabilized by 1 mM Mg2+ but Not Ca2+
Our crystallization studies seemed to indicate that CLCA1 VWA
might not preferentially bind Mg2+, as we were unable to obtain
crystals in the presence of Mg2+. This would be unusual because
VWA domains normally bind Mg2+ with affinities in the low micromolar range, with affinities for Ca2+ about 100-fold worse, in the
range of hundreds of micromolar (Ajroud et al., 2004; Baldwin
et al., 1998; San Sebastian et al., 2006; Vorup-Jensen et al.,
2007). To relatively rank the binding affinities of CLCA1 VWA for
the divalent cations, we assessed whether Ca2+ or Mg2+ impacted
thermal stability by using CD and DSF thermal denaturation exper-
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iments. Both analyses were consistent: Mg2+ significantly stabilizes the VWA domain over Ca2+ or cation-free conditions
(+EDTA), increasing the TM of CLCA1 VWA by 1.0 C–1.2 C by
CD and 8.6 C–9.8 C by DSF (Figure 3D). In addition, Mg2+ even
stabilized CLCA1 VWA under reducing conditions (DTM = +2.1 C
or +6.9 C, by CD and DSF, respectively). In contrast, the addition
of 1 mM Ca2+ was unable to shift the TM of CLCA1 VWA compared
to cation-free conditions. These results are consistent with previous investigations of VWA domain affinities for divalent cations
(Ajroud et al., 2004; Baldwin et al., 1998; San Sebastian et al.,
2006; Vorup-Jensen et al., 2007) and indicate that CLCA1 VWA
preferentially binds Mg2+ over Ca2+.
Solution Structures of CLCA1 Suggest VWA a6 Extends
from the Core Fold
Because we were unable to observe definitive electron density
for the CLCA1 VWA a6 in our high-resolution crystal structure,
we utilized small-angle X-ray scattering (SAXS) to develop a
low-resolution envelope structure of the VWA domain (Figures
4A–4D) as well as CLCA1 containing the catalytic and VWA
domains with an inactivating mutation in the MMP-L domain
(CAT-CYS-VWA E157Q) (Figures 4E–4H). The CLCA1 VWA
structure was docked into these envelopes using SITUS.
Both envelopes display globular regions consistent with onedomain (VWA; Figure 4D) or three-domain (CAT-CYS-VWA
E157Q; Figure 4H) proteins. However, both also included a

Figure 5. Disease-Associated Residue
S357 Sidechain Engages in an Intramolecular Hydrogen Bond
The sidechain of S357 and the backbone and
sidechain of E358 are highlighted. The sidechain
hydroxyl of S357 forms a hydrogen bond to the
backbone carbonyl of E358 (indicated by the
dashed yellow line).

tubular tail extending from the sphere in both envelopes. In light
of the missing a6 helix in our crystal structure, we speculate that
this tail may represent the a6 helix that cannot be resolved in the
crystal structure because it does not pack tightly against the rest
of the domain. Analysis of packing in the CLCA1 VWA crystal
shows that the C terminus for the built structure is located
adjacent to large solvent channels that would allow for multiple
positions for an a6 helix that extends from the core VWA.
Thus, solution structural studies by SAXS suggest that CLCA1
VWA a6 extends from the VWA core fold, in contrast to other
structurally characterized VWA domains.
Structural Insights into the Disease-Associated CLCA1
Variant S357N
In genomic analyses, S357N has been identified as a mutation
modifying the severity of intestinal disease occurring in CF patients, as it was associated with aggravated meconium ileus
(van der Doef et al., 2010). To gain mechanistic insight into how
this mutation might manifest in disease, we analyzed the structural environment of S357 in our CLCA1 VWA structure. S357 is
found distal to the MIDAS motif, and the sidechain hydroxyl donates a hydrogen bond to the backbone carbonyl of the adjacent
residue (E358) (Figure 5). This results in the S357 sidechain being
mostly buried (4.8% side chain solvent accessibility by NACCESS). Given the tightly packed environment, it is highly unlikely
that an asparagine at this position would be able to engage in the
same hydrogen bond, which might disrupt folding or folding kinetics and could result in reduced expression levels. This would
result in decreased potentiation of calcium-activated chloride
currents, reducing hydration and resulting in thick mucus plugging of the intestine. This would be consistent with our published
functional studies in overexpression systems in which S357N
does not affect the ability of CLCA1 VWA to potentiate chloride
currents by TMEM16A (Sala-Rabanal et al., 2017). This is also
consistent with studies in CFTR knockout mice that show that
mouse CLCA1 expression is decreased in mice with aggravated
meconium ileus, which is rescued by overexpression of mouse
CLCA1 (Young et al., 2007).
Structural Implications for CLCA1 VWA Engagement of
TMEM16A
Our crystal structure of CLCA1 VWA reveals the MIDAS in the
high-affinity open configuration and engaging in pseudoligand

interactions with crystal lattice neighbors.
These interactions mimic the mode by
which CLCA1 VWA would engage
TMEM16A. In our previous studies, we
showed that an antibody targeting the
TMEM16A a9-a10 loop could block binding of CLCA1 (Sala-Rabanal et al., 2015b). This result, in combination with our current
structural observations, suggests that an acidic residue located
in the TMEM16A a9-a10 loop is primarily responsible for mediating interaction with the CLCA1 VWA MIDAS. To identify the
most likely candidate residues, we analyzed the recently determined cryoelectron microscopy (cryo-EM) structures of mouse
TMEM16A (Dang et al., 2017; Paulino et al., 2017), making
note of which acidic residues in this loop were most solvent
exposed. This loop contains 9 acidic residues, 5 of which are
highly solvent exposed (>60% sidechain solvent-accessible
surface in NACCESS) (Figure 6). These residues are all
conserved in human TMEM16A (corresponding to D851, D854,
E858, E869, and E874). Thus, one of these five residues is
most likely responsible for mediating the interaction with
CLCA1. Similar modes of engagement have been observed in
the voltage-gated calcium channels system, such as Cav1.1,
where cryo-EM structures reveal an interaction with the a2d
subunit VWA that appear to be primarily mediated by a single
acidic residue in the channel domain (Wu et al., 2015, 2016).
However, it is worth noting that more complex models, such as
three-way modes of engagement, have also been suggested in
this system (Briot et al., 2018). Future mutational, functional,
and structural studies will be required to identify which residues
in TMEM16A are responsible.
DISCUSSION
Here, we present the structural and biophysical analysis of
the CLCA1 VWA, the first structural characterization of a VWA
domain from the CLCA family of channel-modifying proteins.
Our analysis reveals major observations with respect to CLCA
function and a potential role in disease. First, our structure
reveals the MIDAS motif in the high-affinity open conformation,
engaging in pseudoligand contacts that mimic the mode by which
it would engage TMEM16A and suggesting that one of five acidic
residues in the a9-a10 loop are primarily responsible for mediating the interaction (Figure 6). However, it should be noted that
the other two extracelluar loops in TMEM16A (a1-a2 loop and
a5-a6 loop) in the cryo-EM structure are in close proximity to
the a9-a10 loop (Paulino et al., 2017), and therefore, antibody
binding to the a9-a10 loop could potentially sterically hinder access to these loops as well. So, potential involvement of these
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Figure 6. Most Probable Sites of CLCA1TMEM16A Interaction Suggested by Structural and Functional Studies
The cryo-EM model of mouse TMEM16A
(mTMEM16A) dimer (PDB: 5OYB; Paulino et al.,
2017) (purple) with the a9-a10 loop (blue) and
labeled acidic residues in this loop shown in either
yellow (<60% solvent-accessible surface for
sidechain) or cyan (>60% solvent-accessible surface for sidechain). CLCA1 VWA (green) is poised
on the extracellular face of mTMEM16A, as our
structural data suggest that interaction with
CLCA1 VWA MIDAS is likely mediated by one of
these residues. Divalent cations (Ca2+) are shown
in gray.

loops in engagement should not be ruled out. Analysis of
sequence alignments across species indicate that most CLCA4
proteins contain an intact MIDAS motif, whereas most CLCA2
family members do not, missing one or two key residues (Figure 3A). Because members of the CLCA2 family have been
observed to potentiate calcium-dependent chloride currents
(Gruber et al., 1999), this would indicate that either neighboring
residues compensate to complete a non-standard MIDAS motif
or CLCA2 proteins carry out this function utilizing a different
mode of engagement. Our crystal and solution structures suggest
that a6 of the CLCA1 VWA extends from the core, which may
potentially contribute to the CLCA1 VWA MIDAS being accessible
to engage TMEM16A by directing trailing domains further away
from the VWA core structure.
CLCA VWA domains contain three cysteines that are invariant
across species (Figure 3A). Two of them (corresponding to
C386 and C421 in CLCA1) engage in a disulfide bond that is unique
compared to other structurally characterized VWA domains. This
linkage appears to be required for folding and stability of the
domain. In addition, this disulfide is in close proximity to key residues of the MIDAS motif. This disulfide bond appears to bend
the h2 helix toward the MIDAS and possibly constrain both
the a2-a3 and the b4- h2 loops, which contain the conserved
MIDAS threonine (T383) and aspartic acid (D412), respectively,
potentially favoring the open configuration (Figures 2A–2C). It is
interesting to note that in the shift from an open to a closed MIDAS
configuration, it is these two MIDAS residues that alter their
coordination to the divalent cation (i.e., in the open configuration,
threonine directly coordinates the cation and the second aspartic
acid indirectly coordinates through water, but in a closed configuration, threonine indirectly coordinates by water and the second
aspartic acid directly coordinates the cation) (Figures 2C and 2D;
Shimaoka et al., 2003). This disulfide, however, does not appear
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to shift the MIDAS preference for binding divalent cations. Previous computational and biophysical studies on aI
domains indicate that Mg2+ is preferred
to Ca2+ by 100- to 1,000-fold affinity
(Ajroud et al., 2004; Baldwin et al., 1998;
San Sebastian et al., 2006; Vorup-Jensen
et al., 2007). Our thermal denaturation
studies suggest similar trends for the
CLCA1 VWA, indicating that at near physiological concentrations
(1 mM), Mg2+ is preferred over Ca2+ and is likely the cation that
mediates the CLCA1-TMEM16A interaction in vivo. The third
invariant cysteine (C308 in CLCA1) is not required for folding or
stability. Interestingly, the Toxoplasma gondii motility and invasion
protein MIC2 also has a cysteine in this position of b1 that, in
contrast, engages in a disulfide linkage with a4 (C164) in its VWA
domain (Song and Springer, 2014). This is not the case in CLCA
VWAs, as the structurally corresponding position (A392 located
in a3 of CLCA1) is either an alanine or glycine (Figure 3A). It is unclear at this time what its functional role is and why it is invariant
at this position.
The S357N variant of CLCA1 has been associated with
increased severity of meconium ileus in CF patients (van der
Doef et al., 2010). This residue is tightly packed and engages
in a stabilizing hydrogen bond with the backbone. It is unlikely
that a mutation to asparagine would be well accommodated
at this position. Thus, this mutation likely impacts the expression
level of CLCA1, thereby decreasing the ability to potentiate
TMEM16A. Clinical and animal model studies further support
the concept that reduced CLCA1 and TMEM16A activity
contributes to pathology in the CF airway and intestinal diseases.
For example, miRNA targeting TMEM16A is overexpressed in
CF airways, and inhibiting this miRNA-mediated knockdown of
TMEM16A results in increased chloride flux and mucociliary
clearance by TMEM16A in CF cell lines, primary CF cells, and
mouse models (Sonneville et al., 2017). In addition, the peptide
drug thymosin alpha 1 (Ta1) has been demonstrated to increase
anion conductance in F508del-CFTR airway cell lines and
mice, and depleting CLCA1 with small interfering RNA (siRNA)
greatly reduces the ion channel activity enhanced by Ta1 (Benedetto et al., 2017). Furthermore, CFTR-deficient mice with
increased meconium ileus display lower CLCA1 expression

that is corrected by the overexpression of CLCA1 (Young et al.,
2007). Altogether, these published observations and our
previous results suggest that CLCA1-mediated enhancement
of TMEM16A activity plays an important role in mucosal
inflammatory diseases and, thereby, represents a viable therapeutic target. Our structural results and analysis provide an
important framework for studying the role of CLCA proteins in
health and disease.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell Lines
Expi293F cells (RRID: CVCL_D615; sex = female) used for high-level protein expression were cultured at 37 C and 8% CO2 in serumfree Expi293 Expression Media (ThermoFisher Scientific) supplemented with 0.5% penicillin/streptomycin (Pen/Strep, GIBCO). Human embryonic kidney 293T cells (ATCC Cat # CRL-3216, RRID: CVCL_0063; sex = female) were cultured at 37 C and 5% CO2 in
Dulbecco’s modified Eagle’s medium (GIBCO) supplemented with 10% Fetal Bovine Serum (FBS), 1% Non-essential Amino Acids
(Corning Inc., Corning, NY), 1% Glutamax (GIBCO) and 1% penicillin/streptomycin (Pen/Strep, GIBCO).
METHOD DETAILS
Expression constructs
Human CLCA1 VWA domain constructs (302-476 and 302-478) and CAT-CYS-VWA (22-477) were cloned into the mammalian cell
expression vector pHLsec, which contains an optimized signal sequence and C-terminal 6-histidine tag for purification (Aricescu
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et al., 2006). Mutants (C308S, C386S, C421S and C386S/C421S) were first generated in full-length CLCA1 in the vector pcDNA 3.1
using QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent, Santa Clara, CA) (primer sequences in Table S1) and then
subcloned into pHLsec. All constructs were verified by sequencing.
Protein expression and purification
WT human CLCA1 VWA domains (302-476 and 302-478) and CAT-CYS-VWA (22-477) were expressed in Expi293 cells via transient
transfection with either Hype-5 or Hype-293 (OZ Biosciences, San Diego, CA) at a 1:1.5 ratio (mg of DNA: mL of transfection reagent)
using 1 mg of plasmid per 1 million cells, similar to our previous reports (Kober et al., 2015). Media from supernatants were harvested
after 72-96 hours by centrifugation, concentrated to 1/10 of the original volume using a 10 kDa cutoff membrane (Ultracel Ultrafiltration Discs, EMD Millipore) and adjusted to pH 8.5 and 5 mM imidazole. The concentrated protein was purified using Ni-NTA
Superflow resin (QIAGEN, Hilden, Germany) and eluted in 5 mL of buffer containing 50 mM K2HPO4 (pH 8), 300 mM NaCl, and
250 mM imidazole. The eluted protein was concentrated and purified by size exclusion chromatography (Superdex75 Increase
10/300 GL for VWA in 20 mM Tris (pH 8) and 150 mM NaCl and Superdex 200 Increase 10/300 GL for CAT-CYS-VWA in 20 mM
HEPES and 150 mM NaCl (pH 7.4), GE Healthcare). Purified CLCA1 VWA was dialyzed into buffer containing 20 mM HEPES (pH
7.4) and 150 mM NaCl and concentrated in a 10,000 kDA cutoff centrifuge concentrator (Vivaspin 500, Sartorius) to 12 mg ml-1,
as calculated from absorbance at 280 nm, for crystallization. Protein purity was assessed by Coomassie staining of SDS-PAGE.
Crystallization, structure determination, and analysis
Crystals of CLCA1 VWA (302-476) were grown at 17 C by hanging drop vapor diffusion by mixing 1:1 with well solution containing
0.2 M HEPES pH 7.5, 0.1 M CaCl2, 28% PEG 400 or by streak seeding into the same conditions containing 5% glycerol. Crystals
formed within 6 days. Crystals were flash frozen under a nitrogen stream at 160 C. Data were collected at the Advanced Light
Source, beamline 4.2.2 (Berkeley, CA) and scaled and processed to 2.0 Å using XDS (Kabsch, 2010). A molecular replacement solution was found with PHASER (TFZ = 10.2) using uncharacterized membrane spanning protein from Vibrio fischeri (4RCK) (poly-Ala
model) as the probe, locating two molecules in the asymmetric unit (ASU) for a solvent content of 61%. The initial solution was refined
by rigid body refinement in PHENIX (Adams et al., 2010) and initially built using AUTOBUILD in PHENIX. The model was improved
by iterative rounds of manual rebuilding in COOT (Emsley et al., 2010) and refinement using PHENIX. Secondary structure restraints
were used during refinement and hydrogens were added as a riding model in the final rounds. Simulated annealing was used early
in refinement, and optimization of X-ray and ADP or stereochemistry weight was applied in later rounds. The final model is 94%
complete with 17 C-terminal residues (460-476) in both chains and the first N- terminal residue (302) in chain B not visible in the electron density. Chain A contained three N-terminal residues (ETG 299-301) that are a remnant of the vector-encoded signal sequence
(Aricescu et al., 2006). LigPlot+ (Laskowski and Swindells, 2011) was used to analyze cation contacts. Solvent accessibility calculations were carried out using NACCESS (Hubbard and Thornton, 1993). For structure-based alignment, amino acid sequences were
aligned using Clustal Omega (Sievers et al., 2011) and residue conservation scored by ESPript (Robert and Gouet, 2014a). Secondary
structure predictions were generated in JPRED4 (Drozdetskiy et al., 2015). All crystallographic and analysis software used were
compiled and distributed by the SBGrid resource (Morin et al., 2013) and diffraction images were archived with the SB Data Grid
(Meyer et al., 2016). Crystals of CLCA1 VWA (302-478) were grown under similar conditions and diffracted to 2.6 Å. The structure
was solved by isostructural replacement of CLCA1 VWA (302-476), and iteratively refined and rebuilt as above. The final model consisted of residues 302-461 (chain A) and 303-459 (chain B).
Small angle X-ray scattering
SAXS data was obtained at the Advanced Light Source on the SIBYLS beamline 12.3.1 (Dyer et al., 2014). Thirty-three exposures of
0.3 s were obtained for each protein at 1-10 mg/mL and scattering from the dialysis buffer (20 mM HEPES pH 7.4, 150 mM NaCl, and
2% glycerol) was subtracted. Data were inspected for quality and scale-merged in scÅtter 3.0g (Rambo, 2015). Data was subsequently analyzed in the ATSAS 2.8.4 suite (Franke et al., 2017) using PRIMUS (Konarev et al., 2003). Guinier analysis showed no radiation damage, aggregation or concentration effects. I(0) and the pair distance distribution function P(r) were calculated in GNOM
(Svergun, 1992) within PRIMUS. Ten low-resolution ab initio models from DAMMIN (Franke and Svergun, 2009) were automatically
averaged using DAMAVER (Volkov and Svergun, 2003) and converted to a surface map using SITUS (Wriggers and Chacon, 2001).
Graphical Representation of Structures
All molecular graphics images were produced using PyMOL.
Heterologous expression of CLCA1 and Western Blotting
HEK293T cells were grown to 70%–90% confluency and transfected with CLCA1 VWA domain constructs and 293Fectin at a 1:2
ratio (mg of DNA: mL of transfection reagent) using 1 mg of plasmid DNA per 1 million cells. After 24 hours, supernatants were mixed
with 2x SDS containing 2-mercaptoethanol sample buffer. Cells were pelleted and lysed in PBS-1% Triton X-100, then diluted in
2x SDS containing 2-mercaptoethanol sample buffer and sonicated. Samples were boiled for 5 minutes, then loaded on a
4%–12% Bis-Tris NuPage gel (Life Technologies). Proteins were transferred to nitrocellulose membranes using an iBlot Gel transfer
device (Life Technologies). Membranes were blocked with 0.5% blotting-grade blocker nonfat milk (Bio-Rad) in PBS with 0.1%
Tween-20. HRP-conjugated anti-6-histidine antibody (Bethyl Laboratories) diluted 1:5000 in blocking buffer was incubated on the
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membrane for 10 minutes at room temperature. Following three washes with PBS-Tween-20, signal was detected using Pierce ECL
Western Blotting Substrate (Thermo Fisher Scientific, Rockford, IL). Developed films were scanned.
Circular Dichroism
CD spectroscopy measurements were performed using an Chirascan spectropolarimeter equipped with a Peltier temperature
controller (Applied Photophysics). A 1 cm path length cuvette was used and the protein concentration was 50 mg/mL. Thermal denaturation experiments were carried out in 20 mM Tris pH 8.0, 100 mM NaCl and 1 mM of either EDTA, MgCl2, or CaCl2. For reducing
conditions, the buffer contained 1 mM DTT. Ellipticity was measured at 222 nm in 1 C steps from 20 to 90 C at a rate of 1 C/min. Data
was analyzed using ProScan software (Applied Photophysics).
Differential Scanning Fluorimetry
Thermal stability was assessed by differential scanning fluorimetry (DSF) on protein purified by size exclusion chromatography. The
Protein Thermal Shift kit (Applied Biosystems) was used according to manufacturer’s instructions. Briefly, protein was concentrated
to 0.5 mg/mL after buffer exchange into 20 mM HEPES pH 7.5, 150 mM NaCl and 1 mM of either EDTA, MgCl2, CaCl2 or DTT. 5 mL of
reaction buffer and 2.5 mL 8x fluorescent dye were added to 12.5 mL protein on ice. Melt-curve experiments were performed using
Fast7500 qPCR machine (Applied Biosystems) starting at 25 C and with continuous 1% ramp to 95 C (roughly at 1 C/min). The data
were analyzed using Protein Thermal Shift software (Applied Biosystems).
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analyses for differential scanning fluorimetry (DSF) experiments, specifically for melting temperature (TM) determination,
were performed using Protein Thermal Shift software (Applied Biosystems). Representative derivative-curve melting temperatures
from three (n = 3) independent experiments are shown. Melting temperature data are represented as mean ± SEM of triplicate
(n = 3) samples. For circular dichroism (CD) experiments, statistical analyses, specifically for TM determination, were performed using
the ProScan software (Applied Photophysics). Representative spectra of three (n = 3) independent experiments is shown. CD spectra
are plotted as mean ellipticity per residue ± SD of triplicate (n = 3) recordings. Melting temperature data are represented as the calculated melting temperature using a sigmoid curve fit and estimated error reported from the ProScan software. Statistical details are
also included in Figure 3 legends.
DATA AND CODE AVAILABILITY
Coordinates and structure factors for CLCA1 VWA (302-476) and CLCA1 VWA (302-478) have been deposited in the RCSB Protein
Data Bank with accession numbers PBD: 6PYO and 6PYX, respectively. SAXS data for CLCA1 VWA (302-476) and CLCA1 CAT-CYSVWA (22-477) have been deposited in the SASBDB with accession numbers SASBDB: SASDH24 and SASDH34, respectively.
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